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ABSTRACT
Biomarkers have great potential for cancer detection and monitoring, with much o f this 
type o f analysis being carried out using tumour biopsies. This approach requires invasive 
procedures to obtain suitable specimens and only allows analysis o f gene expression at one 
particular time point in the history o f  a cancer and from one location in the body.
Biomarkers detectable in readily accessible body fluids, such as scrum, saliva or urine 
would allow on-going/ sequential monitoring o f the course o f disease (progression, 
response to therapy, etc.). A small number o f studies have indicated the possibility o f 
amplifying extracellular mRNA from the serum and/or plasma o f cancer patients 
supporting the potential o f this route o f analysis. Limitations o f these studies include the 
small numbers o f serum/plasma specimens analysed; limited numbers o f gene transcripts 
analysed; and discrepancies in protocols used, leading to a possibility that cells circulating 
in the bloodstream may be included in the RNA isolations; and the fact that a standard 
technique in general, was not employed.
This thesis aims to address these issues by firstly establishing the possibility o f routinely 
extracting and amplifying extracellular mRNA from the conditioned media (CM) o f  
cultured cells. Having established, in principle, that amplifiable RNA could be isolated, 
comparison and optimisation o f methods o f extracting RNA was carried out to identify a 
reliable and reproducible method. Once this was established, CM samples from different 
cancer cell lines were investigated for expression o f known tumour- related mRNAs by RT- 
PCR and microarray technology was employed to investigate the global expression o f  
mRNAs with both known and unknown functions.
A slightly modified version o f this method was also applied to mRNA extracted from 
serum o f breast cancer patients and normal volunteers, enabling approx. 55,000 transcripts/ 
variants represented on the whole human genome chips to be analysed to identify mRNAs
suitable for further analysis as potential future biomarkers.
2
INTRODUCTION
1.1 Tumour Markers and Biomarkers in Cancer
Biomarkcrs, defined as biochemical features that may be used to measure the progression 
o f disease or the effects o f treatment, have great potential for cancer detection and 
monitoring. The term tumour marker is applied to all substances produced and released 
either by tumour cells or by host cells and whose presence may be detected in the serum or 
other biological fluids, behaving as an indicator o f the presence o f the tumour, but not all 
tumour markers are suitable biomarkers.
There are three types o f biomarkers, diagnostic, prognostic and predictive. A diagnostic 
marker is able to accurately diagnose disease i.e. presence o f a diagnostic biomarker should 
identify with a disease-state. A prognostic marker should be able to distinguish (once a 
disease state has been diagnosed), the likely outcome associated with the presence/ quantity 
o f the marker irrespective o f therapy. Candidates for prognostic markers include EGFR and 
node status. The concentration o f or presence/ absence o f a biomarker in response to 
therapy is a predictive biomarker. It should accurately predict a patients response to therapy 
e.g. HER2/neu.
The ideal tumour biomarker marker should have both a high sensitivity and a high 
specificity so that cancer patients can be effectively distinguished from healthy subjects or 
patients with non- cancerous concentrations. Effective biomarkers can serve as molecular 
signposts o f the physiological state o f a cell, which is essential for treatment decisions. 
Examples o f prognostic markers include hormone receptors, proliferation markers, 
proteases, markers o f angiogcnesis etc.
Predictive markers can help make decisions between different alternative treatments, e.g. 
breast cancer patients that have estrogen receptor positive tumours arc usually treated with 
anti-estrogcn compounds whereas estrogen receptor negative tumour patients are treated 
with chemotherapy.
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Traditionally cancer diagnosis is based on microscopical assessments o f morphologic 
alterations o f cell and tissues. In many cases, there is a clear distinction between benign and 
malignant cells/ tissues.
The TNM staging system circulated by the American Joint Committee on Cancer (AJCC) 
focuses on the anatomical extent o f the disease, which is assessed by combining tumour 
size/ depth (T), lymph node spread (N), and presence or absence o f metastasis (M). Its 
function is to provide clinicians with the ability for prediction o f survival, choice o f initial 
treatment, stratification o f patients in clinical trials, accurate communication among 
healthcare providers resulting in uniform reporting o f outcomes (Ludwig and Weinstein 
2005).
Far more common though is the situation whereby the diagnosis may be ambiguous and 
determination o f prognosis is difficult (Alaiya e t a l  2005). There is a need to find more 
ways to classify cancer using tumour markers/ biomarkers because individual molecular 
markers and patterns o f markers are successfully subdividing traditional tumour classes into 
subsets that behave differently from each other. Also chemotherapeutic and biological 
agents arc more widely used now and more effective than when TNM staging was 
introduced. And lastly, emerging now is the fact that many target agents are effective only 
if  their respective molecular markers arc mutated or expressed at sufficient levels. A good 
example o f this in breast cancer is discovering the oestrogen receptor (ER) and Wccllneit 
status. Independently o f TNM staging ER positive status improves prognosis and directs 
clinicians to use hormone targeting agents like tamoxifen. Originally Her2Jneu positivity 
was considered as a negative prognostic indicator independent o f TNM stage until the 
arrival o f Herceptin (Ludwig and Weinstei, 2005).
Many advances have been made in the understanding o f malignant disease but reliable
prognostic and treatment predictive biomarkers have yet to be found for many cancers.
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Scrum tumour markers can be detected based on the levels o f tumour specific proteins/ 
nucleic acids in scrum by identification techniques such as ELISA (protein) and PCR 
(nucleic acids). Tissue tumour markers are identified by techniques such as 
immunohistochemistry (IHC) for detection o f protein over expression or fluorescent-in- 
situ-hybridisation (FISH) for detection o f gene amplification. Some o f the more common 
scrum protein markers and tissue markers used for the identification/ classification o f  
cancer are detailed.
1.2.1 a-Fetoprotein
a-Fetoprotein (AFP), as a serum protein marker for Hepatocellular carcinoma (HCC), was 
found to have a sensitivity o f 39-65%, a specificity o f 76-94%, and a positive predictive 
value o f 9-50% when results from several studies from 1995 to 2002 were considered 
(Daniele et a l 2004). The higher the cut-off level for AFP detection selected, the higher the 
specificity and the lower the sensitivity.
A serum concentration o f >500^ig/L, in an area with high incidcnce o f HCC and in the 
appropriate clinical setting, is usually considered diagnostic o f HCC. HCC patients with 
high AFP levels at diagnosis tend to have greater tumour size, bi-lobar involvement, 
massive or diffuse types, and portal vein thrombosis (Tangkijvanich et a l 2000).
Even so, an increase from 10- 500pg/L is also common in non-malignant chronic liver 
disease (Poon et a l 2002) and patients with chronic viral hepatitis can also have elevated 
levels o f  AFP with no HCC (Daniele et a l  2004) so that the specificity o f the AFP test for 
HCC patients is low.
A variant o f AFP (AFP-L3), the fiicosylated variant, has a high affinity to the sugar chain 
o f Lens culinaris, and has been shown to be a more useful indicator o f distant metastasis for
1.2 Serum/ Tissue Tumour Markers
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HCC than total AFP (Johnson et a l 2000). An AFP-L3 positive tumour is an advanced 
tumour regardless o f small tumour size and lower serum AFP levels (Qin and Tang 2004). 
It has a 9-12 month lead-time in early recognition when compared to imaging techniques, 
showing a sensitivity of 56% and a specificity o f over 95% (Li, D., e t a l 2001).
Work by Johnson et a l (2000) identified a monosialyated form o f AFP (msAFP) which had 
earlier been described as allowing early, even preclinical diagnosis o f HCC in high -risk  
patients (Johnson et a l 1997). They went on to develop an assay to detect this msAFP and 
found that it had more diagnostic potential than non-diagnostic AFP i.e. serum AFP levels 
between 50- 500|ig/L (Poon et a l 2002).
1.2.2 Human chorionic gonadotropin- p (hCG)
There are four members o f the glycoprotein hormone family, the placental product hCG, 
thyroid-stimulating hormone, follicle stimulating hormone and LH, and all excluding hCG, 
are pituitary products. The hormones share a common glycoprotein hormone a-subunit 
non-covalently linked to a functionally distinct p-subunit, consequently forming four 
different intact heterodimeric hormones (Butler and lies 2003). The P-subunits are 
homologous and allow each hormone, despite performing discrete functions, to act on the 
same receptor.
It is the free P-subunit (hCGP) that is produced by epithelial tumours and is independent of 
glycoprotein hormone a-subunit gene expression (lies et a l 1990). Ectopic expression of 
hCGp by bladder carcinoma occurs in ~35% o f cases and serves as a model for such 
ectopic expression by common epithelial cancers. There is also a correlation o f hCGp 
expression by these tumours with grade, stage and prognosis (Butler and lies 2003). hCGp 
expression has also been significantly associated with failure to respond to therapy 
(Moutzouris et a l 1993).
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1.2.3 CA 125
CA 125 is produced by a variety o f cells, but particularly by ovarian cancer cells. It is an 
antigenic epitope on a high-molecular weight glycoprotein and was discovered in 1981 by 
immunising mice with ovarian cancer cells. It is expressed in coelomic epithelium during 
embryonic development and recognised by a monoclonal antibody developed against a 
human ovarian carcinoma cell line (Bast et a l 1981).
In patients with endometrial carcinoma, preoperative serum CA 125 levels correlate with 
stage, depth o f myometrial invasion, histologic grade, cervical invasion, peritoneal 
cytology, and lymph node status (Gadducci et a l 2004).
1.2.4 CEA
Carcinoembryonic antigen (CEA) was one o f the first tumour markers to be identified and 
characterised. It is a single- chain glycoprotein o f 641 amino acids with a molecular mass 
o f 180- 200kDa containing 45-55% carbohydrate. It consists o f a large family o f at least 30 
closely related cell surface glycoproteins encoded by about ten genes/ pseudogenes located 
on the long arm o f chromosome 19ql3.2. The domain structure o f CEA proteins are similar 
to the y heavy chain o f the immunoglobulin IgG indicating that it may be a part of the 
immunoglobulin super family (Seregni et a l 2004).
CEA molecules can be divided into three subgroups, the first subgroup containing seven 
expressed genes, another containing 11 expressed pregnancy -specific glycoproteins (PSG) 
and a third containing six pseudogenes (Aquino et a l 2004).
CEA, as a tumour-associated antigen, is expressed in over 95% o f colorectal, gastric and 
pancreatic carcinomas. In addition to this it is also expressed in approximately 70% of non­
small cell lung cancer, 50% o f breast cancer, in mucinous ovarian carcinoma, 
adenocarcinoma of the penis and endometrial adenocarcinoma (Aquino et a l 2004).
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Serum CEA is elevated in 30-50% of patients with symptomatic metastatic breast cancer, 
and a positive correlation has been shown between changes in serum CEA and therapeutic 
response in patients with metastatic breast cancer (Cheung e t a l 2000).
An early study by Thompson et a l (1969) described the elevation o f CEA in serum of 
almost all patients with colorectal cancer and rarely in healthy subjects was promising but 
subsequent studies conflicted with these findings. For example Fletcher (1986) concluded 
that using a cut-off point o f 2.5^ig/l, the sensitivity o f CEA for early colorectal cancer was 
only 30-40% resulting in a 250 false positive tests for every patient with cancer. Also 
possibly more important, 60% o f the cancers would remain undetected.
CEA can also be elevated in many benign disorders. As CEA is metabolised by the liver, 
any benign liver disease that would impair liver function preventing clearance o f CEA, 
would consequently result in an increased serum levels (Duffy 2001). Studies o f serum 
CEA levels in male and female smokers and non- smoker groups has also shown that 
smoking can almost double the serum levels o f CEA (Wilson et a l 1999).
Cell associated CEA has been used as a tumour marker to trace circulating cancer cells for 
prediction of recurrence (Lopez-Guerrero et a l 1999) or detection o f micrometastasis in 
lymph nodes and bone marrow (Liefers et a l 1998, Weitz e t a l  1999). CEA has been used 
to target anticancer agents by coupling to tumour-selective anti-CEA monoclonal 
antibodies (mAbs) (Greiner et al 1987) and in immunotherapy, by production o f 
recombinant vaccines able to elicit MHC- restricted immune responses against 
immunogenic CEA-derived peptides (Foon et a l 1997).
1.2.5 Cytokeratins
Cytokeratins are one o f seven classes o f intermediate filaments that, together with 
microtubules and actin microfilaments, make up the cytoskeleton o f most eukaryotic cells.
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Different epithelial cells express characteristic, differentiation- dependent combinations o f 
two or more cytokeratins indicating tissue- specific expression (Sergni et a l 2004). 
Epithelial cells express between two and ten cytokeratin isotypes. Studies have shown that 
cytokeratin 19 (CK19) plays an important role in the regulation o f cell migration and 
invasion (Uenishi et a l 2003a), and can predict early postoperative recurrence o f HCC 
(Uenishi et a l 2003b).
Cytokeratins also exist in soluble form and can be detected serum using monoclonal 
antibodies. Serum CK19 fragments can be detected using an enzyme- immunoassay called 
CYFRA 21-1. Pre-operative serum CYFRA21-1 levels in patients with ovarian carcinoma 
correlated with carcinoma status and tumour stage. Also pathologic complete response rate 
was significantly greater in patients with low pre operative CYFRA21-1 (Gadducci et a l
2004).
The expression o f cytokeratins 8, 18, 19 and 20, at the protein or mRNA level, have been 
evaluated for use as bladder cancer markers. Cytokeratin 20 (CK20) had a sensitivity o f 78- 
87% but a low specificity o f 55-63% and cytokeratin 19 showed a sensitivity o f 75-97% 
with a specificity o f 67-71%. Cytokeratin markers have high false positive rates among 
individuals with a wide range o f clinical disorders which questions their clinical utility 
(Lokeshwar et a l 2005).
Attallah et al (2006), using an office-based dot-enzyme immunobinding assay (dot-EIA), 
evaluated Cytokeratin 10 (CK-10). CK-10 was shown to have a high sensitivity (97%) and 
specificity (94%) in detecting CK-10 from the urine o f 192 bladder cancer patients and 72 
normal controls. Attallah et a l  (2006) found that CK-10 could not be detected in patients 
showing response to radiotherapy.
Gacci et a l (2006) used a Urinary Bladder Cancer (UBC) test on the urine o f 36 bladder
cancer patients. The urine samples were taken pre and at four time-points post transurethral
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resection. The UBC test tests for urinary fragments o f cytokeratin 8 and 18. They found a 
correlation between the postoperative modifications o f UBC levels and the risk o f tumour 
recurrence during the first year o f follow-up.
The importance o f carrying out immunohistochemical analysis o f CK1, CK7 and CK14 
was found by Coletta et a l (2006) to be very useful in distinguishing basaloid squamous 
carcinoma (BSC). Basaloid squamous carcinoma is a relatively rare and aggressive variant 
o f squamous cell carcinoma. Correct diagnosis o f this tumour as the treatment and 
prognosis o f BSC are different to other neoplasms e.g. adcnosquamous carcinoma or small 
cell undifferentiated carcinoma. Analysis o f combinations o f cytokeratin expression has 
also been found useful in diagnosing specific cancer types from each other. Combined 
immunohistochemistry analysis o f beta-catenin, CK7 and CK20 was found by Ikeda et a l  
(2006) to aid in the discrimination o f primary lung adenocarcinoma from metastatic 
colorectal.
1.2.6 EGF receptor family
The EGF receptor family has four members, EGFRI (HERI), ErbB2 (HER2), HER3 and 
HER4. The members o f the family can form four homodimers and six heterodimers to give 
a total o f 10 distinct states. Receptor dimerisation, protein kinase activation, trans- 
autophosphorylation and initiation o f signalling cascades results from the binding o f  
ligands to the ectodomain (Schelessinger 2000). The four members have the potential to 
stimulate the Raf-MEK-ERK protein kinase cascade (Serrano- Oliver et a l 2006).
The EGF family o f ligands are expressed in the extracellular domain o f transmembranc 
proteins and are generated by regulated proteolysis to yield growth factors that contain 49- 
85 amino acids. These growth factors have different specificities for the receptor family 
members and also the transforming potential and signalling pathways activated by different
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dimmers are distinctive. Examples include the high affinity for ErbB 1 that both epidermal 
growth factor (EGF) and transforming growth factor a  (TGFa) have, and the fact that 
ErbBl-ErbB2 heterodimers are associated with a more robust signal than ErbB 1-ErbB 1 
homodimers (Serrano-Olivera et a l 2006).
1.2.6.1 Epidermal growth factor receptor
Epidermal growth factor receptor (EGFR) is a cell membrane tyrosine kinase receptor that 
belongs to the ErbB family. When it is activated by its natural ligands it initiates a complex 
intracellular signal transduction cascade that promotes cancer cell division and migration, 
angiogenesis, and apoptosis inhibition (Galizia et a l  2006).
Galizia et a l  (2006) studied the expression o f EGFR using immunohistochemistry (IHC) on 
tumour tissues for 149 colon cancer patients in relation to other molecular markers, p27, 
p53, and vascular endothelial growth factor (VEGF). The prognostic role o f EGFR 
expression in 126 colon cancer patients that were undergoing potentially curative surgery 
was also examined. They found EGFR expression in 36% of tumour samples and it did not 
correlate with tumour grade, growth pattern and microsatellite status but did correlate with 
Dukes' stages. In patients with early-stage colon cancers (classified as Dukes’ A and B), 
that were not treated with adjuvant chemotherapy, and were positive for EGFR, showed a 
reduction o f nearly 50% in 5 year surv ival probability compared to EGFR negative patients. 
In Dukes’ C and D stages, the five year survival rate o f EGFR positive tumours was cut to 
20.3%. The study suggests a potential for treating colorectal cancer with anti- EGFR 
targeted therapies although the authors noted that previous studies looking at the expression 
of EGFR have shown great variability.
As the human epidermal growth factor receptor 2 (HER2) is known to heterodimerisc 
preferentially with the EGFR, Emlct et a l (2006) sought to investigate whether HER2 had a
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role as a predictive marker for responsiveness to EGFR targeted therapies as tumour EGFR 
expression was previously found not to be useful as a predictive marker o f clinical response 
to EGFR- targeted therapies. They tested EGFR, HER2 and HER3 markers. HER2 
overexpression was found to be the best single predictive marker, but combinations o f two 
markers provided additional predictive information.
1.2.6.2 HER2/NEU
Human epidermal growth factor receptor 2 (HER2) is an 185kDa glycoprotein normally 
expressed in the epithelia o f numerous organs for example lungs, bladder pancreas, breast 
and prostate. HER2 is a member o f the epidermal growth factor receptor (EGFR) family, 
which is comprised o f 4 family members. The HER2//ieu receptor has three domains: an 
intracellular tyrosine kinase portion, a hydrophobic transmembrane domain, and an 
extracellular domain (ECD), which is the ligand-binding portion o f the receptor. The ECD 
undergoes proteolytic cleavage from the full-length protein by metalloproteases, and is shed 
into the blood as a circulating antigen (Codony-Servat et a l 1999). This serum HER2/«ew is 
a glycoprotein o f 97 to 115kDa and is also known as p i05 (Luftner et a l  2003). Proteolytic 
cleavage o f the ECD represents a ligand-independent activation mechanism, which leads to 
HER2¡neu phosphorylation and active HER2/neu  signalling (Kostler et a l 2004). 
Immunohistochcmistry can be used to detect the degree o f HER2/neu  protein over 
expression in paraffin-embedded tissue samples using mono- or polyclonal antibodies. 
These antibodies bind to the HER-2neu  expressed on the cell membranes. Loss o f antigenic 
determinants during the tissue fixation process can compromise the results.
As mentioned earlier, the ECD of HER2 /neu  can be proteolytically cleaved and this 
105kDa molecule shed into serum. Circulating HER2 ectodomain can be detected in about 
80% of patients with tumours over expressing HER2/new compared to 3% o f tumours not
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over expressing the oncoprotein (Seregni et al 2004). A negative prognostic effect o f high 
serum levels o f H EK U neu  seems to be related to resistance to chemotherapy (Pegram et a l 
1998, Mehta et a l 1998).
Elevated serum HER2/new levels in breast cancer patients following primary surgery or 
immediately after the completion o f adjuvant chemotherapy provide prognostic 
information. Retrospective studies have shown that patients with elevated levels detectable 
in scrum may benefit from specific anti-HER2/new- target treatment options early in the 
course o f their disease (Luftner et a l 2003).
Kostler et a l (2004) found that patients with elev ated serum ECD levels were more likely to 
respond to Hcrceptin- based treatment. Herceptin is a monoclonal antibody that targets the 
HER2/neu oncoprotein. The authors also found that changing ECD levels throughout the 
treatment could not only parallel but could precede the clinical course o f disease. This 
allowed for a significant prediction o f response, clinical benefit, and progression-free 
survival as early as after 1 and 2 weeks o f treatment, respectively.
HER2/m?w gene amplification and/ or protein over expression are detected in approximately 
25 to 30% o f primary breast cancers (Slamon e t a l 1987) and are associated with poor 
prognosis, short survival and recurrences (Seregni e t  a l 2004). Fluorescent-in situ- 
hybridisation (FISH) methods can be used to measure the HER-2/weu gene copy number 
per nucleus to identify if  there is DNA amplification.
1.2.7 Cancer cell- secreted proteins
Wu et a l (2005) examined the conditioned media o f nasopharyngeal cancer cell lines for 
proteins secreted by the cancer cells in an attempt to identify biomarkers for early 
nasopharyngeal carcinoma (NPC) diagnosis. MALDI-TOF mass spectrometry was used to 
identify sccrctcd proteins. The sccrctcd proteins dctcctcd were then assessed in NPC
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biopsies using IHC. Three proteins, fibronectin, Mac-2 binding protein (MAC-2 BP) and 
plasminogen activator inhibitor 1 (PAI-1) were found to be highly expressed in NPC 
biopsies but weakly or not expressed in normal nasopharyngeal tissue. Analysis o f serum 
levels o f the proteins in samples from 46 NPC patients and 47 healthy controls using 
ELISA identified that the three proteins were significantly higher in the NPC patients than 
the normal controls.
1.2.8 Exploitation of the immune system for cancer biomarkers
The release/ secretion o f proteins from tumours triggers a response in cancer patients. 
These tumour antigens arise from several mechanisms, including tumour-specific 
alterations in protein expression, mutation, folding, degradation, or intracellular 
localisation. Antibody immune responses show promise as clinical biomarkers because 
antibodies have long half-lives in serum, are easy to measure, and are stable in blood 
samples.
One o f the most well studied auto-antigen in cancer is the p53 protein. The half-life o f 
mutated p53 is much longer than wild type p53 (several hours compared to several 
minutes). The p53 auto antibodies are dependent on the type o f p53 mutation but the 
accumulation o f protein, rather than the mutations results in autoantibody generation 
(Anderson and LaBaer 2005). p53 auto antibodies have also been detected in heavy 
smokers prior to the diagnosis o f lung cancer (Trivers et a l 1996).
1.3 Detection of circulating tum our cells in cancer patients.
Disseminated tumour cells can be detected in blood by using RT-PCR methods to detect 
certain tumour-associated antigen gene transcripts or cell lineage-specific markers. Such 
markers however (for example cytokeratins which identify cells o f an epithelial origin), are 
not tumour specific and may be expressed by non-ncoplastic cells (Vogel and KaltofT
15
2001). Another concern is that the increasingly more sensitive RT-PCR techniques are 
capable o f detecting illegitimate transcription i.e. expression o f transcripts at such low 
levels that the antigen is not expressed and so cannot be relevant for cellular function 
(Zieglschmid et a l 2005). Although if  detection o f the transcript alone is useful as a 
biomarker, relevance to cellular function may not be important.
There are many studies assessing tumour markers by RT-PCR methods on whole blood. 
Many o f these studies make the assumption that presence or absence o f a tumour-related 
transcript in whole blood from cancer patients is indicative o f circulating cancer cells. 
Studies by Vasioukhin et a l (1994) and Kopreski et a l (1997), however, have shown that 
presence o f extracellular tumour DNA can be detected in the absence o f  circulating cancer 
cells and in patients with early disease and low tumour burden. The following is a summary 
o f some recent studies employing RT-PCR methods to detect mRNA transcripts in whole 
blood samples.
Ijichi et a l (2002) looked at the clinical significance o f using AFP mRNA as a predictive
marker o f HCC cells disseminated into the circulation and for metastatic recurrence. They
found that patients with consistent positive AFP mRNA showed the highest recurrence rate
(85%) and a trend to distant or multiple recurrences. If the patients AFP mRNA status went
from positive pre treatment to negative post-adjuvant treatment, their overall, and disease-
free, survival rates were much better than those with permanent positive AFP mRNA.
Minata et a l (2001) found that the presence o f AFP mRNA pre-operative was significantly
correlated with tumour size and presence o f  AFP mRNA post-operatively indicated
metastatic recurrence. Meta-analysis carried out by Ding et a l (2005) on several
publications regarding the expression o f  AFP mRNA one week after surgery (including the
study mentioned above by Ijichi et af), and they concluded that expression o f AFP mRNA
in peripheral blood 1 week after surgery correlated with the recurrence o f  HCC and was a
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useful predictor for tumour recurrence.
Although other reports have noted that circulating AFP mRNA was transiently detectable in 
patients with cirrhosis no predictive value was found for HCC development and recurrence 
(Gross-Goupil el al 2003).
In 2003 Schamhart el a l performed a multi-centre study to investigate methods for 
improving prostate-specific antigen (PSA) mRNA detection, by defining criteria required to 
reduce false positive results. These criteria included positive results in two or more PCR 
tests depending on the number o f  PCR cycles used. The nested PCR assay was carried out 
using either 2 x 25 PCR cycles or 2 x 35 cycles. Analysis o f the results showed that for any 
specimen that was positive after 2 x 35 cycles o f PCR, a diagnostic specificity could only 
be assigned if  the specimen was positive in three or more additional tests. The pre-defined 
diagnostic specificity was set at £  98% and was weighted by the best estimates o f the mean, 
\  (SD), o f the expected Poisson frequency distributions o f the number o f positive tests. The 
authors were able to show that compared to the high sensitivity test (35 x 2 PCR cycles, 
X=1.0), the less sensitive but more relevant (25 x 2 PCR cycles 0.2) test, was affected to 
a lesser extent by illegitimate PSA transcripts without a reduction in detection o f true 
positives.
Human mammaglobin mRNA (hMAM) was studied by Roncella et a l (2005) to evaluate its 
use as a molecular marker for detection o f occult breast cancer cells in peripheral blood. 
The nested RT-PCR assay detected hMAM in 156/165 (95%) o f fresh breast cancer tissues 
analysed, but in only 12% (16/ 137) o f peripheral blood specimens. They found that their 
assay was sensitive down to one tumour cell in 106normal cells. No hMAM transcripts 
were detected in either 66 healthy blood donors or 151 patients with benign breast disease. 
Although the assay proved to be very sensitive, the authors noted that the 5% of stage 1-11
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patients was lower than the expected percentage o f these patients to have circulating cancer 
cells.
Another study performed in 2006 by Mercatali e t a l  evaluated the presence o f  
mammaglobin B mRNA (homolog o f hMAM mRNA) in conjunction with maspin mRNA 
and CK-19 mRNA in peripheral blood o f 140 breast cancer patients and 27 healthy 
volunteers. Evaluation o f CK-19 mRNA was abandoned at an early stage, due to a high 
number o f false positive results. Maspin mRNA was detected in 24% o f breast cancer 
patients but also in 11% o f  healthy volunteers. Mammaglobin mRNA was detected in 7% 
o f breast cancer patients but in none o f the blood samples from healthy volunteers.
Higher levels o f  CK-19 in both bone marrow and peripheral blood has also been shown to 
be a significant predictive marker for breast cancer recurrence (Nakata et al 2000, Nogi et 
a l 2003), and for nasopharyngeal carcinoma micrometastasis (Lin et a l 2002).
In a large study performed by Soeth e t a l 2005, a correlation was found between 
cytokeratin 20 (CK 20) expression in pancreatic ductal carcinoma patients and poor 
survival. They analysed bone marrow and venous blood in 172 patients with pancreatic 
ductal carcinoma. O f 135 bone marrow samples, 45 (33.3%) were positive for CK 20 
mRNA expression and 52 o f the 154 (33.8%) blood samples were positive for CK 20 
expression. The authors also found that detection rates increased with tumour stage. The 
authors measured detection o f CK 20 mRNA and expression was determine to be indicative 
of disseminated tumour cells but they failed to address the false positive results. Whilst the 
expression o f CK 20 was found to be associated with stage of tumour progression, 11.8% 
o f bone marrow samples (8/68) and 16.7% o f blood samples (9/54) from patients with non 
malignant diseases were positive for CK 20 expression. Also 5% (1/20) blood samples 
from healthy volunteers were positive for CK 20 expression.
Koyanagi et a l (2005) developed a multi-marker quantitative real-time PCR method to
18
detect circulating melanoma cells. The multi-marker panel included MART-1, GalNAc-T, 
PAX-3 and MAGE-A3 mRNA transcripts. The study was carried out by firstly assessing 
the detection limits and imprecision o f the assays by diluting melanoma cells originating 
from melanoma cell lines expressing all four markers into peripheral blood samples from 
volunteers. This was repeated with 3 different cell lines. 1 melanoma cell could be detected 
in 10' peripheral blood leukocytes. Detection rates o f the multi-marker quantitative real­
time PCR assay were higher than any o f the individual markers alone. Detection rates were 
also significantly different depending on stage o f  disease, 15% detection o f at least one 
marker in stage I patients compared to 86% detection o f at least one marker in stage IV 
patients. The markers were not detected in healthy donor blood using the optimised assay. 
Microphtalmia transcription factor (Mitf) mRNA which is important in melanocyte 
development and melanoma growth, was assessed using real-time quantitative RT-PCR for 
expression in peripheral blood as a marker for detection o f circulating tumour cells in 
melanoma patients. Employment o f cut-off values aided in discrimination o f healthy 
samples from cancer samples. The authors found that in 90 melanoma patients tested, the 
rate o f Mitf mRNA detection was higher with increasing cancer stage. Comparisons were 
made with samples taken post bio chemotherapy (consisting o f cisplatin, dacarbazine, 
vinblastine, interleukin-2, a-IFN and granulocyte colony-stimulating factor at different 
concentrations on different days) and post surgery and Mitf mRNA detection decreased 
with treatment. Detection o f the mRNA post treatment was associated with a significantly 
lower relapse-free and overall survival.
CEA mRNA was found to correlate with depth o f tumour invasion, vessel invasion, TNM
stage and postoperative metastasis in a study by Wang et a l  2006, in which four mRNA
transcripts were evaluated for significance in predicting colorectal cancer. The other three
markers evaluated were human telomerase reverse transcriptase (hTERT), CK-19, and CK-
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20. Detection o f hTERT, CK-19, CK-20 and CEA mRNA transcripts were found in 69.4%, 
66.7%, 52.8% and 72.2% of 72 patients respectively. No hTERT or CEA mRNA 
transcripts were detected in samples from 30 healthy volunteers however; CK-19 or CK-20 
mRNA transcripts were detected in 2 o f the 30 volunteers. The authors found that only 
detection o f positive CEA mRNA correlated directly with postoperative metastases 
however only 58% of the CEA positive patients metastasised in the course o f the study.
Uen el a l (2006) evaluated MUC1 and c-Met mRNA for use as markers for detection o f  
circulating tumour cells in patients with gastric cancer by. A multiplex PCR studied was 
designed for analysis o f RNA extracted from whole blood. Detection o f c-Met or MUC1 
mRNA was significantly correlated with the depth o f  tumour invasion, lymph node 
metastasis, TNM stage, vessel invasion, peri-neural involvement and post operative 
metastasis. 5.6% and 8.3% o f blood samples from healthy donors were positive for c-Met 
and MUC1 mRNA respectively.
Stathopoulou et a l (2006) investigated whether the detection o f CK-19 in healthy 
individuals in their prior studies was due to poor primer design. New primers were 
designed for CK-19 which avoided amplification o f contaminating genomic DNA and CK- 
19 pseudogenes. Real-time RT-PCR was carried out using RNA extracted from 
mononuclear cells isolated by gradient centrifugation with Ficoll Hypaque-1077 from 222 
peripheral blood samples. Of 62 samples from healthy volunteers, none were positive for 
CK-19 in comparison to 2 positive using previous poorly designed primers with a further 
47 showing late amplification o f CK-19 negating the need to employ a cut-off level to 
distinguish cancer patients from normal patients. 20% o f  the samples from breast cancer 
patients were positive for CK-19 mRNA.
Detection o f CK-19 mRNA in the peripheral blood o f breast cancer patients was used as a
marker to assess the effective targeting o f circulating tumour cells by the anti-HER-2
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antibody, Herceptin. The authors noted that chemotherapy resistant tumour cells found in 
circulation expression o f HER-2 on the disseminated tumour cells had previously been 
found to be an independent prognostic factor associated with increased risk o f relapse and 
survival. The authors found that before Herceptin infusions, CK-19 positive cells were 
found in either the peripheral blood or bone marrow or in both samples corresponding to 
25/30 breast cancer patients. HER2 mRNA expression was found in the CK-19 positive 
samples. After infusion treatment with Herceptin, 93% o f  patients became negative by 
nested RT-PCR and 67% by real-time PCR. After a median follow-up o f 6 months the 
median duration o f CK-19 mRNA negativity was 9, 12 and 6 months for stage 1/11, III and 
IV disease respectively.
It is evident from the studies mentioned that the incidence o f mRNA transcripts being 
detected in the whole blood o f healthy volunteers is to a certain extent accepted. The re­
design o f CK-19 primers by Stathopoulou el a l (2006) indicates the possibility that other 
studies carried out showing detection o f mRNA transcripts in healthy donor blood may also 
be a reflection o f poor primer design and/ or presence o f splice variants/pseudogenes not 
yet identified.
A lot o f the studies, as mentioned earlier, state that detection o f tumour-related transcripts
was indicative o f circulating tumour cells but few studies have actually confirmed that the
mRNA detected originates from circulating tumour cells and not from extracellular mRNA
transcripts. Most o f the studies mentioned above make the assumption, rightly or wrongly,
that the presence o f tumour-related mRNAs in the serum o f cancer patients indicates the
presence o f cancer cells. Whilst this assumption may be okay to make if  the results
obtained indicated that the mRNAs were cancer-specific i.e. no detection o f the transcript
in healthy controls/ detection under a predefined threshold, many o f the studies mentioned
above suffered from positive results in the healthy controls. Whilst this is fine in a
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retrospective study, a false discovery rate o f 5% is too high for prospective studies meaning 
that for every 1000 people screened for the presence o f the tumour-related biomarker, 50 
healthy people will be falsely identified.
To confirm that transcripts found in circulating blood represent circulating tumour cells, the 
ideal method is to separate the cells found in the blood from scrum and analyse and carry 
out RT-PCR for detection o f tumour-related mRNAs on these cells and not blindly on 
whole blood samples.
Detection o f erbB2 mRNA transcripts in the plasma o f breast cancer patients was found to 
be associated with circulating tumour cells and negative estrogen and progesterone receptor 
status by Xu el a l (2006). In this study the authors separated the plasma o f the breast cancer 
patients from the mononuclear cells by Ficoll. RT-PCR was carried out for erbB2 mRNA 
on the plasma sample and detection o f hMAM transcripts in RNA extracted from the 
mononuclear cells was taken to be indicative o f circulating tumour cells mixed in with 
mononuclear cells. ErbB2 mRNA transcripts were detected in 46% o f patients with cancer 
and in 10% o f plasma taken from healthy volunteers.
Expression o f hMAM mRNA in the mononuclear cell fraction was coupled in 7/7 cases by 
erbB2 expression in the corresponding plasma sample. This study however, despite 
separation o f the mononuclear blood cells from the plasma fraction, was slightly flawed in 
that firstly the plasma samples were not re-centrifuged/ filtered to prove there were no 
tumour/ mononuclear cells still present in the plasma sample. The second flaw is that they 
did not assess both samples for the detection o f both mRNAs. This would have highlighted 
whether the positive detection o f crbB2 in the plasma o f 43% of breast cancer patients 
corresponded to positive detection o f erbB2 transcripts from the mononuclear cell fraction 
o f the blood samples and vice versa for the detection o f hMAM.
A study by Stathopoulos et a l (2005) found that detection o f CK-19 mRNA transcripts in
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cells that were separated from whole blood using Ficoll-Hypaque did not indicate relapse o f  
breast cancer patients. They found that adjuvant chemotherapy and hormone treatment 
resulted in the disappearance o f the CK.-19 positive cells in all node negative patients and in 
15/31 node positive patients. However after a 40 month follow-up, all node negative 
patients that were positive for CK-19 mRNA transcripts were relapse-free.
Traditional enrichment techniques using conventional density gradients like Ficoll result in 
a large number o f cells in the enriched fraction however consisting mainly o f blood 
mononuclear cells. In 2005, Muller et a l  tested the efficiency o f an enhanced density 
gradient system using a device called the OncoQuick density gradient system (Greiner Bio- 
One GmbH). The OncoQuick system comprises a liquid density separation medium and a 
porous barrier membrane optimised for the enrichment o f circulating tumour cells. The 
enriched cells were then cytocentrifugcd at a concentration o f 5 x l0 5 cells per 240mm: 
areas. The authors studied the slides for recovery o f MCF 7 breast cancers cells that were 
spiked into 18mls o f blood from healthy donor. Serum taken from breast cancer patients 
were also examined for the presence o f the tumour marker CA15.3 and bone marrow 
aspirations from the same patients were analysed using the OncoQuick enrichment gradient 
system. The authors found that 39.7% o f patients with metastatic disease showed 
circulating tumour cells and a positive correlation was found with the serum levels o f the 
tumour marker CA15.3. Circulating tumour cells were found more frequently in patients 
with progressive disease than in patients wnth stable disease or remission (87.5% compared 
to 43.8%) as assessed by frequent sampling o f the patients.
Other methods have also been developed to enrich blood samples for tumour cells. These 
methods include antibody based methods which are dependent on the ability o f antibodies 
to distinguish between cells o f different tissue origin. The most widely used antibodies are
those that target cytokeratins as they arc markers o f epithelial cell origin and would not
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normally be expected to be found in the blood o f healthy people. Analysis o f cytokeratin 
positive staining cells in blood samples has traditionally been carried out using 
immunocytochemistry, where the cells are fixed to glass slides and analysis is carried out. 
However the low reported sensitivities o f immunocytochemistry detection o f disseminated 
tumour cells at approximately one cell in every 10* or 106 mononuclear cells may 
ultimately mean that circulating tumour cells are missed in these analyses because so many 
slides have to be screened in order to detect circulating tumour cells (Muller et a l 2005).
In a study by Pachmann et a l (2005), non-specific staining o f fixed cells using anti- 
epithelial cell specific adhesion molecule (anti-EpCAM) was overcome by using a live cell 
analysis system called MAINTRAC®. This method enables the relocation o f  cell for visual 
examination and quantification, and for taking fluoromicrographs. They found that they 
were able to monitor the response o f the whole tumour in breast cancer patients to adjuvant 
therapy by using the MAINTRAC® system to analyse the response o f circulating epithelial 
cells. A reduction in the number o f epithelial cells in circulation accurately predicted final 
tumour reduction at surgery.
In 2004, Demel et a l  reported a new sensitive and specific immuno-molecular assay for the
detection o f malignant cells in the peripheral blood o f patients with solid tumours. With
their combined antibody-RT-PCR technique they were able to detect 2 tumour cells in 5mls
o f blood. This was carried out by firstly enriching 5 mis o f blood, from healthy donors that
had been spiked with 2 breast cancer cells, by using 100^1 o f an antibody cocktail fixed on
immunomagnetic beads. This antibody cocktail included 3 different monoclonal antibodies,
ber-ep 4 (an epithelial membrane marker), Mucl (a mucking marker) and GP1.4 (a
glycoprotein marker). After incubation with the antibodies (positive immunomagnetic
separation), and washing o f cells, the cells were lysed and mRNA recovered by a magnetic
separation. Subsequent multi-plex PCR was carried out on the reverse transcribed cDNA
24
for 4 tumour markers, Ga 733.2, Ca 15.3, Her 2 and Claudin 7. All four markers were 
amplifiable by PCR in the “spiked” blood samples and negative in blood samples where no 
breast cancer cells were added. This test is commercially available as AdnaTest 
BreastCancerDetect (AdnaGen) and all reagents e.g. magnetic beads and pre-mixed primer/ 
PCR constituents are provided.
Zieglschmid et a l (2005) reported a similar success with the use o f multiple monoclonal 
antibody enrichment for tumour cells. The cells were enriched by using combinations o f 
monoclonal antibodies coupled to Dynabeads® to target the tumour cells; MOC31, 8B6 
and Ber-EP4 (for the enrichment o f testicular cancer cells) and MOC31 and Ber-EP4 (for 
the enrichment o f colorectal cancer). Detection o f testicular and colorectal cancer cells 
spiked into normal healthy blood was possible by using multiplex PCR. The PCR primers 
contained different amounts o f primer pairs depending on the cancer cells under 
investigation. The authors reported a synergistic effect with enrichment using a 
combination o f antibodies over enrichment using single antibodies.
Guo et a l (2005) used an immunomagnetic assay to enrich peripheral blood specimens from 
colorectal cancer patients for tumour cells. The expression o f CK-20 was evaluated in the 
enriched cell samples. CK-20 mRNA expression was found to correlate with tumour 
diameter, lymphatic metastasis and hepatic metastasis.
Zigcuner et a l (2003) tested methods to positively select epithelial cells with the anti 
epithelial antibody BER-EP4 and deplete mononuclear cells with an anti-leukocyte 
antibody CD45 in order to detect tumour cells that had been added to whole blood 
specimens. The authors found that enriching for tumour cells using either positive or 
negative selection detected tumour cells at a rate significantly higher than compared to 
unenriched cell populations by immunocytochemistry. The tumour cell recovery was 43.5%
for positive selection and 32.6% for negative selection.
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Ulmer et aJ (2004) immunomagnetically isolated circulating melanoma cells using a murine 
monoclonal antibody targeted to the melanoma-associated chondroitin sulphate 
proteoglycan in blood specimens taken from 164 melanoma patients and 50 volunteers 
without malignant disease. In addition to this single-cell comparative genomic 
hybridisation (SCOMP) was carried out on 15 individual cells isolated from 7 patients to 
define their chromosomal aberrations, and so prove their malignant origin. The authors 
found that detection o f two or more cells correlated significantly with a reduced survival o f 
patients with metastatic melanoma. All cells analysed by SCOMP displayed multiple 
chromosomal changes and carried aberrations typical for melanoma.
A negative immunomagnetic assay was utilised by Wiedswang et a l  (2006) to enrich 
peripheral blood samples for the presence o f circulating tumour cells resulting in increased 
sensitivity. The negative immunomagnetic assay is carried out by incubating peripheral 
blood mononuclear cells (isolated by Ficoll density centrifugation) with anti-CD45 
conjugated M450 Dynabeads and placing into a neodymium magnetic particle concentrator. 
Cells were then collected and cytospins were prepared. O f 34 patients that were found to be 
positive for circulating cancer cells, 9 relapsed (7 o f whom systematically relapsed) with 
death resulting from breast cancer occurring in 6 o f  those patients. However the authors 
found that detection o f patients at risk for relapse was superior using immunocytochcmistry 
for detection o f tumour cells in the bone marrow.
1.4 Cell-free Nucleic Acids in Serum/ Plasma
Mandel and M&ais reported the finding o f extracellular nucleic acids in plasma in 1948. 
DNA and RNA were observed in the plasma o f healthy and sick individuals although the 
significance was not recognised at the time.
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1.4.1 Serum / Plasma DNA
1.4.1.1 C ancer T esting
Studies in more recent years showed that the concentration o f circulating DNA in patients 
with metastatic disease was higher, a level at which for some patients decreased with 
successful anticancer therapy (Leon et aI 1977). It has since been proven that tumour cells 
can release DNA into circulation. Two reports in 1994 demonstrated the presence o f 
tumour-derived oncogene mutations in the plasma o f patients with pancreatic cancer, 
myelodysplastic syndrome or acute myeologenous leukaemia (Sorenson et a l 1994, 
Vasioukhin et a l 1994). In 1996, two groups reported the presence o f tumour- associated 
microsatellite alterations in the plasma and scrum o f cancer patients, suggesting that, in 
these cases most o f the plasma/ serum DNA is tumour-derived (Chen et a l 1996, Nawroz et 
a l 1996).
Studies carried out using serum DNA from cancer patients can be grouped as follows (1) 
Quantification o f total DNA, (2) Quantification o f gene expression (qPCR), (3) Detection 
o f microsatellite alterations including loss o f heterozygosity (LOH), (4) Detection o f 
mutations in specific genes and (5) Detection o f aberrantly methylated gene promoter 
regions.
The case number studied in the literature varies greatly (6- 100) along with the control 
group number (0- 100). At the moment there is only one study in which the control group 
have been age, sex and smoker matched (lung cancer study- Sozzi et a l 2003).
1.4.1.1.1 Q uantifica tion  o f  to ta l D N A
Sozzi et a l carried out two studies based on quantifying the total amount o f DNA in the 
plasma o f lung cancer patients. In the first paper published in 2001, 81 patients with
NSCLC were studied during follow-up to see if their mean plasma DNA concentrations
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were higher than in the 38 controls. They found that in 35 clinically relapse-free individuals 
their mean plasma DNA levels were significantly lower than those recorded at time o f  
surgery (~345ng/ ml before surgery to ~34ng/ml). Four patients that showed a 2-20 fold 
increase in the amount o f plasma DNA during follow-up went on to present with liver 
métastasés (2), recurrence o f carcinoma ( 1 ) or new primary tumour o f the liver ( 1 ).
A study carried out by Gal et a l  (2004), showed that the level o f serum DNA in different 
groups o f breast cancer patients was significantly higher than healthy controls. 96 primary 
breast cancer patients showed a mean serum DNA concentration o f 221ng/ml compared to 
63ng/ml from the 24 healthy controls. The serum DNA levels were elevated independently 
of the size o f primary tumour or lymph node métastases.
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1.4.1.1.2 Q uantifica tion  o f  g en e  expression
Quantification o f MYCN DNA in serum/ plasma was found by Combaret el a l (2002) to 
help identify disease progression in neuroblastoma patients during follow- up after 
chemotherapy. They found that the levels o f circulating MYCN DNA were comparable at 
diagnosis and relapse.
A second study by Sozzi et a l in 2003 relied on the quantification o f the human telomerasc 
reverse transcriptasc gene (hTERT). 100 NSCLC were studied and included 100 controls. 
The amount o f plasma DNA corresponding to the hTERT gene was quantified using real­
time quantitative polymerase chain reaction (QPCR). They found that the amount o f  
hTERT plasma DNA in the cancer patients was almost eight times the value detected in 
controls (24.3ng/ml compared to 3.1ng/ml).
1.4.1.1.3 D etection o f  m icrosatellite alterations in c lud ing  L O li
Narow et a l and Chen et a l first reported the presence o f microsatellite DNA in serum in
1996. Narow et a l studied the DNA from scrum and corresponding lymphocytes and
tumours o f patients with head and neck cancers. They were then scored for alterations,
either presence o f new alleles or LOH at each o f 12 markers. Six out o f 21 patients (29%)
had one or more microsatellite alteration, which matched the primary tumours. Chen et a l
looked at the plasma o f SCLC patients. They found that microsatellite alterations were
present in 16/21 (76%) tumours and in 15/21 (71%) corresponding plasma samples. Thirty
o f 49 (61%) o f NSCLC patient plasma studied by Sozzi et a l (1999) showed a change in
plasma DNA that correlated to the corresponding tumour. The plasma DNA abnormalities
were detectable in approximately 44% o f either stage I cases or those with tumours up to
2cm in diameter showing that this type o f study is applicable to early and late cancers.
Microsatellite alterations and LOH studies have been carried out on tumours o f various
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cancers. Panels o f markers have been studied depending on the cancer type. One o f the 
most common microsatellite alterations studied in the serum/ plasma o f lung cancer patients 
is the fragile histidine triad (FHIT). FHIT is a tumour suppressor gene that is often has a 
high rate o f LOH in lung cancer patients especially in smokers (Sozzi et al 1999). A lot o f 
the analyses published since follow a similar trend (Bruhn et a l 2000, Sozzi e t a l  2001, 
Chang et a! 2002. Beau-Faller et a l 2003, and Adriani et a l 2004). The repeated studies 
suggest that the more microsatellite alterations and LOH that are found in the plasma/ 
serum DNA of cancer patients after surgery/ chemotherapy the poorer the prognosis.
1.4.1.1.4  D etection o f  m  u ta t ions in  specific  genes
Two o f the most widely studied mutated genes detectable in the serum o f cancer patients 
are the TP53 gene and the K-ras oncogene. Most o f the studies involving detection o f TP53 
gene mutations in the plasma/ serum o f a number o f cancers look at its detection in 
combination to microsatellite alterations and LOH. Gonzalez et a l (2000) found that 71% of  
lung cancer patients studied had either TP53 mutations or microsatellite modifications. 
Gocke et a l (2000) found it was possible to detect p53 mutations in the plasma o f colorectal 
cancers. Silva et a l (2002) looked at the microsatellite alterations and TP53 mutations in the 
plasma o f breast cancer patients to see if presence o f the tumour-related DNA was a 
predictive factor relating to recurrence and disease-free survival. They found that 61/142 
(42.9%) patients showed molecular alterations in their plasma DNA. During follow-up they 
found that 17/23 (74%) o f patients that recurred showed presence o f tumour-related DNA 
persistent in their plasma. Adriani et a l (2004) used a panel o f genetic markers to study to 
plasma DNA of lung cancer patients. They found that at least 1 o f the three genetic markers 
studied (p53 mutation, FHIT and 3p LOH) was identified in the plasma o f 51.6% o f all 
patients and 60.7% o f stage I patients.
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Kopreski et a l reported in 1997 that they could detect mutant K-ras in the plasma/ serum of  
12/31 (39%) o f colorectal patients and in none o f 28 control samples. A later study again by 
Kopreski et a! (2000) was carried out on the plasma o f 232 colorectal cancer patients and 
that K-ras mutations were detectable in 28% o f these patients. Out o f the patients that had 
tissue available (135) K-ras mutations were found in 35 (26%) o f these patients with 29 
(83%) o f the correlating plasma samples positive also for the mutation. Detection o f K-ras 
mutation in scrum post curative resection surgery has also been shown to correlate with 
disease recurrence (Ryan et a l 2003).
1.4.1.1.5 Detection o f  aberrantly  m ethyla ted  DIVA
Promoter methylation studies o f plasma/ serum DNA have been used to quantify the 
mcthylation status o f a number o f oncogenes. Esteller et a l (1999) probed for detection o f  
aberrant mcthylation status o f tumour suppressor genes in serum DNA o f NSCLC patients. 
The authors looked at the methylation status o f genes that were found to be commonly 
hypermethylated in tumours o f NSCLC patients. The methylation status o f  p i6, DAP 
kinase, GSTP1 and MGMT promoters were studied in 22 NSCLC patients using primary 
tumours and paired normal tissue and serum specimens. Of the 15 primary tumours that 
showed aberrant methylation o f at least one o f the promoters studied, 11 also had abnormal 
methylated DNA in the matched serum specimens with no false positives. The detection 
rate in plasma/ serum of -50%  o f methylated promoter DNA (corresponding to the tumour) 
was also noted by Usadel et a l 2002. They found that out o f 95 lung cancer patients that 
had detectable methylation o f the Adenomatous Polyposis Coli (APC) promoter, 42 also 
had methylated APC DNA in their serum/ plasma.
Aberrant methylation o f the p l6  gene has been detected in the plasma/ serum o f  a wide 
variety o f cancers: Liver (Wong et a l 1999), NSCLC (Esteller et a l 1999), Head and Neck
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(Sanchez- Cespedes et a l  2000, Wong e t a l 2003), Esophageal SCC (Hibi e t a l 2001), 
Glioblastoma (Ramirez et a l 2003), Colorectal (Nakayama et a l 2003) and Nasopharyngeal 
(Wong et a l 2004). The occurrence o f promoter methylation o f this gene in plasma/ serum 
specimens varied from 23- 66% in the different cancer groups. Where no aberrant 
methylation o f the gene was found in the tumour, the plasma/ serum specimens also 
showed no methylated p 16 DNA. None o f  the healthy controls in any o f these studies 
showed aberrant methylation o f the p 16 gene. Wong et a l (2004) also found a correlation in 
the detection o f aberrant methylation post surgery and recurrence o f disease. None o f the 
patients they studied that were in remission showed evidence o f serum p l6  methylation, 
while 38% of those that recurred had detectable levels o f p 16 methylation in their plasma. 
Most o f the publications use methylation- specific PCR (MSP) to determine the 
methylation status o f gene promoters. Either the promoter sequence is methylated, 
unmethylated or both. Some o f the more recent publications report a quantitative method 
using real-time PCR (Usadel et a l 2002, Wong et a l 2003a Wong et a l 2003b, 
Widschwendter et a l 2004, and Wong et a l 2004). This new method has been shown to 
have a 10 fold greater sensitivity compared to traditional MSP methods (Usadel et a l 2002).
1.4.1.1.6 D etection o f  viral sequences
Quantitative analysis o f cell-free Epstein-Barr virus DNA in the plasma o f patients with 
nasopharyngeal carcinoma (NPC) has been found to be a useful way o f monitoring NPC 
patients. Advanced-stage patients were found to have higher plasma EBV DNA levels than 
those with early-stage disease. A month after radiotherapy was completed, plasma EBV 
DNA could not be detected in 7 o f  15 subjects but levels were still high in the remaining 8 
patients. After fiirther clinical examination all o f the seven with no detectable levels o f the 
virus had complete tumour regression while six o f the eight patients with high levels o f
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plasma EBV DNA showed tumour persistence or distant metastasis (Lo et a l 1999). 
Epstein-Barr virus (EBV) DNA has been detected in the serum o f patients with 
nasopharyngeal carcinoma (NPC). A more recent study has shown that these EBV DNA 
molecules are “naked” and not contained in virions. Also the DNA fragments were found to 
be mostly shorter than 181 bp (Chan et aI 2003). Other cancers associated with EBV have 
shown a correlation between EBV levels and disease progression (Ngan et a l 2002). 
Quantitative detection o f human papillomavirus (HPV) DNA sequences in patients’ sera 
was found to be a potential marker o f early metastatic disease in HPV-associated head and 
neck squamous cell carcinoma (HNSCC) (Capone et a l 2000). Detection o f HPV DNA in 
plasma o f  cervical cancer patients was associated with disease metastasis (Pomthanakasem 
e t a l 2001). HPV DNA detection in serum o f early-stage cervical cancer patients was found 
to be associated with poor prognosis factors such as lymphovascular invasion and deep 
stromal invasion. The serum from 112 patients with cervical cancer was probed for 
presence o f the virus, 27 o f the samples were positive (24.1%) while none o f the patients 
with carcinoma in situ or benign disease were positive (Hsu et a l 2003). Ho et a l (2005) 
found a link between the detection o f viral DNA in the blood o f cervical cancer patients 
within three months o f treatment and recurrence o f the disease, 87.5% o f positive samples 
involved distant metastasis a summary o f some o f the publications relating to serum DNA 
are listed in Table 1.4.1.1.
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M utation/ virus Reference Tum our type positive cases
Microsatcllie alterations Nawroz et al (\996) HNSCC 68/152 (45%)
Gonzalez et a l (1999) SCLC 35/87 (40%)
Taback et al tfOOl) Breast 12/56 (21%)
Sozzi et al (2001) Lung 9/33 (27%)
Silva et a! (2002) Breast 561/142 (42.9%)
Andriani et al(2004) Lung 19/40(47.5% )
Hypcrmcthylation Esteller e /a /(1 9 9 9 ) NSCLC 11/22 (50%)
Wong et o / ( l  999) Liver 13/22(59% )
Sanchez-Cespedes et al (2000) HNSCC 21/50(42% )
Lee e ta l  (2002) Gastric 45/54 (83%)
Usadel et al(2002) Lung 42/89 (47%)
Müller et al (2003) Breast 11/62(17.7% )
Yamaguchi et al (2003) Colorectal 3/14(21% )
Wong e t a l (2004) Nasopharyngeal 29/41 (71%)
Fiegl et al (2005) Breast
K-Ras mutations Kopreski et al (2000) Colorectal 27/70 (38%)
Ryan et al (2003) Colorectal 32/78 (41%)
Camps et al (2005) NSCLC 20/60 (30%)
APC mutations Diehl e t a l (2005) Colorectal >60%
EBV DNA Mutirangura et al (1998) NPC 13/42(31%)
Lo et a l (1999) NPC 55/57 (96%)
Gallagher et a l (1999) Hodgkins 30/33 (91%)
Chan et a! (2002) NPC 155/170(91% )
T able 1.4.1.1 Sum m ary T able o f  serum / plasm a DNA cancer studies
1.4.1.2 Prenatal Diagnosis
For almost 40 years it has been known that foetal nucleated haematopoietic cells circulate 
within the maternal blood (Walknowska et a l 1969). Conventional prenatal diagnostic 
procedures like chorionic villus sampling (CVS) or amniocentesis carry a risk to the unborn 
child so the discovery o f foetal DNA amplifiable from maternal plasma and serum by Lo et 
al (1997) has given rise to the opportunity for non-invasive prenatal diagnosis and 
monitoring. Honda et a l (2002) accurately detected with 100% sensitivity, Y-chromosomal 
signals in maternal plasma using real-time PCR in samples taken from women in their fifth 
week o f pregnancy.
Prenatal diagnosis o f certain neurological disorders, foetal chromosomal aneuploidies, sex-
linked disorders and foetal rhesus D (RhD) status using foetal DNA from maternal plasma
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has been shown to be possible. Non-invasive diagnosis o f  RHD genotype is now part o f  
routine prenatal care in the United Kingdom, France, and the Netherlands (Bianchi et a l
2005).
1.4.2 Serum/ Plasma RNA
1.4.2.1 C ancer testing
In 1999, Kopreski e t a l extracted and amplified mRNA from the serum o f patients with 
malignant melanoma. They successfully detected tyrosinase mRNA in 4/6 patients samples 
with all 20 control samples remaining negative. The study also included some serum RNA 
stability tests whereby the effects o f  successive rounds o f freeze-thawing aliquots o f  serum, 
the effect o f leaving thawed scrum at 4°C and also the usefulness o f adding RNase 
inhibitors prior to freezing were assessed. Tyrosinase and c-abl mRNA were found to be 
detectable after the first round o f freeze thawing, but a notable reduction was seen by the 
second round o f freeze-thaw in at least one sample. By the third round, it was no longer 
possible to detect tyrosinase mRNA gene transcripts. The addition o f RNasin prevented the 
degradation o f RNA for one additional freeze-thaw only. With the serum specimens that 
were stored at 4°C once thawed, aliquots taken at 15 minute intervals showed it was 
possible to amplify RNA at only the 0 and 15min time samples.
Since the study reported by Kopreski et al; there have been a few studies relating to the 
extraction and amplification o f mRNA from the plasma/ serum o f cancer patients have been 
reported. Chen et a l (2000) were able to amplify telomerase RNA from the serum o f  breast 
cancer patients that had small, well-differentiated tumours without either nodal or distant 
spread. Normal somatic cells have little or no  detectable telomerase levels, while cancers 
have detectable telomerase activity in 85-100% o f cases. They detected mRNA 
corresponding to the two subunits o f human telomerase: telomerase RNA template (hTR)
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and its catalytic component, telomerase reverse transcriptase protein (hTERT). hTR was 
found in 94% o f the tumours and 28% o f the corresponding serum. hTERT was also found 
in 94% o f the tumours and in 25% of the corresponding tumours. All controls including 
two patients with benign disease had undetectable levels o f both mRNAs.
Silva et a l (2001) performed a study using the plasma o f breast cancer patients. They chose 
mammaglobin and CK-19 mRNA as their target transcripts. O f the 45 patients, 27 were 
positive for mammaglobin and 22 were positive for CK-19. In the control samples 3/25 
were positive for mammaglobin and 5/25 were positive for CK-19. The differences were 
statistically significant and presence o f both transcripts in the plasma was associated with 
tumour size and proliferative index.
5T4 mRNA, which is the transcript that relates to a trophoblast glycoprotein frequently 
overexpressed in epithelial malignancies, was found to be expressed in 2/5 breast cancer 
sera and 6/14 lung cancer sera and 3/25 control sera (Kopreski e t a l 2001).
In 2001 Fleischhacker el a l looked at the serum o f lung cancer patients and screened them 
for detection o f a number o f mRNAs including CK- 19, MAGE- 2, TTF-1, PGP9.5, 
Her2/neu and HnRNPBl. CK-19 was found to be expressed in control samples (in this case 
all controls were positive). The combination testing o f Her2/neu and HnRNPBl were found 
to be the most useful in that one or both o f these markers detected all lung tumours. TTF-1 
and MAGE-2 were negative in all serum specimens while PGP9.5 was positive in only one 
serum sample.
Plasmsa P-catenin mRNA levels were measured in colorectal carcinoma and adenoma
patients by Wong et a l (2004) and compared to levels in the plasma o f healthy controls.
The gene transcript was found to have a median concentration (as determined by qPCR) to
be 8737, 1218 and 291 in the colorectal carcinoma, colorectal adenoma and healthy
subjects respectively. The plasma concentration o f p-catenin mRNA was found to be
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correlated with tumour stage. In addition to this, the concentration o f 0-catenin decreased 
significantly after tumour removal in 16/19 patients.
In 2005, Miura et a l developed a quantitative detection method for detection o f hTERT and 
AFP mRNA in the serum o f hepatocellular carcinoma (HCC) patients. A total o f 104 
patients, were tested (64 with HCC, 20 with liver cirrhosis, and 20 with chronic hepatitis) 
were tested against 50 healthy individuals. Serum hTERT mRNA was detected at higher 
levels in patients with HCC over those with chronic liver diseases. Expression o f  hTERT 
mRNA was found to be correlated with tumour size, number, and degree o f differentiation. 
It has also been found possible to amplify virus-related RNA from the plasma o f  patients 
with virus- related cancer (Lo et a l 1999). In this study the small EBV-cncoded RNAs that 
are expressed in all NPC cases, and that are widely used for the detection o f  EBV- 
associated human tumours, were expressed in 23/26 (88.5%) plasma samples from NPC 
patients. All control samples were negative.
Wong et a l (2006) carried out the first reported microarray study on RNA extracted from 
the serum of 10 oral cancer patients and 10 normal controls. They found that a higher 
number o f probe sets were called Present in the cancer patient serum in comparison to the 
normal control serum specimens (2,623± 868 probe sets compared to 1,792± 165 probe 
sets). Five o f ten cancer-related gene transcripts were validated by qPCR on serum 
specimens to be significantly differentially expressed between the two sample groups. They 
achieved a sensitivity o f 91% and specificity o f 71% in distinguishing oral squamous cell 
carcinoma.
A lot o f the work to date regarding the testing o f blood samples o f cancer patients has 
related to detection o f circulating malignant melanoma cells, the amount o f circulating 
cancer cells has been shown to correlate with tumour burden, with lower rates seen in those
with early disease. Extracellular DNA, however, has been shown to be detectable even in
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the absence o f  circulating cancer cells (Kopreski et a l 1997). The finding that extracellular 
mRNA is detectable in cancer patients (see Table 1.4.2.1. for summary) indicates the 
potential for a more sensitive, non-invasive means o f diagnosing cancer patients at an early 
stage o f disease. However, techniques to detect both cellular and extracellular mRNA are 
quite complementary and thought should be given to the analysis o f both. Whilst analysis 
o f whole blood specimens may yield conflicting results, separate analysis o f tumour-related 
mRNA expression in circulating tumour cells and extracellular mRNA may aid in better
definition o f detection thresholds, sensitivities and specificities etc.
M arker R eference C ancer Type No. o f positive No. of No. o f
(m R N A ) patients cases controls contro ls +ve
Tyrosinase Kopreski et al Malignant 6 4 (67%) 20 0
(1999) melanoma
EBV assoc. Lo el al Nasopharyngeal 26 23(88.5%) 29 6(20.7%)
(1999)
hTR Chen et al Breast 18 5 (28%) 23 0
hTERT (2000) 16 4 (25%) 23 0
Mammaglobin Silva et al Breast 45 27 (60%) 25 3 (12%)
CK-19 (2000) 45 22 (49%) 25 5 (20%)
CK- 19 Fleischhacker Lung 18 15(83%) 12 12(100% )
HnRNP B1 et a l (2001) 18 14(78%) 12 0
HER2/ neu 18 8 (44%) 12 0
TTF-1 18 0 12 0
PGP 9.5 18 1 (5%) 12 0
MAGE -2 18 0 12 0
5T4 Kopreski et a I Lung + Breast 19- (5 breast. 2 (40%) 25 3 (12%)
(2001) 14 Lung) 6 (43%)
P-catcnin Miura et al Colorectal 58CRC 58(100% ) 43 36 (84%)
(2005) 49 CRA 49(100% )
Table 1.4.2.1 Sum m ary T able o f serum / plasm a RNA studies, C R C = colorectal
carcinom a, C R A = colorectal adenom a, +ve= positive
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1.5 AIMS OF THESIS
The aims o f this thesis were to
i. Establish if it is possible to routinely extract and amplify extracellular mRNA 
from the conditioned media o f cultured human cancer cells,
ii. Compare methods o f extracting the mRNA to find a reliable and reproducible 
method.
iii. Investigate if  any known tumour-related mRNAs are expressed and, if  so, at 
what levels.
iv. Establish if it is possible to reliably and reproducibly amplify, label and 
hybridise CM cRNA to AfTymetrix U133A Plus 2.0 array chips.
v. To compare CM obtained from various cell lines and their drug selected variants 
to find out if there are any changes in CM mRNA expression between the 
groups
vi. To study the mRNA expression profile o f breast cancer patients using 
microarray technology by extracting mRNA from serum pre and post 
lumpectomy surgery and comparing it to mRNA extracted from the matched 
tumour and normal tissue.
vii. To study the nucleotide sequence o f mRNAs detectable in serum/ CM to find 
m otifs domains that may have an effect on the stability o f the mRNA.
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►2 Materials & Methods
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2.1 WATER
U1 trapure (UHP) water was used in the preparation o f all media and solutions. This water 
was purified by a reverse osmosis system (Millipore Milli-RO 10 Plus, Elgastat UHP) to a 
standard o f 12 - 18 Mft/cm resistance.
2.1.1 DEPC treated water
All water used in RNA extractions/ RT-PCR reactions was either commercially available 
RNase- free water or, UHP water treated with Diethyl Pyrocarbonate (DEPC -Sigma 
D5758). DEPC inactivates RNases in solution at about 0.1%v/v ensuring that there were no 
endogenous RNases present in the water which would affect the experiments. lOO^ il o f 
DEPC solution was added to 100ml o f UHP. The solution was then stirred, left overnight at 
37°C to allow the DEPC inactivate RNases. The next morning the solution was autoclaved 
for 20 minutes at 121°C to inactivate the chemical.
2.2 GLASSWARE
Solutions required for cell culture and maintenance were prepared and stored in sterile glass 
bottles. Bottles (and lids) and all other glassware used for any cell-related work was 
prepared as follows: - all glassware and lids were soaked in a 2% (v/v) solution o f RBS-25 
(AGB Scientific) for at least 1 hour. Following scrubbing and several rinses in tap water, 
the bottles were then washed by machine using Neodisher detergent, an organic, phosphate- 
based acid detergent. The bottles were then rinsed twice with distilled water, once with 
ultrapure water and were sterilised by autoclaving.
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2.3 STERILISATION
Water, glassware and all thermostable solutions were sterilised by autoclaving at 121°C for 
20 minutes (min) under pressure o f lbar. Thermolabile solutions were filtered through a 
0.22|im sterile filter (Millipore, millex-gv, SLGV-025BS). Low protein-binding filters were 
used for all protein-containing solutions.
2.4 MEDIA PREPARATION
Medium was routinely prepared and sterility checked by Joe Carey. The basal media used 
during routine cell culture were prepared according to the formulations shown in Table 
2.4. L lOx media were added to sterile ultrapure water, buffered with HEPES and NaHCOs 
and adjusted to a pH o f 7.45 - 7.55 using sterile 1.5M NaOH and 1.5M HC1. The media 
were then filtered through sterile 0.22|im bell filters (Gelman, 121-58) and stored in 500ml 
sterile bottles at 4°C. Sterility checks were carried out on each 500ml bottle o f medium as 
described in Section 2.5.6.
The basal media were stored at 4°C up to their expiry dates as specified on each individual 
lOx medium container. Prior to use, 100ml aliquots o f basal media were supplemented 
according to requirements (see Table 2.4.1) and this was used as routine culture medium. 
This was stored for up to 2 weeks at 4°C, after which time, fresh culture medium was 
prepared.
COMPONENTS DMEM(Gibco, 12501-029)
Hams F12
(Gibco, 21700-109)
R P M I1640
(Gibco)
10X Medium 500ml Powder Powder
U ltrapure H20 4300ml 4700ml 4700ml
1M HEPES”Sigma , H-9136 100ml 100ml 100ml
7.5% N aH C 03BDH, 30151 45ml 45ml 45ml
Table 2.4.1 Preparation of basal media
* HEPES = N-(2-Hydroxyethy 1 ) piperazme-N'-(2-ethanesulfomc acid)
42
All ccll culture work was carried out in a class II down-flow re-circulating laminar flow 
cabinet (Nuairc Biological Cabinet). Strict aseptic techniques were adhered to at all times. 
The laminar flow cabinet was swabbed with 70% industrial methylated spirits (IMS) before 
and after use, as were all items used in the cabinet. Each cell line was assigned specific 
media and waste bottles. Only one cell line was worked with at a time in the cabinet, which 
was allowed to clear for 15min between different cell lines. The cabinet itself was cleaned 
each week with industrial detergents (alternating between Virkon, Antec. International and 
TEGO, TH. Goldschmidt Ltd.), as were the incubators. The cell lines used during the 
course o f this study, their sources and their basal media requirements are listed in Table 
2.5.1. Cell Lines were maintained in 25cm2 flasks (Costar; 3050), 75cm2 (Costar; 3075) or 
175cm‘ flasks (Coming, 431079) at 37°C (with 5% CO2 if required) and fed every two to 
three days.
2.5 CELL LINES
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Cell line Basal m edium  (Plus additives) ^ C elH y p e Source
DLK P ATCC (HAMS FI2  + DMEM) (5%FCS) Human poorly-differentiated lung carcinoma
Dr Geraldine Grant, 
NCTCC
R PM I 2 650  M l (RPMI TAX) MEM (5%FCS. 2mM L-glut,1% Sodium Pyruvate, 1% NEAA. 5% CO;)
Nasal septum carcinoma, 
melphalan selected variant Dr Yizheng Liang, NICB
RPM1 2 6 5 0  T A X  (RPMI TAX) MEM (5%FCS, 2mM L-glut. 1% Sodium Pyruvate. 1% NEAA, 5% CO; )
Nasal septum carcinoma, taxol 
selected variant Dr Yizheng Liang, NICB
M CF-7 MEM (5%FCS. 2mM L-glut. 1% Sodium Pyruvate. 5% COj ) Breast carcinoma ATCC
M D A -F
(M DA-M B-435S-F)
RPMI 1640
(10%FCS. 2mM L-glut. 5% CO; )
Melanoma (formerly described as 
breast ductal carcinoma) Dr Sharon Glynn, NICB
M D A -F-A D R -SI
(M DA-MR-435-F/ADR-IOplOp SI)
RPMI 1640
(10%FCS. 2mM L-glut,5% CO; )
Melanoma (formerly described as 
breast ductal carcinoma) 
adriamycin selected variant
Dr Sharon Glynn, NICB
M D A -F-T A X -SI
(\1DA-M B-435-F/T«xol-10p4p SI) RPMI 1 6 4 0  (10%FCS. 2mM L-glut.5% CO; )
Melanoma (formerly described as 
breast ductal carcinoma) taxol 
selected variant
Dr Sharon Glynn, NICB
BT474 DMEM (10%FCS. 1% Sodium Pyruvate) Breast ductal carcinoma ATCC
NCI H I 299 (H i299) RPMI 1 6 4 0  (5% FCS 1% Sodium Pyruvate) Large cell lung carcinoma cell line ATCC
NCI I I 1299 T A X  (H 1299 TAX) RPMI 1640 (5% FCS 1% Sodium Pyruvate) Large cell lung carcinoma cell line, taxol selected variant. Dr Laura Breen, NICB
H M E C -1001-10 (HM EC) MEGM Bullet kit Breast mammary cells Biowhittaker
T able 2.5.1 Cell lines used during the course o f this study
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2.5.1 Subculture of Adherent Lines
During routine sub-culturing or harvesting of adherent lines, cells were removed from their 
flasks by enzymatic detachment.
To achieve this, waste medium was removed from the flasks and flasks were rinsed with a 
pre-warmed (37°C) trypsin/EDTA (TV) solution (0.25% trypsin (Gibco, 25090-028), 
0.01% EDTA (Sigma, EDS) solution in PBS (Oxoid, BR14a)). The purpose of this was to 
remove any naturally occurring trypsin inhibitor which may be present in residual serum. 
Fresh TV was then placed on the cells (2.5ml/75cm: flask) and the flasks incubated at 37°C 
until the cells were seen to have detached. The trypsin was deactivated by addition of an 
equal volume of growth medium (i.e. containing serum). The entire solution was 
transferred to a 30ml sterile universal tube (Sterilin; 128a) and centrifuged at 900 rpm for 5 
min. The resulting cell pellet was resuspended in pre-warmed (37°C) fresh growth medium; 
cells were counted (Section 2.5.2) and used to re-seed a flask at the required cell density or 
to set up an assay.
2.5.2 Cell Counting
Cell counting and viability determinations were carried out using a trypan blue (Gibco, 
15250-012) dye exclusion technique.
An aliquot of trypan blue was added to a sample from a single cell suspension in a ratio of 
1:5. After 3 min incubation at room temperature, a sample of this mixture was applied to 
the chamber of a haemocytometer over which a glass coverslip had been placed. Cells in 
the 16 squares of the four outer comer grids of the chamber were counted microscopically, 
an average count per comer grid was calculated with the dilution factor being taken into 
account, and final cell numbers were multiplied by 104 to determine the number of cells per 
ml. The volume occupied by the chamber is 0.1cm x 0.1cm x 0.01cm i.e. 0.0001cm3.
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Therefore cell number x 104 is equivalent to cells per ml. Non-viable cells were those that 
stained blue while viable cells excluded the trypan blue dye and appeared unstained.
2.5.3 Cell Freezing
To allow long-term storage of cell stocks, cells were frozen and cryo-preserved in liquid 
nitrogen at temperatures below -180°C. Once frozen properly, such stocks should last 
indefinitely.
Cells to be frozen were harvested in the log phase of growth (i.e. actively growing and 
approximately 50 - 70% confluent) and counted as described in Sections 2.5.2. Pelleted 
cells were re-suspended in serum. An equal volume of a DMSO/serum (1:9, v/v) was 
slowly added drop wise to the cell suspension to give a final concentration of at least 5xl06 
cells/ml. The careful performance of this step was very important, as DMSO is toxic to 
cells. When added slowly, the cells had a period of time to adapt to the presence of the 
DMSO, otherwise cells may have lysed. The suspension was then aliquoted into labelled 
cryovials (Greiner, 122 278) which were then quickly placed in the vapour phase of a liquid 
nitrogen container (approximately -80°C). After 2.5 to 3.5 hours, the cryovials were 
lowered down into the liquid nitrogen, where they were stored until required.
2.5.4 Cell Thawing
Prior to the removal of a cryovial from the liquid nitrogen stores for thawing, a sterile 
universal tube containing growth medium (5ml) was prepared and placed at 37°C for 
approximately 30mins prior to use. The rapid thawing and subsequent dilution of thawed 
cells is required to reduce their exposure time to the DMSO freezing solution, which is 
toxic at room temperature. The cell suspension was centrifuged at 900rpm for 5 min, the 
DMSO-containing supernatant removed and the cell pellet re-suspended in fresh growth 
medium. Thawed cells were placed into tissue culture flasks with the appropriate volume of
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medium (5ml/25cm2 flask, 8-10ml/75cm2 flask and 15- 18ml/ 175cm2 flask) and allowed to 
attach overnight. After 24 hours, the cells were re-fed with fresh medium to remove any 
residual traces of DMSO and non-viable cells.
2.5.5 Sterility Checks
Sterility checks were routinely carried out on all media, supplements and trypsin used for 
cell culture. Samples of basal media were inoculated into Columbia (Oxoid, CM331) blood 
agar plates, Sabauraud (Oxoid, CM217) dextrose and Thioglycollate (Oxoid, CM 173) 
broths which detect most contaminants including bacteria, fungus and yeast. Growth media 
(i.e. supplementedas shown in Table 2.5.1) were sterility checked at least 2 days prior to 
use by incubating samples at 37°C. These were subsequently examined for turbidity and 
other indications of contamination.
2.6 MYCOPLASMA ANALYSIS
Mycoplasma examinations were carried out routinely (at least every 3 months) on all cell 
lines used in this study. These analyses were performed by Aine Adams and Michael 
Henry.
2.6.1 Indirect Staining Procedure
In this procedure, Mycoplasma-ntgdfove NRK cells (a normal rat kidney fibroblast cell line) 
were used as indicator cells. These cells were incubated with supernatant from test cell 
lines and then examined for Mycoplasma contamination. NRK cells were used for this 
procedure because cell integrity is well maintained during fixation. A fluorescent Hoechst 
stain was utilised which binds specifically to DNA and so will stain the nucleus of the cell 
in addition to any Mycoplasma DNA present. A Mycoplasma infection would thus be seen 
as small fluorescent bodies in the cytoplasm and sometimes the extracellular region of the 
NRK cells.
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NRK cells were seeded onto sterile coverslips in sterile Petri dishes at a cell density of 
2xl03 cells per ml and allowed to attach over night at 37°C in a 5% CO2 humidified 
incubator. 1ml of cell-free (cleared by centrifugation at 1,000 rpm for 5 min) supernatant 
from each test cell line was then inoculated onto a NRK Petri dish and incubated as before 
until the cells reached 20 - 50% confluency (4- 5 days). After this time, the waste medium 
was removed from the Petri dishes, the coverslips washed twice with sterile PBS, once with 
a cold PBS/Camoys (50/50) solution and fixed with 2ml of Camoys solution (acetic 
acid:methanol-l:3) for 10 min. The fixative was then removed and after air-drying, the 
coverslips were washed twice in deionised water and stained with 2ml of Hoechst 33258 
stain (BDH) (50ng/ml) for 10 min.
From this point on, work was carried out in the dark to limit quenching of the fluorescent 
stain. The coverslips were rinsed three times in PBS. They were then mounted (using 50% 
(v/v) glycerol in 0.05M citric acid and 0.1M disodium phosphate) and examined by 
fluorescence microscope under a UV filter.
2.6.2 Direct Staining
The direct stain for Mycoplasma involved a culture method where test samples were 
inoculated onto an enriched Mycoplasma culture broth (Oxoid, CM403) - supplemented 
with 16% serum, 0.002% DNA (BDH; 42026), 2mg/ml fungizone (Gibco, 15290-026), 
2x10' units penicillin (Sigma, Pen-3) and 10ml of a 25% (w/v) yeast extract solution - to 
optimise growth of any contaminants. These were incubated at 37°C for 48 hours. Samples 
of this broth were then streaked onto plates of Mycoplasma agar base (Oxoid, CM401) 
which had also been supplemented as above and the plates were incubated for 3 weeks at 
37”C in a CO2 environment. The plates were viewed microscopically at least every 7 days; 
the appearancc of small, “fried egg” -shaped colonics is indicates Mycoplasma infection.
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2.7 Cell growth and Conditioned Media (CM)/ serum collection.
2.7.1 Identifying a suitable time point for CM collection
The experimental design to identify a suitable time point for CM collection and analysis is 
shown in Fig. 2.7.1, RPMI ML cells were set up in T75cm2 flasks at a density of 2 x 
106cells and 8mls of media was added. After each 24 hours, 1ml of conditioned media 
(CM) was taken off the cells, filtered with a 0.22nm filter and immediately added in 250^1 
aliquots to 750^1 aliquots of Tri Reagent and stored at -80°C until RNA extraction (see 
Section 2.8.2.2) was carried out.
T75cm flasks 
2 x 106cclls 
8 mis media
24 hours v - >  1ml CM ------ ► 500 i^l 0.22^m filtered
48 hours
■> 1ml CM ------ ► 500nl 0.22nm filtered
72 hoursi
■> 1ml CM ------ ► 500fil 0.22|im filtered
96 hours^ lml CM 500nl 0.22nm filtered
Figure 2.7.1 Experim ental design o f study to identify a suitable tim e point post cell 
seeding for CM  collection and analysis
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2.7.2 Study to find a reproducible minimum detection level
In this study, cells were set up as in the previous study, i.e. 2 x 106 cells/ flask. The cells 
were cultured for 48 hours, after which CM was taken and filtered through a 0.22nm filter. 
For RNA extraction using the Promega SV Total Isolation kit, 100^1 of the CM was 
immediately added to the lysis buffer and processed according to the manufacturer's 
protocol (see Section 2.8.2.1). For samples whereby RNA was to be extracted using Tri 
Reagent, either 250^1 of the filtered CM was immediately added to 750^1 of Tri Reagent, 
or lOOul of filtered CM was added to 150^1 of water and then added to 750^1 of Tri 
Reagent, and either processed immediately according to Section 2.8.2.2 or stored at -80°c 
until required (see Fig 2.7.2 for overv iew).
9»*l uscd in RT 1.8^1 used in RT 4^1 used in RT* to 9*il CM/ RT ... * to 9 ^ 1  cm / r t  ... * to 50m1 cm / r t
Figure 2.7.2.1 Experim ental design o f  study to finddeterm ine conditions fro 
reproducible detection o f m RNA in CM , RT= reverse transcription.
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2.7.3 Analysis of transcripts in RNA isolated from cell lines and CM
Flasks of cells for this study (75cm2) were set up at a cell density of 2 x 106 cells/ flask. 
8mls of media (sec Table 2.5.1 for details of cell lines and media) was added to each flask. 
After 48 hours CM was taken off the cells and split into two aliquots. One aliquot was 
filtered through a 0.22pm filter and the other aliquot was filtered through a 0.45pm filter. 
250pl aliquots of filtered CM were immediately added to 750pl of Tri Reagent and stored 
at -80°C until required for RNA exraction.
2.7.4 Concentration protocol 1
DLKP cells were seeded at a density of 4 x 10'’ cells per 175cm2flask with two flasks set 
up, and 15 mis of media was added to each flask. After 48 hours, the conditioned media 
(CM) from the each pair of flasks was taken off and pooled. Half of the CM was filtered 
through a 0.22pm filter and the other half through a 0.45pm filter. A 250pl aliquot from 
each filtered sample was immediately mixed with 750pl aliquots of Tri Reagent (0.22B/ 
0.45B) and placed in the -80°C freezer for RNA extraction at a later time using the protocol 
described in Section 2.1.22.
The remainder of the 15mls of the 0.45pm filtered or 0.22pm filtered CM was placed in 
Ultrafree-15 millipore concentrators. The samples were then centrifuged for 15 mins at 
500rcf, 15 mins at 2000rcf and 15 mins at 3220rcf at which time the samples had been 
concentrated down to approximately 300pl (0.22pm filtered sample) and 500pl (0.24pm 
filtered sample). The centrifugal speed was increased to help aid with concentration of the 
CM sample. 250pl aliquots of each concentrated sample were immediately mixed with 
750pl aliquots of Tri Reagent (0.22C/ 0.45C) and stored at -80°C for RNA extraction at a 
later time using the protocol described in Section 2.7.2.2.
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Finally 250pl aliquots from each of the “flow- through” CM were also mixed with 750pl 
aliquots of Tri Reagent (0.22FT/ 0.45FT) for RNA extraction at a later time using the 
protocol described in Section 2.7.2.2 (see Fig 2.7.4.1 for experimental design of protocol 1)
250pl aliquot 
added to 750p 1 
Tri Reagent
T 175cm flasks 
4 x 106 cells 
15mls media
Remove CM an 
pass through 
0.22pm filter
48 hours
/  N*a Renmove CM and 
pass through
0.45 am filter
-13 mis flow 
through 
250pl aliquot 
added to 750pl Tri 
Reagent
Add remaining CM to individual 
Millipore 10K concentrators
15 mins @ 500rcf 
15 mins @ 2000rcf 
15 mins @ 3220rcf
~300pl concentrated 
sample 
250pl aliquot added to 
750ul Tri Reagent
▼
~500pl conccntrated 
sample 
250pl aliquot added to 
750ul Jri Reapent
0.45C
250pl aliquot 
added to 750pl 
Tri Reagent
~13 mis flow 
through 
250pl aliquot 
added to 750pl Tn 
Reagent
Figure 2.7.4.1 Experim ental design o f concentration protocol 1. 0.22/ 0.45 refer to the 
filter size the CM  sam ples were filtered through. The suffixes B, C and FT refer to 
sam ples taken before concentration (B), taken after concentration (C ), or taken from  
the CM  that flow ed- through the concentrator colum n (FT).
5 2
To establish if it was possible to further concentrate the samples obtained in the first 
concentration protocol (see Section 2.7.4), the procedure was repeated using 0.45pm 
filtered samples only, and at every sampling point, i.e. before concentration, concentrated 
and flow through. Four 250pl aliquots were taken at each of these sampling points (see Fig.
2.7.5.1 for experimental design). The centrifuge speed was also lowered to 500rcf until the 
sample was concentrated to approximately 1ml. The four aliquots of250pl for each sample 
underwent the RNA extraction procedure as before (see Section 2.8.2.2) with the exception 
that the four RNA pellets for each sample were resuspended into one 15pl volume of DEPC 
treated water.
2.7.5 Concentration protocol 2
T 175cm flask 
4 x 106 cells 
15mls media
Remove CM and pass 
through 0.45pm filter
Add remaining CM to Millipore 10K 
concentrator
90 mins @ 500 ref
-1 .3mls concentrated sample 
4 x 250pl aliquots added to 4 x 750pl 
aliquots of Tri Reagent, 4 resulting RNA 
solutions resuspended into single 15pl 
H;Q aliquot ^ -  0 45C(4X)
4 x 250pl aliquots added to 4 x 750pl 
aliquots of Tri Reagent, 4 resulting 
RNA solutions resuspended into 
single 15pl H2O aliquot
~ 12mls flow through 
4 x 250pl aliquots added to 4 x 750pl 
aliquots of Tri Reagent, 4 resulting 
RNA solutions resuspended into 
single 15pl H2O aliquot
0.45FT (4X)
Figure 2.7.5.1 Experim ental design for concentration protocol 2 0.45 refers to the 
filter size the CM  sam ples w ere passed through. The suffixes B, C and FT refer to 
sam ples taken before concentration (B), taken after £onccntration (C ), or taken from
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the CM  that flow ed- through the concentrator colum n (FT). (4X ) refers to the four 
individual RNA pellets resuspended into one R NA suspension o f 15pl.
2.7.6 Concentration protocol 3
To investigate whether the addition of RNasin and/ or a decrease in centrifuge time would 
increase the integrity of the RNA yield, the procedure outlined in Section 2.7.5 was 
repeated again with two CM samples. Into one 3750 Units (~100pl) of RNase inhibitor 
(Sigma) was added and nothing was added into the second. The centrifuge speed was also 
increased to 3220rcf in order to shorten the time required for concentration (see Fig 2.7.6.1 
for experimental design)
48 hours
T 175cm‘ flasks 
4 x 106 cells 
15mls media
Remove Cl^and pass through 0.45pm filter 
Mix gently with lOOpl RNasin
Add remaining CM to individual Amicon 10K concentrators
~13 mis flow through 
250pl aliquot added to 
750pl Tri Reagent
0.45 FT +RNasin
20 mins 
@ 3220rcf -13 mis flow through 
250pl aliquot added to 
750pl Tri Reagent
^ J ) .4 5 F T  - R I N a s in ^
~1.3mls concentrated sample,
4 x 250pl aliquots added to 4 x 
750pl aliquots of Tri Reagent, 
4 RNA pellets resuspended into 
single 15pl H2O aliquot
C o .4 5 C  (*X) +RNasin_
~1.3mls concentrated sample,
4 x 250pl aliquots added to 4 x 
750pl aliquots of Tri Reagent, 
4 RNA pellets resuspended into 
single 15ul H?Q aliquot
).45C (4X) -RNasin
Figure 2.7.6.1 Experim ental design o f concentration protocol 3. 0.45 refers to th e filter 
size that the CM  sam ples w ere passed through. The suffixes B, C and FT refer to 
sam ples taken ¿efore  concentration (B), taken after concentration (C ), or  taken from 
the CM  that flow ed- through the concentrator colum n (FT). (4X) refers to the fact
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that four individual RNA pellets resulting from  R NA extraction o f 4x 250pl CM  
sam ples were resuspended into one RNA suspension o f  15pl. +RNasin refers to the 
CM  sam ple w here RNasin was added to the CM  after filtration and before 
concentration, com pared to the CM  sam ple w ere no RNasin was added (-R N asin).
2.7.7 Pilot DLKP microarray study
To investigate if extracellular RNA was suitable for global analysis of gene transcripts, a 
pilot study using RNA isolated from the CM of one cell line, DLKP was performed.
DLKP cells at passage 54 were seeded in 75cm2 flasks at a density of 2 x 10b cells/ flask 
and 8mls of media was added. After 48 hours, CM was removed from the flask, filtered 
through a 0.45pm filter and six 250pl aliquots of CM were added to six 750pl aliquots of 
Tri Reagent respectively. RNA was extracted from all six aliquots individually (see Section 
2.8.2.2) and the RNA from one of these samples (DLKP 1) was selected to undergo the 
Affymetrix two- cycle amplification and biotinylation protocol (see Section 2.12). The 
same procedure was carried out for DLKP cells set up in duplicate at passage 58. RNA was 
extracted from both of these samples (see Section 2.8.2.2) and one of the six aliquots of 
extracted RNA for both samples (assigned DLKP 2 and DLKP 3) were selected to undergo 
the Affymetrix two-cycle amplification and biotinylation protocol (see Section 2.12).
2.7.8 Analysis O f mRNA Expressed By Various CM Using M icroarray
All cells for this study were set up in 175cm2 flasks so that they were no more than 80%
confluent after 48 hour» in culture and fed with 18ml of media (for this study, the cells were
seeded and maintained by other researchers, Dr Laura Breen, Isabella Bray and Helena
Joyce). The flasks were set up in triplicate. After 48 hours in culture the conditioned media
was removed and half was passed through a 0.22pm filter and the other half through a
0.45pm filter (only the CM passed through the 0.45pm filter was used in this study).
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Within 10- 20 minutes, the filtered CM was added in 250pl aliquots to 750pl aliquots of Tri 
Reagent respectively and stored at -80°C until required.
2.7.9 Culture of normal breast cells
The normal breast cells, HMEC 1001-10 (HMEC) were cultured in a 25cm2 flask until they 
were approximately 60% confluent. The media (see Table 2.5.1 for details) was then 
replaced with fresh media and the cells left in culture for a further 48 hours to reach an 
approximate confluency of 80%. After 48 hours, the CM was removed, filtered through a 
0.45pm filter and 250pl aliquots were added to aliquots of 750pl Tri Reagent, respectively 
and the samples were stored at -80°C until required for RNA extraction, which was carried 
out using the protocol described in Section 2.8.2.2. The cells were lysed in 1ml of Tri 
Reagent and processed according to the manufacturer's protocol.
2.7.10 M icroarray analysis of Breast cancer serum/ tissue samples
From each patient recruited with consent for the Breast cancer microarray study, 2 serum 
specimens and 2 tissue specimens were taken. On the morning of surgery to remove the 
breast tumour, approximately 10ml of blood was collected. These specimens (termed Pre­
serum) were processed within four hours of blood draw. Tumour and matched normal 
tissue specimens were also collected at time of surgery and stored at -80°C until required. 
Approximately 2- 4 months post surgery, a second blood specimen was collected (termed 
Post- serum), and was processed within 4 hours of collection. Serum specimens from six 
normal volunteers were also collected and processed within four hours of collection .
All serum specimens were processed by removing the serum from the clotted blood and 
placing into a 10ml centrifuge tube. A balance tube was made by adding an equal amount
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of water to another 10ml centrifuge tube. The tubes were then centrifuged at room 
temperature for 15 minutes at 500rcf. After centrifugation the cleared scrum was carefully 
removed and passed through a 0.45nm filter to further ensure no particles/ platelets were 
retained. The serum was then aliquoted into 500^1/ 1ml aliquots and stored at -80°C until 
required. RNA extraction of the serum was carried out using a slightly modified version of 
the optimised Tri Reagent protocol developed here (see Section 2.8.2.2). In order to 
minimise the amount of time the serum was defrosting without protection from RNases, 
when required, 500^1 of Tri Reagent was added to the frozen serum specimens and the 
samples were gently pipetted to ensure thorough mixing. This scrum-Tri Reagent mix was 
then added in 500^1 aliquots to clean eppendorf tubes containing 250^1 of Tri Reagent, so 
that the final ratio of Tri Reagent to serum was 3:1 (i.e.750^1: 250^1).
Tumour and matched normal tissue specimens were cut into small sections and manually 
cut up in a petri dish containing 1ml of Tri Reagent. RNA was then extracted from these 
tissue specimens according to the manufacturer’s protocol.
2.8 RNA EXTRACTION
2.8.1 Cells
Approximately 1 x 1 0  cells were trypsinised, washed once with PBS, pelleted and lysed 
using 1ml of Tri Reagent,M (Sigma, T-9424). The samples were allowed to stand for 5 min 
at room temperature to allow complete dissociation of nucleoprotein complexes and then 
stored at -80°C. When required, RNA was extracted according to the manufacturer's 
protocol.
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2.8.2 Conditioned Media
2.8.2.1 Prom ega SV Total RNA Isolation System
Chen et a! (2000) used the Promega SV Total isolation system to extract RNA from 100^1 
of scrum specimens and perform RT-PCR on the extracted RNA, so this kit was tested 
using CM samples.
CM was taken from flasks as required and filtered through a 0.22nm filter. lOOjil of CM 
was added to 175 i^l of SV RNA lysis buffer that had p- mercaptoethanol added, as 
recommended by the manufacturer. The solutions were then mixed by inversion. To this, 
350^1 of SV RNA dilution buffer was added and again mixed by inversion and incubated at 
70°C for 3 minutes. After the incubation, the samples were centrifuged for 10 minutes and 
to the cleared lysate (in this case there was little/no sediment) 200^1 of 95% ethanol was 
added and the solution was mixed by pipetting. The mixture was then transferred to a spin 
basket supplied in the kit and centrifuged for 1 minute. After discarding the eluant, 600^1 of 
SV RNA wash solution was added. Again the tubes were centrifuged for 1 minute and the 
eluant discarded. To destroy any possible DNA contamination, 50^1 of DNase mix was 
applied to the membrane and incubated for 5 minutes at RT, after which 200^1 of SV 
DNase stop solution was added and the tubes centrifuged for 1 minute. SV RNA wash 
solution (600^1) was added and the tubes were centrifuged for 1 minute. The flow through 
was discarded. 250^1 of SV RNA wash solution was added to the spin baskets and the 
samples were centrifuged for 2 minutes. The spin baskets were then transferred to elution 
tubes and 100^1 of nuclease-free water was added to the membrane. The RNA was eluted 
by centrifuging the tubes for 1 minute (all centrifugation steps carried out >13,000rpm).
2.8.2.2 Tri Reagent
CM was taken from flasks as required and filtered through either a 0.22/ 0.45nm filter. CM,
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in volumes of 250^1 (or 100^1 of CM and 150pl H2O) were added to 750^1 of Tri 
Reagent'M. As recommended when using Tri Reagent, the samples were allowed to stand 
for 5 min at room temperature to allow complete dissociation of nucleoprotein complexes 
and then stored at -80 C. When required, the samples were thawed and allowed to stand for 
5 min before 0.2ml of chloroform was added per 750|il of Tri Reagent™ used. Samples 
were then shaken vigorously for 15 sec and allowed to stand for 15 min at room 
temperature, after which they were centrifuged at 13000rpm in a microfuge for 15 min at 
4°C. This step separated the mixture into 3 phases; the RNA was contained in the 
colourless upper aqueous layer. This layer was then transferred to a fresh Eppcndorf tube, 
to which glycogen (final concentration 120 ng/ml) and 0.5ml of ice-cold isopropanol were 
added. The samples were mixed and incubated at room temperature for 5-10 minutes and 
stored at -20°C over-night, to ensure maximum RNA precipitation. Eppendorf tubes were 
then allowed to stand at room temperature for 10 mins before centrifugation at 12,000rpm 
for 30 minutes and 4°C to pellet the precipitated RNA. Taking care not to disturb the RNA 
pellet, supernatant was removed and the RNA pellet was subsequently washed by the 
addition of 750 (il of 75% ethanol and vortexing. Following centrifugation at 7- 10,000 rpm 
for 5 minutes at 4°C, the supernatant was removed (this wash step was repeated). The RNA 
pellet was then allowed to air-dry for 5-10 minutes and subsequently was re-suspended in 
the required amount of RNase- free or DEPC-treated H2O. To facilitate dissolution, samples 
were mixed by repeated pipetting and incubated at 55-60°C for 10-15 minutes.
Volumes of water used to resuspend the RNA pellets varied depending on the study 
involved and expected yield of RNA.
• RNA used for RT-PCR study in Section 2.7.3 was resuspended in 20^1 of DEPC 
treated water.
• RNA used in concentration of biological samples in Section 2.7.4- 2.7.6 was
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resuspended in 15^ 1 DEPC treated water.
• RNA used for CM microarray studies in Sections 2.7.7- 2.7.9 was rcsuspendcd into 
6^1 of DEPC treated water.
2.9 Quantification/ visualisation of RNA
2.9.1 The NanoDrop ND-1000 Specrophotometer (Labtech
International).
»The NanoDrop ND-1000 is a full-spectrum (220-750nm) spectrophotometer that measures 
1 nl samples with high accuracy and reproducibility. It uses a sample retention technology 
that relies on surface tension alone to hold the sample in place eliminating the need for 
cuvettes and other sample containment devices. In addition, the NanoDrop has the 
capability to measure highly concentrated samples without dilution (50X higher 
concentration than the samples measured by a standard cuvette spectrophotometer).
To quantify an RNA sample, 1 jil of the sample is pipetted onto the end of a fiber optic 
cable (the receiving fiber, see Fig. 2.9.1.1 (a)). A second fiber optic cable (the source fiber, 
see Fig. 2.9.1.1(b)) is then brought into contact with the liquid sample causing the liquid to 
bridge the gap between the fiber optic ends. The gap is controlled to a 1mm path (see 
Fig.2.9.1.1 (c)). A pulsed xenon flash lamp provides the light source and a spectrometer 
utilising a linear CCD array is used to analyse the light after passing through the sample. 
The instrument is controlled by special software run from a computer, and the data is 
logged in an archive file on the computer (see Fig. 2.9.1.2 for screenshot).
When measurement of the sample is complete, the sample can be simply wiped away using 
a soft laboratory wipe. This is sufficient to prevent sample carryover because each 
measurement pedestal is a highly polished end of a fiber optic cable, with no cracks or 
crevice* fur residual sample to reside in.
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Figure 2.9.1.1 Samples arc quantified by loading 1^  onto the receiving fibre (A), the 
source fiber, connected to the sampling arm (B) is brought down into contact with the 
sample allowing a 1mm gap between the upper and lower pedestal (C), through which 
the light is passed. (Pictures adapted from ND-1000 Spectrophotometer users manual 
V 3.1.0).
Figure 2.9.1.2 Example screen shot of Nanodrop readouts, wavelength is plotted on 
the X-axis and absorbance is plotted on the Y-axis, RNA absorbs at 260nm. Coloured 
lines correspond to measurements obtained for different RNA samples
2.9.2 Agilent 2100 bioanalyser
The Agilent 2100 Bioanalyser is a microfluidics-based platform for the analysis of proteins, 
DNA and RNA. The miniature chips are made from glass and contain a network of 
interconnected channels and reservoirs. The RNA 6000 Nano LabChip kit enables analysis 
of samples containing as little as 5ng of total RNA. The channels are firstly filled with a gel
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matrix and the sample wells with buffer or sample, there are 12 sample wells per chip. 1^ 1 
of each sample is loaded into a sample well along with a fluorescent dye (marker). An RNA 
ladder is loaded into another sample well for size comparison. When all the samples are 
loaded, the chip is briefly vortexed and loaded onto the bioanalyser machine (see Fig. 
2.9.2.1(A) for picture of chip). The machine is fully automated and elcctrophoretically 
separates the samples by injecting the individual samples contained in the sample wells into 
a separation chamber (sec Fig. 2.9.1 (B)).
Figure 2.9.2.1 T he RNA 6000 Nano chip, a picture o f  the front o f the RNA Nano chip 
(A) and a diagram  o f the m icrochannels in the chip (B), the sam ple m oves through  
m icrochannels (1) and is injected into separation cham ber (2) were com ponents are 
elcctrophoretically separated (3) and detected by their fluorescence and translated  
into gel-like im ages and electropherogram s. Both pictures available from  
http://www.aiiilent.corn/chem/lahonachip..
The resulting data is presented as an electrophcrogram (See Fig 2.9.2 (a) and (b)). The 
fluorescensce is measured on the Y-axis and the time in seconds is measured on the X-axis. 
The smaller fragments are detected first and are shown on the left-hand side of the 
electrophoreogram. Fig. 2.9.2.2 (a) is an example of good quality cell RNA, the 18S and 
28S ribosomal RNA peaks are quite sharp and the 28S is higher than the 18S peak. As 
RNA degrades, the 28S RNA peak decreases and smaller fragments are visible. An
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example of slightly degraded cell RNA is shown in Fig. 2.9.2.2 (b). The 28S peak is 
smaller than the 18S peak and an extra peak is visible at approximately 25 seconds. This 
peak represents the fragmented RNA.
Fig. 2.9.2.2 Exam ples o f  electrophoreogram s generated using the A gilent Bioanalyscr. 
(a) intact DLK P cell RNA as evident by the sharp 18S and 28S ribosom al bands, (b) 
slightly degraded BT474 cell RNA as evident by the extra peak at approxim ately  
20secs indicating the presence o f sm aller fragm ents o f  RNA.
2.10 Reverse transcriptase reaction
Reverse transcriptase (RT) reactions were carried out using micropipettes which were 
specifically allocated to this work. The micropipettes were cleaned down using RnaseZap 
(Ambion 9870) according to the manufacturer’s instructions.
First-strand cDNA was synthesised using the following procedure:- 
2^1 oligo (dT) 18 primers (500ng/|il) (Sigma)
+ X nl RNA* (from CM)/ l^g RNA from cultured cells 
+ Xnl water*
*the volumes of CM RNA were different depending on the protocol employed (see note
below), so water was added to bring the total volume to 6|il.
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The contents were mixed in a 0.5ml Eppendorf tube (Anachem 96.9216.9.01), heated to 
72°C for 5 min and then chilled on ice. To this, the following were added:-
•  2pl of a 1 Ox buffer (500 mM Tris-HCl, pH 8.3, with 500 mM KC1, 30 mM MgC12, 
and 50 mM DTT, B 8559)
• 1^ 1 RNasin (4011/^1) (Sigma R2520)
• 1 nl dNTPs (1 OmM of each dNTP) (Sigma DNTP100)
• 9pl DEPC -treated water
•  1^ 1 Moloney murine leukaemia virus-reverse transcriptase (MMLV-RT) (200U/nl)
(Ml427 Sigma).
The solutions were mixed and the RT reaction was earned out by incubating the Eppendorf 
tubes at 37°C for I hour. The MMLV-RT enzyme was then inactivated by heating to 95°C 
for 2 min. The cDNA was stored at -20°C until required for use in PCR reactions as 
outlined in Section 2.11
*Notc: With the exceptions of the study to find a reproducible minimum detection level 
(amounts shown in Fig. 2.7.2.1, Section 2.7.2) and the validation of microarray results (see 
below), the amount of RNA solution used for reverse transcription was 4jil.
Validation o f m icroarray results
In all reverse transcription reactions carried out in the validation RT-PCRs on samples used 
for microarray analysis (see validation of microarray data Sections 3.8.7 and 3.8.11), the 
amount of RNA used was double the original volume used in the microarray amplification 
and labelling procedure (see Table 2.10.1 for summary of volumes used for microarray 
amplification protocol). The reason for this is that the minimum equivalent volume of CM 
required for reproducible RT-PCR was determined to be 50*il (see Section 3.2). The
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minimum volume of 50|xl would equate to \2 \i\ of RNA solution for the samples used in 
the microarray study (because of the smaller volumes of DEPC treated water that the RNA 
samples were resuspended in, see Section 2.8.2.2). As the volume of RNA for these 
samples used in the microarray amplification procedure were below the 1.2^1 volume (see 
Table 2.10.1), the volume of each RNA solution used for the validation of microarray 
results by RT-PCR was doubled (see Section 3.8.7 and 3.8.11 for these RT-PCR results). 
Ultimately this meant that the volume for each sample used in the microarray validation 
RT-PCRs was an exact reflection of the volumes used for the amplification and labelling 
procedures.
6 5
Sample
Amount used for amplification 
and labelling (Section 2.12) 
Volume(fil) = lOOng
Amount used for 
validation of 
microarray results 
using RT-PCR (nl)
HI 299
1 0.9 1.8
2 1 2
3 1.2 2.4
HI 299 
TAX
1 1.3 2.6
2 1 2
3 1.1 2.2
RPMI
1 1.4 2.8
2 1 2
3 1.5 3
RPMI
TAX
1 0.6 1.2
2 0.7 1.4
3 0.7 1.4
RPMI
ML
1 1 2
2 0.8 1.6
3 0.8 1.6
MDA-F
1 0.9 1.8
2 1.1 2.2
3 0.8 1.6
MDA-F-
TAX-SI
1 0.9 1.8
2 0.9 1.8
3 0.8 1.6
MDA-F-
ADR-SI
1 0.9 1.8
2 0.8 1.6
3 0.9 1.8
Table 2.10.1 Volume of RNA extracted from CM and used for microarray 
amplification protocol and in subsequent RT-PCR validation studies.
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A modified polymerase chain reaction (PCR) procedure was followed in this study.
5 \i\ cDNA from CM or 2.5 [il cDNA from cells was amplified in a 25 \il PCR reaction 
Each PCR tube contained the following:-
❖ 1 4 .2 5n rU H P
❖ 2.5|il lOx buffer (100 mM Tris-HCl, pH 8.3,500 mM KC1, Sigma D4545)
❖ 1.5jxl 25mM-MgCl2 (Sigma 4545)
❖ 0.5jil dNTPs (25mM each of dATP, dCTP, dGTP and dTTP) (Sigma DNTP100)
❖ 1 jil each of first and second strand target primers (250ng/|il)
❖ 0.5^1 of 5U/jxl Tag DNA polymerase enzyme* (Sigma D4545)
❖ 5 p,l cDNA from CM/ 2.5^1 cDNA from cells + 2.5^1 UHP
v If an endogenous control was required to be amplified along with gene of interest, this 
amount was reduced to 12.25nl and 0.5|il of each primer also added to the mix.
cDNA was amplified by PCR as follows:
95°C for 5 min - to denature double-stranded cDNA 
30 cycles*: 95°C for 30 sec - denature
54°C-58°C for 30 sec - anneal 
72°C for 45 sec - extend 
72°C for 10 min. -  extend
The reaction tubes were then stored at 4°C until analysed by gel electrophoresis as 
described in Section 2.11.2
❖ 30 cycles were sufficient when amplifying gene transcripts from cell RNA however, it
was sometimes necessary to increase this to 45 cycles when using RNA extracted from
2.11 Polymerase chain reaction
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CM.
In the validation of microarray results using RT-PCR, it was found necessary to reduce the 
cycle number to 35 for the CM samples to prevent saturation of the PCR bands and allow 
semi-quantitative differences between samples to be ascertained. All primer sequences used 
in RT-PCR studies are listed in Tables 2.11.1.1 and 2.12.1.2.
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2.11.1 Primer sequences used for RT-PCR studies
All primers listed in Table 2.11.1.1 and 2.11.1.2 (not published elsewhere), were designed 
to be RNA specific. Human Blat searches (http://gcnome.ucsc.cdu ^  were carried out on all 
transcripts of interest to identify exon- intron boundary regions (Kent, 2002). At least one 
primer of the primer pair set was designed to cross an exon- intron boundary junction, so 
that only amplification of an mRNA transcript was possible. Fig. 2.11.1.1 shows the 
regions of the mRNA transcripts amplified using the primers listed in Table 2.11.1.1
Bcl-2 y y  [6.03 Kb; 0.719 Kb]
m r p -1 y 3 ’
S ’
[5.927 Kb; 4.595 Kb] 
3'
G ST n y
[4.646 Kb; 3.842 Kb]
3'  (0.737 Kb; 0.632 Kb]
T O PO II 5 ' 3 ’
H rPN P B l5 3 fl-7« Kb; 1.061 Kb]
[5.698 Kb; 4.595 Kb]
C K -1 9 3 [1.513 Kb; 1.202 Kbl
R-A PT1N  .A -----■¿r; > [1.793 Kb; 1.127 KbJ
Figure 2.11.1.1 Location of regions selected for am plification. 5’, central or 3 ’ location
o f the regions selected for am plification ( -------) along the coding regions ( )
o f  transcripts analysed, using prim ers described in Table 2.11.1.1. Inform ation on size  
o f full gene transcripts, as well as size o f coding regions only -  as illustrated here -  are 
included for all gene products | ] analysed.
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cDNA Primer Sequences Amplified Product(bp)
bci-r (F): 5’ TCATGTGTGTGGAGAGCGTCAA 3' 
(R): 5’ CTACTGCTTTAGTGAACCTTTTGC 3’
306
mrp-T (F): 5’ GTACATTAACATGATCTGGTC 3’ 
(R): 5 ’ CGTTCATCAGCTTGATCCGAT 3’
203
mdr-T (F): 5’ GTTCAAACTTCTGCTCCTGA 3’ 
(R): 5’ CCCATCATTGCAATAGCAGG 3’
157
GST-x1 (F): 5’ ATGCTGCTGGCAGATCAG 3’
(R): 5’ GTAGATGAGGGAGATGTATTTGCA 3’
270
Topo If1 (F): 5’ AACTTTGGCTGTTTCAGG 3*
(R): 5* ATCATTATCTTCCCATAACGAAGCGT 3*
216
HnRNPBl5 (F): 5* GGAGAGGAAAAAGAGAGAAAAG 3’ 
(R): 5 ’ TTGATCTTTTGCTTGCAGGA 3*
155
CK-19* (F): 5’ GCGGG AC A AG ATT CTT GGT G 3’ 
(R): 5’ CTTCAGGCCTTCGATCTGCAT 3’
214
p-actinx (F): 5’ TGGACATCCGCAAAGACCTGTAC 3* 
(R): 5* TCAGGAGGAGCAATGATCTTGA 3’
142
p-actin (F): 5* CTTTGCCGATCCGCCGCCCGTC 3’ 
(R): 5 ’ CATCACGCCCTGGTGCCTGGGG 3’
171
p-actin5 (F): 5’ ACGGCTCCGGCATGTGCAAG 3’ 
(R): 5 ’ TGACGATGCCGTGCTCGATG 3*
196
p-actin (F): 5’ GAAATCGTGCGTGACATTAAGGAGAAGCT 3’ 
(R): 5’ TCAGGAGGAGCAATGATCTTGA 3*
383
Table 2.11.1.1 Primer sequences used for CM RT-PCR study (see Section 3.1-3.4). 
Note: p-actin primers were designed to amplify a range of products (142, 171, 196 and 
383) at a range of locations (5’, central, or 3* along the length of the transcript). All 
PCRs carried out at 54°C annealing temperature and 45 PCR cycles, x/ $ = primers 
published elsewhere, x= O’Driscoll et al (1996), $= (w ith the exception of HnRNPBl 
forward primer)primers published by Fleischhaker et al (2001).
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For the primers designed to validate the microarray study, they were also designed to be as 
close to, or within the region of the mRNA transcript also targeted by the Affymetrix 
probes (Fig 2.11.1.3 for example and Table 2.11.1.3 for details).
cDNA Primer Sequences (5’- 3’) AmplifiedProduct
(bp)
Annealing 
Temp 
(cycle no)
Hyp Protein 
F U S 2784
(F): ACT AC AT ACCT CT GGT GT CT CT GCAG 
(R): CTTGGACTCAGACGGGCG 158
56°C 
(45 cycles)
SM AF1 (F): ATTAGAGTTTGGTTTTCCTGGAGTCA (R): GGCTTT C AC ATGTCGGTCT G A 152
54°C 
(45 cycles)
Clone IMAGE: 
5528716
(F): CAT AT CT C AGGT G AC A AG AAGGTT ACC 
(R): TTAGAGCTCCTGAAAGTGACACCA 152
54°C 
(35 cycles)
ABCB4 (F): G ACT AG AT ATGCAT ATT ACT ACTCAGG ATTG (R): T AATTT CT AT AT G A AAGTGT GAC ATT A AC AAT G 239
54°C 
(35 cycles)
Clone HLUNG  
2003061
(F): CCC AG AG AGG AAG AGT A AAGAGG AC 
(R): GC AAT ACC AACGCCTT CATTT C 154
54°C 
(35 cycles)
NBR2 (F): GTTCATTTAGCAGCTCCGAGG (R): TTCGCGAAGCTGGGCT 179
56°C 
(35 cycles)
COM T (F): TCTCTTGGAGGAATGTGGCC (R): CTCCCT GT ATT CCAGG AACG AT 151
54°C 
(35 cycles)
HLXB9 (F): TTCAACTCCCAGGCGCAGT (R): CAAATCTTCACCTGGGTCTCG 180
56°C 
(45 cycles)
DDI2 (F): GGTCAAAGGGATCAGCAGAAAAC (R): TTGTTCTTT AG AT G AACAGGT CTTT ACC 163
54°C 
(35 cycles)
APIP (F): C AA AACC AT GT GT G AGT GTT ATG ACT (R): TT CTTTT GGCTT AG AC A ATT CC ATT 119
54°C 
(35/ 45 
cycles)*
SCD5 (F): G AA AT AC ACAGC AC AT CC AG A AAG A A  (R): G AGT GGTT AC A AT G AGT AT GT A AC A AAG CT 151
54°C 
(45 cycles)
Table 2.11.1.2 Primers used to validate microarray study data. *45 cycles used for
validation of Present/ Absent call study (see Section 3.8.7.3), 35 cycles used for 
validation of trend change in expression (see Section 3.8.11).
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Worked Example 9f Up* p c r  Primers for Validatipn of Microprray ¡taait§jygr.g 
Chosen
The Netaffx database (sec section 2.13.9.3) was accessed to find the transcript assignment 
for the probe set 1570505 at. The sequence of the transcript assignment (BC020618) was 
then retrieved from the NCBI database. This full sequence was imported into BLAT to aid 
in selection of exon- intron boundary sites.
Fig. 2.11.1.2 shows the results of the BLAT search. The letters highlighted in light blue 
often indicates exon- intron boundary junctions. Any text in black indicates a region that 
does not align to the genome, as per example the poly A tail in Fig. 2.11.1.2. The exon- 
intron boundary circled in red in Fig 2.11.1.2 was chosen for incorporation into primer 
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Figure 2.11.1.2 BLAT results for transcript BC 020618 (A BC B4). The letters in dark  
blue are the nucleotides that align exactly  with the genom e, the letters in light blue 
indicate points w here the sequence aligns w ith the genom e i f  a piece o f genom ic data is 
taken out (E xam ple o f one circled in red).
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Next, the transcript sequence was aligned with both the AfTymetrix target region and the 
proposed selected primers to establish if there was overlap using multalin software 
fhttp://prodes.toulousc.inra.rr/multalin multalin.htmh. Affymetrix recommends picking 
primers in the same region that they target so that the resultsfor subsequent RT-PCR 
analysis have a higher probability of validating the microarray data.
In Fig. 2.11.1.3 the first (and longest) sequence shown is the transcript assignment 
BC020618. The second sequence if the Affymetrix target region (called HG-U133PLUS; 
see left-hand side). The concensus/ overlap sequence between these is on the bottom. The 
part of the transcript highlighted in red is the part that overlaps with the Affymetrix target 
and it is clear that parts of this region is within the first 50 bases of the 3’ end of the 
sequence. The dark blue undashed lines indicate the primer annealing sites and the dashed 
lines between then, the amplified region.
The region circled in red was the most 3’ exon-intron boundary site identified. The closest 
region that could be targeted using mRNA specific primers (blue line) overlaps the start of 
the Affymetrix targeted region. Details of the regions targeted by Affymetrix and by our 
RT-PCR primers for the validation of microarray data study are listed in Table 2.11.1.3.
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Figure 2.11.1.3 Multalin results for transcript/ Affymetrix target region and proposed
primer positions. The first (and longest) sequence is the transcript assignment 
BC020618. The second sequence is the Affymetrix target region (called HG- 
U133_PLUS on the left hand side). The consensus/ overlap sequence is on the bottom. 
The part of the transcript highlighted in red is the part that overlaps with the 
Affymetrix target. The blue undashed lines indicate the primer annealing sites and the 
dashed lines between them, the amplified region. The region circled in red was the 
most 3' exon- intron boundary site that could be found (sequence GA, see also Fig.
2.11.1.2, this sequence is shaded light blue indicating that it is most likely a splice site).
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Probe set ID 
HG U133A 
Plus 2.0
Accession No. 
(NCBI)
Gene Name mRNA length 
(CDS)
PCR Amplicon 
Region
Affymetrix 
Target Region
1552853_at . NMJ446231 \ Hyp ProteinFLJ32784 ; :v .
4181bp 
/(1194-3398bp) . 3673-3830 . 3619-3678 ; j
1554128_at NM 001018082 small adipocyte factor 1 (SMAF1) 770bp(57-229bp) 403-554 191-285
1561573j a t ; -V - -V 4 ;”f ~ * '■ < " ”. : BC039476 ;  . V/ . Clone IMAGE:5528716 : ‘ 1023bp 'v' , • ' v  v (?) - : ■ ;287-438 ' ' ; • *' 439- 957- ' . i ^
1570505_at BC020618 ATP-binding cassette, subfamily (MDR/TAP), member 4 (ABCB4)
117bp 
(8- 547bp) 346-584 529-1079!*. •' , .. ■ » . .? v! .
1557996 '¿t V,? Ak091784 ; ^  ;v \ cDNA FLJ34465 fIs,clone - ,V HLUNG2003061 : . ; ^
1866bp . .• ' . r-t-, •
(?) A .'564-71:7 V ; ^
- :-y tii' * v  ^ *
Cll281-i829 ' ;  ;
20763 l_at NM_005821 Neighbour of BRCA1 gene (NBR2) 1392bp(332-670bp) 975-1153 803-1293
208817_at • ‘ ! NM 0007542/ ‘ '•>' - 7nMi007316 . •; 1
Catechdl-6:methyltransferase '' 
(COMT) \ ’-V A
; 1289bp (203-1018bp) 
'1067bp (131:796bp)
808- 958 .. 
586- 736' '
653-1000
431-778
214614_at NM_005515 Homeo box HB9 (HLXB9) 2176bp(304-1509bp) 987-1166 1643-2115
¿24449 a t , ; BC006011 - : ; V DNA damage inducible proteih 2, /  (DD12) ^ A "
v 1524bp 
(129-764bpV * " 625-787 : “ . .995- 1464 ‘ ;. • *;
218698_at NMO15957 APAF1 interacting protein (APIP) 1226bp (78- 806bp) 698-816 627-1190
Table 2.11.1.3 Details of ten probe sets chosen for microarray confirmation RT-PCR analysis. CDS= coding sequence, Sequence 
removed by NCBI Refseq staff since the study was carried out. 2NM_000754 is 220 bases longer than NM 007310 at the 5’ end, but 
the rest of the sequence is identical. As Affymetrix probe sets targets the identical part, RT-PCR primers were designed to this part 
also, (?) indicates sequences for which the length of the coding sequence was not listed on the NCBI website listing for that gene 
transcript.
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2.11.2 Electrophoresis of PCR products
A 2% agarose gel (Sigma, A9539) was prepared in TBE buffer (5.4g Tris, 2.75g boric acid, 
2ml 0.5M-EDTA pH 8 in 500ml water) and dissolved in a microwave oven. After allowing 
cooling, 0.003% (v/v) of a lOmg/ml ethidium bromide solution was added to the gel after it 
was poured into an electrophoresis apparatus (BioRad). Combs were placed in the gel to 
form wells and the gel was allowed to set.
5\i\ loading buffer (50% glycerol, lmg/ml xylene cyanol, lmg/ml bromophenol blue, ImM 
EDTA) was added to 25\i\ PCR samples and lO^ il was run on the gel at 80-90mV for 
approximately 2 hours. When the dye front was seen to have migrated the required 
distance, the gel was removed from the apparatus and examined on a UV-transilluminator 
and photographed.
2.11.3 Densitometry Analysis
Densitometry analysis of the PCR gels was carried out using Labworks Analysis Software 
(Version 3.0) to measure the maximum OD of the PCR bands in each gel. The results were 
imported into Microsoft Excel and bar charts were generated from this data.
2.12 RNA amplification, labelling and fragmentation of cRNA in 
preparation for hybridisation to Affymetrix array chips
Components required for this protocol were included in the Two-Cycle Target Labelling 
and Control Reagents (Affymetrix, P/N 900494) and MEGAscript® High Yield 
Transcription Kit, Ambion Inc, P/N 1334 with the exception of Ethanol (Sigma E7023).
The positive control Poly-A RNA is firstly diluted before spiking in with the sample RNA 
(see Section 2.12.1 for more information). It is important to note that the Poly-A spikes
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were made up in non-stick RNase/ DNase free tubes (Ambion cat no, 12450(L5ml)/ 
12350(0.5ml)), which prevents the Poly-A spikes from sticking to the sides of the tubes and 
interfering with the final concentration of the positive controls.
2\i\ of the Poly-A spike control was mixed with 2\i\ of Affymetrix approved T7-01igo dT 
primer (50[iM) and 16 of RNase-free water. The tube was then flicked and centrifuged 
briefly. 2^1 of this mix was added to 2|il of the 50ng/^il RNA sample (see Table 2.10.1, 3^1 
stock solutions of 50ng were made based on the volumes listed in Table 2.10.1 for lOOng of 
RNA) and 1^ 1 of RNase-free water. The tubes were flicked and centrifuged briefly before 
being incubated for 6 minutes at 70°C. They were then incubated for 2 minutes on ice and 
centrifuged briefly.
As summarised in Fig. 2.12.1, the first cycle, first strand master mix was prepared by
mixing 2|xl of 5X first strand reaction mix, l|il DTT (0.1M), 0.5|il RNase Inhibitor, 0.5jal
dNTPs (lOmM) and l|il Superscript II for each sample required. It is worth noting that
Affymetrix suggest that if there are more than* 2 samples that it is prudent to include extra
to compensate for potential pipetting inaccuracy or solution lost during the process. The 5\i\
of first strand master mix was added to each sample, the tube gently flicked, briefly
centrifuged and placed immediately at 42°C for lhour and 72°C for 10 minutes before
being placed on ice for 2 minutes. The first cycle second strand master mix was prepared
by adding 4.8^1 of RNase-free water, 4^1 of MgCh (17.5mM), 0.4^1 dNTP’s (lOmM),
0.6|xl E.Coli DNA Polymerase I and 0.2^1 of RNase H together for each sample required.
This 10|xl mix was then added to each tube which were then flicked and centrifuged briefly
before being placed at 16°C for 2 hours and 75°C for 10 minutes and then ice for 2 minutes.
The components for the first cycle IVT amplification (Ambion Megascript T7 kit) were
assembled at room temperature. 5^1 of each of the components ATP, CTP, UTP, GTP,
enzyme mix and lOx reaction buffer were added together for each sample included before
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being added to each sample. The tubes were gently flicked, centrifuged and placed at 37°C 
for 16hours.
The cRNA was then purified using the GeneChip Sample Cleanup module (Affymetrix, 
900371) as recommended by the manufacturers instructions.
The quantity of the cRNA was subsequently checked by diluting 2jil of cRNA in 18^ 1 of 
H2O and reading the quantity by using the Nanodrop (see Section 2.9.1). 600ng is required 
for the second cycle of the protocol. (All CM and serum specimens had less than 600ng so 
all 9|il left was used for the next step, see Tables 3.7.1.1, 3.8.1.1 and 3.9.2.1 for results). 
2fil of freshly diluted random primers (3|ig/jil) was added to each sample and the tubes 
were flicked, centrifuged briefly and placed at 70°C for 10 minutes before being placed on 
ice for 2 minutes.
As summarised in Fig. 2.12.2, the second cycle first strand mix was prepared by adding 4^1
of 5x first strand mix, 2\i\ of DTT (O.lmM), 1^ 1 RNase Inhibitor, l/il dNTP’s (lOmM) and
1^ 1 Superscript II together for each sample included. This 9jil was added to each sample
before they were flicked, centrifuged and placed at 42°C for lhour and ice for 2 minutes.
After this, 1 |xl of RNase H was added to each sample before they were flicked, spun, and
placed at 37°C for 20 minutes, 95°C for 5 minutes and ice for 2 minutes.
4jxl of a freshly prepared aliquot of T7 Oligo dT primer was added to each sample before
they were flicked, centrifuged briefly and incubated at 70°C for 6 minutes and ice for 2
minutes. The second cycle second strand master mix was prepared by adding the following
in a tube for each sample required; 88|il RNase-free water, 30^1 5x second strand reaction
mix, 3|lx1 of dNTPs (lOmM) and 4^1 E.Coli DNA polymerase I. This 125^1 mastermix was
added to each sample before being flicked, centrifuged briefly and incubated for 2 hours at
16°C. T4 DNA polymerase (2jal) was then added to each sample before incubating at 16°C
for a further 10 minutes. After incubating the samples at 4°C for 2 minutes, they were
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immediately purified using the GeneChip Sample Cleanup module (Affymetrix, 900371) 
following the manufacturers instructions.
All 12nl of cDNA were used for the second IVT step. The reagents required for this step 
were assembled at room temperature. The master-mix included 8pl RNase- free water, 4^1 
of IVT labelling butter, 12^ 1 IVT labelling NTP mix and 4^ il labelling enzyme mix for 
each sample included. The 28^1 volume was added to each sample before flicking, 
centrifuging briefly and incubating at 37°C for 16 hours.
The biotin-labelled cRNA was purified using the GeneChip Sample Cleanup module 
(Affymetrix, 900371), as recommended by the manufacturers, and quantified using a 
Nanodrop (a sample can also be taken at this point for analysis using a Bioanalyser nano 
chip). For quantification of cRNA when using total RNA as starting material, an adjusted 
cRNA yield needed to be calculated to reflect carryover of unlabeled total RNA. Using an 
estimate of 100% carryover, the formula below was used to determine adjusted cRNA 
yield:
adjusted cRNA yield =  RNAm  - (total R N A i) (y
w here RN A m  *  am ount o fcR N A  m easured afte r IV T (jig ) , total R N A i *  starting  am ount o f  total RNA (jig) 
y  = fraction o f  cD N A  reaction  used in IVT (=  1 for CM  sam ples)
The final step of the entire process was to fragment 20pg of the biotin-labelled cRNA by 
adding 8pl of fragmentation buffer to 20jig of cRNA and bringing the total volume of the 
reaction to 40^1, so that the concentration of the cRNA is 0.5ng/jil. This mix was incubated 
for 35 minutes at 94°C. A sample can be taken at this point for analysis on a Bioanalyser 
nano chip. From the fragmented cRNA 30^1 (=15ng) was hybridised to the Affymetrix 
U133+2 chip. Figs. 2.12.1 and 2.12.2 present an overview of the 2 cycle amplification 
procedure discussed above.
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Total RNA Sample (10-1 OOng)
I l  I I I I I I I I Iaaaaaaa y
synthesis
1 s t cycle. 1 s t  s tra n d  cDNA
1st cycle. 2nd strand cDNA 
sy n th esis
Add Poly-A RNA control* r  | | | | | |a a a a a a a  r  
Add T7-Oligo (dT) Primers TTTTTTT- H  S’
Add superscript jj
AAAAAAA 3'
TTTTTTT-I
Add RNase H (cleaves RNA kn an RNA/DNA hybrid)
AAA r  )
' i n
Add E.Coli DNA polymerase
AAAAAAA- r  
TTTTTTT- 5* rrfAAAA
Add T4 DNA Polymerase (fHls in 5' overhang*)
AAAAAAA-
TTTTTTT-
j
1st cycle, in vitro transcription 
(IVT)
Add Unlabelled Ribonucleotides 
Add IVT enzyme
Antisense RNA(cRNA) 3* I I I I I I I I I I I UUUUU 5*
Clean-up of antisense RNA (cRNA)
measure cRNA, proceed with 600ng
Fig 2.12.1 D iagram m atic overview o f 2 cycle am plification and labelling protocol- 
cyclel
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Figure 2.12.1 Diagram m atic overview  o f  2 cycle am plification and labelling protocol- 
cycle 2
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2.12.1 Two-Cycle Target Labelling and Hybridisation Controls for 
Quality Control
Affymetrix supply a Eukaryotic Poly-A RNA Control Kit along with the Two-Cycle Target 
Labelling and Control Reagents. The kit is designed specifically to provide exogenous 
positive controls to monitor the entire GeneChip eukaryotic target labelling process. Each 
array contains probe sets for several B. subtilis genes that are absent in the samples 
analysed (lys, phe, thr, and dap). Dap, lys, phe, thr, and trp are B. subtilis genes that have 
been modified by the addition of poly-A tails, and then cloned into pBluescript vectors, 
which contain T3 promoter sequences. Amplification of the poly-A controls with T3 RNA 
polymerase yields sense RNAs, which can be spiked into RNA samples, carried through the 
sample preparation process, and evaluated like internal control genes. These Poly-A spike- 
in controls are pre-mixed at staggered concentrations to allow assessment of the overall 
success of the assay. The final concentrations of the controls, relative to the total RNA 
population, are: 1:100,000; 1:50:000; 1:25,000; 1:7,500, respectively. All of the Poly-A 
controls should be called Present with increasing Signal values in the order of lys, phe, thr, 
dap.
The hybridisation controls also provided with the Two-Cycle Target Labelling and Control 
Reagents include bioB, bioC, and bioD (from the biotin synthesis pathway of E. coli), and 
ere (from the recombinase gene of bacteriophage PI). The Affymetrix arrays contain probe 
sets for these non-eukaryotic transcripts, which serve as controls for hybridisation, washing, 
and staining procedures. These transcripts were labelled separately then added to the 
biotinylated target cRNA before hybridisation at 1.5 pM, 5 pM, 25 pM, and 100 pM final 
concentrations for bioB, bioC, bioD, and ere, respectively. A synthetic biotinylated control 
oligo (Oligo B2) is also added to the hybridisation solution to provide alignment signals for
image analysis commonly known as “landing lights”.
82
BioB is at the threshold level of assay sensitivity (1:100,000 complexity ratio) and should 
be called Present at least 50% of the time. BioC, bioD, and ere should always be called 
“Present** with increasing signal values, reflecting their relative concentrations.
The hybridisation controls can be used to indirectly assess RNA sample quality among 
replicates. When global scaling is performed, the overall intensity for each array is 
determined and is compared to a Target Intensity value in order to calculate the appropriate 
scaling factor. The overall intensity for a degraded RNA sample, or a sample that has not 
been properly amplified and labelled, will have a lower overall intensity when compared to 
a normal replicate sample. Thus, when the two arrays are globally scaled to the same Target 
Intensity, the scaling factor for the “bad” sample will be much higher than that for the 
“good” sample. Since the hybridisation controls are added to each replicate sample equally 
(and are independent of RNA sample quality), the intensities of the bioB, bioQ bioD, and 
ere probe sets will be approximately equal in all cases. As a result, the signal values 
(adjusted by scaling factor) for these control probe sets on the “bad” array will be adjusted 
higher relative to the signal values for the control probe sets on the “good” array.
2.13 Affymetrix GcneC'hips®
(All pictures in this section taken, with permission, from the Affymetrix website 
www. AtTvmetrix.com unless otherwise stated)
The microarray gene expression experiments which were performed in this body of work were 
carried out using Affymetrix® Human Genome U133A Plus 2 GeneChips®. The GeneChip® 
Human Genome U133 Plus 2.0 Array offers comprehensive analysis of genome-wide expression 
on a single array by analysing the expression level of over 47,000 transcripts and variants, 
including 38,500 well-characterised human gene transcripts. It is comprised of more than 54,000 
probe sets and 1,300,000 distinct oligonucleotide features. These features are only 11 microns. 
Fig. 2.13.1.1 (A) shows the size of the Human Genome Plus 2.0 Array chip.
GcneChip probe arrays are manufactured using technology that combines photolithography and 
combinatorial chemistry. Up to 1.3 million different oligonucleotide probes are synthesised on 
each array. The surface of the Affymetrix array is like a giant grid of squares that has been shrunk 
down to the size of a thumbnail. Each oligonucleotide is located in a specific area on the array 
called a probe cell. Each probe cell contains hundreds of thousands to millions of copies of a 
given oligonucleotide (see Fig.2.13.1.1 (B)). _____________  ____________
Figure 2.13.1.1 (A) Affymetrix GeneChip Human Genome Plus 2.0 Array, (B) Picture 
representation of feature design on arrays.
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The probe arrays are manufactured in a series of cycles. Initially, a glass substrate is coated with 
linkers containing photo labile protecting groups. Then, a mask is applied that exposes selected 
portions of the probe array to ultraviolet light. Illumination removes the photo labile protecting 
groups enabling selective nucleoside phosphoramidite addition only at the previously exposed 
sites (see Fig. 2.13.1.2 for example). Next, a different mask is applied and the cycle of 
illumination and chemical coupling is performed again. By repeating this cycle, a specific set of 
oligonucleotide probes is synthesised with each probe type in a known location. The completed 
probe arrays arc packaged into cartridges.
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Figure 2.13.1.2 Photolithography process
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2.13.1 Perfect/ Mismatch Probe Strategy
A core element of Affymetrix microarray design is the Perfect/Mismatch probe strategy. 
For each probe that is designed to be perfectly complimentary to a given target sequence, a 
partner probe is also generated that is identical except for a single base mismatch in its 
centre (see Fig. 2.13.1.1). These probe pairs, called the Perfect Match probe (PM) and the 
Mismatch probes (MM), allow the quantitation and subtraction of signals caused by non­
specific cross-hybridisation. The differences in hybridisation signals between the partners, 
as well as their intensity ratios, serve as indicators of specific target abundance.
The chips have a “distributed probe set format’’, where the probe pairs of the same probe 
set are scattered into various places on the chip. This is to prevent a local image 
contamination to completely destroy the PM and MM information of a probe set.
Porfoct Match Mismatch
Figure 2.13.1.1 An exam ple o f  a probe pair with perfect m atch/ m ism atch  
oligonucleotides.
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An example of a PM/ MM result for a probe set using GeneChip software is shown in Fig.
2.13.1.2. Each box represents the signal proportional to the bound target for each probe. 
The amount of light emitted at 570 nm is proportional to the bound target at each location 
on the probe array. Target abundance is calculated by subtracting the MM signal from the 
PM signal for each probe pair.
Figure 2.13.1.2 An exam ple o f  scanned results for an individual probe set (generated  
using m icroarray data originating from  our laboratory)
The PM/MM data for the same probe set (for a different sample) shown above in Fig.
2.13.1.2 was calculated using dChip software and is shown in Fig. 2.13.1.3. On the left, a 
grid displays the PM and MM data in blue and green curves, with the x-axis ordering probe 
sets from 1 to 20, and y-axis for probe intensities with the range (0, 5763).
Y display range:(0,5763). C a llP , P%: 1 00% [Gene 196S7: 220232_a1J [H2_18_4_05l
Model method: PM/MM difference model
Figure 2.13.1.3 An exam ple o f PM / M M  signal analysis using dChip software 
(generated using m icroarray data originating from our laboratory).
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The sequences, from which the probe sets were derived, were selected from GenBank®, 
dbEST, and RefSeq. The sequence clusters were created from the UniGene database (Build 
133, April 20, 2001) and then refined by analysis and comparison with a number of other 
publicly available databases, including the Washington University EST trace repository and 
the University of California, Santa Cruz Golden-Path human genome database (April 2001 
release). Sequences from these databases were collected and clustered into groups of 
similar sequences.
The sequences were aligned to the draft of the human genome. They were subsequently 
orientated using consensus splice sites from the genome alignments, detected 
polyadenylation sites, coding sequence (CDS), and EST read direction annotations. Vector 
sequences were identified and removed along with low quality regions of EST sequences. 
Unigene (NCBI, Jan. 2003, Build 159) was then used to create initial clusters of cDNA 
sequences and sequence based subclustering was achieved using special software. 
Alternative transcript isoforms were split into separate clusters. At least 75% identity in all 
of the member sequences was required to create a consensus sequence.
The alignment process also extended the annotation information supplied by the databases 
pinpointing low quality sequences. These areas were usually trimmed for subsequent 
generation of high quality consensus sequences or, alternatively, Affymetrix employed 
quality ranking to select representative sequences, called exemplars, for probe design. 
Exemplar sequences are ESTs and mRNAs that are directly represented on the GeneChip 
array, whilst consensus sequences are built by the base calling algorithm, derived base-by- 
base from a cluster of public mRNA and/ or EST sequences. These sequences can be quite 
problematic. Fig. 2.13.3.1 shows an example of a consensus sequence built entirely on
2.13.2 Sequence retrieval
8 8
ESTs. As ESTs have lower sequence accuracy, resulting probes may show as flawed when 
compared to the genome sequence and transcript record over time. mRNA sequences, 
which may appear later, are usually truncated at the 3’ end so that EST- based consensus 
will overlap poorly with subsequent mRNA sequences that they correspond to in vivo (see 
top of Fig 2.13.2.1).
Probe target regions were selected from the 600 bases closet to the 3’ end of each 
transcript. The regions were categorised by having either 3' ends of RefSeq and complete 
coding sequence (CDS) mRNA sequences (full length end) or containing eight or more 3’ 
EST reads terminating at the same position (strong evidence for polyadenylation) or 3' end 
of the assembly (consensus end).
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2,13.3 Probe Set Design
The probe selection method used by Asymetrix for their U133 Plus 2.0 GeneChips takes 
into account probe uniqueness and the hybridisation characteristics of the probes, which 
allow probes to be selected, based on probe behaviour. Affymetrix use a multiple linear 
regression (MLR) model in the probe design that was derived from thermodynamic model 
of nucleic acid duplex formation. This model predicts probe binding affinity and linearity 
of signal changes in response to varying target concentrations. An advantage of this type of 
model-based probe selection system is that it provides a physical and mathematical 
foundation for systematic and large-scale probe selection. Also, an essential criterion of 
probe selection by Affymetrix for quantitative expression analysis is that hybridisation 
intensities of the selected probes must be linearly related to target concentrations 
For each target, eleven probe pair sets have been selected, based on predicted probe 
characteristics including performance, uniqueness metrices and spacing rules. The probe 
sets were given different suffixes to describe their uniqueness and/ or their ability to bind 
different genes or splice variants.
• “ at” describes probes set that are unique to one gene
• “_a_at” describes probe sets that recognise multiple transcripts from the same gene
• describes probe sets with common probes among multiple transcripts from 
separate genes. The s at probe sets can represent shorter forms of alternatively 
polyadenylated transcripts, common regions in the 3’ ends of multiple alternative 
splice forms, or highly similar transcripts. Approximately 90% of the _s probe sets 
represent splice variants. Some transcripts will also be represented by unique _at 
probe sets.
• “_x_at” designates probe sets where it was not possible to select either a unique
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probe set or a probe set with identical probes among multiple transcripts. Rules for 
cross-hybridisation were dropped in order to design the x probe sets. These probe 
sets share some probes identically with two or more sequences and therefore, these 
probe sets may cross-hybridise in an unpredictable manner.
Fig. 2.13.3.1 shows how the probe sets are designated “ at”, *_s_at” and “_a_at’\  Not 
included in Fig 2.13.4.1 are probe sets with the suffix of “ x at”
Figure 2 .133 .1  Probe set suffix assignm ent, yellow  =  “ at" unique probe set, pink = 
“ s at" probe set, green = “ a_at” probe set.
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2.13.4 Probe Set Grade Annotations
As well as defining the probe sets by their “uniqueness”, AfTymetrix also assign an 
annotation grade to each probe set. This annotation gives more information about the 
transcripts for which the probe sets are designed. The grades start at A, indicating that the 
probe sets match the mRNA sequence indicated as the assigned transcript. Other annotation 
grades include grade E and grade R annotations (grade R= probe sets that match only 
computationally predicted sequences) see Fig. 2.13.4.1 for example of grade A to C 
annotations.
Matching Probas (C lass A)
Genome Target Overlap (C lass B)
Genome Consensus/Exemplar Overlap C lass C
C onsensus mRNA
Ti
Probes ------- Genome
Figure 2.13.4.1 Annotation Grade assigned to probe sets, yellow line =  consensus, 
green line =  target, thick black line =  genom e and thin black line =  mRNA.
Due to the different probe set suffixes and annotation grades, care must be taken when 
interpreting data that includes non-unique probe sets or probe sets without a class A grade 
annotation. It is possible to have a probe set that is unique to one gene, but that gene has 
been computationally predicted, so although the probe set suffix would be “ at”, its 
annotation grade would be “R" and, therefore, not reliable.
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2.13.5 Detection call
2.13.5.1 G eneChip softw are
Affymetrix have a system that analyses the raw data and assigns a “Presence” or “Absence” 
call to each gene transcript represented on the array. This analysis generates a Detection p- 
value, which is evaluated against user-definable cut-offs to determine the Detection call. 
This call indicates whether a transcript is reliably detected (Present) or not detected 
(Absent). Additionally, a signal value is calculated which assigns a relative measure of 
abundance to the transcript. Each probe pair in a probe set is considered as having a 
potential vote in determining whether the measured transcript is detected (Present) or not 
detected (Absent). The vote is described by a value called the Discrimination score [R]. The 
score is calculated for each probe pair and is compared to a pre-defined threshold Tau. 
Probe pairs with scores higher than Tau vote for the presence of the transcript. Probe pairs 
with scores lower than Tau vote for the absence of the transcript The voting result is 
summarised as a p-value. The greater the number of Discrimination scores calculated for a 
given probe set that are above Tau, the smaller the /?-value and the more likely the given 
transcript is truly Present in the sample. The p-value associated with this test reflects the 
confidence of the Detection call.
The Discrimination score is a basic property of a probe pair that describes its ability to 
detect its intended target. It measures the target-specific intensity difference of the probe 
pair (PM-MM) relative to its overall hybridisation intensity (PM+MM):
R  = (PM  - M M ) / (PM  + M M )
For example, if the PM is much larger than the MM, the Discrimination score for that probe 
pair will be close to 1.0. If the Discrimination scores are close to 1.0 for the majority of the 
probe pairs in a set, the calculated Detection p-value will be lower (i.e. more significant). A
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lower /7-value is a reliable indicator that the result is valid and that the probability of error 
in the calculation is small. Conversely, if the MM is larger than or equal to the PM, then the 
Discrimination score for that probe pair will be negative or zero.
The next step towards the calculation of a Detection /?-value is the comparison of each 
Discrimination score to the user-definable threshold Tau. Tau is a small positive number 
that can be adjusted to increase or decrease sensitivity and/or specificity of the analysis 
(default value = 0.015). The One-Sided Wilcoxon’s Signed Rank test is the statistical 
method employed to generate the Detection p- value. It assigns each probe pair a rank based 
on how far the probe pair Discrimination score is from Tau.
The user-modifiable Detection p-value cut-offs, Alpha 1 (ai) and Alpha 2 (a 2), provide 
boundaries for defining Present, Marginal, or Absent calls. At the default settings, 
determined for probe sets with 16-20 probe pairs (defaults a 1 = 0.04 and a 2 = 0.06), any p- 
value that falls below a 1 is assigned a Present call; above a 2 is assigned an Absent call. 
Marginal calls are given to probe sets that have/»-values between a 1 and a 2 
The p -\alue cut-offs can be adjusted to increase or decrease sensitivity and specificity. 
Percent Present (%P) values depend on multiple factors including cell/tissue type, 
biological or environmental stimuli, probe array type, and overall quality of RNA. 
Replicate samples should have similar %P values.
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2.13.5.2 dChip softw are
dChip can also accommodate the data from GeneChip software that detects Presence/ 
Absence calls using the methods described in Section 2.13.5.1 if it is included in a .txt file 
along with the .cel file. If these text files are not generated and included, as was the case in 
this study, dChip calculates the Presence/ Absence calls using a simplified version of the 
MAS4 algorithm that Affymetrix first used that is, the same decision matrix making calls is 
used but the background calculation is on the whole chip instead of 16 sectors.
In general the %Present calls using the dChip software is higher. In this thesis the 
%Present calls listed in the Affymetrix QA tables for each sample were taken from the 
GeneChip software, but as the data was normalised with dChip, the scatter plots/ Venn 
diagrams were generated using the dChip Present/ Absent calls. Although the %Present call 
was higher in the samples assessed by dChip, the increase was uniform across the samples.
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2.13.6 Quality assessment of Affymetrix microarray chips
The quality of the data generated with Affymetrix microarray chips is assessed based on 
different criteria including the scaling factor, background and noise levels, GAPDH 37 5’ 
ratios and the %Present call.
The scaling factor is the multiplication factor applied to each signal value on an array. A 
scaling factor of 1.0 indicates that the average array intensity is equal to the target intensity. 
Scaling factors vary across different samples and so there are no set guidelines for any 
particular sample type. However, Affymetrix advise that if scaling factors differ by too 
much (i.e. > 3 fold) within a set of experiments, that this may indicate wide variation in the 
.dat files and that the analysed data (in the .chp file) should be treated with caution.
A high background implies that impurities, such as cell debris and salts, are binding to the 
probe array in a non-specific manner, and that these substances are fluorescing at 570 nm 
(the detection wavelength). This non-specific binding causes a low signal-to-noise ratio 
(SNR), meaning that transcripts present at very low levels in the sample may be incorrectly 
called as Absent. High background creates an overall loss of sensitivity in the experiment. 
The noise is a measure of the pixel-to-pixel variation of probe cells on a GeneChip array.
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The purpose of data normalisation is to minimise the effects of experimental and technical 
variation between microarray experiments so that meaningful biological comparisons can 
be drawn from the data sets and that real biological changes can be identified among 
multiple microarray experiments. Several approaches have been demonstrated to be 
effective and beneficial.
2.13.7.1 Genespring software
For the majority of experiments where a relatively small subset of transcripts is changing, a 
global method of scaling/normalisation is recommended. In such cases, since the majority 
of transcripts are not changing among samples, the overall intensities of the arrays should 
be similar. Differences in overall intensity are most likely due to assay variables including 
pipetting error, hybridisation, washing, and staining efficiencies, which are all independent 
of relative transcript concentration. Applying aglobal method of normalisation corrects for 
these variables. For global scaling, it is imperative that the same Target Intensity value is 
applied to all arrays being compared.
For some experiments where a relatively large subset of transcripts is affected, the 
“Selected Probe Sets” method of scaling/normalisation is recommended. The global 
approach does not make sense in this situation since the overall intensities among arrays are 
no longer comparable. In this case differences in overall intensity are due to biological 
and/or environmental conditions. Applying a global method skews the relative transcript 
concentrations. One option is to apply the “Selected Probe Sets” method using the 100 
Normalisation Control probe sets, which are available for the major catalogue arrays. For 
replicates and comparisons involving a relatively small number of changes, the 
scaling/normalisation factors (calculated by the global method) should be comparable
2.13.7 Microarray Data Normalisation
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among arrays. Larger discrepancies among scaling/normalisation factors (e.g., three-fold or 
greater) may indicate significant assay variability or sample degradation, leading to 
“noisier” data. Scaling/normalisation factors calculated by the “Selected Probe Sets” 
method should also be equivalent for arrays being compared. Larger discrepancies between 
scaling/normalisation factors may indicate significant assay or biological variability or 
degradation of the transcripts used for scaling/normalisation, which leads to noisier data.
2.13.7.2 dChip softw are
DNA-Chip Analyzer (dChip) is a software package implementing model-based expression 
analysis of oligonucleotide arrays and several high-level analysis procedures (Li and Wong 
2001(a) and (b)). This model-based approach allows probe-level analysis on multiple 
arrays. By pooling information across multiple arrays, it is possible to assess standard 
errors for the expression indexes. This approach also allows automatic probe selection in 
the analysis stage to reduce errors due to cross-hybridising probes and image 
contamination.
Since scanned images may have different overall brightness, generally normalisation is 
needed to adjust the brightness of the arrays to comparable level. dChip software needs to 
normalise arrays at PM and MM probe level before computing model-based expression 
levels. This is because the MAS algorithm analyses one array at a time (thus the Signal or 
Average Difference of different arrays can be scaled or normalised after computing them); 
while model-based method assumes the arrays are already at comparable brightness.
By default for dChip analysis, an array with median overall intensity is chosen as the 
baseline array against which other arrays are normalised at the probe intensity level. The 
software allows a different array to be chosen as the baseline, if by checking array images 
or outlier image it is found that the default baseline array has problems (due to
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dChip uses invariant set normalisation to normalise the arrays. This is carried out by 
choosing a subset of PM probes with small within-subset rank difference in the two arrays, 
to serve as the basis for fitting a normalisation curve. The fitted curve is the running median 
curve in the scatterplot of probe intensities of two arrays (with the baseline array on Y-axis 
and the array to be normalised on X-axis). When fitting the running median curve at the 
two ends, 5% of the “invariant” points are used to fix data at one end to make the high-end 
normalisation relationship more smooth and robust. The final running median curve is a 
piece-wise linear curve.
The normalisation transformation is then carried out for all the points (probes) in the array 
on X-axis (Y-axis is the baseline array and is not changed). The normalised probe values 
beyond the range of expression values [0, 65535] are truncated at the boundaries. The total 
effect of normalisation is a rotation and straightening of the scatter plot, so it better centres 
on the diagonal line y = x (see Fig. 2.13.7.2.1 for example of data before and after 
normalisation). It has been observed that when an experiment contains various tissue types, 
normalising all arrays together may reduce the similarity among the same tissue type at the 
expression index level. The likely cause is the wide scattering when plotting data for two 
tissues against each other and there are not enough points centering on the diagonal line to 
form a convincing normalisation curve (especially at high-end), thus the normalisation 
between different tissues may not work well and may introduce additional variation. If, by 
looking at such normalisation plots, the scattering is large between different tissues or 
conditions (e.g. correlation <0.5), tissue type-/ sample- specific normalisation can be 
carried out separately and the data pooled at a later stage.
contamination or bad hybridisation).
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Figure 2.13.7.2.1 Examples of normalisation curves obtained using dChip. (a) 
Replicate CM samples, (b) Parent vs. drug selected variant CM samples and (c) CM 
vs. cell RNA samples. Each dot represents PM or MM probe values in the two arrays 
(for a, b and c respectively). The blue line is the diagonal line y=x, the red circles are 
the probes selected in the “Invariant set”, and the green curve is the running median 
normalisation curve based on the “Invariant set”.
(a)
(b)
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Usually the deviation of the blue line and the green curve indicates the need for 
normalisation (that is, one array is brighter than the other). Fig. 2.13.7.2.1 (a) is an example 
of two replica samples before and after normalisation (correlation score of 0.989 before 
normalisation and 0.99 after normalisation). Fig 2.13.7.2.1 (b) shows plots before and after 
normalisation of two different samples (correlation score 0.976 before and after 
normalisation). Fig. 2.13.7.2.1 (c) shows the plots before and after normalisation of two
different sample types, in this case a CM sample and a cell sample. The correlation scores/
of 0.23 and 0.31 before and after normalisation, respectively, shows that these two samples 
cannot be normalised together; rather, they need to be normalised in separate groups and 
pooling of the data, at a later stage. This step also requires further scaling of values and 
application of a new MBEI if samples are to be compared against each other for changes in 
expression.
2.13.8 M icroarray data visualisation/ manipulation
2.13.8.1 G enespring
The Genespring software allows visualisation, organise and manipulation of gene 
expression data. GeneSpring provides a host of tools to ask detailed questions about 
complex data sets. Sixteen transformations are available for creating powerful and flexible 
normalisation scenarios. Normalisation steps can be applied in virtually any order and 
include operations such as dye swapping experiments and median polishing. Scenarios can 
be saved and applied in other experiments. GeneSpring offers visually intuitive filtering 
tools for both entry-level and advanced users. All visual filtering windows generate graphs 
of results in real-time. These filters allow researchers to exclude particular conditions, set 
minimum and maximum values and choose specific gene lists to filter. The advanced
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filtering window allows creation complex Boolean expressions to identify gene transcripts 
with a highly specific expression pattern. It also provides various analysis tools, such as t- 
tests, 2-way ANOVA tests and 1-way post-hoc tests for reliably identifying differentially 
expressed gene transcripts.
GeneSpring also has class prediction tools that can identify gene transcripts capable of
discriminating between one or more experimental parameters or sample phenotypes.
Groups of gene transcripts identified by expression profiling can be further characterised by
performing sequence searches for potential regulatory elements. GeneSpring provides
sophisticated clustering methods to uncover patterns of gene expression data and the
relationships between these patterns. Researchers can use one, or a combination of,
clustering option(s) to characterise their data: gene trees (hierarchical clustering),
experiment trees, self-organising maps, k-means, Principal Components Analysis (PCA)
and QT clustering. (QT clustering is an unsupervised technique that allows specification of
both the minimum size and maximum correlation coefficient of each cluster). Principal
Components Analysis (PCA) allows reduction of the complexity of the data by discovering
a number of principal components that define most of the data variability.
The Genespring software was used in this study to plot the data from the replicate samples
onto an X, Y, and Z 3-D scatter plot (or X, Y scatter plot if only 2 replicate samples
available). Each probe set is represented by a dot and its placement on the scatter plot
corresponds to the expression level of the probe set in each of the three samples (see Fig.
3.7.3.1, Section 3.7.3 for example). These “dots” representing individual probe sets can be
coloured according to assigned criteria allowing the data to be quickly visually interpreted.
The first step carried out to further enhance the detail of the scatter plot was to create an
associated Venn diagram. The exact numbers of probe sets called Present (P) or Marginal
(M) (see section 2.13.6 for explanation of detection call) in each sample is overlapped with
1 0 2
the other replicate samples. Any probe sets not called P or M are coloured grey (these 
would be assigned as Absent (A) in all three arrays) and the number of probe sets in this 
category is written outside the Venn diagram.
Hierarchical clustering was also performed on the samples in this study using a Pearson 
correlation to interpret how similar the samples are to each other.
2.13.8.2 dChip softw are
As well as normalisation of data dChip can be used to compare gene expression profiles of 
different sample groups to identify gene transcripts that are reliably differentially expressed 
between the two groups. When a group contains multiple samples, the group mean and its 
standard error is computed by pooling arrays considering measurement accuracy. Different 
filter criteria can be employed when comparing two groups. They are fold change, absolute 
difference between the two group means and p-value. The default p-value threshold of 0.05 
filters gene transcripts that differ in group means with a two-tailed p-value<0.05. Other 
comparison criterion requires that the percentage of samples called Present in the samples 
used in both groups be larger than a threshold and finally there is another optional criterion 
that specifies the p-value for a paired t-test. This option assumes the first baseline sample is 
to be compared with the first experiment sample and the second baseline sample is to be 
compared with the second experiment etc. This paired t-test has larger power that the 
unpaired t-test. The results for the sample comparisons are exported into tab delimited files 
and can be easily viewed using Microsoft Excel.
Since tens of thousands of gene transcripts are compared, many gene transcripts can be 
false positives. However, gene transcripts are not all independent and gene transcripts in the 
same pathway could have similar t-statistics or p-values. In dChip, the empirical false 
discovery rate (FDR) can be estimated by permutation. The option “Analysis/Compare
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samples/combine comparison/Permute samples to assess False Discovery Rate” can be 
chosen to assess how many gene transcripts would be obtained by the same comparison 
criteria when permuting group labels randomly. It is usually good to try different 
comparison criteria to finally obtain a list of gene transcripts with median FDR <5% or 
10%.
The gene lists can also be used for combined comparisons, for example if you compare 
sample groups A and B to obtain a gene list 1, and compare sample groups C and D to get a 
gene list 2, there is a provision in dChip to find the gene transcripts that are common on 
both lists or gene transcripts that are in one list but not the other.
When a list of gene transcripts is obtained by comparing the samples, dChip has a “classify 
gene” option which classifies the gene transcripts in the list into different groups according 
to GeneOntology or other annotational terms. DChip has gene information files (obtained 
from Affymetrix) which enables annotations to be attached to certain probe sets, the files 
include 1200 Gene Ontology terms, 3 Protein Domain terms, 160 Pathway terms and 257 
Chromosome terms. The gene ontology terms range from reproduction to positive 
regulation of lyase activity. P- values are calculated for the groups to identify any 
significantly overrepresented groups, for example if a certain number of gene transcripts 
were randomly selected, out of all the annotated gene transcripts, what is the significance if 
a large number of them have the same gene ontology?.
2.13.8.3 Netaffx
The NetAffx- Analysis Centre is a comprehensive resource of integrated array contents and 
functional annotations available through the Affymetrix website. The flexible query 
capabilities provided help to retrieve biological information for specific probe sets. The 
software is freely available to users via registration through the Affymetrix Netaffx
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website:
http://www.aiTymetrix.com/analysis/indcx.afTx
AfTymetrix also have a Gene Ontology (GO) tool. Gene Ontology is widely accepted as the 
standard for vocabulary describing the biological process, molecular function, and cellular 
component for gene transcripts (Ashbumer et al. 2000). The Gene Ontology Mining Tool 
maps GeneChip probe sets to these hierarchical vocabularies. In addition to providing the 
GO terms for annotated gene transcripts, it provides graphical, interactive views of probe 
set representation within the biological process, molecular function, or cellular component 
hierarchies. The graphs allow the user to visualise input probe lists in the context of 
biological information and to visually determine the relationships among probe sets, based 
on their locations in the GO graph, which aids in the biological interpretation of a complex 
set of results.
As the graph is hierarchical, users can view their results within a context of broad or 
detailed GO categories. By clicking on a specific GO term in the output graph, a list of 
probe sets with annotations at or downstream to this term will be retrieved. This 
functionality allows the partitioning of probe sets based on the molecular function, 
biological process or cellular component of gene transcripts.
The original or reference category can be thought of as the parent category. The categories 
branching to the right directly from the reference category are the child categories. For 
example, in Figure 2.13.11, the parent category 8371 obsolete contains 16 gene transcripts 
and has 5 associated children categories: 6832 small molecule transport, 9315 drug 
resistance, 9406 virulence, 7012 actin, and 7048 oncogenesis. GO categories become more 
detailed as you move from parent to child, or from left to right.
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Figure 2.13.8.2.1 Exam ple screenshot o f Netaffx GO maps. The parent category in the 
biological Process map, 8371 obsolete, contains 16 gene transcripts and has 5 
associated children categories: 6832 small m olecule transport, 9315 drug resistance, 
9406 virulence, 7012 actin, and 7048 oncogenesis. G O  categories becom e more 
detailed as you m ove from  parent to child, or from left to right, (from  Affym etrix  
Netaffx A nalysis C entre User’s G uide, A ffym etrix P/N 701757 Rev. 1)
2.13.8.4 O nto-Express
Intelligent Systems and Bioinformatics Laboratory, Computer Science Department, Wayne
State University developed Onto-Express (OE) as a novel tool able to automatically
translate lists of gene transcripts from microarray experiments of differentially regulated
gene transcripts into functional profiles characterising the impact of the condition studied.
The software is freely available to academic users from
http://vor1cx.cs. wavne.edu^OSO/ontocxpress/servlet/Userlnfo. OE constructs functional
profiles (using Gene Ontology terms) for the categories: biochemical function, biological
process, cellular role, cellular component, molecular function and chromosome location.
Statistical significance values arc calculated for each category.
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Essentially, the software works on the same principles as netaffx software (see section 
2.13.9.3) but instead of generating a map of parent-child category relationships, the Onto- 
Express software generates detailed pie-charts, with one category per segment. It uses the 
detailed child categories to generate the pie-charts so, depending on the input list; it can 
potentially become quite detailed. One possible limitation of the software is that if a gene 
has two or more known molecular functions, it will be listed twice, or more, so that an 
input list of for example 100 probe sets, may generate a pie chart where the individual 
numbers of gene transcripts in each segment add up to many more than 100 gene 
transcripts. In general though, both Netaffx and Onto- Express can help to visualise a list of 
gene transcripts/ probe sets in a biologically-relevant context,
2.13.9 Sequence analysis
The UTRdb is a non redundant database of 5’ and 3 s UTR sequences generated by a 
computer program through the scanning of EMBL/ GenBank database entries. A software 
program called CleanUP removes redundant sequences. These redundant sequences are 
removed if they are the shorter of two matching sequences that have sequence identity and 
overlapping percentage above 95 and 90% respectively.
Also included in the UTRdb entries is information regarding the number of exons spanning 
the UTR gene region, whether the UTR region is complete or incomplete and the presence 
of repeat elements. In addition to this, is information regarding whether or not functional 
activity has been experimentally proven. The information is cross-linked with the 
Accession Number of the primary EMBL entry as well as between 5’UTR and 3’UTR 
sequences corresponding to the same region.
Information regarding a description of the biological role of the corresponding element, the
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pattern consensus structure and the related bibliography are found in the connected 
UTRsite.
The part of the UTR database used for work presented in this thesis is the UTRscan 
program. The UTRscan program scans sequence data submitted to it for functional 
elements defined in the UTRsite collection. The program is internet based and is free to use 
after registering with the database. Sequences are submitted in Fasta format and the results 
of the scan are emailed back to the submitter detailing any regulatory elements found and 
the exact position and sequence of the elements are listed also.
Descriptions for regulatory elements (as per database) found in sequences submitted to 
UTRscan during the course of this work are listed and described here.
2.13.9.1 15-Lipoxygenase Differentiation Control Element, (15-LOX DICE)
The 15-LOX DICE regulatory sequence can be found in both 5’ and 3’ UTR regions. 
Erythroid 15-lipoxygenase (15-LOX) synthesised in the early stages of erytropoiesis 
catalyses the degradation of lipids and is an important factor responsible for the degradation 
of mitochondria during reticulocyte maturation. The 3'UTR of 15-LOX mRNA contains 
tandem repeat sequences, referred to as "DICE" for "Differentiation Control Element" 
which specifically bind to regulatory proteins, formerly called LOX-BP. This binding 
specifically inhibits 15-LOX mRNA translation. In rabbit 15-LOX mRNA, 10 tandem 
copies of the repeat sequence have been found, but only 4 (3 tandem) in human. 
Experimentally, a functional DICE consisting of two repeat elements has been described. 
The regulatory binding proteins have been identified as hnRNP K and hnRNP El.
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Many Notch pathway target gene transcripts in Drosophila, including most members of the 
basic helix-loop-helix repressor family and the Bearded family, contain a series of 
conserved sequence motifs in their 3' UTRs, including the Brd box, the K box, and the GY 
box.
2.13.9.2 Brd-Box (Brd)
The Brd box (pattern AGCTTTA) is present in one or more copies in many 3'UTRs and 
mediates negative post-transcriptional regulation by affecting transcript stability and 
translational efficiency. Regulation by the Brd box is spatially and temporally ubiquitous, 
and likely involves the formation of RNA-RNA duplexes with complementary sequences 
found at the 5'end of certain micro RNAs (miRNAs). Brd box-complementary miRNAs are 
also found in other nematodes, suggestive of functional conservation.
2.13.9.3 K-Box (KB)
The K box (pattern cTGTGATa) is present in one or more copies in many 3'UTRs and 
mediates negative post-transcriptional regulation, mainly effected by decreased transcript 
levels. Regulation by the K box is spatially and temporally ubiquitous, and likely involves 
the formation of RNA-RNA duplexes with complementary sequences found at the 5’end of 
many micro RNAs (miRNAs). K box-complementary miRNAs are found in other metazoa, 
suggestive of functional conservation.
2.13.9.4 GY-Box (GY)
The GY box (GTCTTCC) is present in one or more copies in several of these 3’ UTRs, but 
does not appear to have strong cis-regulatory activity.
However, its function likely involves the formation of RNA duplexes with a 
complementary sequence found in the 3' UTRs of proneural basic helix-loop-helix gene
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transcripts (the proneural box, ATGGAAGACAAT) and with complementary sequences 
found at the 5' ends of certain micro RNAs (miRNAs).
2.13.9.5 Alcohol dehydrogenase 3’UTR downregulation control element (ADH_DRE)
A highly conserved eight base sequence (AAGGCTGA) within the 3' untranslated region of 
the Drosophila Alcohol dehydrogenase (Adh) mRNA, identified by phylogenetic analysis, 
was found to produce a two-fold downregulation of Adh gene expression. The experimental 
assay was carried out by in vitro deletion mutagenesis followed by P element mediated 
germline transformation, Downregulation was found to be the result of a temporally and 
spatially generated decrease in the Adh transcript possibly resulting by either a reduction of 
transcription rate or most likely by a reduction of the mRNA stability.
2.13.9.6 Cytoplasmic polyadenylation element (CPE)
Cytoplasmic polyadenylation is an evolutionarily conserved mechanism regulating
translational activation of a set of quiescent maternal messenger RNAs (mRNAs) during
early development. Cytoplasmic poly (A) elongation occurs in a wide range of species,
ranging from clam to mouse. The relevance of this process during late oogenesis and early
embryogenesis has been shown by studies in the mouse, Xenopus, and Drosophila. In
mouse and Xenopus, the only vertebrates so far examined, the critical regulatory sequences,
referred to as Cytoplasmic Polyadenylation Elements (CPEs), are AU-rich and located in
the 3' untranslated region (3'-UTR) near the canonical nuclear polyadenylation element
(AAUAAA), which also is required for proper poly (A) addition. The CPE has the general
structure of UUUUUUAU. However, the CPE is not identical in all mRNAs and its
position varies relative to AAUAAA (generally within 100 nucleotides). The minimal CPE
capable to stimulate elongation of a poly (A) tail appears to be UUUUAU, and recent
experiments show also the existence of substantial context and position effects on CPE
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function.
2.13.9.7 Internal Ribosome Entry Site (IRES)
Internal mRNA ribosome binding is a mechanism of translation initiation alternative to the 
conventional 5-cap dependent ribosome scanning mechanism. The internal initiation 
mechanism, first observed in picomavirus, is also found in some cellular mRNAs, such as 
human immunoglobulin heavy chain binding protein (BiP) mRNA, Antennapedia mRNA 
of drosophila and FGF-2 mRNA. This mechanism may be advantageous for specific 
translation of mRNAs during cell cycle when undeiphosphorilated eIF-4F prevents 
conventional translation initiation. The internal initiation mechanism is dependent on a cis- 
acting element, defined as internal ribosome entry site (IRES), located in the 5'UTR region 
of the mRNA.
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RESULTS
1. To establish if it is possible to routinely extract and amplify extracellular mRNA 
from the conditioned media of cultured human cancer cells.
2. To compare different methods of extracting the RNA and determine which method, 
if any provides both reliable and reproducible results.
3. To establish if the mRNA is present in full length transcripts
The aims of Section 3.1, 3.2 and 3.3 were:
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In order to establish an appropriate point for sampling CM, cells were cultured over 96 
hours with CM samples removed from the media every 24 hours. See Ssction 2.7.1 for 
details of the experimental design of the study.
After samples were collected and stored at -80°C until required, RNA was extracted from 
the samples and reverse- transcribed (see section 2.10). PCR was then carried out for p- 
actin. Fig 3.1.1 shows the expression of p-actin in the conditioned media over the 96 hours. 
P-actin mRNA was detected at all time points sampled indicating that any time point over 
the 96 hours could be selected. The next step was to look at the cells under the microscope 
over the 96 hours to check the viability of the cells and make sure that the mRNA detected 
in the CM was not due to lysis of cells resulting from an over-confluent population.
3.1 Identifying suitable time point for CM collection and analysis
-©- +  rrl Oh
' >  i
Figure 3.1.1 Expression of p-actin at time points over 96 hours in RPMI ML CM. (3- 
actin gene transcript (arrow) was detected in RNA isolated from all CM samples after 
passing through a 0.22 Jim filter. Amplified product was detected in the positive 
control, RPMI TAX cell RNA, and was undetected in the negative control samples (- 
VE RT = RT reaction with H20 instead of RNA as control; -VE PCR = PCR reaction 
with H20 instead of cDNA as control).
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At each time point analysed, the cells were viewed under the microscope before every CM 
sample was taken to check for large amounts of cells/ cell debris floating in the media. As 
an example, DLKP cells after 48 hours in culture are shown in Fig 3.1.2. These cells were 
photographed to show that any mRNA isolated from the CM was not from lysis of dead 
cells due to over- confluent cell populations. Figure 3.1.2 shows that after 48 hours the cells 
are not confluent and look healthy and viable with little/ no dead cells floating in the media. 
At 72 but, more so at 96 hours, the confluency of the cells was more than 80% and much 
more cell debris could be seen floating in the medium.
Figure 3.1.2 DLKP cells in culture for 48 hours (a) 20X and (b) 40X. The size bars in 
the bottom right-hand side of the photographs correspond to 100pm (a) and 50fim (b).
3.2 Determining a reproducible minimum detection level
P-actin was amplifiable at all time points, i.e. 24- 96 hours using RNA extracted with Tri 
Reagent (see Section 3.1). In order to ensure that other less abundant transcripts were also 
amplifiable by RT-PCR, we analysed the CM RNA for other transcripts including CK-19, 
HnRNP B1 and MDR1. The reason for this choice was that both CK-19 and HnRNPBl 
gene transcripts were found in the serum of lung cancer patients in a study by Fleischhacker 
et al (2001) and MDR1 is a P-glycoprotein that has a role in multiple drug resistance. As 
RPMI 2650 Taxol (RPMITX) are known to overexpress MRP1 mRNA with no expression
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in RPMI2650 Melphalan (RPMI ML), this transcript was also chosen (Liang et al 2001).
3.2.1 RNA Extracted using Promega SV Total Isolation Kit
Flasks of RPMI TAX and RPMI ML cells were set up in duplicate. 1ml volumes of CM
was collected at 24 hour intervals over 96 hours and were filtered through 0.22|im filters as 
described in Section 3.1. RNA extraction was carried out on a lOOfil volume of filtered 
CM, using the Promega SV Total Isolation kit (see Section 2.8.2.1 for details).
RT-PCRs were then performed on the duplicate samples to check for expression of CK-19. 
Fig 3.2.1.1 (a) and (b) show that the PCR results obtained using this RNA extracted from 
100|il of CM using the Promega SV Total Isolation kit when trying to amplify the CK-19 
gene transcripts were not reproducible. Duplicate samples showed little/ no concordance 
with each other. The different sampling time points used had no effect on the 
reproducibility.
CK-19
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Figure 3.2.1.1 Expression of CK-19 in RPMI TAX (a) and RPMl ML (b) over 96 
hours. CK-19 gene transcript (arrow) was not detected in all duplicate RNA samples 
(see 48A and B samples in Fig 3.2.1.1 (a) and (b) above). Amplified product was 
undetected in the negative control sample (-VE PCR = PCR reaction with HiO instead 
of cDNA as control).
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3.2.2 Comparison of RNA Extracted Using Tri Reagent with RNA 
extracted using the Promega SV Total Isolation system
As the duplicate samples analysed in Section 3.2.1 did not show similar results, it was 
decided to concentrate the mRNA available for RT-PCR by eluting extracted RNA into a 
smaller volume of RNase- free water. As lOOjal was the minimum eluant possible for the 
Promega system, the extraction procedure could not be scaled- up to accommodate this 
without a significant increase in cost by having to buy in extra buffers for the kits, it was 
decided to try using Tri Reagent to extract the RNA.
Requirements for Tri Reagent extraction are that for every 250|il of solution sample, 750|il 
of Tri Reagent is added. As the RNA is precipitated using isopropanol, washed in ethanol, 
and then the resulting pellet is resuspended in any desired amount of RNase- free water, it 
meant that this protocol could be readily scaled-up to obtain greater yields of RNA.
Two CM sample sizes were chosen, lOOjil (for comparison with Promega kit results) and 
250jj.1 (to allow RNA to be extracted from a larger amount of CM). The lOOjil volume 
enabled the equivalent of 9|il of CM to be used in each RT-PCR reaction whilst the 250jal 
volume enabled the equivalent of 50|al of CM to be used in each RT-PCR, i.e. over five 
times more CM/ RT-PCR reaction (see Section 2.7.2 for experimental design of study). 
RNA extractions were carried out according to Section 2.8.2. The RNA was eluted using 
RNase-free water with the Promega system as it was supplied with the kit. UHP water was 
treated with DEPC (see Section 2.1.1) to remove/ destroy RNases and this was used to 
resuspend the RNA pellets precipitated using the Tri Reagent protocol.
The RT-PCR results using RNA extracted with Tri Reagent, in Figs. 3.2.2.1-2 and 3.2.2.4-5 
seem to indicate a general increase in reproducibility compared to the RT-PCR results 
obtained using RNA extracted with the Promega system (see Fig. 3.2.1.1) especially with
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RNA extracted from RPMI TAX CM. Although P-actin transcripts were amplifiable for all 
samples (Fig. 3.2.2.1), when RNA extracted from the smaller volume of CM was used in 
the RT reaction (9jnl instead of 50^1), PCR results for both CK-19 and HnRNP B1 were 
conflicting in the RPMI ML duplicate samples (see Figs 3.2.2.2 (b) and 3.2.2.4 (b), 48.100 
samples). This indicates the possibility that RNA extracted from the smaller volume of CM 
may be at the limit of detection for RT-PCR to detect it.
MDR1 transcripts were amplifiable in the RPMI TAX CM samples and not the RPMI ML 
CM samples indicating that the detection of gene transcripts in the CM of cultured cells 
may be a cell- specific process (Fig. 3.2.2.5).
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Figure 3.2.2.1 Amplification of P-actin (196bp) in RPMI TAX (a) and RPMI ML (b). 
48.100 = RNA extracted from lOOjil of CM conditioned for 48 hours (comparable to 
results obtained using Promega Total Isolation SV kit *9)i\ CM/ RT-PCR). 48.250 = 
RNA extracted from 250^1 of medium conditioned for 48 hours (~50fil CM/ RT-PCR), 
p-actin gene transcript (arrow) was detected in RNA isolated from all CM samples 
from RPMI TAX (a) and RPMI ML (b). Amplified product was detected in the 
positive control, RPMI cell RNA, and was undetected in the negative control samples 
(-ve RT = RT reaction with H2 O instead of RNA as control; -ve PCR = PCR reaction 
with H20 instead of cDNA as control).
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Figure 3.2.2.2 Amplification of CK-19 in RPMI TAX (a) and RPMI ML (b). 48.100 = 
RNA extracted from lOOjil of CM conditioned for 48 hours (comparable to results 
obtained using Promega Total Isolation SV kit *9}ü CM/ RT-PCR). 48.250 = RNA 
extracted from 250jil of CM conditioned for 48 hours (-50^1 CM/ RT-PCR). CK-19 
gene transcript (arrow) was detected in RNA isolated from all CM samples from 
RPMI TAX CM (a) and in all RPMI ML CM samples except sample Ml B 48.100 (b). 
Amplified product was detected in the positive control, RPMI cell RNA, and was 
undetected in the negative control samples (-ve RT = RT reaction with H2O instead of 
RNA as control; -ve PCR = PCR reaction with H2O instead of cDNA as control).
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HnRNP B1
Initially the PCR primers used to amplify the HnRNPBl transcript were chosen from 
Fleischhacker et al (2001), but the primers were not RNA specific and PCR bands 
attributable to DNA contamination were detected (see Fig. 3.2.2.4). This showed a possible 
weakness with the Tri Reagent protocol in so far as DNA was present in the RNA 
suspension. To overcome this, the forward primer was redesigned so that it crossed an 
exon-intron boundary allowing only amplification of mRNA transcripts (see Fig. 3.2.2.5). 
All future PCR primer pairs were designed with this in mind (see Section 3.8.11.1 for more 
information).
Figure 3.2.2.3 RT-PCR of RPMI TAX CM for HnRNP B1 (166bp). 48.100 = RNA 
extracted from lOOpl of CM conditioned for 48 hours (comparable to results obtained 
using Promega Total Isolation SV kit ^9^1 CM/ RT-PCR). 48.250 = RNA extracted 
from 250^1 of CM conditioned for 48 hours (~50pl CM/ RT-PCR). HnRNP B1 mRNA 
gene transcript (black arrow) was detected in one CM sample (B. 48.250), whilst PCR 
products attributable to DNA contamination (red arrow, 420bp) were amplified in all 
samples. Amplified product was undetected in the negative control samples (-ve RT = 
RT reaction with H20 instead of RNA as control; -ve PCR = PCR reaction with H2O 
instead of cDNA as control).
*
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Figure 3.2.2.4 Amplification of HnRNP B1 in RPMI TAX (a) and RPMI ML (b). 
48.100 = RNA extracted from 100^1 of CM conditioned for 48 hours (comparable to 
results obtained using Promega Total Isolation SV kit il CM/ RT-PCR). 48.250 = 
RNA extracted from 250pl of CM conditioned for 48 hours (~50jil CM/ RT-PCR). 
HnRNP B1 gene transcript (arrow) was detected in RNA isolated from all CM 
samples from RPMI TAX CM (a) and RPMI ML CM except sample Ml B 48.100 (b). 
Amplified product was detected in the positive control, RPMI cell RNA, and was 
undetected in the negative control samples (-ve RT = RT reaction with H20 instead of 
RNA as control; -ve PCR = PCR reaction with H20 instead of cDNA as control).
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Figure 3.2.2.5 Amplification of MDR1 in RPMI TAX (a) and RPMI ML (b). 48.100 = 
RNA extracted from 100^1 of CM conditioned for 48 hours (comparable to results 
obtained using Promega Total Isolation SV kit =9pl CM/ RT-PCR). 48.250 = RNA 
extracted from 250jil of CM conditioned for 48 hours (*50*11 CM/ RT-PCR). MDR 1 
gene transcript (arrow) was detected in RNA isolated from all CM samples from 
RPMI TAX CM (a) and RPMI ML CM (b). Amplified product was detected in the 
positive control, RPMI cell RNA, and was undetected in the negative control samples 
(-ve RT = RT reaction with H20 instead of RNA as control; -ve PCR = PCR reaction 
with H2O instead of cDNA as control).
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Previous studies of human serum/ plasma have suggested that the RNA detected in cell-free 
samples is probably present as short fragments (El- Hefnawy et al 2004). Morozkin et al 
(2004) suggested that extracellular RNA isolated from Hela and A431 growth medium was 
represented by 100-200 nucleotide long fragments. To investigate if full-length transcripts 
may be detected extracellularly, we designed primers that would anneal to different parts of 
the P-actin mRNA transcript (See Fig 3.3.1 for locations). The size of the amplified regions 
ranged from 142bp to 383bp. One of the sets of primers annealed to the 5’ untranslated 
region (UTR) of the P-actin transcript, and, as the mRNA is reverse transcribed using only 
Oligo dT as the reverse primer, any amplification of this region would indicate that for p- 
actin at least, full-length mRNA transcripts are present. Fig 3.3.2 shows that all four 
regions were successfully amplified.
3.3 A m plification of p-actin  gene using 5’ an d  3 ’ specific p rim ers
Figure 3.3.1 Location of amplified regions along p-actin gene transcript. 5’
untranslated region is denoted by broken line (....... ), the blue line indicates a region
of 171 bp that includes the 5’UTR region, the pink line represents a 196bp region that 
starts at approximately the 5’ UTR region (sequence analysed by Fleischhaker et aI 
2001). The yellow and green lines represent regions of 383bp and 143bp, respectively. 
The reverse primer for these two amplified regions is the same.
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Figure 3.3.2 Amplified regions of p-actin gene using DLKP CM RNA. p-actin gene 
transcripts (the coloured arrows here correspond to the target regions shown in Fig 
33.1) were detected in RNA isolated from CM after passing through a either a 0.22^m 
or 0.45|im filter. Amplified product was detected in the positive control, RPMI TAX 
cell RNA, and was undetected in the negative control samples (; -ve PCR = PCR 
reaction with HjO instead of cDNA as control). The length of each amplified product is 
written above the PCR bands in black.
The RT-PCR results shown in Fig 3.3.2 indicate for P-actin, at least, the presence of full- 
length transcripts in conditioned media that has been filtered through either a 0.22nm or
0.45nm filter.
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Having established that extracellular mRNA could be reliably and reproducibly amplified 
using a modified Tri Reagent protocol for RNA extraction, the aim of Section 3.4 was:
1. To investigate if any known tumour-related mRNAs already studied in out 
laboratory are expressed in a panel of human cancer cell line conditioned media 
samples
2. If tumour- related mRNAs are expressed, at what levels are they expressed?
3. To investigate if tumour- related mRNAs are expressed in all of the conditioned 
media samples corresponding to cells expressing the gene transcript.
4. To establish that the extracellular mRNA amplifiable from the conditioned media 
was not attributable in some way to the media that the cells are conditioned in.
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3.4 Analysis of gene transcripts in RNA isolated from cell lines and 
conditioned media
Once it was established that we could successfully extract and amplify mRNA from CM 
using a reproducible protocol, developed during the course of this study and that full-length 
mRNA transcripts were present in the extracellular environment of cancer cells, a more 
comprehensive study was performed, to include other known tumour markers previously 
studied in cell lines in our laboratory. Two different filter sizes were used to filter the CM. 
Ng el al (2002) showed that filter size can have an effect on the amount of RNA extractable 
from samples, so here the CM was filtered with 0.22|im and 0.45|im filters, (both of which 
would exclude cells from the CM) to establish if there was any effect on the gene 
transcripts amplifiable. Seven target gene transcripts were chosen and primers were chosen 
that amplified different regions of the transcripts, i.e. some were targctedto the 5’ end of the 
transcript (HnRNP B l, GST ?t); to the middle of the transcript (MRP 1, TOPO II, CK-19) 
and to the 3'end of the transcripts (Bcl-2, MDR 1). Fig 2.11.1.1 (Section 2.11.1) details the 
positions of the amplified regions of the mRNA transcripts selected for the study.
All transcripts underwent 45 PCR cycles at an annealing temperature of 54°C. RT-PCR 
was carried out on the corresponding cell RNA for the same transcripts, with co­
amplification of P-actin as an internal control. 30 PCR cycles were found to be sufficient 
for cell line samples with annealing temperature of 54°C. Cell RNA was also used as a 
positive control for all CM PCR reactions.
Although p-actin was routinely amplified in all CM, attempts to co-amplify P-actin 
inhibited detection of other gene products of interest. For this reason, p-actin was not co- 
amplified with the cDNA, when analysing CM. To ensure that any negative result obtained 
for a tumour- specific target gene transcript was not a false negative i.e. as a result of
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problems in the RT or PCR step, for every set of PCRs carried out using fresh cDNA, one 
aliquot was used to amplify the 5’ UTR region of P-actin mRNA.
The P-actin transcript co-amplified with the target mRNA of interest in the cell RNA 
samples amplified a region in the 3’ end of the mRNA transcript. The reason for not using 
the same set of primers for both CM and cell cDNAwas simply that the size of the PCR 
product for the 5’UTR targeted primers (171bp) was similar to the PCR product size for 
some of the target gene transcripts in the study, so to ensure clear separation of the PCR 
products when run on an agarose gel, p-actin primers with a larger amplicon size (383bp) 
were chosen for co-amplification with the cell RNA.
p-actin, CK-19 and HnRNP B1 gene transcripts were amplifiable for all cell lines and for 
their corresponding CM samples filtered through either a 0.22}im or 0.45 pin filter (Figs. 
3.4., 3.4.2 and 3.4.3 respectively).
Fig. 3.4.4 shows that GST % mRNA gene transcripts were detected in all cell line RNA
except MCF-7 and BT474 cell lines. Detection of this mRNA in CM filtered through both
size filters was found only in the CM samples that corresponded to the cell lines positive
for expression of this transcript with the exception of the 0.45 }im filtered CM taken from
MCF-7 cultured cells. A faint band corresponding to GST n mRNA was present in this
sample. This result was reproducibly found. Detection of Topoisomerase II and MRP1
transcripts were found in all cell line RNA, however differential expression of the transcript
was detected in the corresponding CM samples (Fig. 3.4.5 and 3.4.6 respectively).
Topoisomerase II mRNA gene transcripts were detected in 7/8 0.45|im filtered CM and in
only 3/8 0.22jim filtered CM samples. MRP1 mRNA gene transcripts were detected in 5/8
of the 0.45 p-m filtered CM samples and in only 2/8 of the 0.22jim filtered CM samples.
This indicates the possibility that these mRNA transcripts may be bound to proteins/
vesicles inhibited by filtration of the CM with a 0.22|im filter.
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Bcl-2 was expressed (albeit at relatively low levels) in the entire 8 cell lines analysed (see 
Fig. 3.4.7 (a)). However, this gene transcript was apparently not secreted by these cells i.e. 
with the exception of a very weak band resulting following amplification of 0.45 |xm 
filtered RPMI-TAX CM, bcl-2 mRNA was undetected in all CM.
MDR1 mRNA transcripts were detected in 3/8 of the cell lines analysed, with faint 
expression in a further 2/8 samples (Fig. 3.4.8). Detection of the mRNA in the 
corresponding CM samples however, was only reproducibly found in RPMI TAX CM 
samples.
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Figure 3.4.1 Expression of p-actin (171bp) in cells and filtered CM. p-actin gene 
transcript (arrow) was detected in RNA isolated from all cell lines analysed (a) and in 
corresponding CM after passing through a (b) 0.22 pm or (c) 0.45 pm filter. Amplified 
product was detected in the positive control and was undetected in the negative 
control samples (-ve RT = RT reaction with H20 instead of RNA as control; -ve PCR = 
PCR reaction with H20 instead of cDNA as control).
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Figure 3.4.2 Expression of CK-19 in cells and filtered CM. CK-19 (black arrow) and 
P-actin (yellow arrow) gene transcripts were detected in RNA isolated from all cell 
lines analysed (a) and CK-19 gene transcripts in corresponding CM after passing 
through a (b) 0.22 pm or (c) 0.45 pm filter. Amplified product was detected in the 
positive control and was undetected in the negative control samples (-ve RT = RT 
reaction with H20 instead of RNA as control; -ve PCR = PCR reaction with H20 
instead of cDNA as control).
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Figure 3.4.3 Expression of HnRNP B1 in ceils and filtered CM. HnRNP B1 (black 
arrow) and p-actin (yellow arrow) gene transcripts were detected in RNA isolated 
from all cell lines analysed (a) and HnRNP B1 gene transcripts in corresponding CM 
after passing through a (b) 0.22 pm or (c) 0.45 pm filter. Amplified product was 
detected in the positive control and was undetected in the negative control samples (- 
ve RT = RT reaction with H20 instead of RNA as control; -ve PCR = PCR reaction 
with H20 instead of cDNA as control).
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Figure 3.4.4 Expression of GST n in cells and CM. GST n  mRNA (black arrow) was 
expressed by most cell lines and CM. In the case of MCF-7, no product was detected 
in cell or CM samples; for BT474, GST n was undetected in cell RNA and 0.22 |im 
filtered CM (b), but a weak band was detected in the 0.45 |im filtrate (c). p-actin was 
co-amplified with GST it when analysing RNA from cell lines (yellow arrow). 
Amplified product was detected in the positive control (+VE) (-RT = RT reaction with 
H2 O instead of RNA as control; -PCR = PCR reaction with H2O instead of cDNA as 
control).
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Figure 3.4.5 Expression of TOPO II in cells and CM. Topoisomerase II mRNA (black 
arrow) was expressed by all cell lines, detected in all 0.45 pm filtered CM (c), but in 
only 3 0.22pm filtered CM specimens (b). p-actin was successfully co-amplified in cell 
RNA (yellow arrow (a)). Amplified product was detected in the positive control and 
was undetected in the negative control samples (-ve RT = RT reaction with H2O 
instead of RNA as control; -PCR = PCR reaction with H2 O instead of cDNA as 
control).
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Figure 3.4.6 Expression of MRP1 in cells and CM. MRP1 (black arrow) was expressed 
by all cell lines, detected in only 2 of the 0.22 pm filtered CM (b), but in 5 of the 0.45 
pm CM specimens (c). p-actin was co-amplified with MRP1 when analysing RNA 
from cell lines (yellow arrow (a)). Amplified product was detected in the positive 
control and was undetected in the negative control samples (-ve RT = RT reaction 
with H2 O instead of RNA as control; -PCR = PCR reaction with H2O instead of cDNA 
as control).
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Figure 3.4.7 Expression of bcl-2 in cells and CM. bcl-2 (black arrow) was expressed, to 
some extent, by all cell lines analysed (a), but with the exception of RPMI-TAX 0,45 
pm filtrate (c), was undetected in CM ((a) and (b)). P-actin was co-amplified with bcl- 
2 when analysing RNA from cell lines (green arrow (a)). Amplified product was 
detected in the positive control (+VE) and was undetected in the negative control 
samples (-ve RT = RT reaction with H2O instead of RNA as control).
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Figure 3.4.8 Expression of MDR 1 in cells and CM. MDR1 mRNA was expressed in 
RPMI ML, RPMI TAX, MDA-F-TAX-SI, and to a lesser extent MDA-F and BT474 
cell mRNA (a), p-actin was co-amplifled with MDR1 when analysing RNA from cell 
lines (yellow arrow (a)). Amplified product was detected in the positive control and 
was undetected in the negative control samples (-ve = RT reaction with H2 O instead of 
RNA as control; -PCR = PCR reaction with H2 O instead of cDNA as control).
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As mRNA gene transcripts have been detected in serum specimens from normal, healthy 
humans, it is likely that mRNA transcripts are also detectable in foetal calf serum. To 
eliminate the possibility that the mRNA found to be amplifiable in CM could be attributed 
to the foetal calf serum used in the media to culture the cells, the Tri Reagent extraction 
protocol was carried out on ATCC media (5% FCS) that was unconditioned i.e. unexposed 
to any cells and filtered with a 0.45pm filter (see Section 2.8.2.2). RT-PCR was carried out 
on the sample for p-actin as it was present in all the CM samples, therefore if any human 
mRNA was present in the media unconditioned by any cells, the likelihood is that P-actin 
would be amplified. 45 cycles of PCR were used. Fig 3.4.1.1 shows that no P-actin gene 
transcripts were detected in the media that was unexposed to cells indicating that human p- 
actin mRNA previously detected in the CM samples from cultured human cancer cell lines 
was not attributable to the FCS used in the preparation of the cell culture media/ or by 
contamination of the media by any other source.
3.4.1 RT-PCR of media unconditioned by any cells
Figure 3.4.1.1 RT-PCR of media unconditioned by cells for p-actin (171bp). p-actin 
gene transcript (arrow) was detected in the positive control, DLKP cell RNA, sample 
only. Amplified product was undetected in the unconditioned media sample and 
negative control samples (-ve RT = RT reaction with H2 O instead of RNA as control; - 
ve PCR = PCR reaction with H20 instead of cDNA as control). A.FCS = ATCC+ 
5%FCS media.
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The aim of Section 3.5 was to test biological sample concentration columns that are used in 
our laboratory to concentrate protein solutions, to see if they could be employed to 
concentrate the quantity of RNA in the conditioned media to levels required for labelling 
and hybridisation to Affymetrix array chips.
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It was decided that because we had proven that it was possible to amplify cancer related 
target gene transcripts in CM samples (Section 3.4) that we should investigate the 
possibility of concentrating the RNA in CM samples by using Millipore concentrators.
The concentrators can be used to concentrate biological samples containing protein/ nucleic 
acids based on a process called ultra-filtration. RNA would then be extracted from the 
concentrated sample to see if there was an increase in the yield of RNA. The aim was to 
achieve a high enough yield of RNA to be able to use it in microarray studies. The 
minimum RNA required, at the time, for amplification, labelling and hybridisation to an 
Affymetrix Plus chip was 5jig.
DLKP cells were used for this study analysis. The experimental designs for the 
concentration protocols are detailed in Section 2.7.4- 6. RNA was extracted from all of the 
samples using the Tri Reagent protocol described in Section 2.8.2.2 and resuspended in 
15|il DEPC treated water. RNA was also extracted from 25mls of CM using a scaled- up 
Tri Reagent protocol where the volumes of all solutions were increased 10 fold and the 
protocol followed as per Section 2.8.2.2, so for example 75mls of Tri Reagent was mixed 
with the 25 mis of CM.
The RNA samples from all of the protocols mentioned were compared using the Nanodrop 
to measure the yield (see Section 2.9.1), and the Bioanalyser to look at the fragment sizes in 
the samples (see Section 2.9.2). RT-PCR was also carried out using selected samples to 
detect P-actin mRNA transcripts in the different samples.
3.5.1 RNA yield before and after concentration.
The yield of RNA in all of the concentrated samples (C) is higher than the yield in the
3.5 Concentration of CM with Millipore concentrators
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samples before concentration (B) and the yield of RNA in the samples before concentration
(B) is higher than in the flow- through samples (FT) (see Fig. 3.5.1.1).
The total RNA yield of the CM passed through a 0.22pm filter (as measured by the
Nanodrop), was 897ng, 1.13 fig and 443ng before concentration (0.22B), with concentration
(0.22C) and in the flow- through (0.22FT) respectively. The CM passed through the
0.45pm filter yielded slightly higher amounts of RNA in all three samples; 987ng 1.26pg
and 502ng in the RNA samples before concentration (0.45B), with concentration (0.45C)
and in the flow- through (0.45FT) respectively. This indicates that the different filter sizes
the CM was filtered through had a slight affect on the yield of RNA and also that RNA was
able to pass through the column. Whilst there was an increase in the RNA yield in both
concentrated samples (0.22/ 0.45C) compared to the RNA yield of the samples before
concentration (0.22/ 0.45B), the increase was not in line with the magnitude of
concentration of the sample i.e. 14.5mls of CM was concentrated to ~500pls, but the RNA
yields, as determined by the Nanodrop, showed an increase in RNA yield of less than 1.5
fold. The RNA yield of the samples from the second concentration protocol (0.45B (4X),
0.45C (4X) and 0.45FT (4X)) are approximately 4 times more concentrated than the RNA
yield of the samples obtained in the first concentration protocol (0.45B, 0.45C and 0.45FT)
with the exception of 0.45B (4X) (see Fig. 3.5.1.1). This was a direct result of re-
suspending the 4 RNA pellets, resulting from the Tri Reagent RNA extraction of 4 x 250pl
CM aliquots, into one 15pi volume of water in the second concentration protocol as
opposed to one RNA pellet being resuspended in 15pl water in the first concentration
protocol. The addition of RNasin had no effect on the yield of RNA in the samples obtained
with the third concentration protocol (see Fig. 3.5.1.1, samples 0.45C (4X) +/- RNasin).
A total of 2.7pg of RNA was extracted from 25mls of CM using 75mls of Tri Reagent
(sample 25.45 in Fig. 3.5.1.1). This was achieved by scaling up the volumes of all solutions
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required for the Tri Reagent RNA extraction protocol and employing the use of an 
ultracentrifuge at 4°C instead of a bench top centrifuge. This low yield however, is more 
likely due to the problems encountered during the extraction protocol. The ultracentrifuge 
tubes have a round bottom, so when the RNA was precipitated using isopropanol and 
centrifuged, a uniform pellet was not formed. To try to get a uniform pellet, all of the 
isopropanol was removed, with the exception of approximately 1ml in each o f  the four 
tubes, and the tubes were vortexed to lift the RNA pellets. The isopropanol- pellet mixes 
were then poured into 1.5ml eppendorf tubes so that they could be centrifuged again to 
obtain a single pellet. This resulted in a large loss of RNA due to the transferral process.
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0
Figure 3.5.1.1 Yield of RNA before and after concentration of CM. The samples 
obtained using the different protocols are plotted on the X-axis (sample name above 
each column), with the total RNA yield (ng) plotted on the Y-axis. CP1= 
Concentration Protocol I, CP2= Concentration Protocol 2, CP3= Concentration 
Protocol 3.
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3.5.2 Bioanalyser traces of RNA before and after concentration.
As the Nanodrop can determine the concentration of RNA in the sample but not the
integrity of the RNA, aliquots of each sample were run on an Agilent Bioanalyser RNA 
nano chip to see if  fragments of RNA were visible on the chips.
The bioanalyser tracing shown in Fig 3.5.2.1 (a) shows a typical bioanalyser tracing 
obtained using good quality cell RNA. Integrity of this RNA is measured by 18S and 28S 
ribosomal bands that appear at 40 and 47 seconds (time is plotted on the X-axis) correlating 
to 2000 and 4000 nucleotides in length respectively.
None of the RNA samples obtained from CM, before concentration, with concentration or 
flow-through show the presence of 18s and 28s ribosomal bands regardless of protocol, 
centrifuge speeds or time taken to process. This result was not unexpected as it would mean 
that ribosomal RNA is secreted into the CM.
With the exception of the 0.45FT (4X) sample, all RNA samples, were four RNA pellets 
were resuspended into one \5\i\ volume of water (0.45B (4X), 0.45C (4X), 0.45C (4X) -  
RNasin, 0.45C (4X) +RNasin) and the RNA sample resulting from the scale-up of the Tri 
Reagent protocol (25.45), show evidence of RNA fragments in the samples ranging in sizes 
up to lOOOnts as denoted by the peaks at 25 seconds to 40 seconds (Figs. 3.6.5.2.1 (h), (i), 
(k), (1) and (m) respectively). The addition of RNasin also had little effect on the profile of 
RNA extracted from the concentrated CM. (Fig 3.5.2.1 (1) with RNasin, 3.5.2.1 (k) without 
RNasin).
It was decided at this stage to carry out RT- PCR using some of the samples shown in Fig
3.5.2.1 to test for the presence of {J-actin mRNA gene transcripts using oligo dT as the 
reverse transcription primer and PCR primers that amplify a region of the P-actin gene 
transcript close to the start of the 5’ coding region.
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Figure 3.5.2.1 Bioanalyser traces of CM RNA before and after concentration, a = 
DLKP cell RNA (+ve control), b = 0.22B, c = 0.22C, d -  0.22FT, e = 0.45B, f  =0 .45C, g 
-  0.45FT, h -  0.45B (4X), i = 0.45C (4X), j = 0.45FT (4X), k = 0.45C (4X) -RNasin, I = 
0.45C (4X) + RNasin, m = 25.45. The time in seconds is plotted on the X-axis with the 
fluorescence plotted on the Y-axis. Smaller fragments move more quickly through the 
gel and are detected first, so peaks on the left hand side of the electrophoregram 
represent smaller fragments and the height of the fluorescent peaks indicate the 
abundance of the fragments.
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3.5.3 RT-PCR of CM RNA samples before and after concentration for p- 
actin
p-actin gene transcripts were amplifiable in all CM samples before concentration, after 
concentration or in the flow through samples with the exception of the flow through sample 
corresponding to the CM that was passed through a 0.22|im filter (see Fig 3.5.3.1).
In summary, the biological sample concentration columns did increase the yield of RNA 
extractable from the CM, as evident by the nanodrop, bioanalyser and RT-PCR , but the 
yield was not enough for labelling and hybridisation to Asymetrix microarray chips as 5pg 
of total RNA was required at the time.
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Figure 3.5.3.1 RT- PCR for P-actin (196bp) in CM before and after concentration. (3- 
actin gene transcripts (arrow) were detected in all samples except the flow-through 
sample that had been filtered with a 0.22pm filter before it was concentrated. 
Amplified product was detected in the positive control samples (+ 0.22 CM, + 0.45CM 
and +CELL) and was undetected in the negative control samples (-ve RT = RT 
reaction with H2O instead of RNA as control; -ve PCR = PCR reaction with H2O 
instead of cDNA as control). The 0.22 CM and 0.45 CM positive control samples were 
DLKP CM samples previously used in RT-PCR and found to be positive for p-actin, 
and the cell RNA was from DLKP cell RNA.
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The aim of Section 3.6 is to investigate if quantification of RNA from CM extracted using 
Tri Reagent was overestimated when quantified using the Nanodrop.
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The previous study (Section 3.5) indicated that there were some discrepancies with the
readings obtained using the Nanodrop with both the bioanalyser traces and the RT-PCR 
results. Ginzinger (2002) advised caution when using nucleic acids purified with phenol-/ 
chloroform- based methods for Q-PCR experiments as trace amounts of phenol can 
contribute to reduced reverse-transcription efficiencies and over estimation of RNA 
quantification using a UV spectrophotometer. Even though reverse transcription of the CM 
samples did not seem to be affected, we decided to test if the Tri Reagent method of RNA 
extraction was contributing to an overestimation of the RNA in the CM samples when read 
using the Nanodrop (see Section 2.9.1)
To do this, firstly an aliquot of Tri Reagent was diluted 1:100 with both phosphate buffered 
saline (PBS) and ultra high processed water (UHP) then quantified using the Nanodrop (see 
Fig. 3.6.1).
UHP (in place of a solution containing RNA) was then processed using the Tri Reagent 
RNA modified extraction protocol (Section 2.8.2.2) or processed using an RNeasy RNA 
extraction kit according to the manufacturers protocol. The Tri Reagent extraction protocol 
involved adding 250/il of UHP to 750/a 1 of Tri Reagent and processing the sample 
according to the modified protocol with or without an overnight isopropanol precipitation 
step. This was compared to samples of UHP and PBS that were either firstly processed with 
Tri Reagent then cleaned up using an RNeasy clean-up protocol or processed only using the 
RNeasy extraction protocol. The RNeasy RNA extraction procedure is a column- based 
extraction protocol which relies on lysing RNA using a lysis buffer and adding an ethanol 
based solution to enable the RNA to bind to a column. The column is then washed with an 
ethanol based solution and finally eluted using RNase- free water. No phenol is required for
3.6 Interference in quantification of small amounts of RNA
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this protocol, so comparisons between the phenol and non-phenol based methods were 
achievable.
The Tri Reagent/ RNeasy clean-up involves processing the samples using Tri Reagent 
according to Section 2.8.2.2, then instead of adding isopropanol to precipitate the RNA 
from the colourless upper aqueous layer, one volume of 70% Ethanol was added and the 
gently mixed solution was put on to an RNeasy column. The samples were processed 
according to the manufacturers clean-up protocol.
The Nanodrop reading obtained for diluted Tri Reagent shown in Fig. 3.6.1(a) shows that 
there is a major peak at 270nm and a minor peak at 260nm. As RNA is quantified by the 
amount of UV absorbed at 260nm, the Nanodrop is falsely stating that the sample contains 
~1.6pg/ pi of RNA.
When an RNA solution is replaced with UHP and the Tri Reagent RNA extraction protocol 
followed (see Section 2.8.2,2), the Nanodrop falsely quantifies that there is >100ng of RNA 
in the UHP sample (Figure 3.6.1(b)). There are two peaks at 260 and 270nm which are 
similar to the peaks obtained when diluted Tri Reagent was read using the Nanodrop (see 
Fig. 3.6.1(a)). The use of ice- cold or room temperature isopropanol in the protocol does 
not reduce the interference in the Nanodrop reading.
When an RNA solution is replaced with UHP and the Tri Reagent RNA extraction protocol 
followed as above with the exception that the isopropanol precipitation step is not carried 
out overnight, the Nanodrop falsely quantifies that there is >60ng of RNA in the UHP 
sample (Figure 3.6.1(c)). There is again a peak at 270nm which is similar to the peaks 
obtained when diluted Tri Reagent was read using the Nanodrop (see Fig. 3.6.1(a)). The use 
of ice- cold or room temperature isopropanol does not reduce the interference in the 
Nanodrop reading. The inclusion of an overnight isopropanol precipitation at ~20°C step
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does seem to increase the false reading (Fig.3.6.1(b)- Nanodrop reading of >100ng 
compared to >60ng when no over-night isopropanol precipitation step is included (Fig 
3.6.1(c)).
The UV readings obtained using UHP/ PBS processed with Tri Reagent and cleaned up 
using a Qiagen RNeasy column according to the manufacturer’s protocol are shown in Fig 
3.6.1(d). The sample was eluted using 30^1 of RNase free water. A peak at 270nm is still 
visible in both samples indicating that clean- up of the sample using the RNeasy column 
was not enough to eradicate the interference in sample quantification.
Figure 3.6.1. Nanodrop screenshots of quantified samples. Wavelength is plotted on 
the X-axis and UV absorbance on the Y-axis, (a) Tri Reagent diluted with PBS/ UHP. 
Tri Reagent was diluted 1:100 with either PBS or UHP and lp l was read using the 
Nanodrop (b) Tri Reagent extraction of UHP overnight (O/N) precipitation. Either 
ice- cold isopropanol (black line) or room temperature isopropanol (red line) was used 
in the RNA extraction protocol. l\i\ from a 15pl sample was tested (c) Tri Reagent 
extraction of UHP with no O/N precipitation step. Either ice- cold isopropanol (green
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line) or room temperature isopropanol (pink line) was used in the RNA extraction 
protocol. l\i\ from a 15pl sample was tested (d) Tri Reagent extraction of UHP with 
using RNeasy cleanup protocol. Either UHP (pink line) or PBS (green line) was used 
instead of RNA and processed using a modified Tri Reagent protocol that includes an 
RNeasy cleanup step, lp l from the 30jul eluted from the column was tested.
Fig. 3.6.2 shows that unlike the UHP/ PBS samples that were processed only with Tri 
Reagent (pink and black lines) or processed with Tri Reagent and cleaned up using an 
RNeasy column (Fig 3.6.1(d)), the UHP/ PBS samples that were processed with the 
RNeasy kit RNA extraction procedure alone (light green and brown lines in Fig. 3.6.2),
Tri Reagent 
extraction with 
O/N isopropanol 
precipitation, 
(see Fig 3.6.1 
(B))
Figure 3.6.2 RNeasy extraction of UHP. Wavelength is plotted on the X-axis and UV 
absorbance on the Y-axis. Samples already shown in Fig 3.6.3 are re- read and 
compared to UHP (light blue line) or PBS (brown line) that was processed using the 
RNeasy RNA extraction procedure only, with no Tri Reagent
which does not require phenolshow no absorbance at 260nm.
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The extraction of RNA from CM using Tri Reagent shows evidence of phenol 
contamination as indicated by two peaks at 260 and a larger one at 270nm (Fig 3.6.3). 
However RNA extracted from cells (Fig 3.6.1) shows no indication of a contaminating 
peak at 270nm despite also being extracted using Tri Reagent. This seems that phenol 
carryover leading to overestimation of samples containing RNA only affects/ interferes 
with the quantification of RNA when the RNA solution cannot be diluted before 
quantification as in the case of RNA extracted from CM.
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RNA extracted using Tri Reagent (Section 2.8.1 and 2.8.2.2) RNA. The wavelength is 
plotted on the X- axis and the UV Absorbance on the Y-axis.
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The aim of Section 3.7 was to assess if it was possible to amplify enough cRNA from CM 
samples to be hybridised to an Affymetrix human genome Plus 2.0 microarray chip.
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Although quantification of RNA extracted from CM is overestimated when using the 
Nanodrop (see Section 3.6), there is no doubt to the presence of mRNA in these samples 
because of all the RT-PCR work carried out on these samples (see Sections 3.1- 3.4). 
Affymetrix recently released a 2-cycle amplification protocol that enables the amplification 
and labelling of RNA when as little as lO-lOOng of starting material is available. We 
decided to test if CM RNA could be successfully amplified and labelled to yield the 15pig 
of biotinylated cRNA required for the protocol. As there is no other reliable means of 
quantifying the CM RNA at the time, lOOng from each sample, as quantified by the 
Nanodrop, were used as starting material. As the protocol can handle lOng- lOOng, it was 
hoped that we would have adequate RNA in the samples to fall into this range. This would 
mean that the need to concentrate the RNA with biological sample concentrators would not 
be necessary.
DLKP cells were set up and CM collected and processed according to Section 2.7.7. 
Initially only one sample was tested (DLKP 1), but when we found it was possible to 
profile CM RNA using CM extracted from this sample, a further 2 biological repeat 
samples were prepared (DLKP 2 and DLKP 3). RNA was extracted from the CM samples 
according to Section 2.8.2.2. lOOng of the extracted RNA, as measured by the Nanodrop 
was then linearly amplified using the methods described in Section 2.12. 15|xg of this 
cRNA for each of the three replicate CM samples was then successfully hybridised to an 
Affymetrix U133A Plus 2.0 chip.
3.7 Pilot Microarray Study of DLKP CM
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The Nanodrop readings shown in Fig 3.7.1.1 show that whilst the profile of the DLKP 3 
CM sample before amplification (Fig. 3.7.1.1 (a)) shows the presence of two distinct peaks 
at 260 and 270nm indicating the presence of phenol/ Tri Reagent carryover, the profile of 
cRNA after two rounds of amplification (Fig 3.7.1.1 (b)) shows no evidence of any phenol 
contamination/ Tri Reagent carryover as evident by the presence of just one single peak at 
260nm.
3.7.1 Nanodrop/ bioanalyser traces for DLKP CM
(a)
(b)
Figure 3.7.1.1 An example of Nanodrop readings obtained for DLKP CM RNA before 
amplification ((a), multiple samples) and after two rounds of amplification (b) (1.1= 
DLKP 3 sample, green line). Wavelength is measured on the X-axis, absorbance on 
the Y-axis. RNA absorbs UV at 260nm.
The quantity of cRNA generated after both cycles of linear amplification is listed in Table
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3.7.1.1. The results show that after two rounds of linear amplification, the mRNA in the 
three DLKP samples have been amplified enough to yield the 15jag of labelled cRNA 
required for hybridisation to the Affymetrix Plus 2.0 microarray chips.
Following fragmentation of the cRNA in preparation for hybridisation to the Affymetrix 
microarray chips, an aliquot of the samples before amplification, after amplification and 
after fragmentation were run on an Agilent Bioanalyser chip (see Section 2.9.2).
Sample After Is* IVT After 2nd IVT
DLKP 1 335.7ng 26.65ng
DLKP 2 143.6ng 21.56ng
DLKP 3 243ng 23.75|ig
Table 3.7.1.1 Quantity of RNA during 2 cycle amplification protocol. DLKP 1/ 2/ 3 
indicate the CM samples that were linearly amplified, IVT= in vitro transcription.
The results of the bioanalyser tracings shown in Fig 3.7.1.2 indicate that even with a sample 
of RNA that showed no fragments visible in a bioanalyser RNA nano trace (Fig 3.7.1.2 
(a)), the two cycle amplification protocol was able to successfully amplify 23.75|xg of 
biotinylated cRNA (Fig. 3.7.1.2 (b)). This cRNA was then fragmented into nucleotides of 
approximately 200bps long (Fig 3.7.1.2 (c)) and hybridised to the Affymetrix Plus 2.0 chip. 
Initially, the DLKP 2 CM sample did not yield the 15ng of RNA required for hybridisation 
to the Affymetrix chips so the amplification and labelling process was repeated for this 
sample. The second attempt was successful in yielding the required 15|xg cRNA.
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Figure 3.7.1.2 Bioanalyser traces of DLKP CM before and after IV'T. The time in 
seconds is plotted on the X-axis with the fluorescence plotted on the Y-axis. Smaller 
fragments move more quickly through the gel and so are detected first, so peaks on 
the left hand side of the electrophoregram represent smaller fragments and the height 
of the fluorescent peaks indicate the abundance of the fragments, (a) RNA extracted 
from DLKP 3 CM (b) DLKP 3 cRNA after two rounds of amplification and labelling 
(c) DLKP 3 cRNA, fragmented to 200 nucleotides.
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There was an average Present call of 23.1% as determined by Affymetrix calculations. The 
scaling factors of the DLKP CM samples (Table 3.7.2.1), although higher than the scaling 
factor usually obtained when dealing with cell derived RNA (1-3), they are similar to each 
other and therefore are acceptable.
The six probes sets that target p-actin and GAPDH mRNA (3 each) were called Present in 
all three samples. The GAPDH 375’ and 37M ratios were higher than expected (compared 
to ratios no higher than 3 with cell RNA). But as the RNA we are using to amplify and 
hybridise to the arrays is essentially extracellular mRNA and this RNA has never been 
hybridised to microarray chips in publications before, we have nothing to compare it to 
other than the profiles resulting from the “perfect RNA” extracted from cells. The noise and 
background QA parameters were within acceptable ranges.
3.7.2 Microarray Q.A results for DLKP CM
Parameter DLKP 1 DLKP 2 DLKP 3
Scaling Factor 8.858 10.268 8.269
Noise 1.17 1.210 1.34
Background 37.83 36.77 40.15
% Present 23.2 22.6 23.5
3V 5’ GAPDH ratio 11.66 6.31 7.15
37M GAPDH ratio 3.15 1.47 1.27
Table 3.7.2.1 QA results of DLKP CM Affymetrix U133A Plus 2.0 chips. (Explanation 
for the QA parameters measured with the microarray chips to determine the quality 
of the chips can be found in Section 2.13.7.)
The data for the three DLKP CM samples were normalised with dChip (Section 2.13.8.2) 
and imported into Genespring (Section 2.13.9.1) for visual inspection.
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3.7.3 Scatter plot and Venn diagrams of gene transcripts expressed in 
DLKP CM RNA
Approximately 20,000 probe sets are called P in each of the replicate samples, of this 9,528 
probe sets are called P in all three arrays (See Venn diagram Fig. 3.7.3.1). 22,099 probe sets 
are called A in all three DLKP CM samples. Over 6,000 probes sets called P in each sample 
is also called present by at least 2 of the three replicate samples. The remainder of the probe 
sets called P in each of the replicate samples are called Absent in the other two replicate 
arrays (approximately 4,500 probe sets per replicate sample.
The Venn diagram in Fig. 3.7.3.2 indicates that there is a distinction between the D1 
sample and D2 and D3 samples, D1 has approximately 1,100 more probe sets with 
expression levels over 100 than the D2 and D3 samples. The D2 and D3 samples have 
about 200 probe sets each that are expressed at levels over 100 in only those samples 
compared to 1,307 probe sets expressed at levels over 100 in the D1 and not in the D2 or 
D3 samples . 2,139 probe sets are commonly expressed at levels over 100 by all three 
replicate samples.
The scatter plot shown in Fig. 3.7.3.2 demonstrates that the majority of gene transcripts 
with levels of expression over 100 fluorescent units are expressed at similar levels by all 
three samples (indicated by the white dots). The gene transcripts with low levels of 
expression (under 100 expression units, coloured by grey dots), are not uniformly expressed 
in the three replicate samples i.e. they do not group around a central line indicating similar 
expression levels, instead they form a bell- shape curve signifying wide variation. This 
indicates that samples with a low level of expression <100 units, may simply be attributable 
to noise and so care must be taken when assessing changes in gene expression at such low 
levels.
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Figure 3.7.3.1 Scatter plot and Venn diagram of probe sets called P or M in DLKP 
CM samples. In the scatter plot (left-hand side) the expression levels of the probe sets 
in the different samples are plotted, DLKP 1 CM on the X-axis, DLKP 2 on the Y-axis 
and DLKP 3 on the Z axis. The colour of each dot, which represents a probe set, 
correlates to its grouping on the Venn diagram (right- hand side). In the Venn 
diagram, Dl= DLKP 1, D2= DLKP 2, D3= DLKP 3
Figure 3.73.2 Scatter plot and Venn diagram of probe sets with expression over 100 in 
DLKP CM samples In the scatter plot (left-hand side) the expression levels of the 
probe sets in the different samples are plotted, DLKP 1 CM on the X-axis, DLKP 2 on 
the Y-axis and DLKP 3 on the Z axis. The colour of each dot, which represents a 
probe set, correlates to its grouping on the Venn diagram (right- hand side). In the 
Venn diagram, Dl= DLKP 1, D2= DLKP 2, D3= DLKP 3
The gene expression profiles for the DLKP CM samples were also compared to the profiles
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obtained with DLKP cell RNA. The DLKP cell RNA samples RNA extraction, 
amplification, labelling and hybridisation were prepared by Helena Joyce and Jason 
McMorrow. It must be noted that the DLKP CM RNA in this study was not conditioned by 
these cells and also that these cells underwent just one round of amplification so any 
comparisons between the two profiles must be made with these notes in mind.
3.7.4 Scatter plot and Venn diagrams of gene transcripts expressed in 
DLKP cell RNA
22, 381 probe sets are called P in all three DLKP cell samples compared to just 9,528 probe 
sets commonly called Present in the three replicate DLKP CM samples (see Fig. 3.7.4.1 for 
details). 19,056 probe sets are called A in the three cell samples. Approximately 2,500 
probe sets are called P or M in the each of the three cell samples that are called Absent in 
the other two replicate samples and a further 3,200- 3,700 probe sets are called P in each 
replicate sample that are also called P in at least one other replicate sample.
Visually it is clear comparing the scatter plots in Fig. 3.7.4.1 to the 3-D scatter plot 
obtained for DLKP CM samples (Figs. 3.7.3.1/ 2) that the expression pattern of probe sets 
called P or M in the cell RNA samples is much more uniform and with tighter clustering 
around a central line. A scatter plot with a linear 45° angle on an X Y Z scatter plot would 
indicate that the expression levels of the probe sets in the three samples were identical, so 
the tighter the expression pattern in the 3-D scatter plot to a 45° angle, the more uniform 
the expression.
This is also reflected in the fact that of all the probe sets called P or M in the DLKP cell
RNA samples, 63% of the probe sets (22,381) are commonly called P or M in all three
samples (Fig. 3.7.4.1) compared to only 30% of the probe sets called P or M in the DLKP
CM samples (9,528/ 32, 576 probe sets, Fig. 3.7.3.1).
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Figure 3.7.4.1 Scatter plot and Venn diagram of probes called F or M in DLKP cell 
RNA. In the scatter plot (left- hand side), DLKP 1 cell RNA is plotted on the X-axis, 
DLKP 2 cell RNA on the Y-axis and DLKP 3 on the Z-axis. The colour of the dots in 
the scatter plot correlates to their grouping according to the Venn diagram (right- 
hand side). In the Venn diagram, D l= DLKP 1 cell RNA, D2 = DLKP 2 cell RNA, D3= 
DLKP 3 cell RNA.
3.7.5 Common gene transcripts called P or M in 3 DLKP cell arrays and 
3 DLKP CM arrays
Of the 9,528 probe sets called P in all of the CM samples, 80% of them (7, 645 probe sets) 
were also called P in the three DLKP cell samples. 20% of the probe sets called P in all 
three CM samples however were not called P in all three cell samples.
Figure 3.7.5.1 Gene transcripts called P or M in 3/3 DLKP cell arrays vs. Gene 
transcripts called P or M in 3/3 DLKP CM arrays. The number of probe sets called P 
or M in all DLKP cell RNA samples (left circle) are overlapped with the number of 
probe sets called P or M in all DLKP CM RNA samples (right circle).
1 6 2
It was decidcd to apply an expression cut -  off of 100 to the CM samples only because Fig. 
3.7.3.2 showed that these probe sets displayed more uniform expression to see if the 
concordance of overlap between the two different sample types could be increased.
3.7.6 Common gene transcripts called P or M in 3 DLKP cell arrays and 
3 DLKP CM arrays when expression cut- off of 100 is applied to 
CM only
Of the 2,139 probe sets that are expressed at over 100 fluorescent units in the CM samples. 
Fig. 3.7.6.1 shows that 70% of these are also called P or M in 3/3 cell samples. Of the 2,139 
probe sets with expression over 100 fluorescent units in 3/3 CM samples, 1,432 (67%) have 
a P or M call assigned to them. This result indicates that only including CM probe sets with 
an expression value of over 100 did not increase the concordance of overlap between the 
probe sets in the DLKP cell RNA samples and the probe sets in the DLKP CM samples.
Figure 3.7.6.1 Gene transcripts called P or M in 3 DLKP cell arrays vs. Gene 
transcripts called P or M in 3 DLKP CM arrays when cut-off of 100 is applied to CM 
only. The number of probe sets called P or M in all three DLKP cell samples (left 
circle) are overlapped with the probe sets that are expressed at higher than 100 
fluorescent units in the DLKP CM samples (right circle).
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3.7.7 Overview of gene ontology’ of gene transcripts common to DLKP 
CM and cells using Onto-Express
The gene transcripts called P or M DLKP cell RNA that were also called P or M with an 
expression cut -o ff of 100 in the DLKP CM samples were entered into Onto- Express for 
functional annotation to be assigned (see Section 2.13.9.4). Two pie charts shown in Figs.
3.7.7.1 and 1.1.12 show the results obtained from the Onto-Express software. Only 
categories with a minimum number o f 20 gene transcripts were included, if there were less 
than 20 gene transcripts in a category they were grouped in a segment called “other".
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Fig 3.7.7.1 Gene ontology of the biological process related gene transcripts common to 
DLKP CM and cell samples. UnknownP = unknown process, Other « categories with 
less than 20 gene transcripts.
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Fig 3.7.7.2 Gene ontology of the molecular function of the gene transcripts common to 
DLKP CM and cell samples. UnknownF = unknown function. Other = categories with 
less than 20 gene transcripts.
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The aim of Section 3.8 was to assess the changes in CM samples taken from a panel of 
parental and drug-selected cell lines by microarray to see if  any CM specific gene 
expression profiles were obtainable and also whether any potential markers for drug 
resistance could be identified. This also involved validation of the microarray Presence 
using a second technique, RT-PCR, to confirm Present or Absence call assigned and/ or 
trend of change in expression.
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3.8 Analysis of mRNA Expressed By Various CM Using Microarray
The trial run using DLKP CM, to see if  it was possible to get valuable array information 
from CM RNA proved to be successful, so the study was increased to investigate 
differences in mRNA expression across cell lines. Groups o f parental human cancer cell 
lines and their drug selected variants were cultured (in triplicate and at the same passage 
number) and their CM was harvested after 48hours and filtered with a 0.45jam filter. 
The RNA was then extracted and amplified, labelled and hybridised to Affymetrix 
U133A Plus 2 chips (as described in Section 2.12)
The CM samples were taken from eight different cell lines; NCI H I299 (H I299) and its 
taxol selected variant (H I299 TAX), RPMI 2650 (RPMI) and its taxol (RPMI TAX) 
and melphalan (RPMI ML) selected variants and MDA-MB-435-F (MDA-F) and its 
super invasive adriamycin (MDA-F-ADR-SI) and taxol (MDA-F-TAX-SI) selected 
variants (see Table 2.5.1 in Section 2.5 for details of cell lines).
One CM sample, RPMI TAX 2, did not yield the minimum requirement of 15|xg of 
cRNA after two attempts of amplification and so was excluded from the study and the 
remaining 23 CM cRNA samples were hybridised to the Affymetrix Human Genome 
Plus 2.0 chips.
The following Section contains details o f the quality control parameters analysed, 
scatter plot and Venn diagrams of gene expression, hierarchical clustering of the 
samples, generation of lists containing significantly changing gene transcripts, gene 
ontology and RT-PCR studies to assess if  the data found using microarray techniques 
could be reproduced with RT-PCR.
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3.8.1 cRNA yield throughout amplification procedure
The average yield o f labelled cRNA obtained in this study was 53.5^,g± 26.6 (ranging 
from
15^ig-103ng per CM). With the exception of RPMI 2 and H1299 3 CM samples, the 
cRNA yield obtained for the CM samples were as good as, but mostly much higher than 
the cRNA yields obtained with the DLKP CM samples (see Table 3.8. 1.1).
Sample After 1st IVT(ng) After 2nd IVT(^g)
H1299
1 356.4 39.39
2 369.9 30.62
3 420.3 15.04
H1299
TAX
1 363.6 50.45
2 325.8 55.46
3 363.6 23.75
RPMI
1 253.8 28.32
2 268.2 6.97
3 329.4 28.91
RPMI
TAX
1 424.8 49.39.
2 471.6 69.57
3 531.9 75.85
RPMI ML
1 476.1 51.12
2 531 30.03
3 311.4 34.03
MDA-F
1 431.1 65.74
2 392.4 78
3 425.7 92.86
MDA-F-
TAX-SI
1 425.7 99.86
2 530.1 103.91
3 457.2 48.77
MDA-F-
ADR-SI
1 447.3 96.13
2 298.8 35.95
3 439.2 74.05
Table 3.8.1.1 Quantity of cRNA generated with 2 rounds of linear amplification 
(IVT= in vitro transcription)
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3.8.2 M icroarray QA results for CM samples
The quality control parameters listed in Table 3.8.2.1 show that the scaling factor, noise 
and background are all at acceptable levels except in the case o f  samples MDA-F 1 and 
MDA-F-TAX-SI 2. Both o f these samples have high background and noise levels 
compared to the other samples. They also have lower scaling factors and together these 
correlate with a decrease in %  Present call.
MDA-F-TAX-SI 2 was excluded from further data analysis as it had a scaling factor 
more than 3 fold different than the other samples in the group in case it biased the 
results. The MDA-F 1 sample however, although having background levels higher than 
the other CM samples, was within the accepted range o f  20-100, the scaling factors 
were within a 3 fold difference o f  the other CM samples so the sample was included. 
MDA-F-ADR-SI 1 CM sample had a %Present call o f 19.4%, which was higher than 
the other CM samples but as all QA parameters were acceptable it was included.
In general, the present calls for each o f the samples were considerably lower than were 
achieved with the DLKP CM, ranging from 4.8- 19.4% with an average % Present call 
o f 10% compared to an average %Present call o f  23.1% with the DLKP CM samples. 
This may have been due to the time delay in processing the CM once it was taken o ff  
the cultured cells. There was a time delay o f up to twenty minutes before the filtered 
CM was added to Tri Reagent because these samples were being collected from cell 
lines cultured by other researchers. With the DLKP CM samples, there was no time 
delay and so perhaps more unstable mRNAs were protected from degradation by quick 
sample processing, i.e. addition o f Tri Reagent which inhibits RNase activity.
DChip software was used to normalise the entire set o f CM microarray data before 
further analysis o f  the data was carried out (see Section 2.13.8.2).
169
H l299 H1299 TAX M DA-F M DA-F-TAX-SI MDA-F-ADR-SI
I 2 3 1 2 3 1 2 3 1 2 3 1 2 3
Scaling Factor 22.5 16.8 20.25 18.34 16.9 17.14 9.86 16.9 14.92 20.44 6.994 24.84 11.18 20.92 15.29
Noise 1.07 1.2 1.09 1.25 1.24 1.15 2.49 1.36 1.4 1.27 3.35 1.06 1.32 1.05 1.59
Background 33.41 36.07 35.01 39.08 38.49 35.7 73.82 40.11 43.51 40.21 113.2 33.33 40.04 34.94 47.82
% Pres 9.7 12.3 11.1 10.4 11.8 11.7 6.3 11.2 11.8 8.5 4.8 8.1 19.4 10.5 8.9
GAPDH 3 7 5 ’ 3.65 6.74 4.5 11.87 5.73 1.77 2.79 3.13 8.21 5.35 4.81
GAPDH 37M 4.03 3.65 2.14
RPM I RPMI TAX RPMI ML
1 3 1 2 3 1 2 3
Scaling Factor 24.52 30.5 18.21 18.2 16.37 19.61 20.6 22.9
Noise 1.09 1.02 1.31 1.34 1.4 1.08 1.04 1.15
Background 35.64 32.32 40.62 40.11 42.2 34.01 32.63 35.98
%  Pres 7.7 5.9 9.9 10.3 11.7 10.5 10.2 8.3
GAPDH 3 7 5 ’ 1.56 2.19 1.47
GAPDH 3’/M - - - - - - - -
Table 3.8.2.1 Quality' control results for Affym etrix chips in CM , numbers highlighted indicate background values that are unusually high in 
comparison to the other CM samples shown.
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3.8.3 Expression of Two-Cycle Target Hybridisation and Labelling 
Controls
All hybridisation controls graphed in Fig.3.8.3.1 were called Present in all o f the 23 CM 
samples. Figure 3.8.3.1 shows that the 5’ and 3 ’ probes are also expressed at similar 
levels across all 23 samples, which indicate that, the hybridisation, washing and staining 
procedures were without incidence. The targets were detected according to the ratio o f  
their concentration in the initial hybridisation cocktail i.e. ere  was the most abundant 
followed by bioD, b ioC  and bioB.
The Poly- A controls are B . subtilis genes that have been modified by the addition o f  
poly-A tails and cloned into pBluescript vectors, further processing yields sense RNAs 
which are spiked into the RNA samples before the 2 cycle amplification procedure is 
carried out to help evaluate the amplification process. The Poly-A controls were called 
Present in all 23 o f  the CM samples. Figure 3.8.3.2 shows that the expression o f the 3’ 
target probes (yellow lines) is higher in ail samples than the expression o f  the 5 ’ (dark 
blue lines) or middle probes (pink lines). This indicates that there was a 3’ bias in the 
amplification procedure.
The average expression o f the Poly-A controls in all CM samples is shown in Fig.
3.8.3.3 and indicates that the ratios at which the Poly-A controls (detected by 
microarray) to each other do not correlate fully with the ratios in which they are present 
in the original stock solution (before amplification).
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Figure 3.8.3.1 Expression levels o f Hybridisation controls. CM samples are plotted 
on the X-axis with the expression level o f each hybridisation control plotted on the 
Y-axis. Cre, BioD, BioC and BioB arc the hybridisation spikc-in controls and the 
suffix denotes the region targeted by the probe set i.e. 3_at targets the 3* end, M at 
targets the middle and 5_at targets the 5’ end.
—A— Dap-5_at —• — Thr-5_at -  R ie-5_at —« —  Lys-5_at —a— Dap-M_at — Thr-M at
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ADR-SI TAX-SI
Figure 3.8.3.2 Expression levels o f Poly A controls. CM samples are labelled on the 
X-axis w ith the expression level o f each Poly A- control plotted on the Y-axis. Dap, 
Thr, Phe, Lys are the Poly-A spike in controls (see Section 2.12.1) and the suffix 
denotes the region targeted by the probe set i.e. 3_at targets the 3’ end, M targets 
the middle and 5_at targets the 5’ end.
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Figure 3.8.3.3 Average expression o f Poly-A controls in 23 CM samples. 
Affymetrix Poly-A controls (sec Section 2.12.1) are plotted on the X-axis and the 
average expression for the controls plotted on the Y axis. The three linear lines 
(yellow, pink, and dark blue) are the trend lines for each data set and the black 
lines connect the actual relative expressions for the 5* A middle El.and 3’^  targeted 
probe sets
Overall the ratio o f  the expression levels o f  the 3 ’ probe sets to either the middle or 5 ’ 
probe sets were more than 1:1. The average 3' to 5’ ratio for all the dap  and p h e  Poly-A 
controls is 4:1, and the average 3’ to 5' ratios for the lys  and thr  Poly-A controls is 
higher at 7- 8:1. The ratios o f  the Poly-A controls to each other in each sample should 
be dap> thr> phe> lys. The trend lines in Fig 3.8.3.3 suggest that the ratios o f  the Poly-A 
controls to each other match the ratios in the original pre-mixed control, but the actual 
relative expression o f  each Poly-A control to each other tells a different story.
The ratios o f  the 3’ targeted Poly-A probes to each other are most similar to the ratios in 
the original pre-mixed controls (with the exception o f  lys), but they are not as high as 
they should be (see Section 2.12.1).
A good example o f  this is with the dap  Poly A control, in the original spike- in cocktail, 
it is present at a concentration over three times higher than the thr  Poly-A control.
However from the data generated in the microarray study, out o f the 5', middle and 3’
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targeted probe sets, only the expression o f  the dap  5’ probe set compared to the thr  5 ’ 
probe set comes close to this ratio with an expression level o f 2058 compared to 794. 
The ratios o f the expression o f  the dap  M and 3 ’ probe sets to the thr M and 3 ’ probe 
sets are 2.2:1 and 1.6:1 respectively instead o f 3:1.
Because the Poly-A controls are obtained commercially pre-mixed and thus leaving no
r
chance for the wrong relative ratios to be spiked in, any discrepancies between the 
relative ratios obtained and the original ratios is attributable to either the amplification 
procedure itself and/ or different hybridisation efficiencies for the target probe sets.
In summary, there were no problems with the hybridisation o f the chips but the poly-A  
spike-in controls were not amplified to a level that reflected their original concentration. 
There was also a 3’ amplification bias in the 2-cycle amplification procedure, but as the 
Affymetrix probes target the 3’ end o f  gene transcripts this should not be problematic.
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3.8.4 Venn Diagrams of probe set expression for CM samples
The microarray data obtained for these samples was normalised using dChip before 
being imported into Genespring. Genespring enables visual interpretation o f  the data 
using Venn diagrams and scatter plots.
The scatter plot o f  expression levels o f the probe sets in the replicate samples follow the 
same pattern as for the DLKP CM samples (see Section 3.7.3). The probe sets expressed 
at levels under 100 are quite variable between the replicate samples resulting in a large 
spread o f dots (which represent the expression level o f a particular probe set in each 
individual sample). At higher levels o f  expression, the probe sets are more uniformly 
expressed by the replicate samples, as indicated by the fact that the probe sets centre on 
a central line, meaning that they are expressed at similar levels in the three replicate 
samples. The scatterplots for H1299 are shown as an example (see Fig. 3.8.4.1 and
3.8.4.2).
Two different Venn diagrams were also generated using the microarray data for each 
group o f replicate samples. The first overlaps the probe sets called Present (P) or 
Marginal (M) in each individual sample with the replicate samples and the second Venn 
diagram overlaps the probe sets expressed at levels over 100 in the individual samples 
with its replicate samples. The probe sets called P or M in all replicate samples for those 
groups are in the centre o f  the Venn diagram. Table 3.8.4 summarises the data shown in 
the Venn diagrams (Fig. 3.8.4.1-3.8.4.3) for all o f  the CM samples and shows that, in all 
cases, there is a higher percentage o f overlap between replicate samples when only 
probe sets with an expression value over 100 are included.
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HI 299
Normalised data with Present or Marginal call
29,359 gene transcripts are called Absent (A) in all three HI299 CM samples (see Fig
3.8.4.1). 3,269 probe sets are called Present (P) or Marginal (M) in all three samples, 
which represent just fewer than 13% o f  the probe sets called P or M in at least one o f  
the three HI299 CM samples. An average o f  5,000 probe sets are called P or M in one 
H I299 CM sample with a further average o f  2,400 probe sets P or M in at 2/3 HI299 
CM samples. The scatter plot on the left o f Fig. 3.8.4.1 shows that the probe sets called 
P or M in all 3 H I299 CM samples are not all highly expressed, rather they are mixed 
through the scatter plot. It is interesting that a number o f  highly expressed probes 
(signal intensity between 100- 1000) also have an A call in all 3 CM samples, as 
denoted by the grey dots.
P or M in H1 CM P or M in H2 CM
29359
__ ^  , ail genes
P orM in H3 CM
Figure 3.8.4.1 Scatter plot and Venn diagram of probe sets called P or M for 
H1299 CM. In the scatter plot (left-hand side) H1299 1 CM (H I) is plotted on the 
X-axis, H I299 2 CM (H2) on the Y-axis and H I299 3 CM (H3) on the Z-axis. Each 
dot represents a probe set and the colours denote the group in which the probe set 
belongs in the Venn diagram (right-hand side). P or M -  Present or M arginal call
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Normalised data with expression >100
When an expression cut- o ff  o f  100 expression units is applied to the data the number o f  
probe sets that come through this filter drops by nearly 12 fold compared to the number 
o f  probe sets with a P or M call from 25, 316 probe sets to 2,149 probe sets. However 
the percentage o f probe sets with expression over 100 common to the three HI299 CM 
samples rises to 60% compared to -13%  o f  probe sets called P or M common to the 
three HI299 CM samples (Fig. 3.8.4.1). The scatter plot shows that the probe sets with 
expression levels over 100 common to the three samples (white dots), tend to be similar 
in the three samples as denoted by the way the white dots cluster more tightly around a 
central line than for example, the grey dots, which represent the 52, 526 probe sets with 
expression levels under 100 in all three HI299 CM samples and show wide variation 
denoted by the bell shaped curve o f  the data points.
Figure 3.8.4.2 Scatter plot and Venn diagram of probe sets with expression >100 
for H I299 CM samples. In the scatter plot (left-hand side) H I299 1 CM (H I) is 
plotted on the X-axis, H1299 2 CM (H2) on the Y-axis and H1299 3 CM (H3) on 
the Z-axis. Each dot represents a probe set and the colours denote the group in 
which the probe set belongs in the Venn diagram (right-hand side).
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Figure 3.S.4.3 Venn diagrams representing the number o f probesets in the 
individual samples that are similarly (A) called Present or Marginal (P or M) in 
the replicate samples or (B) expressed at levels >100 in the replicate samples. HT= 
H I299 TAX, R= RPMI, RT= RPMI TAX, R M - RPMI ML.
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Figure 3.8.4.3 contd. Venn diagrams representing the number o f probesets in the 
individual samples that are similarly (A) called Present or Marginal (P or M) in 
the replicate samples or (B) expressed at levels >100 in the replicate samples. M= 
MDA F, MA= MDA F ADR SI, MT= MDA F TAX SI
% o verlap b e tw e e n  rep lica te sam p les
P o r M exp>100
H 1299 13 60
H 1299  TA X 16 63
R P M I 25 77
R P M IM L 13 70
R P M IT A X 16 72
M D A  F 12 55
M D A  F ADR 14 45
M D A  F TA X 20 77
Average 16.125 6 4 .875
Table 3.8.4.1 Summary o f the percentage o f probe sets either called Present or 
Marginal (P or M) or expressed at levels >100 (exp>100) in all replicate samples 
for each group
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3.8.5 Gene Ontology of probe sets called Present in all CM samples
To get an idea o f the molecular function o f the gene transcripts called Present in all 23 CM 
samples (335 probe sets), they were loaded into Netaffx online software so that Gene 
Ontology could be assigned (see Section 2.13.9.3). As annotated gene transcripts can have 
multiple functions, only the primary molecular functions/ parent category (see Fig. 2.13.11 
for example) o f the gene transcripts assessed were recorded.
As categories o f molecular function can be subdivided many ways e.g. binding can be 
divided into nucleotide binding, ion binding etc, it was decided to chart only the main 
branch o f molecular function, thus avoiding counting the same probe set into many 
different groups and many different subdivided branches. Although some probe sets were 
still counted in more than one group, the pie chart in Fig. 3.8.5.1 still serves to give an 
overall impression o f the molecular function o f the gene transcripts corresponding to the 
probe sets called Present in all CM samples.
Just under half (165) o f the 335 probe sets were un-annotated. Fig. 3.8.5.1 shows that the 
molecular function o f most o f the annotated gene transcripts involves binding. This binding 
function includes nucleotide-, nucleic acid-, DNA-, damaged DNA-, RNA-, receptor-, 
integrin-, ion/ cation-, protein-, ATP-, GTP- and transcription factor binding.
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signal transducer activity 
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transcription regulator activity 
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binding
30.3%
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transporter activity 
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motor activtty 
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translation regulator activity 
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Unknown
36.4%
antioxidant activtty 
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Figure 3.8.5.1 Gene Ontology of probe sets called Present in all CM samples (n= 335)
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3.8.6 Hierarchical clustering of CM samples
Hierarchical clustering analysis was carried out on all the CM samples using both 
Genespring and dChip software to find out how similar the samples are to each other. The 
Hierarchical clustering o f the samples in Genespring was carried out based on the 
expression of all gene transcripts (54,675) using a Pearson correlation.
Using dChip software, a filter was applied to the CM microarray data to firstly filter out 
any probe sets whose expression did not change across the samples. The criteria employed 
required that the ratio o f the standard deviation and the mean o f a gene’s expression values 
across all samples be greater than a certain threshold. This ratio is also known as 
Coefficient of Variation (CV). The default formula used in this study was that the variation 
across the samples (after pooling replicate arrays) was 0.5< (Standard deviation/ Mean) 
<1000. The more variable a gene is across samples, the larger the ratio is. This is 
unsupervised sample clustering as the gene transcripts are selected by large variation across 
samples and the sample group information is not used. A similarity measure was then 
employed to cluster the samples together.
Genespring was able to cluster at least 2, if  not three, o f the replicate samples for each 
sample group beside each other for 5/ 8 groups (Fig. 3.8.6.1).
dChip was able to cluster the different sample groups better than Genespring (Fig. 3.8.6.2). 
Five groups were classed as significant sample clusters, RPMI TAX (p-value: 0.022727), 
RPMI ML (p-value: 0.006494), MDA-F-ADR-SI (p-value: 0.002597), H I299 (p-value:
0.012987) and H I299 TAX (p-value: 0.012987). Only the MDA F 1 (M l) sample is out o f  
place, this is possibly due to the fact that the background levels for this chip were much 
higher than the rest o f the samples included in this analysis (see Section 3.8.2).
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Figure 3.8.6.1 Condition Tree of CM samples using Gen esp ring, this condition tree 
was performed using a Pearson correlation. H= H1299, HT= H1299 TAX, M= MDA- 
F, MA= MDA-F-ADR-SI, MT= MDA-F-TAX-SI, R= RPMI, RM= RPMI ML, RT= 
RPMI TAX.
r r m  m  m n  m T n T m
£2 ^  <N (0 <“  P  CM *2
T— C o S S S l —  I— I—  CN|<Ol—  I—  CMCOl—  T— |—  |—  < < ■ « — <
a : a : o i a : c r : a ' a : c r : 5 5 S S i i i i i i 5 5 S 5
R R R R R R R R M M M M H  H H H H H M M M M
Figure 3.8.6.2 Hierarchical clustering of CM samples by dChip, this clustering was 
carried out using a similarity measure. Gene transcripts that did not change in 
expression across all the CM samples were removed and the similarity of the CM 
samples computed on the 21, 357 remaining gene transcripts. 11= H I299, HT= H I299 
TAX, M= MDA-F, MA= MDA-F-ADR-SI, MT= MDA-F-TAX-SI, R= RPMI, RM= 
RPMI ML, RT= RPMI TAX.
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3.8.7 Validation of M icroarray Data (Part 1)
In Affymetrix arrays there are a set o f probe sets designed to target different traditional 
housekeeping gene transcripts e.g. P-actin and GAPDH. Three different probe sets are 
designed so that they align to the 5’, middle and 3’ end o f these gene transcripts. In 
calculating the integrity o f the cRNA used for the arrays, the ratio o f the expression o f the 
3’ probe set to either the middle or 5’ probe set is used. A  ratio o f 1:1 is ideal but anything 
up to 3:1 is acceptable. As we had previously designed mRNA specific primers for 
different regions o f the P-actin mRNA transcript, an attempt to validate the Presence/ 
Absence call assigned to the samples was carried out using these primers.
In addition to this, two transcripts were chosen, one that had a Present call assigned to all 
23 o f the CM samples and the other which had an Absent call assigned to all 23 o f the CM 
samples. RT- PCR was used to test for amplification o f either o f these transcripts. Original 
unamplified RNA was used as a template for reverse transcription in all cases.
3.8.7.1 Expression of “housekeeping gene transcripts” in CM RNA arrays
The expression levels o f the GAPDH probe sets in Fig. 3.8,7.1.1 show that according to the 
microarray data, the expression of GAPDH is slightly higher in the 3’ region of the mRNA 
transcript especially in the HI299/ HI299 TAX and MDA-F-ADR-SI 1 CM samples. In all 
other CM samples, the expression is negligible.
Although the expression o f the 5’ region o f GAPDH mRNA, in Fig. 3.8.7.1.1 is very close
to 0, the accompanying Present/ Absent call data for this probe set indicates that in 16/22
o f the samples this probe set is assigned “Present” (Table 3.8.7.1). 17/22 o f the samples
have a Present call assigned to the probe set that targets the 3’ end o f the GAPDH mRNA,
and more interesting is that fact that only 3/22 CM samples have a Present call assigned to
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the probe set that targets the middle o f the mRNA transcript.
A similar trend in expression is seen in the probe sets that target the different regions o f  the 
p-actin gene transcript i.e. there seems to be higher expression o f the 3’ region o f the 
mRNA than the 5’ or middle region (Fig. 3.8.7.1.2). With the exception o f the 5’ targeted 
probe set in MDA-F-TAX-SI 1 and the middle region targeted probe set in MDA-F-ADR- 
SI 1, all probe sets targeted to the 5’ and middle region o f  the P-actin mRNA transcript are 
called Absent. The probe set that targets the 3’ end o f the p-actin gene transcript are called 
Present in 22/22 CM samples.
For the CM samples, calculation o f both housekeeping gene 3’/M or 375’ ratios were not 
carried out becausc the call assigned to the probe sets was Absent more than it was Present 
(see Tables 3.8.7.1/ 2 for details).
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Figure 3.7.1.1 Expression levels (Y-axis) of GAPDH probe sets in CM samples (x- 
axis). Blue line ■ 5' targeted probes, pink line = middle region targeted probes, yellow 
= 3’ targeted probes.
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Table3.7.1.1 Present/ Absent calls assigned to GAPDH probe sets for CM samples.
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Figure 3.7.1.2 Expression levels (Y-axis) o f 0- actin probe sets for CM samples (X- 
axis). Blue line »  5’ targeted probes, pink line = middle region targeted probes, yellow 
= 3* targeted probes.
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Tab e .7.1.2 Present/ Absent calls assigned to i-actin probe sets for CM samples.
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3.8.7.2 RT-PCR for p-actin using 5’ and 3’ specific primers
It was decided to carry out RT-PCR on the unamplified RNA CM samples using primers 
designed for a previous study (see Section 3.3) that amplify different regions o f the p-actin 
gene transcript and 45 cycles of PCR to see if  the Presence/ Absent call assigned with the 
microarray data could be correlated to RT-PCR results.
The results in Figs. 3.8.7.2.1-3, show that whilst detection o f p-actin gene transcripts 
corresponding to the 5’ UTR region o f the p-actin mRNA was only possible in 6- 14/ 23 
CM samples, PCR products were amplifiable in all CM samples targeted by 5’ coding and 
3’ region specific primers. (Expression levels o f P-actin as determined by microarray were 
not possible for the MDA-F-TAX-SI 2 CM sample as it was excluded before normalisation 
because o f bad QA results (see Section 3.8.2) but it was included in this RT-PCR study). 
These results however may be a consequence o f the 3’ bias of the 2 cycle amplification 
procedure as detailed in Section 3.8.3. As the Affymetrix probes target the 5’ and middle 
regions o f the housekeeping gene transcripts as well as the 3’ region, it is possible that the 
Absent call assigned to these regions is a direct result o f this bias.
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Figure 3.8.7.2.1 Expression of 5fUTR specific p-actin mRNA. p-actin gene transcript 
(171bp) (arrow) was detected in RPMI 1, RPMI TAX 1, 2 and 3, MDA-F-ADR 1 and 
MDA-F-TAX 3 CM samples with faint bands visible in at least 8 other CM samples. 
Amplified product was detected in the positive control and was undetected in the 
negative control samples (-ve RT = RT reaction with H2O instead of RNA as control; - 
ve PCR = PCR reaction with H20 instead of cDNA as control).
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Figure 3.8.7.2.2 Expression of 5fCDS specific p-actin mRNA. p-actin gene transcript 
(arrow) was detected in all CM samples tested. Amplified product was detected in the 
positive control and was undetected in the negative control samples (-ve RT = RT 
reaction with H2O instead of RNA as control; -ve PCR = PCR reaction with H2O 
instead of cDNA as a control).
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Figure 3.8.7.2.3 Expression of 3* specific p-actin mRNA. p-actin gene transcript 
(arrow) was detected in all CM samples tested. Amplified product was detected in the 
positive control and was undetected in the negative control samples (-ve RT = RT 
reaction with H2O instead of RNA as control; -ve PCR = PCR reaction with H20 
instead of cDNA as a control).
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It was decided to investigate the correlation o f Present/ Absent calls assigned to other 
mRNA transcripts by microarray with RT-PCR. To do this, two transcripts were chosen, 
one with a Present call assigned to the probe set in all CM samples, and the other an Absent 
call assigned to the probe set in all CM samples.
The results shown in Figs. 3.8.7.3.1/ 2 confirm the results previously found (in Section
3.8.7.2) that mRNA gene transcripts assigned as Absent can be detected by PCR. In all 22 
CM samples were the detection call assigned to the probe set targeting APAF 1 interacting 
protein mRNA was Absent, detection o f the gene transcript was possible with 45 cycles o f 
PCR. With the probe set that was called Present in all CM samples (220232_at), detection 
o f its target mRNA by RT-PCR was possible.
3.8.7.3 Validation of Presence/ Absence call
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Figure 3.8.7.3.1 RT-PCR of all CM for stearoyl-CoA desaturase 5 (151bp). Stearoyl- 
CoA desaturase 5 gene transcripts (arrow) were detected in all CM samples tested. 
The probe set corresponding to Stearoyl-CoA desaturase 5 mRNA (220232_at) is 
called Present in all CM samples. Amplified product was detected in the positive 
control and was undetected in the negative control samples (-ve RT = RT reaction 
with H2O instead of RNA as control; -ve PCR = PCR reaction with H2O instead of 
cDNA as control).
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Figure 3.8.7.3.2 RT-PCR of all CM samples for APAF1 interacting protein mRNA. 
APAF1 interacting protein mRNA gene transcripts (arrow) were detected in all CM  
samples tested. The probe set corresponding to APAF1 interacting protein mRNA 
(218698_at), is called Absent in all samples. Amplified product was detected in the 
positive control and was undetected in the negative control samples (-ve RT = RT 
reaction with H2O instead of RNA as control; -ve PCR = PCR reaction with H2O 
instead of cDNA as a control).
3.8.8 Gene transcripts significantly up/ down-regulated between parental 
and drug selected variant CM
The following Section is an overview o f the probe sets found to be significantly changed 
between the parental CM samples and their drug selected variant CM samples. DChip 
software was used to generate these lists (see Section 2.13.9.2), the mean of the replicate 
samples in each group were calculated (along with the standard deviation) and compared to 
other sample groups looking at gene expression o f all probe sets available. Presence/ 
Absence calls assigned to probe sets did not influence the lists generated as results in the 
previous section (Section 3.8.7) indicated that gene transcripts called Absent can still be 
detected by RT-PCR. The criteria specified for probe sets to be deemed significantly 
changed were:
1. A difference in expression >50 fluorescence units
PC
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2. A fold change> 1.2
3. A p-value o f significance< 0.05
The lists are sorted by fold change, no colour shading indicates gene transcripts that are up- 
regulated and grey shading indicates gene transcripts that are down-regulated. The dChip 
classify gene function was also used to determine the molecular function for the 
significantly changed gene transcripts (see Section 2.13.9.2).
H1299 vs. H1299 TAX
43 probe sets were significantly changed in H I299 TAX CM samples compared to HI299 
CM. 34 o f these were down-regulated and 9 were up-regulated (see Table 3.8.8.1). Gene 
ontology annotation was available for 19 of the 43 gene transcripts corresponding to probe 
sets significantly changed however; no gene category was significantly overrepresented as 
determined by dChip. 16 of the 19 gene transcripts significantly changed have a known 
function o f binding, including nucleic acid binding (forkhead box A2, eukaryotic 
translation elongation factor 1 alpha 1, zinc finger protein 573, THAP domain containing 6 
and nuclear receptor subfamily 1, group H, member 4), actin binding (myosin IXB) and 
calcium ion binding (KIAA0494 gene product and calcium channel, voltage-dependent, L 
type, alpha 1C subunit).
With 12/43 probe sets significantly changed the chromosomal region is known for the gene 
transcripts they correspond to, six of them to map to the chrlp chromosomal region. Four 
of these six gene transcripts (DNA-damage inducible protein 2 (224449_at), Leucine zipper 
and CTNNBIP1 domain containing (22608 l_at), Similar to bA476I15.3 (novel protein 
similar to septin- 232953_at) and Hypothetical protein FLJ32784 (1552853_at)) correspond 
to gene transcripts mapping to the chrlp36 chromosomal region giving an over­
representation p-value o f 0.000704. All four o f the gene transcripts were down-regulated.
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Of the 19 gene transcripts significantly changed, pathway annotation was known for 4; 
eukaryotic translation elongation factor 1 alpha 1 belongs to the GenMAPP Translation 
Factors pathway, protein kinase, AMP-activated, alpha 2 catalytic subunit belongs to the 
GenMAPP Fatty_Acid_Synthesis pathway, adenylate kinase 3 belongs to the KEGG 
Pyrimidine metabolism pathway and calcium channel, voltage-dependent, L type, alpha 1C 
subunit belongs to the GenMAPP Calcium Channels pathway.
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233406_at gb:AW0221 OO. 1 /DB_XREF=gi: 1O AKD221OO
204347_at adenylate kinase 3 /// adenylate IAI653169 
213477_x_at eukaryotic translation elongation AL515273 
242323_at g b : AV714268 /D B_JXR E F= g i : 107S AV714268 
227732_at ataxin 7-like 1 AB033044
208397_x_at potassium inwardly-rectifying cha U39195 
233658_at g b : AWD22413.1 /D B_XR E F= g i : 10- AKD22413 
207709_at protein kinase, AMP-activated, al NM_006252 
238766, at gb:AI800311 /DB_XREF— gi:5365? AI800311
213924_at ■ gb: BF476502 /DB_XREF=gi: 1154 BF476502 .
2G1777f_s_aV KIAA0494 gene product BC002525
236428Jat gb: D59900 /DBj<REF= gi:961006 D59900 
224449Vat * . jDNA-.damage inducible protein 2 .* BC00601 1
2 1 7 6 2 7 _ a t ' zinc finger protein 573 . * 1 BE515346 ■
242099_at . gb:TB3938 /DB_XREF= gi:7.12226 7B3938
1552853^at " hypothetical protein FLJ32784 • N M J 44623
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1554128_at ^hypothetical protein MGC39724 BC029594
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1554375Ja_^at nuclear receptor subfamily 1 , groi AF478446 
208452_x_at . myosin IXB . ■ NM_004145
243691 _at gb: AA150455 /DB_XREF=gi: 1721 AA150455 . 
206491 _s:_at N-ethylmaleimide-sehsitive, factor NM_003827 
208020:_s_at .calcium channel, yoltage-dependf NM_OOG719 
211238_at a disintegrin and metalloproteinas AF215824 
1563754_at glutamate receptor; ionotropic, ks AJ252246 
232756_at :gb: AK022394.1t /DB_XREF=gi: 10- AKD22394 
242853^at gb:C18965 /DBJXREF=gi: 158056 C18965 
232953_at Similar to bA476i15.3 (novel prote Al_137028 
235218_x_at THAR domain containing G  BF33920T ‘
204158_s_at T-cell, immune regulator 1 , ATPa: NM_006019 
241593_l x_atl gb: B F476913 /D B_XREF= gi: 1 154 BF476913 
210103_s_at , forkhead box A2 < . " AB028021 .
242712i_x_at* gb: BE856960 /DB_XREF=gi:1037 BE856960. , 
202223_^at . integral membrane protein 1 NM__002219
244471 _x_atj gb: BF515177 /D B_XR Ê F= g » : 1160 BF515177 
233412_x_:ât Transcribed locus', weak I y similar AW971238 / 
1555792_a_at hypothetical protein FLJ36Q46 BC033499 
232516_x_at , YY1 associated protein V  , AU150385
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Table 3.8.8.1 Probe sets significantly up or down-regulated between H1299 and H I299 
TAX CM samples. The list of gene transcripts is sorted by fold change. All down- 
regulated gene transcripts are shaded grey with no shading applied to the up- 
regulated gene transcripts.
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RPMI vs. RPMI ML
73 probe sets were significantly changed in RPMI ML CM samples compared to RPMI CM 
samples, 46 were up-regulated and 26 down-regulated (see Table 3.8.8.2). The gene 
transcripts corresponding to 40 o f the 73 probe sets significantly changed were annotated 
for gene function. 28 grouped into the organelle gene ontology group giving a significant 
over representation p value o f 0.000202, 9 o f these were down-regulated and 19 were up- 
regulated.
Chromosomal location was known for 23 of the 73 gene transcripts that the significantly 
changed probe sets correspond to. The gene transcripts mapped to different regions o f  
chromosomes 1-7 and 9 but no chromosome/ chromosomal regions were significantly over 
represented.
Similarly no pathways were significantly over represented. Of the 73 probe set significantly 
changed between the RPMI and RPMI ML CM samples only 10 corresponded to gene 
transcripts belonging to known pathways. The pathways represented included KEGG Fatty 
acid metabolism (1), gamma-Hexachlorocyclohexane (1) and Tryptophan metabolism (1) 
pathways and GenMAPP Apoptosis (1), Ribosomal Proteins (2), G_Protein_Signalling (1) 
and Electron_Tronsport_Chain pathways.
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220794_at gremlin 2 homolog. cysteine knot NM_022469
222266 at gb: BF796940 /DB_XREF=gi: 1210 BF796940
204347 at adenylate kinase 3 / / /  adenylate I AI653169
218464_s_at hypothetical protein FLJ10700 NM_01B182
2199B5_at heparan sulfate (glucosamine) 3-C NMJ006042
227227 at Transcribed locus, moderately sirAI344332
1566001_at Ankyrin repeat domain 11 AWD96064
212195_at Interleukin 6 signal transducer (gp AUD49265 
23S983_at gb:A I360l67 /DB_XREF=gi:41 1 17 AI360167
20491 4_s_at SRY (sex determining region Y )-t AW1 57202 
241904_at gb:BE068893 /D0_XREF— gi:8413 BE068893
229871 ^ .at hypothetical protein FLJ10211 W 74622
1 563209_a_at Homo sapiens, clone IMAGE:451 BC035876 
23881 1_at DMRT-like family C2 AI6514B2
236484_at gb:AW85061 1 /DB_XREF=gi:794l AW05O61 1
1 569181 _x at gb: BC01 7896.1 /DB_XREF=gi:22- BC017898
21 3931 _at inhibitor of DNA binding 2, domins AI81 9238 
208905.^.at cytochrome c. somatic BCO05299
241 600_at g b: AI270986 /D B_XR E F= g i:38901 AI27O906
21 5304 at Clone 23948 mRNA sequence U79293
222565 s_at protein kinase D3 BF978541
2321 50 at gb:AA134418 /DB_XREF=gi:1691 AA134418
1 5691 80 at gb: BC01 7896.1 /DB_XREF= g i:22* BC01 7896 .
21 4323 s at UPF3 regulator of nonsense transN36842
227952_at Zinc finger protein 595 AI580142
20B66B_x_at high-mobility group nucleosomal I BC003689
21 493B x at high-mobility group box 1 AF283771
229447 x at hypothetical protein LOC200030 N32025
21 071 B_s at ADP-ribosylation factor-like A F 119889
200630_x_at SET translocation (myeloid leuke AV702810 
201 103_x_at hypothetical protein MGCB902 / / /  BE299495 
21432D_x_at cytochrome P4SO, family 2, subfsT67741
20081 7 x at ribosomal protein S10 NM_001014
21 2854 x_at AG 1 AB051 480
213356_x_at heterogeneous nuclear ribonuclec ALj56B1 86
242896 at gb:BF223302 /DB_XREF=gi: 1113 BF223302
207631 —at neighbor of BRCA1 gene 2 NM_OOS821
229567 at sim ilar to CG10671 -like AI74237.0
201220_x__at C-terminal binding protein 2 NM_001329
215852_x_at KIAAD889 protein AWD22023
2391 27_at CDNA FLJ42086 fis. clone TESO T61954 
210334_x_at baculoviral IAP repeat-containing AB028869 
1561S73_at Homo sapiens, clone 1 M AGE:552 BC039476 
52005_at W idely-interspaced zinc finger mt AA422049
223815_at Hypothetical protein BCOO9510 AF130069 
243895_x_at gb:AW452435 /DB_XREF=gi:699: AW 452435
233816 at Solute carrier family 8 (sodium/cs AW 658517
21 5724 at
21 9058 x at
220808 at
1 5541 20_at . 
21B922_^s_at 
226538_at 
218698„at . 
240304_^s_at ,
208020_s at ,
206491_s_at
1554375 a_s»t
2O04S2_x_at :
231590_x at
225276_at .
220725_x_làt 
239805_at ,
231 286 at . \
236389_x_at 
20881 7_at 
216153^x la t 
238701__x^ _at 
217696j,at v 
216362_at 
210201 _x^_at 
214614_>t . 
2191 13 x at
^phospholipase ,D1 . phophatidylch AJ276230- 
jipocalin 7'* ' : ' j '  NM_022164
Theg homolog (mouse) ' NM_G16585
hypothetical protein MGC39724 BC029594
LAG1 longevity assurance homoi* NM_024552 
m annosidase, alpha, class 2A. rr AV700323 
likely ortholog of mouse monocyt NM_i015957 
Transnhembrane channel-like 5 BG494769
calcium channel, voltage-dependc NM_000719 
N-ethylmaleim ide-sensitiye factor. NM_p03827 
nuclear receptor subfamily 1 . grotAF470446 ,,r 
myosin. IXB ' . ' NM_004145'
gb: AI379823 /DB_XREF=gi:4189E AI379023 
<31 to S phase transition 1 ' ' AA143579
Dynein, axonemal, heavy, polype): NM_025095 
gb:AW1 36060 /DB_XREF= g i:61 4i AW1 36060 
chromosome 9 open reading framAW 452080 
gb:T90064 /DB_XREF== g»:718577 T90064 \
calechol-O-methyltransferase . B C00041 9. 
reversion-inducing-cysteine-rich p AWD22897 ; 
FLJ4S803 pro!ein - - . ’ ‘ V ■ . “B E 176566
fucosyltraYisferase 7 (alpha (1 ,3) f AA767713 
gb: AJ251 844.1,' /DB_XRE F= gi:93E AJ251 844 . 
bridging integrator; 1 AFOO.1 383 "
horheo box HB9 AI73B662jdeh^drogenase/reductasi^fSDRj^NM^O^B24&
Table 3.8.8.2 Probe sets significantly up or down-regulated between RPMI and RPMI 
ML CM samples. The list of gene transcripts is sorted by fold change. All down- 
regulated gene transcripts are shaded grey with no shading applied to the up- 
regulated gene transcripts.
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RPMI vs. RPMI TAX
The RPMI CM samples compared to the RPMI TAX CM samples showed 150 probe sets 
that were significantly different (Tables 3.8.8.3(a-b)). More probe sets were up-regulated 
(92) than down-regulated (58) as was the case with RPMI CM samples compared to RPMI 
ML CM samples (see Table 3.8.8.2). Gene ontology annotation was known for just under 
half (70) o f the gene transcripts corresponding to the probe sets on the list but no gene 
ontology group was determined to be significantly overrepresented by dChip. 11 o f the 70 
annotated gene transcripts have a known molecular function in regulation of metabolism 
and another 12 have a function in protein metabolism. 11 o f the 70 have a known molecular 
function in the regulation o f DNA-dependent transcription and 38 o f the 70 are annotated to 
have a known function of binding, 16 of which are nucleic acid/ DNA binding and a 
different 15 nucleotide binding. One of these gene transcripts with a function o f adenyl 
nucleotide binding and transferase activity, adenylate kinase 3, was also up-regulated in the 
taxol- selected CM samples by 4.3 fold compared to the parental CM sample in the HI299 
CM vs. HI299 TAX CM sample group. Other molecular function categories represented by 
the significantly changed gene transcripts in the RPMI CM samples against the RPMI TAX 
CM samples include catalytic activity (29), cell communication (14) and receptor/ signal 
transducer activity (10).
16 o f the 70 gene transcripts significantly changed had known pathway annotations for 16
different pathways, none of which were deemed to be over represented. The pathways
represented included GenMAPP TGF_Beta_Signaling_Pathway (1),
Inflammatory_Response_Pathway (1) and Ribosomal_Proteins (2) and KEGG
Phosphatidylinositol signalling system (3) and Pyrimidine metabolism (2).
Chromosomal annotations were known for 49/70 gene transcripts corresponding to the
significantly changed probe sets. 13/ 49 o f these gene transcripts mapped to chromosome 7
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giving an over represented p-value o f 0.000399. 5 o f the 13 further mapped to the chr7q21 
region o f the chromosome giving a significantly over represented p-value o f 0.000087. 
Another 4 o f the 49 chromosome annotated probe sets mapped to the chr5p!5 region and
the region was also deemed over represented with a p-value o f 0.000370)
probé set yeiie | Accession fol«l difference P value
clu iiK ie of m em is
214B54 at Transcribed locus, moderately simil] A0004490 53.31 52.31 0.037248
216480 x at 
236520 at
gb: AF060927.1 /DEI XR EF=oi:31 391AFQ60927 22.79 52.65
50.74
0.002647
0.012573Ctb'- AW972380 /DB XR E F= pi: Q1622? AW972380 13.2
204347 at adenylate kinase 3 /// adenylate kin[AI653169 10.65 72.6 0.010142
244350 at qb:N33403 /DB XREF=qi:11530O2 /.N33403 10.58 70.4 0.000354
0.022038215657 at gb:AKD25D44.1 /DB XREF=pi:1043 AKD25044 8.09 55.25
232330 at Hypothetical protein FLJ10803 AKD24Q61 7.74 56.04 0.032577
215321 at Rap2-binding protein 9 AI82S798 7.57 99.60
72.84
0.0100
236472 at 
22405Í at
ci b: A  IS06586 /DB XREF=qi:539315 Í AI80656B 7.57 0.010493
cyclin-dependent kinase 6 AW2747S6 7.42 58.46 0.01727
227227 at 
243902. at
Transcribed locus, moderately simil AI344332 7.03 136.32 0-014621
gb:AI434866 /DB XREF=gi:429919C 
pb:BE9B1949 /DB XREF=gi: 1 17643
AI434068 6.97 67.63 0.01 1572
241617 x at 
1570505 at
BE961949 6.57 61.11 0.007142 
0.01 1712ATP-bindinq cassette, sub-family BIBCO2O610 5.61 1 18.83
236404 at qb:AW19732Q /DB XREF=ai:64765: AW19732Ó 5.58 64.43 0.014634
225431 x at 
202850 at
Aminoacylase 1-like 2 BE779764 5.32 121.80 0.01 1O01 
" 0.004703 
0.026949
ATP-binding cassette, sub-family D ÑM 002856 5.3 64.55
242106 at Two pore segment channel 1 AA00161S 5.19 81.11
230466 s at gb: AI092770 /DB XREF= ni:343174E AI092770 5.07 66.63 0.013971'
204712 at WNT inhibitory factor 1 NM 007191 4.62 76.27 0.037360
215386 at Autism susceptibility candidate 2 AU1481B1 4.76 62.65 0.023977
235381 at Hepatitis B virus x associated prote BFÓ33BS5 4.73 51 .6 0.032579
241600 at gb:AI270986 /DB XREF= gi:3890152 AI270986 4.63 136.50 0.000626
O.Ó29Ó36219108 x at DEAD (Asp-G1 u-Ala-Asp) box polypi ÑM 017695 4.51 60:77
237330_at gb;AAB03494 /DB XREF=gi:24373E AA603494 4.43 50.6 0 030540
244866 at gb:H72108 /DB XREF=gi: 1043924 /¡H721Q8 4.33 53.9 0.043566
0.044761236484 at g b: AW05Ó61 1 /DB XR EF=gi:794611AW85QB1 1 4.15 75.24
205814 at glutamate receptor, metabotropic 3 NM 000840 3.88 03.55 0.017967
218412 s at GTF2I repeat domain containing 1 NM 016320 3.86 52.09 0.048293
213576 at bone morphogenetic protsin recepto AI670679 3.61 50.71 0 033799
238549 at core-binding factor, runt domain. alp‘AI420611 3.77 115.41 0.02B758 
0 007047226462 at 
1557599 a at
iroquois homeobox protein 2 Ta I920O35 3.74 204.56
CDNÁ clone I MAGE:5274693 . parti? BCO41370 3.56 71 .65 0.013607
2371 57 at gb:AW1 17547 /DB XREF=gi:BOS61: AW1 1 7547 3.53 71 .5 0.031215
234258 at MRNA; cDNA DkFZp434F0472 ffrorAL13733i 3.52 54.26 0.03713
230713 at gb:BF1 15766 /DB XREF=ai: 109652 
Homo sapiens, clone IIVIAGE:S31 1 3
BF115786 3.47 50.75 0.021 18
239082 at BF437161 3.41 59.27 0.028904
0.039815226332 at hypothetical protein MGC404DS 1AI569932 3.4 58.42
203296 s at 
225045 át
Jumonji, AT rich interactive domain : NM 004973 3.18 57.2 0.04161
HSPCOB3 protein 1BG253664 3.16 90.72 0.019224
232113 at 
202391 at
Hypothetical gene supported by BXE N90870 3.14 92.51
75.77"
0.010047
0.032290brain abundant, membrane attachecNM 006317 2.94
200833 s at RAR1B, member of RAS oncogene NM 015646 2.70 52.3 0.034405
221740 x at Transcribed locus, moderately si mi I AM 40364 2.76 52.05 0.019407
2D3917 at coxsackie virus and adenovirus race NM 001338 2.74 57.22 0.039020
242759 at 
236602 at 
216058 at
gb; A1021 726 /DB XREF=ai:544080£ AI021726 2.69 83.31
93.41
0.005837
0.020767gb:AI7321 32 /DB XREF=gi:5053267 AI732132 2.65
DÉP domain containing 6 NM 022763 2.58 51 .64 0.035523
0.022823
0.032037
23251 1 at RAN binding protein 2-like 1 AKD22038 2.47 77.12
244612 at gb:AW1 17161 /DB XREF= c*i:6O057I AW1 17181 2.43 120.94
1557996 at gb-.AKD917B4.1 /DB XREF=gi:2175¡AKD91 784 2.39 129.39 0.031 114
216364 s at 
243271 at
fragile X mental retardation 2 IAJOO1550 
AI064690
2.34 50.50
57.59
0.040093
0.015776gb:AI064690 /DB XREF=ai;635096^ 2.26
228054 at gb:AI492368 /DB XREF=gi;4393391 AI492360 2.25 70.96 0.017299
230497 at bruno-like S. RNA binding protein (DBES03640 2.24 56.07 0.026641
232256 s at Hypothetical gene supported by AMAF143329 2.23 96.04 0.031610
0.040579212654<i_x at AG1 ABOS1 480 2.09 85.14
200017 x at ribosomal protein S10 NM 001014 2.00 111 .60 0.040509
0.046759
0.009922
213081 x at 
233037 at
SMT3 suppressor of mif two 3 home AI971724 2.00 125.83
57.7CDNA clone IMAGE:4BO1O09. parti* AF138859 2.05
242920 at «b: AW59DB38 /DB XRE F = gi:72779Í AW590836 2.05 71.43 0.039764
209134 s at ribosomal protein S6 B0000524 1 .97 109.68 0.01 1572
214320 x at cytochrome P450, family 2. subfam T67741 1 .95 120.77 0.000449
222380__s__at
200080 e at
Similar to Microneme antigen AI907063 1 .9 157.62 0.000093
H3 histone, family 3 A /// H3 histone Al955655 1 .86 57.07 0.034131
81811 at Similar to Microneme antigen AI744451 1 .85 96.21 0.019962
1561471 at Homo sapiens, clone IMAGE:48311 B0039114 1 .85 00.50 0.03691
0.037144207631 at neighbor of BRCA1 gene 2 ÑM_OOS821 1 .76 1 15.101
Table 3.8.8.3 Probe sets significantly up-regulated in the RPMI TAX compared to the 
RPMI CM samples. The list of gene transcripts is sorted by fold change. All down- 
regulated gene transcripts are shaded grey with no shading applied to the up- 
regulated gene transcripts.
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probe set «jene Accession fol«lchange differenceof means P value
200801 _x_at
229567_at___
231831 at
actin. beta NM 001101 1.73 59.12 0.027541
similar to CG10671-like AI742370 1.72 06.94 0.033326
210718 s at
hypothetical protein LQC9Q639 AU153267 1.67 79.96 0.027296
ADP-ribosylation factor-like AF119889 1.65 53.91 0.035000
1561573, at___
1560562 a at 
212525 s at
Homo sapiens, clone IMAGE:55287 BC03947G 1.64 110.74 0.014761
Hypothetical protein MGC48625 AKD26366 1.56 83.28 0.026495
236267_at_____
1S70257_x_at 
207134 x"at
H2A histone family, member X AA760862 1.53 115.33 0.034113
zinc finger protein 346 BG178775 1.52 68.65 0.030424
231886 at
gb : BC034527.1 /DB _XREF=gt .2290': 
tryptase beta 2
BC034S27 1.51 62.98 0.028286
Hypothetical LOC38a572
210722 _at____
215852_x_at 
221270 s at
pancreatic lipase-related protein 1
KIAAQ889 protein
239127 _at 
239311 _at 
243724 _at 
231715_s_ 
240397 _x_ 
210965_x_ 
203045 at
214488 at____
243895_x_at
2287QO_at____
201671_x_at
238572_at
215724_at
206491 _vs_at
1554128^ at.
240304J¿_at
222365_at.
218698_at
1554375_a_at
2080201s_at
218922_slat
225276^at. 1
201422 a^t'
226538j.at . '
208452_x_at .
231598j>Cat
1557330_at‘
220808_at ‘
1564155_x_at
236186_x_at.
206936_x_at
241675_s_iat
244490_at
15S3326^at
236389_x_iat
240882_at
239805__ at
217684__at
21935B_s_at
216153_x_at
216362_at
216560_x_at
201109_s_at
203565_s_at
214614jat.
1561305_at 
201370_s^at',‘ 
207742^s_>t 
209881 _¿s_át 
1561614 j_at. ‘ ' 
207138_at 
233605_x^at .
-231597_x at
218836_at 
219113_x a^t; 
208148 at
queuine tRNA-ribosyltransferase 1 f
CDNA FLJ420Q6 fis. clone TESOP1
NM 024164 1.47 95.99 0.040107
AL137655 1.47 51.75 0.040335
BC005233 1.46 88.50 0.045881
AKD22023 1.46 510.43 0.01624
N M_Q31 209 
T61954
1.44 81.11 0.036975
1.44 66.24 0.038714
gb: AI367034 /DB _XREF=gi:41 3677S AI367034 
gb:AW979182 /DB XREF=gi:B17041AW979182 
pyrrolìne-5-carboxYlate reductase fai ÑM 013328
1.42 62.38 0.016186
1.42 53.17 0.034216
1.34 58.54 0.047646
gb:AI801626 /DB XREF=gi:5367Q9£ AI801 626 1.28 179.26 0.046197
celt division cycle 2-like 5 (cholinest BCQ01274 1.27 412.48 0.025637
ninj urin 1
RAP2B, member of RAS oncogene
gb:AW452435 /DB_XREF=gi:69932
Chromosome X open reading frame
ubiquitin specific protease 14 (tRNA,
NM 004148 1.25 142.63 0.030042
NM 002886 1.25 77.47 0.021701
AW452435 1.24 819.39 0.006006
AA063608 1.22 57.13 0.047997
BC003556 1.2 365.64 0.000614
hypothetical protein MGC16211 AI082836 >35.42 -63 84 0.017643
phospholipase D1 , phophatidylcholii AJ276230 : I ’-14.13 -75.22 0.032333
N-ethylmaleimide-sensitive factor at-NMJ003827 / /  -5!89 -90.17 0.016714
hypothetical protein MG.C39724 BC029594 1 Y -5 33. . -408.63 0.000983
Trans membrane channel-like 5 BG484769 - ' \  -4,79 -157.25 . 0.03476
t g b : A \ / y 9 7 A G 6 e  /DB_XREF==gi:81 658: AW974666 . * -4.69 •. -58-64 0.03185
likely"ortholog ,of mouse monocyte r NMJQ15957-; / - . v-3.89 -147/93 0.007462
nuclear receptor subfamily W , group AF478446 . -3.8 /  -95:-13 0ÜÖ36446
 ^c aIciüm.channel, voltage-dependent NM_OOQ719 , ‘ -3.59 -188.58 0;006098
LAG1 longevity assurance homolog NMJ024552 ■ . -3.46 . -82 91 0.005124
G1. to S phase transition 1 , AA143579 ;; -3.38 . ; -77:99 .0.027384
interferon,gamma-inducible protein NM^_006332 ,, -3.07 ., , . -67-49 0.046016
. mannosidase, alpha, clasS'2Ä, merÄV700323 V . -2.97', * -73.43 0.033573
myosin IXB ■ " ' v • NMJ004145. • -2.91 / . -68.73 0.01053
g b:ÄI379823 /D B_XR E F.=gi:41 8967E AI379823 - -2.75 -02.4 0.014557
CDNA clone I MAGE:4836946. parti? BC027619 -2 48 . -72.14 0.007088
Theg homolog (m ouse)1 ‘ ’ NMj_016585 • .  -2.35 * /-86.89,‘ 0.009031
gb:BC041466.1 /DB J<RE F“  gi:2737I BC041466 .. ‘ -2.31 •••’ - -72.71 0.016593
interleukin 17 receptor E AW003256 -1.98 / -71.31 0.030851
gb:l<IM_02233S.1 /DB_XREF=gi: 11 6 NMJ02233S ; -1.9 ' ’-11 9.28 0.031 369
. gb: A1349737 /DB_XREF=gi:4086942 ÄI349737 . ■ >19 , -60.15 0.023155
gb:AA748520 /DB_XREF=gi:278847 AA74852Ö- - . -1 .88. . -50 27 0.021363
leucine-rich-repeat-contäining G prö AF453828 i V -1.88 - -85.37 ‘ 0.032413
•'gb:T90064 /DB_XREF=gi:718577 */D T90064 - -.1.86 -116.29 0 025084
.MRNA; cDNA DKFZp313N0236 (fro. R85522 • -1.71 ' -256 08 0.042304
gb:AW136060/DB_XREF=gi:6140l! AW136060 ' -1.64 ; -50.2 0.011323
thymidylate synthetase . BG281679 % . -1.62 . -87.56 0 047231
centaurin, alpha 2. " NMJD18404 .. -1.62 .; M 66.05 0.012815
' reversion-inducin’g-cysteine-rich prot AKD22897 -1:6 > -246.45 0.021247
gb" AJ251844.1 /DB_XREF=gi:9360iAJ251844 ,v- -1.51 -103.03 0.022368
lg lambda-chain V-J-C region (HCV-l D87021 -1* 45 . -56.24 0.01853
thrombospondin.1 v . ; . AV726673 ' * -1.39 . -503.84 0.032746
menage a  trois 1-‘(CAK assembly fa NMJ302431 -1.39 , , -98.06 0.009458
homeo box HB9- \  ÄI738662, -1.39 -243.22 0.036664
Homo sapiens.'clone IMAGE 48375 BC040325 ; : -1 .39 -170.01 0.046302
ubiquitin.associated protein 2-likö NM_Q14847" ' -1.34? - -5 0 0 .^  0.011166
nuclear receptor subfamily 6, group NM^OOI^Sg: , , > '■ -1.34 . -788.3 Cl.007115
linker folr activation ofiT cells > ' AF036905 -1':31 v -186.9 0.029199
'Solute carrier family ,8 (sodiüm/calci AW452398 /  ^-1.3^ -55.28 -0.019365
PHD finger protein 2 : ‘ NM_005392 . , . -1.29 " C -925 98' 0.0104
Heterogeneous nuclear ribonucleopr Al<022050 < '  ... -1.29 -513.96 Ö.001636
gb: AI37.1550 /DB_XREF= gi:4150303 AI371550 -1 .28 , r628 64' - 0.04252
ribdnuclease P 21 kDa subunit' NM_024839 s -1-.26 ’ * -255.48 . 0 025326
dehydrogenase/reductase (SDR farr NM^OI6246 . , -1:22 . -459.86 0 .033826
^ n ^ b s in jT e a v ^ ^ o l^ e g t id e ^ ^ ^ k e le U \IM ^ ^ 5 3 ^ ^ ^ ^ ^ ^ ^ 2 V ^ ^ ^ ^ ^ ^ ^ ^ 0 ^ 0 4 5 9 5
Table 3.8.3.3 (contd) Probe sets significantly up or down-regulated between RPMI 
and RPMI TAX CM samples. The list of gene transcripts is sorted by fold change. All 
down- regulated gene transcripts are shaded grey with no shading applied to the up- 
regulated gene transcripts.
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MDA-F vs. MDA-F-ADR-SI
Tables 3.8.8.4 (a) and (b) list the probe sets called significantly changed between MDA-F 
and MDA-F ADR CM samples. When this list was generated a function in dChip was 
selected that allowed for the expression value o f probe sets in individual CM samples 
deemed to be “array outliers” to be excluded. This was used because the large difference in 
%Present call in the MDA-F-ADR 1 CM sample meant that a gene that was called 
significantly changed when MDA-F-ADR 2 and 3 CM samples were compared to the three 
MDA-F CM samples, would possibly not have been determined significantly changed 
when the expression value for the MDA-F-ADR 1 sample was also included. Of the 94 
probe sets that were significantly changed between the MDA-F CM and the MDA-F-ADR 
CM samples, 72 o f these would not have been deemed significantly changed if  the “treat 
array outlier as missing expression” option (see Section) had not been checked.
A large majority o f the 94 gene transcripts significantly changed were up-regulated (85). 71 
of these probe sets were annotated for molecular function and some o f the significantly 
overrepresented gene ontology groups were protein complex (33), macromolecule 
biosynthesis (29), structural constituent o f ribosome (25), RNA binding (19) each with a 
significant over representation p-value of 0.00000.
The GenMAPP Ribosomal_Proteins pathway was significantly over represented with 19 o f  
the 29 non- redundant probe sets that correlated to gene transcripts with known pathway 
annotations, belonging to it giving a significantly over represented p-value of 0.00000.
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|>rol>e set yene Accession foldchancie
tliff
of means P va lue
217733_s_at
1553570_x_at
211969_at
1553588_at
1553567_s_at
211072_x_at
224373_s_at
224372_at
212082_s_at
200610_s_at
208628_s_at
214687_x_at
200006_at
214114_x_at
213414_s_at
200966_x_at
1553538__s_at
204892_x_at
201615_x_at
229353_s_at
200651 _at
211073_x_at
201550_x_at
211970_x_at
215963_x_at
211620_x_at
211983_x_at
219762_s_at
201217_x_at
211968_s_at
203034_s_at
212988_x_at
200031_s_at
206559_x_at
200909_s_at
200858_s_at
212039_x_at
213453_x__at
213614_x_at
201530_x_at
201429_s_at
226131_s_at
200926_at
223734_at
201105_at
201305_x_at
20D834_s_at
213583 x at
thym osin, beta 10 NMJD21103
cytochrom e c oxidase II NM_173705
heat shock 90kDa protein 1, alph BG420237 
gb: N M J  73710.1 /DB_XREF=gi:2 N M J  73710 
ATP synthase 6 N M J  73702
tubulin, alpha, ubiquitous // / tu b u l BC006481 
NADH dehydrogenase 4 / / /  NADI-AF253979 
NADH dehydrogenase 4 / / /  NADh AF253979 
m yosin, light polypeptide 6 , alkali BE734356 
nucleolin NM_005381
nuclease sensitive element bindir BC002411 
aldolase A , fructose-bisphosphat« AKD26577 
Parkinson disease (autosomal reiNM_007262 
FAST kinase AKD23141
ribosomal protein S19 BE259729
aldolase A . fructose-bisphosphat* NM_000034 
gb:NM_173704.1 /DB_XREF=gi:2 NM_173704 
eukaryotic translation elongation NM_001402 
caldesmon 1 AI685060
nuclear ubiquitous casein kinase AW 515443 
guanine nucleotide binding proteir NM_006098 
ribosomal protein L 3 / / /  ribosomal BC006483 
actin. gamma 1 NMJ301614
actin, gamma 1 BG026805
gb:Z98200 /DB_XREF=gi.600229^ 298200 
runt-related transcription factor 1 L21756 
actin, gamma 1 BE741683
ribosomal protein L36 NM_015414
ribosomal protein L3 NM_000967
heat shock 90kDa protein 1, alph AI962933 
ribosomal protein L27a NM_000990
actin, gamma 1 AL515810
ribosomal protein S11 / / /  ribosom NM_001015 
eukaryotic translation elongation NMJ001403 
ribosomal protein, large P2 NMJ301004
ribosomal protein S8 NMJ301012
ribosomal protein L3 BG339228
glyceraldehyde-3-phosphate deh* BF689355 
eukaryotic translation elongation BE786672 
eukaryotic translation initiation faiNM _001416 
ribosomal protein L37a NM_000998
ribosomal protein S16 AA583817
ribosomal protein S23 NM_001025
ovary-specific acidic protein AF329088 
lectin, galactoside-binding, solubl NMJD02305 
acidic (leucine-rich) nuclear phos| AV712577 
ribosomal protein S21 NM_001024
gb:BE964125 /D B XREF= g i: 1170 BE964125
15.05 123.23 0.020834
12.86 223.4 0.002722
11.07 209.55 0.000107
10.2 329.16 0 000069
8.75 86.17 0.009519
8.55 163.06 0.018613
8.51 76.98 0.040145
8.29 249.73 0.005462
8.2 50.6 0.006232
7.19 56.06 0.008283
6.87 285.46 0.000215
6.07 110.41 0.003151
5.98 57.39 0.03086
5.92 50.15 0.043193
5.89 186.98 0.008803
5.68 101.6 0.008403
5.63 112.43 0.003017
5.28 254.84 0.001117
5.26 56.57 0.00463
5.21 173.78 0.000024
4.95 52.88 0.046231
4.81 86.58 0.004552
4.74 62.43 0.005118
4.66 77.56 0.046674
4.64 82.36 0.003245
4.55 142.11 0.048554
4.54 80.96 0.019703
4.5 50.99 0.042117
4.45 79.46 0.00763
4.29 99.94 0.028257
4.28 66.62 0.006574
4.28 51.14 0.046588
4.24 94.47 0.041127
4.24 229.36 0.004421
4.19 52.49 0.027566
4.13 84.31 0.003764
4.1 77.41 0.047231
3.91 66.6 0.03134
3.9 404.14 0.004142
3.87 87.27 0.004562
3.8 319.04 0.004944
3.77 239.74 0.025219
3.63 71.3 0.041146
3.61 71.81 0.031442
3.6 56.62 0.027375
3.57 1017.32 0.027835
3.4 96.13 0.00346
3.31 528.73 0.003062
Table 3.8.8.4 (a) Probe sets significantly up/ down-regulated between MDA-F and 
MDA-F-ADR CM samples .The list of gene transcripts is sorted by fold change. All 
down- regulated gene transcripts are shaded grey with no shading applied to the up- 
regulated gene transcripts.
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probe set gene Accession foldchancle cliffof m eans P va lu e
224616_at dynein, cytop lasm ic, light interme BG 110975 3.26 62.74 0.039549
200763_s_at ribosom al protein, large, P1 NM_001003 3.25 89.93 0.007455
212284_x_at tum or protein, translationally-cont BG49B776 3.09 127.31 0.010554
200089_s_at ribosomal protein L 4 / / / ribosomal AI953886 3.06 99.72 0.002703
216342_x_at gb:AL121916/D B_XR EF=gi:7406 AL121916 3.02 52.96 0.019242
1559489_a_at hypothetical protein LOC257358 AKD93725 2.97 118.9 0.044835
217398_x_at glyceraldehyde-3-phosphate dehy AW026525 2.86 55.15 0.020471
211787_s_at eukaryotic translation initiation fai BC006210 2.82 79.76 0.010322
221775_x_at ribosomal protein L22 BG152979 2.82 112.19 0.022805
201306_s_at acidic (leucine-rich) nuclear phos| NM_006401 2.76 131.08 0.027315
200594_x_at heterogeneous nuclear ribonuclec NMJD04501 2.75 60.44 0.030674
1558173_a_at leucine zipper protein 1 AK093016 2.71 56.99 0.012152
209134_s_at ribosomal protein S6 BC000524 2.62 350.63 0.003657
208768_x_at ribosomal protein L22 D17652 2.59 102.86 0.025973
213757_at gb: AA393940 /DB_XREF=gi:2046 AA393940 2.52 246.29 0.016118
210646_x_at ribosomal protein L13a BC001675 2.47 97.63 0.013184
212790_x_at ribosomal protein L13a BF942308 2.47 96.78 0.013129
208695_s_at ribosomal protein L39 BC001019 2.45 294.85 0.000971
200716_x_at ribosomal protein L13a NM_012423 2.4 96.06 0.012137
200817_x_at ribosomal protein S10 NM_001014 2.29 295.82 0.016535
220209_at peptide YY, 2 (sem inalplasm in) NM_021093 2.19 59.8 0.030716
200715_x_at ribosomal protein L13a BC000514 2.11 68.81 0.017213
211542_x_at ribosom al protein S10 BC004334 2.1 252.01 0.024807
200095_x_at ribosomal protein S 1 0 / / / ribosom AA320764 2.09 307.34 0.023518
201254_x_at ribosom al protein S6 NM_001010 2.01 78.98 0.015147
213941_x_at ribosomal protein S7 AI970731 2.01 213.11 0.015483
221488_s_at chrom osom e 6 open reading fram AF230924 1.74 72.47 0.017006
1552319_a_at kallikrein 8 (neuropsin/ovasin) NM_144506 1.71 160.25 0.045895
213867_x_at actin, beta AA809056 1.63 119.95 0.009981
200801_x_at actin, beta NM_001101 1.61 97.16 0.03492
62987_r_at calcium  channel, voltage-depende AI675178 1.59 87.07 0.012971
214938_x_at high-m obility group box 1 AF283771 1.56 164.84 0.031716
205827_at chotecystokin in NM_000729 1.55 50.57 0.02541
221544_s_at thyroid hormone receptor associa BG339606 1.52 158.66 0.001977
216153_x_at reversion-inducing-cysteine-rich p AK022897 1.45 157.94 0.025483
59999_at hypoxia-inducible factor 1 , alpha :W 37897 1.41 67.16 0.012406
208817_at catechol-O -m ethyltransferase BC000419 1.37 190.71 0.000717
229961 x at FU 44968 protein_______________ AI871270 1.3 65.29 0.033242
210601 Jat . cadherin 6, type 2, K-cadherin (fe BC000019 / -2.48, ;. -85.23 0.033697{)563052^at Homo sapiens' clone IM AGE:529 BC040832 -2.4S -55 .4* 0:048218
215197_at M annosyl (alpha-1 ,6-)-gly coprotei AWD23838 < -2 07 -  , -59.66 0:021508
219610_at ; ;• Rho-guanine nucleotide.exchange NM_022448 "  -2!05 / /  -80.22 0.003526
230D77^at - succinate dehydrogenase comple W 90764;; * ’ s -1 59 . ' -54.69 0.022441
.1554663_a_at nuclear m itotic apparatus protein BC043499. A .4 . A 18.73 0.048052
233658__at. gb;AKD22413.1 /DB_XREF=gi:10- A k022413 , -1.36 ' \  -164 4 0.037888
1553258_at . hypothetical protein FLJ30679 NM_153017 - 1 3 2  . ^57.2 01035894:
Table 3.8.8.4 (b) Probe sets significantly up or down-regulated between MDA-F and 
MDA-F-ADR CM samples. The list of gene transcripts is sorted by fold change. All 
down- regulated gene transcripts are shaded grey with no shading applied to the up- 
regulated gene transcripts.
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MDA-F vs. MDA-F-TAX-SI
39 probe sets were significantly different between MDA-F CM samples and MDA-F-TAX- 
SI CM samples (see Table 3.8.8.5). The majority o f these (31) were down-regulated, with 8 
up-regulated. Only 15 o f the 39 probe sets are annotated. One gene ontology group 
“oxidoreductase activity\, acting on the CH-NH group o f donors" was determined to be 
overrepresented (p-val 0.000299) as 2 o f the 15 annotated gene transcripts alcohol 
dehydrogenase 4 (class II), pi polypeptide (22378 l_x_at), and Quinoid dihydropteridine 
reductase (238616_at) belong to the group which itself only contains 45 gene transcripts.
Of the 14/ 39 gene transcripts with a known chromosomal location, no region was 
determined to be over represented but the chromosomes represented include 1, 2, 4- 7 and 
the X chromosome..
l>rol»e set • je n « Accession fold
c li.inc ie
dlff
of lll«.1IIS
P v.ilue
228452 at
220406 at
21 2B54 x at
2223BO s at
1552771_a_at
21 3B1 1 x at
2301 62 at
1552504_a_at 
TS60325_at ^
21 7878^3 at
21 1921 x at
2421 36 x at'
235693_at
231 598 x át
243489_at
219754 at ■
21 7793 at- ‘
20201 5 x sit
1 55286D_at 
201293/x^_at
2171 37 x__at
1 5B1 81 3^ _at ,
215545 at" 1
21961 O at
23391 2_x_at 
234753_x_at
240222 at
2242B1_at vt' 
201564_s_at r 
233658j_at 
21 6051Nx_at v
20B404^_x at «
21 7.1 26_at : 
230B16_at .*■>>’/ 
22B544j_x_at 
21 4605_x_at 
223781 i.x^at T 
234723_x_at4 
15629D5 at
chromosome 17 open reading fra r AAJB27865 3.38 56.63 0.019761
gb: NM 003238.1 /DB_XREF=gi:4 NM_003238 2.64 53.13 0.037613
AG1 AB051400 2.25 106.95 0.002303
Sim ilar to Microneme antigen AI907083 1.96 207.96 0.013562
TUDOR gene sim ilar NM_173083 1.53 56.15 0.008524
transcription factor 3 (E2A im m ur AWD62341 1.20 60.12 0.046306
gb: AI951 640 /DB_XREF=gi:5743£ AI951 640 A .28 61 .08 0.031092
KIAA1811 protein NM_032430 1.27 69.7 0.039655
gb: A llB32767.1 /DB_XREF=gi:21 7 AL832767 -208.95 -207^95 . 0 .023244
cell division cycle 27  ^ "• AI2O30BO ' -2.92* . ’ -78.22 0.022409
prothymosin! alpha (gene eequen AF3485.14 ",‘ -2 54 1 * -302.1 2- 0.04578:3
Hypothetical L00403340 \  TB6145 -2.40 -55 05 .0.039270
gb: 081004 /DB_XREF=gi:1 17088 D01004* -2.45, -76.15 0.020459
gb:AI379023 /DB_XREF=gi:4189E AI379823 .-2.39 -68.1 0 028666
gb: BF514098 /DB_XREF=gi: 1 159 BF514098 -2 2 -082.52 0 012061:
hypothetical protein lfUJ11016 NM_018301 -2,1 -125.78 0.041206
RAB1 1 B. member RAS oncogen« AL575337 . ■ -2 .08^ ’ -58.23 0.047095
gb: NM_006B38.1 /DB_XREF=gi:5 NM_006838 -1.99 . -476.45 0.034393
transci'iption. elongation factor B p MM 14-5653 ' -1.97- ' -60.54 - 0.03051 5
peptidylprolyl isomerase A  (cyclo NM_021.130 -1 .95' -51.79, .0.045005
gb: K00627.1 /DB_XREF=gi:3376i W00627 i ' -1 .72 r.150.03 0.020739
fvlRIN1A fuII length insert. cDNA cIo AL10971 1 -1 .69 -111.24 0 .025205
Excision repair cross-comp|emenA|<024185 : -1 .66 -52 32 ,0 023454
Rho-guanine nucleotide' exchange l\IM_O22440 .. -1.64 -60:03 0.01361 1
ELMO,domain containing 2 ’ /  AKD21525 . : -1 :6 -127.94 0.044832
gb:AKD26434..1 /DB_XREF=gi:10 AKD26434 ' -1.54 i220.92 0.013630
gb: BF34775B /DB_XREF=gi:1 129 BF347758 -1 .49 ' -206.12 0.007601
gb:AF119917.1 /DB_XREF=gi:77i AF1 19917 - -,1 47 . •’ -80.28 0,008088
fascin Komolog 1 , actin-bunclling | NM_003088 * -1-.46 ' -53.9 0.047014
gb:AM022413.1 /DB_XREF= gi:10. AKD22413 V-1/43 ■ .,-188.40 . 0 031617
gb: AKD22045.1 /D 0  XREF=gi:10 AK022045 -1.41. -98.26 0.046445
gb:NM_OOO09O.2,/DB^XREF=gi:4.NM_OOb89O - 1  .35 , <-1 2 8 . 1 6  0.036164
Transcribed locus, moderately sir «00627 • ( , -1:32 ‘-314.05 .^0.025867
Quinoid dihydropteridine reductas AA044132 . ’ -1.32 - -72:42 0.023704
mut ed ' homolo g (mouse) . v AV734582 . . -1.20 -170.81 Q.O35701
G protein-coupled receptor 1 r ALJD46992 *. • '■/ ‘ -1:25 -70:94 ^0.038136,
alcohol dehydrogenase 4 (class IIM15943 >1:24 . 1 -275.8, O!O18670
CDNA: F U 2 1 228 fis , clone COUO AKD248B1 ’ , -1 23'’  ^ -530 0.047210
A ttra c tin - lik e l ‘ : 1 • : B ¡0042015 ” r1 .2' ’ -110.15 0.037857
Table 3.8.8.5 Probe sets significantly up or down-regulated between MDA-F and 
MDA-F-TAX CM samples. The list is sorted by fold change. All down- regulated gene 
transcripts are shaded grey with no shading applied to the up- regulated gene 
transcripts.
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H1299 +RPM I+M DA-F vs. H1299 TAX +RPMI TAX +MDA-F-TAX-SI
34 probe sets were significantly different when the parental CM samples HI299, RPMI and 
MDA-F were pooled and compared to the pooled taxol selected variant CM samples. The 
average expression of the parental CM group was compared to the average expression o f
the taxol- selected variant CM group. 8 gene transcripts were up-regulated in the taxol
\selected variants compared to the parental CM samples, with the majority o f significantly 
changed gene transcripts down-regulated in the taxol selected CM samples.
18 of these probe sets corresponded to gene transcripts that were annotated with one gene 
ontology group designated as overrepresented. Both myosin IXB (208452_x_at) and Rho 
GTPase activating protein 26 (215955_x_at) belong to the Rho GTPase activator activity 
group, which contains only 43 gene transcripts giving an over representation p-value o f 
0.000385.
Of the 34 probe sets changed, eight have a known function o f binding, including nucleotide 
binding; DNA binding and transcription factor activity and calcium ion binding function; 
calcium channel (208020_s_at) and similar to NOTCH2 protein (214722_at). The rest o f 
the probe sets have known functions from transporter activities to regulation o f cell cycle. 
The KEGG Pyrimidine metabolism and GenMAPP Calcium_Channels pathways are 
represented with one gene from the gene list in each.
The chromosomal location was known for 11/ 34 gene transcripts found to be significantly 
different between the groups. The chromosomes that had at least one gene from the list on 
it were chromosomes 1 and 2 and chromosomes 5-8. No regions were determined as 
significantly over represented.
Whilst the parental CM samples as one group compared to the taxol- selected variants as
one group yielded 34 gene transcripts deemed to be significantly changed, it was decided to
look more closely at the significance o f these gene transcripts in the individual parental vs.
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taxol selected variant to see if  any gene transcripts were consistently determined as 
significant in the individual selections as well as in the larger grouping listed in Table 
3.8.8.6.
Table 3.8.8.7 shows that when the individual parental CM samples compared to their 
respective taxol selected CM samples, the gene transcripts found to be significantly 
changed (listed in Table 3.8.8.6) were not always found to be significantly changed or, in a 
few cases, even show the same patterns in change of expression in the individual groupings. 
For example the gene similar to NOTCH2 protein (214722_at) is significantly up-regulated 
when the parental CM samples are grouped against the taxol selected variants, however 
when the individual parental CM samples are tested against their taxol selected variant, 
although the three groups show up regulation o f the gene, it is only found to be significant 
in the RPMI vs. RPMI TAX CM sample grouping.
Overall the gene transcripts do follow the same trend in change o f expression in the 
individual parental vs. taxol selected variant groupings with 6 exceptions, 5 o f which are in 
the MDA-F vs. MDA-F-TAX-SI group.
None o f the 34 gene transcripts found to be significant in the larger parental grouping vs. 
taxol selected variant grouping listed in Table 3.8.8.6 were found to be significantly 
expressed in all three o f the individual groupings listed in Table 3.8.8.7, especially in the 
MDA-F vs. MDA-F-ADR-SI. This meant that this comparison did not yield any candidate 
gene transcripts that may be possible candidate markers for taxol resistance. This may be a 
reflection o f the fact that whilst the RPMI TAX and HI299 TAX cells were solely selected 
based on their resistance to taxol, the MDA-F-TAX-SI cells were a subgroup o f the taxol 
selected MDA-F-TAX cells that were also found to be super invasive and so may have 
different mRNA gene expression profiles related more to super invasion than taxol- 
resistance.
203
probe set gene Accession foldchange
cliff
of menus P value
204347_at adenylate kinase 3 / / /  adenylate \ AI653169
241600_at gb: AI270986 /DB_XREF=gi:38901AI270986
1559054_a_at Protein phosphatase 1, regulatory BC027905 
227732_at ataxin 7-like 1 AB033044
214722_at similar to NOTCH2 protein AW516297 
1559956_at synaptotagmin VII BF109699
211792_s_at cyclin-dependent kinase inhibitor U17074 
2 4 2 6 5 9 j i  g b: T70285 /DB_XREF=gi:681433 T70285 .
215955_x_at Rho GTPase activating protein 26 Y10388 
22444?_at DNA-damage inducible protein 2 t BC006011, 
222359_x_at Follicular lymphoma variant transl BF573849 *
242099_at gb:TB39387DB^XREF=gi:712226 T83938 ;
1552853_at hypothetical protein FU 32784 . NM_144623 
1554128_at hypothetical protein MGC39724 BC029594.: 
1563754_at . glutamate receptor, ioriotropic, ksAJ252246 ’
1567333_at' Vg b: AJ431618! 1 /D B_XR E F=g i: 18E AJ431618 , /  
206491_s_at N-ethylmaleimicle-sehsitive factor NMJ303827 
23703l^at; Full length insert cDNA clone YPl A I743452; /  
240304^s^at Transmembrane bhannelflikea5 BG484769 : 
208452>x-at myosin IXB ' NMJD04145,
225489^_at, transmembrane protein 18 . ? ; AI720705
1554375_a_at nucIear receptor subfamily 1, groiAF478446. : 
218698iat v. Jikely ortholog of mouse monocyt NM_015957. 
208020_s_at calcium channel, voltage-dependeNMjj00719' 
217512_at ( ; gb: BG398937 /DB_XREF=gi:132E BG398937 
229421 £s_at ; gb:.BF4353297pB^XREF=gi:1144 BF435329 
211238_at ; a disintegrin and metalloproteinas AF215824 
229453_at . gb:NI640257DB_XREF=gi:121185 N64025 -
210103^s_at forkhead box A2. . , . ; AB028021
241593_xjat gb:BF476913 /DB_XREF=gi: 1154BF476913  
204158_:s_at Trcell, immune regulator 1, ATPa; NM_006019 
243489_at gb:BF514098 /DB_XREF=gi:1159 BF514098
1558875_at sterol regulatory element binding S66168 
219358_s_at centaurin, alpha 2; , NM_018404
2.52 56.98 0.004665
1.8 55.01 0.034356
1.68 66.59 0.009337
1.65 76.59 0.005944
1.29 98.28 0.019443
1.26 68.8 0.04762
1.24 58.04 0.01278
■6.86 ; -163.47 0.029237
•5.01 -29195 0,020765
4 .67  . -129.86 0.013029
•4.19 -146 24 0.030241
-3.06 -71.19 0:019875
-3.04 -249.53 Ò.020049
-2.92 . -248.41 0.00131
•2.78 • -165 54 0.042744
■2.75 . -62.27 0 005717
-2.74 \  -61 3 0.000438'
-2.69 , ; -190:9 0.004832
-2:39 , -83.12 0:001933
•2:38 ' -56.43 0.004152
2 37 3 -51 ; 63, 0.ÒÒ8922
•2.26 .-58.17 0.022124
•2.25 :87.55 0.006169
•2.18 ‘ -115.69 • 0.002549
•2.15 -56.8 0.042082
•2:09: . -62.55 0.045025
-2:04 : ; -88 8 6 ‘ 0.007309;
•2:04 .-55.8 0.003252
•1.86 . , -316 41 0.045586
:1:53 V -76.9 0,025298
-i 52 -238.44 0.036178
•1.48;' ! -499.9 0.020936
■i.*38/-4 -55.19 0.032389
:1‘27 -75.57 0.019505
Table 3.8.8.6 Probe sets significantly up or down-regulated between H1299, RPMI 
and MDA-F CM samples vs. H1299 TAX, RPMI TAX and MDA-F-TAX-SI CM  
samples. The list of gene transcripts is sorted by fold change. All down- regulated gene 
transcripts are shaded grey with no shading applied to the up- regulated gene 
transcripts.
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! j H1299 v H1299 TAX RPMI v RPMI TAX M D A ivM D A JJA X-S I
fold difference fold difference fold difference
probe set nene Accession change of means P value change of means P value change of means P value
204347 at adenylate kinase 3 / / / ad A1653169 4.32 104.06 0 001076 10.65 72.6 0.010142 -1.08 * -4  7  . 0.687948
241600 at gb:AD70986 /DB XREF=A1270986 | w 1 .3 :-26 18 Ó.412Ò58 '1 4.63 136.58 0.008626 2.08 69.92 0.111566
1559054 a at Protein phosphatase 1. r BC027905 2.19 93.27 0.070647 1.55 50.11 0.052653 1.42 56.65 0.544534
227732j t  ataxin 7-like 1 AB033044 2.23 83.8 0.009627 1.99 107.7 0.109151 1.27 46.41 0.033728
214722_at similar to N0TCH2 proteiA\W16297 1.09 33.83 0.408408 1,94 230.32 0.081387 1.17 65.39 0.502534
1559956_at synaptotagmin VII BF109699 1.26 63.26 0.114592 1.6 152.04 0.064288 -1.07, ~• -19.16' 0.757612
211792 s at cyclin-dependent kinase U17074 1.12 28.39 0.282474 1.58 117.03 0.091668 1.13 34.07 0.350073
242659,a i gb:T702857DB.XREF=giT70285 • -8.25 -241.92 0.114172 -21:17 * *242.43 0.418001 -1.54 -22.97 0.690136'
215955 x at Rho GTPas'e activating p Y10388 '-4.09 1 -333.2 0 088783 -15:17 ' -596.22 .0.229522 Í -1.6 ■' -39.86 0.315857
2 24449 jr ; .DNArdamage inducible p BC00B011. -5.11 ; ’ •201.62 0.0Ì3541 -8.89. ., -180.77 ' 0:290179 j  -1.46 -15.83 • 0.542548.
222359 x at Follicular lymphoma varii BF573849 -3.63 -178.58 0.097553 -11.32. • -299.73 0.245289' -1:16 -6:46 . 0.770529
242099jt~ .gb:lB3938/DB_XREF=gi"fB3938 ' -3.24... -110.99, 0.000656 -6.1 * -108.21' ■0.229696 -1.1 . . -317 0.889932
1552853_at hypothetical protein FLCNMJ4462 ..■3.18 -  -367.12 0.02148 -5.77 , v -410.58 0.264662, -1.22 ; -22177 0.537239
1 5 5 4 1 2 8 hypothetical protein MGCBCK9594 ,-2.59 -263.25 0.044604 -5.33, . -408:63 0.000983 -1.95 -117.65. -.0.148508
1563754 at glutamate receptor, ionot AJ252246 : .*2.1 . . -138.83 ' 0.012696 -6.59. -349.97. 0335966 .■ -1 03 ‘ -2.48 ' -0.935712
1567333:atv  gb:AJ4316181 /DB^XRE AJ431618. -2:53 -61.32. 0.020938 -4.63 -107.01 0.291644 -1.85 -31.63 ' 0.340363
206491 s at: N-ethyIma!eimide-sensiti' NM 00382 :2:35 « .7 3 0.025851. -5.89 ' *-90.17 , 0.016714 -1.79 1 -31.37 0191407
237031 >  , Full length insert cDNA c A17^452 : -2.49 . ;195.34 0.124621 ! -4.96 -336.06, 0.19093 . *1.65 .-80.16 0.220376
240304 s at Transmembrane channel BG484769. -1192 ’ -70,37 0.123513 . -479 ,-157.25. ; 0.03476 -1:62 -38.77 0.289076
208452Vat'myosin.IXB ’ V  ;V .  NMJB414 -2:47 ^ -74:53 ’ 0.005262 -2.91. -68.73 : 001053 *1.48 -16.63 0.341669:
225489_af transmembrane protein i  AI73D705 -2.53 ‘ -67.24 . 0.095783 *2 82 • -89.55: 0.222022: • -1.94' -26.95 0.287469
1554375^a_at nuclear receptor subfami AF478446. * -2Ü9 ,*91 ’ 0.01629 -3.8 ? -95.13., '0:036448 ."••1.35 ; -14.53 * 0 577499
218698_at .likely ortholog of mouse iNM_01595 -2:31 ■ /  -98.76' 0.187531 -3.89' -147.93 0.007462 *1.26. . --22.94 0:446629
208020 s at vcalcium channel .^voltage-NM- 00071 -2.22 -136.12 0.046526 *3.59 -188.58 0.006098 1.29 : -33.4' 0.463812.
217512'au/gb:BG398937 /DB )ff?EFBG^8937 .-2:57, • : 'á .7 4 - ; 0.212319 -  -2.94 • + -89 82 0'l8tü23' ■ -113 . , *-6.48 0510801 <
229421_sjt. gb:BF435329 /DB_XREF;BF43S329. -2.19 \ . -91.1 * 0.086264. ‘ -3.98 -120.27 ' 0.0705461! i l 4.71 0.721226
211238 at a disintegrin and metaI!o|AF215824 *2:16 ' *106:79- 0.044771 -  -3.35 ,-160.88 0.156656, < -1 .12 .-11.94 ,■ 0.699475.
23453 at- gb:N64Q25 /DB XREF=g N64025 : í *2.3 -65.64 ,.0.094404 -2.37 -74.47-, *"0.18023* ■ '-1 -5 8 / -33.31 ; 0.171475
210103 s at forkhead box A2 AB028021 -i 65 -289:39 0lQ14169. -375 -792.37; • 0.27893 v , - V _■ -0.09: 0.999062
241593_x_at gb:BF476913 /DB_XREF BF476913: -\á ’ -103.62 ;o .o ¿ ¿ 3 *2.16 • -151.44 , 0.132736:j 1.03 4.39 0.910418
204158 s at T-ceit, immune regulator NM 00601 -1:69 -367.9 .0.02937.. . -2.16 :412.58 .. 0:24005'! 1.12 52.79 0.600987
2 4 3 4 8 9 gb: BF514098 /DB^XREF BF514098-,: -1.04; -65.98 0.825766 .*1 7 7 ' -572.14 i 0:128885. - -2.2 : -882.52 •0.012861
1558875_at ’ sterol,regulatory,eTemenl: S66168 -1:26. ; ,-39.26 0.052425 -1. 92 ■122 77 ‘ 0.274113 ,;--1:02 ;■ -3.94/ 0.88832?
219358_s_at.. centaurin, alpha 2 . , ' NM_01840. ,1.15 . ■38.44- 0.511605 -1.62, . -166.05 0.012815 -1.14: •' ’ -43.34 0:06136
Table 3.8.8.7 The 34 gene transcripts determined to be significantly differentially 
expressed between parental CM group (H1299 + RPMI+ MDA-F) against the taxol 
selected variants (H1299 TAX+ RPMI TAX+ MDA-F-ADR-TAX-SI) are examined in 
the individual parental vs. taxol selected variant groups. The list is sorted based on 
gene placement in Table 3.8.8.6. The probe set, gene and Accession columns are 
shaded according to the fold change o f the grouped parental vs. drug selected variant 
in Table 3.8.8.6, no shading^ up-regulated, grey shading = down-regulated. The fold 
change, difference of means and p-value information listed in the three columns 
H1299 vs. H1299 TAX, RPMI vs. RPMI TAX and MDA-F vs. MDA-F-ADR-SI are 
coloured based on the fold change of the gene transcripts in the individual groupings 
e.g. H1299 vs. H1299 TAX.
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3.8.9 Gene Ontology of probe sets significantly changed between 
parental CM and drug selected variant CM
The probe sets that showed a change in expression greater than 100 fluorescent units as 
well as having a fold change greater than 1.2 and a p-value less than 0.05 in the drug 
selected variants compared to the parental CM samples were submitted to netaffx (see 
section 2.10.82). The molecular function o f these probe sets were graphed in a pie chart in 
(see Fig 3.8.9.1).
The pie-chart in Fig. 3.8.9.1 is quite similar to the one generated for the probe sets assigned 
as Present in all CM samples (see Fig. 3.8.5.1). The amount o f represented gene transcripts 
in the categories shift though, after the categories binding and catalytic activity, in the gene 
transcripts called Present in all CM samples the next largest represented groups were 
structural molecule activity, signal transducer activity, transcription regulator activity, 
transporter activity, enzyme regulator activity, motor activity and translation activity. In 
Fig. 3.8.9.1, the most represented categories after binding and (a smaller) catalytic activity 
group, are transcription regulator activity, signal transducer activity, transporter activity and 
a noticeably smaller structural molecule activity group. Both pie charts show that a high 
percentage o f the probe sets in the list are un-annotated (Figs. 3.8.5.1 and 3.8.9.1).
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bindlni
34%
motor activity
transcription regulator 
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structural molecule activity 
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30%
Figure 3.8.9.1 Gene ontology of significantly changing gene transcripts between 
parental and drug selected variant CM samples (n=88).
3.8.10 Number of gene transcripts significantly different between 
individual CM sample groups
The numbers o f gene transcripts found to be different between each CM sample group are 
listed in Table 3.8.10.1. The CM sample groups with the highest amount o f differentially 
expressed gene transcripts are the parental RPMI CM samples compared to the MDA-F- 
ADR-SI CM samples. The next 2 groups o f CM samples with the highest number o f  
differentially expressed gene transcripts also involves the parental RPMI CM group and the 
MDA-F-ADR-SI group, the former in comparison to its drug selected variant group RPMI 
TAX and the latter with the RPMI ML CM group.
There seems to be no pattern to how different the sample groups are from each other as 
determined by the number o f gene transcripts significantly differentially expressed between 
the sample groups.
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SAMPLE # significant gene transcripts
RPMI v MDA-F-ADR-SI 167
■ ! * RPMI v RPMI TAX: ’ ' \ \ L - . *- * . ' Jr' y^V-yis o: 'a^ ;
RPMI ML v MDA-F-ADR-SI 133
: ; vI H1299 vRPMI
RPMI TAX v MDA-F-ADR-SI 125
‘ V, .HI 299 TAX v. RPMI  ^ '
HI299 v MDA-F 110
.> /. HI 299 v MDA-F-ADR-SI - ; . ;  106
MDA-F-ADR-SI v MDA-F-TAX-SI 99
; MDA-F v MDA-F-ADR-SI „ , ; 1 94  ■ v:'*v ■7 - • . ir • ■ -v, r j.‘ •
HI299 v RPMI TAX 93
•'.M :yv;-02; ; ^ v ;
H I299 v MDA-F-TAX-SI 81
o V V ' ^ '5 ■ " . .. • ■
H1299 TAX v MDA-F-TAX 71
V * RPMI TAX V MDA-F -  ■ -,v'
RPMI TAX v MDA-F-TAX-SI 66
 ^ ; HI 299 TAX v MDA:F •>/' ; r:
RPMI v MDA-F-TAX-SI 63
" * p ^ ; M L  .V- RPMI TAX [V ;;.-:-:59r-
RPMI ML v MDA-F 56
:  ^■’ HI299 vRPMI ML ^;' V * :
H I299 TAX v MDA-F-ADR-SI 48
; . ,  H1299 J ^ X  v RPMI TAX - • ; - -S . -i. . ■ . V- . ! • ,
H1299 v H1299 TAX 43
MDA-F v MDA-F-TAX-SI 39
- RPMI ML. v MDA-F-TAXrSI ‘ ,
Table 3.8.10.1 Number of gene transcripts significantly different between all CM  
sample groups. Each of the sample groups were compared with each other using 
dChip and the criteria for selection as significantly different were; expression 
difference> 100, fold change>1.2 and p-value<0.05. The list is sorted in order of the 
sample groups with the most differences.
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Gene transcripts significantly up/ down- regulated were selected for confirmation o f change 
in trend of expression by RT-PCR. Probes sets that showed a change in expression o f >100 
fluorescent units coupled with a fold change >1.2 and a p-value<0.05 between parental CM 
samples and their drug selected variant samples were assessed for suitability.
From this list, only probes sets with the suffix “_at” were considered as they indicated a 
unique probe set that only hybridised to one gene. From this shortened list all mRNA 
sequences connected to the probe sets were entered in to a BLAT search (see Section
2.11.1) to check that exon- intron boundaries were known enabling selection o f mRNA 
specific primers to target this region. O f the probe sets that successfully passed all o f these 
criterion, ten were randomly chosen but they included probe sets that had differing ranges 
o f fold change between sample groups e.g. from 1.3 to 5.6 fold.
Due to the results obtained in the validation o f the Presence/ Absence call i.e. that gene 
transcripts with Absent calls assigned to their corresponding probe sets were amplifiable by 
RT-PCR, Presence/ Absent call o f a probe set in any/ all CM samples had no influence on 
the probe sets chosen for validation. RT-PCRs were carried out to validate trend o f change 
onely, i.e. up/ down regulation The microarray expression data, RT-PCR results and 
densitometry analysis for all probe sets chosen for validation are shown in Figs. 3.8.11.2- 
10. Table 3.8.11.1 summarises the results showing that 5/10 o f the RT-PCRs validated the 
trend o f change also found in the microarray results. However, results shown in Section
3.8.11.1 indicate that some o f this may be attributed to amplification o f genomic DNA. 
Details o f the primer sets chosen and the region o f the mRNA transcript amplified along 
with the region o f the transcript targeted by the Affymetrix array chip, are summarised in 
Table 2.11.1.3 (Section 2.11.1).
3.8.11 Validation of Microarray Data (Part 2)
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Hyp Protein F U 32784 mRNA (1552853_at)
(A)
Sample
Expression value 
Call
(B)
?
H1299 HI299 TAX
1I-649.71
P
438.13
P
520.49 
A
* h 1140.28 
A
175.47
A
HI 299 HI299 TAX
Q£
a
■I190.4
P
(C)
QO 20
10
1 1
HI 299 HI299 TAX
Figure 3.8.11.2 (A) Expression levels and Presence/ Absent call for probe set 
1552853_at (Hyp Protein FLJ32784). Hyp Protein FLJ32784 mRNA is 2.5 fold down 
regulated in the H I299 TAX CM samples compared to the H I299 CM samples with a 
significant p- value of 0.02. (B) RT-PCR of CM samples for HYP Protein FLJ32784 
(158bp). Hyp Protein FLJ32784 mRNA (arrow) was expressed, to some extent, by all 
H I299 and H I299 TAX samples analysed. Amplified product was detected in the 
positive control (RPMI TAX cell RNA) and was undetected in the negative control 
samples (-VE = PCR reaction with H20 instead o f cDNA as control). (C) Densitometry 
analysis of RT-PCR for HYP Protein FLJ32784 mRNA indicating that the transcript 
is upregulated in the H1299 TAX samples compared to the H1299 samples. CM 
samples are plotted on the X-axis with maximum OD for each PCR band plotted on 
the Y-axis.
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Small Adipocyte factor 1 (SMAF1) (1554128_at)
(A) H1299 H1299 TAX RPMI RPMI ML RPMI TAX
Sample  ^ 1 2 3 n 1 2 3 , , 1____3 n  1 2 3 I ! 1 2 3 |
Expression 310 431 547 77 237 186 518 493 114 231 11 102 110 82
Call A A A A A M A A A  P A A A A
(B)
H P* & O
? II
Figure 3.8.11.2(A) Expression levels and Presence/ Absent call for probe set 
1554128_at (SMAF1 mRNA). SMAF1 mRNA is 2.6 fold down-regulated in H1299 
TAX CM compared to H1299 CM with a p- value of 0.044, and 4 fold down-regulated 
in RPMI ML CM samples compare to RPMI CM samples with a p-value of 0.02 and 
finally 5 fold down-regulated in RPMI TAX CM samples compared to RPMI CM 
samples with a p-value of 0.0009. (B) RT-PCR of SMAF 1 mRNA (152bp). SMAF 
1 mRNA (black arrow) transcripts were expressed in H1299 TAX 1, H1299 TAX 3, 
RPMI TAX 3 CM samples, with faint bands in H1299 2, RPMI ML 1 and RPMI ML 2 
CM samples. Amplified product was detected in the positive control (RPMI TAX cell 
RNA), and was undetected in the negative control samples (-VE RT = RT reaction 
with = H2O instead of RNA, -VE PCR = PCR reaction with H2O instead of cDNA as 
control). (C) Densitometry analysis o f RT-PCR for SMAF1 in (B). CM samples are 
plotted on the X-axis with maximum OD for each PCR band plotted on the Y-axis.
(C)
400
300
o  200
< 100 
2 0
H I 299 H I299 TAX RPMI RPMI ML RPMI TAX
- J U - - J S L — _ , *= 1 ■—3 i------ r—1
H I 299
2
H1299 TAX RPMI RPMI ML RPMI TAX
211
Clone IMAGE: 5528716 (1561573_at)
(A) Sample
RPMI 
1 3
RPMI TAX 
1 2 3h ■iExpression value 169.14 176.66 311.32 277.15 261.1
Call P P P A P
(B)
(C)
RPMI RPMI TAX
400 
O  300 
5  200 $ 100 5  0 .0 □ o
J  3 I 2 3
RPMI RPMI TAX
Figure 3.8.11.3 (A) Expression levels and Presence/ Absent call for probe set 
I561573_at. The probe set is called Present in all RPMI and RPMI TAX CM samples 
except RPMI TAX 2. Clone IMAGE: 5528716 mRNA is 1.65 fold up-regulated in the 
RPMI TAX CM samples compared to the RPMI CM samples with a p- value of 0.04.
(B) RT-PCR of CM samples for Clone IMAGE: 5528716 (152bp). The Clone IMAGE: 
552876 mRNA (arrow) is expressed in all samples except RPMI 3 CM. Amplified 
product was detected in the positive control (RPMI TAX cell RNA), and was 
undetected in the negative control samples (-VE RT = RT reaction with = H2O instead 
of RNA, -VE PCR = PCR reaction with H20 instead o f cDNA as control). (C) 
Densitometry analysis o f RT-PCR for Clone IMAGE: 5528716. CM samples are 
plotted on the X-axis with maximum OD for each PCR band plotted on the Y-axis.
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ATP-binding cassette, subfamily (MDR/TAP), member 4 (ABCB4) (1570505_at)
(A) Sample
Expression value 
Call
RPMI 
1 3
17.43
P
■i h
RPMI TAX 
1 2 3
35.15 132.07 121.9 178.83
A P P P
(B)
(C)
RPMI RPMI TAX
Figure 3.8.11.4 (A) Expression levels and Presence/ Absent call for probe set 
1570505_at. The probe set is called Present in all samples with the exception of RPMI
3. ABCB 4 mRNA is 5.6 fold up-regulated in the RPMI TAX CM samples compared 
to the RPMI CM samples with a p-value o f 0.011. (B) RT-PCR of CM samples for 
ABCB4 mRNA (239 bp). ABCB4 mRNA gene transcripts (arrow) were anipliflable in 
all RPMI and RPMI TAX CM samples. Amplified product was detected in the 
positive control (RPMI TAX cell RNA), and was undetected in the negative control 
samples (-VE RT = RT reaction with = H2O instead of RNA, -VE PCR = PCR reaction 
with H2O instead of cDNA as control). (C) Densitometry analysis of RT-PCR for 
ABCB4. CM samples are plotted on the X-axis with maximum OD for each PCR band 
plotted on the Y-axis.
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cDNA FLJ34465 fis, clone HLUNG2003061 (1557996_at)
(A)
(B)
(C)
RPMI
Sample
Expression value 
Call
1I- 3 1-H  I—
RPMI TAX
2 3
RPMI
~  400 
g  300 
X  200 
< 100 * 0
108
P
76
P
173
P
262
P
RPMI TAX
D U D
— I
231
P
RPMI RPMI TAX
Figure 3.8.11.5 (A) Expression levels and Presence/ Absent call for probe set 
1557996_at. The probe set is called Present in all RPMI and RPMI TAX CM samples 
and is calculated to be 2.4 fold up-regulated in the RPMI TAX CM samples compared 
to the R CM samples with a p- value of 0.03. (B) HLUNG2003061 mRNA gene 
transcripts (arrow) are expressed in all R and RT CM samples. Amplified product 
was detected in the positive control (RPMI TAX cell RNA), and was undetected in the 
negative control samples (-VE RT = RT reaction with = H2O instead of RNA, -VE PCR 
= PCR reaction with H2O instead of cDNA as control). (C) Densitometry’ analysis of 
RT-PCR for clone HLUNG2003061. CM samples are plotted on the X-axis with 
maximum OD for each PCR band plotted on the Y-axis.
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Neighbour of BRCA1 gene (NBR2) (207631_at)
(A) RPMI RPMI TAX
Sample 1 3  1 2  3F I------------------1 I----------------------------1
Expression value 163 143 232 250 320
Call A A A A A
Figure 3.8.11.6 (A) Expression levels and Presence/ Absent call for probe set 
20763l_at. The probe set 207631_at was assigned as Absent in all RPMI and RPMI 
TAX CM samples. Despite this there was still a 1.76 fold up-regulation of the probe 
set in RPMI TAX CM samples compared to RPMI CM samples with a p-value of 
0.037. (B) RT-PCR of CM samples for NBR2 mRNA (179bp). NBR2 mRNA gene 
transcripts (arrow) were only faintly detected in RPMI TAX 1 and RPMI TAX 2 CM  
samples. Amplified product was detected in the positive control (RPMI TAX cell 
RNA), and was undetected in the negative control samples (-VE RT = RT reaction 
with = H2O instead of RNA, -VE PCR = PCR reaction with H 2O instead of cDNA as 
control). (C) Densitometry analysis of RT-PCR for NBR2. CM samples are plotted on 
the X-axis with maximum OD for each band plotted on the Y-axis.
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Catechol-O-methyltransferase (COMT) (208817_at)
(A)
(B)
(C)
1Sample j
Expression value 536
Call A
MDA-F
2
MDA-F-ADR-SI 
1 2 3
499
A
519
A
697
A
732
A
400 - 
200  - 0 o  D. . O. D.0
MDA-F
I 2 3
MDA-F-ADR-SI
714
A
Figure 3.8.11.7 (A) Expression levels and Presence/ Absent call for probe set 
208817_at. The probe set 208817_at is called Absent in all MDA-F and MDA-F-ADR- 
SI CM samples. The expression values however are fairly high ranging from 519 to 
732 and there is an increase in expression o f 1.37 fold with a p-value of 0.0007. (B) 
RT-PCR of CM samples for COMT mRNA (151bp). COMT mRNA gene transcripts 
(arrow) were amplifiable in all samples tested. Amplified product was detected in the 
positive control (RPMI TAX cell RNA), and was undetected in the negative control 
samples (-VE RT = RT reaction with = H20 instead of RNA, -VE PCR = PCR reaction 
with H20 instead of cDNA as control). (C) Densitometry analysis of RT-PCR for 
COMT. CM samples are plotted on the X-axis with maximum OD for each band 
plotted on the Y-axis.
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Honico box HB9 (IILXB9) (214614 at)
(A)
(B)
(C)
RPMI
Sample h 1 h —■
RPMI ML
2 3
RPMI TAX
H f 1
Expression g93 g5 g34 g2 6?g Qg ?4? g2 g9 623 ?g 7]g09
value
Call
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o  300
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100
0 I
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I 2 
RPMI ML
I 2 
RPMI TAX
Figure 3.8.11.8 (A) Expression levels and Presence/ Absent call for probe set 
214614_at. HLXB9 niRNA is assigned as Absent in all samples with the exception of 
RPMI TAX 3 CM. The expression values for this probe set are high in all samples 
ranging from 521 to 893. HLXB9 mRNA is significantly down-regulated in both 
RPMI ML and RPMI TAX CM samples compared to RPMI CM samples, with a fold 
change (and p- value) o f 1.26 (0.033) and 1.39 (0.036) respectively. (B) RT-PCR of CM 
samples for HLXB9 mRNA (arrow) (180bp). Amplified product was detected in the 
positive control (RPMI TAX cell RNA), and was undetected in the negative control 
samples (-VE RT -  RT reaction with = H2O instead of RNA, -VE PCR *  PCR reaction 
with H20 instead of cDNA as control). (C) Densitometry analysis o f RT-PCR for 
HLXB9. CM samples are plotted on the X-axis with maximum OD for each PCR band 
plotted on the Y-axis.
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DNA- damage inducible protein 2 (DDI2) (224449_at)
(A)
(B)
(C)
Sample
Expression value 
Call
H1299
2
H1299 TAX 
1 2
299
P
196
A
256
P
34
A
67
A
HI 299 H1299 TAX
46
A
Figure 3.8.11.9 (A) Expression levels and Presence/ Absent call for probe set 
224449_at. The probe set 224449_at is assigned as Present in 2/3 H1299 CM samples 
and Absent in 313 H1299 TAX CM samples. The probe set is also deemed to be 5 fold 
down-regulated in H1299 TAX CM samples compared to H1299 CM samples with a 
p-value of 0.013. (B) RT-PCR of CM samples for DDI2 mRNA (163bp). DDI2 mRNA 
(arrow) was detected in all samples tested. Amplified product was detected in the 
positive control (RPM1 TAX cell RNA), and was undetected in the negative control 
samples (-VE RT = RT reaction with = H2O instead of RNA, -VE PCR = PCR reaction 
with H2O instead of cDNA as control). (C) Densitometry analysis of RT-PCR for DDI2. 
CM samples are plotted on the X-axis with maximum OD for each PCR band plotted 
on the Y-axis.
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APAF1 interacting protein (APIP) (218698_at)
RPMI RPMI ML RPMI TAX
(A) s<nlnl,  J 3 1 2 3 1 2  3Sample ,----------------- , ,--------------------------- , ,------------------------- ,
Expression value 208 193 53 119 1 62 76 17
Call A A A A A A A A
(B)
T 1
RPMI
1 2 
RPMI ML
1
RPMI TAX
a*
(C)
RPMI RPMI ML RPMI TAX
Figure 3.8.11.10 (A) Expression levels and Presence/ Absent call for probe set 
218698_at. The probe set 218698 at is assigned an Absent call in all CM samples. The 
expression level of the probe set however is deemed to be down-regulated by just 
under 4 fold in both RPMI ML and RPMI TAX CM samples compared to the RPMI 
CM samples w ith p-values of 0.04 and 0.007 respectively. (B) RT-PCR of CM samples 
for APIP mRNA (119bp). APIP mRNA gene transcripts (arrow) were amplifiable in 
all CM samples tested. Amplified product was detected in the positive control (RPMI 
TAX cell RNA), and was undetected in the negative control samples (-VE PCR = PCR 
reaction with H20 instead of cDNA as control). (C) Densitometry analysis of RT-PCR 
for APIP. CM samples are plotted on the X-axis with maximum OD for each PCR 
band plotted on the Y-axis.
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Table 3.8.11.11 shows that o f the ten probe sets chosen for the validation study, five validated the trend o f change found by the microarray 
analysis i.e. up/ down regulation in the drug selected variant CM compared to the parental CM samples. O f the five probe sets that validated 
the microarray data trends, four had primers that amplified regions close to or in the Affymetrix target region, three had a majority Present 
call among the samples tested, and three were from the set o f 4 gene transcripts that were functionally annotated. The fourth well annotated 
mRNA, HLXB9, was called Absent in 7/8 CM samples tested and the region amplified by RT-PCR was not close to the region targeted by 
the Affymetrix probe sets.
Probe ID Accession No. 
(NCBI) Gene Name
PCR target close 
to/ overlap Affy 
target region?
Gene
function
annotated?
How many 
samples with 
Present call?
Validate
Array
Result?
1552853 at NM_144623 Hyp Protein FLJ32784 Y N 3/6 N
1554128 at NM 001018082 small adipocyte factor 1 (SMAF1) N N 1/14 N
1561573_at BC039476 ' Clone IMAGE:5528716 " --Y- : ■ ■ ■ - N ’ 4/5 Y '
; 1570505^ai 
1557996_at
BC020618 _  
AK091784
ATP-binding cassette, subfamily 
(MDR/TAP), member 4 (ABCB4) 
cDNA FLJ34465 fis, clone 
HLUNG2003061 v  v
Y
n /  : . N
4/5
.. ,5/5
Y 
;  Y
207631_af. 
208817_at
NM 005821 ' 
NM 000754/ rv .  
NM 007310
Neighbour o f BRCA1 gene (NBR2) 
Catechol-O-methyltransferase (COMT)
Y
y  ■
Y
Y
0/5
2/6
Y !
. Y - ;  ••
214614_at NM_005515 Homeo box HB9 (HLXB9) N Y 1/8 N
224449_at BC006011 K M -dam age inducible protein 2 N N 2/6 N
218698_at NM_015957 APAF1 interacting protein (APIP) Y N 0/8 N
Table 3.8.11.1 Summary of gene transcripts selected for validation by RT-PCR and the results obtained. The microarray trend 
changes validated by RT-PCR are shaded in grey. N= No, Y= Yes, Affy= Affymetrix
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3.8.11.1 No reverse transcriptase controls
All o f the primers designed for the RT-PCR work to validate the microarray results were 
designed to be specific for mRNA transcripts. To do this, one o f the primers in the primer 
pair was designed to cross an exon-intron boundary (see Section 2.11.1 for example). For 
this reason the controls included for the RT-PCR study were water controls, i.e. water 
instead of RNA in the RT part and water instead o f cDNA in the PCR part. These controls 
helped to ensure that no components (reagents/ tips/ tubes) were contaminated with either 
cDNA or PCR product carried over from previous experiments.
After the validation study was carried out PCR was carried out using RNA from some of  
the microarray samples to confirm that the results obtained were not due to amplification o f 
genomic DNA sequences. PCR products were found in the (-) reverse transcription samples 
for 10/11 primer sets designed for the study (see Figs. 3.8.11.1.2/3 and 5). This was a 
surprising result because the primers pairs used in the RT-PCR study in Section 3.4, which 
were designed exactly the same way as those used in the microarray validation study did 
not show amplified product in the (-) reverse transcriptase samples. This indicates that the 
validation RT-PCR results shown in Section 3.8.11 may have been influenced by the 
amplification o f genomic DNA sequences.
An added control was tested for some o f these samples also, where all components were 
added except Oligo dT. The results shown in Figs. 3.8.11.1.9 and 3.8.11.1.10 (B) however, 
show that these samples were positive for PCR product whilst the (-) reverse transcriptase 
samples were negative. The primers for GSTrc mRNA align to two different exons, and 
therefore amplify a larger band if genomic DNA is present, however the PCR product was 
the same size as the mRNA amplicon. This indicates that either the mRNA is somehow
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capable o f self- priming but most likely that one o f my RT components is contaminated 
with Oligo dT.
The primer design for two o f the microarray validation primer sets are shown in Figs
3.8.11.1.1 and 3.8.11.1.3. The primer design for two of the PCR primer pairs used in the 
RT-PCR study from Section 3.4 are shown in Figs. 3.8.11.1.6 and 3.8.11.1.8 for 
comparison. The latter primer pairs do not amplify genomic DNA in comparison to the 
microarray primers that do. There are no distinctly obvious differences between the designs 
of the primers. Another possible explanation is that the gene transcripts chosen for 
validation o f the microarray results have unknown intron-less pseudogenes, which would 
be amplified if  genomic DNA was present and yield a PCR product o f exactly the same size 
as expected with RNA.
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Clone IMAGE: 5528716 mRNA, 152hp
Figure 3.8.11.1.1 Multalin results for mRNA sequence (black letters) with Affy target 
region (red letters). Forward and reverse RT-PCR primers are designated by the 
continuous blue line, dashed blue line is the amplified sequence and the region 
encircled (red) is the exon-exon junction site.
Cell -RT H20  <>174 
cDNA PCR
Figure 3.8.11.1.2 RT-PCR results for Clone IMAGE: 5528716 mRNA, 152bp. RPMI 
TAX cell cDNA was used for the cDNA sample, -RT is the RPMI TAX CM sample 
that was processed using PCR with no reverse transcription step. UHP was used in the 
HjO PCR sample instead o f cDNA as a control.
Pr
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ABCB4 mRNA, 239bp
itiriasynn«  
■ungga^iB« :
■tggy^g^ss E
Figure 3.8.11.1.3 Multalin results for mRNA sequence (black letters) with Affy target 
region (red letters). Forward and reverse RT-PCR primers are designated by the 
continuous blue line, dashed blue line is the amplified sequence and the region 
encircled (red) is the exon-exon junction site.
4» 174 CM Cell -Oligo -RT RT PCR
cDNA dT H20
Figure 3.8.11.1.4 RT-PCR results for ABCB4 mRNA, 239bp. RPMI TAX CM and cell 
cDNA were used for the cDNA samples, -Oligo dT is were everything except oligo dT 
was added to the samples, -RT is the RPMI TAX CM sample that was processed using 
PCR with no reverse transcription step. UHP was used in the H2O RT and PCR 
samples instead of RNA and cDNA as controls respectively.
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+174 CM Cell -RT RT PCR ^ 7 4  Cen _RT h 20  Cell -RT H20  Cell -RT H20  (J>174
cDNA h 70  cDNA P^ R cDNA P<^ R cDNA P^ R
----------------------------------------  SMAF NBR2 COMTHyp Protein FLJ32784
HLXB9 DDI2  APIP SCD5
Figure 3.8.11.1.5 RT-PCR results for primers targetted to (A) Hyp Protein FLJ32784 
mRNA, (B) SMAF mRNA, (C) NBR2 mRNA, (D) COMT mRNA, (E) HLXB9 mRNA, 
(F) DDK mRNA, (G) APIP mRNA and (H) SCD5 mRNA. RPMI TAX CM and cell 
cDNA were used for the cDNA samples, everything except oligo dT was added to the - 
Oligo dT samples, -RT is the RPMI TAX CM sample that was processed using PCR 
with no reverse transcription step. UHP was used in the H20  RT and PCR samples 
instead of RNA and cDNA as controls respectively.
p-actin 171bp
i l l 5016088IrefIXH.00 
forward
Consensus
ell5016088lreflRLOO 
forward 
reverse
131 140
mjTimfiecacfflTficccca^ GscteTcnixaTamET
iil5016088lreflMU»
Consensus
iil5016088lreflK»U)0
10 100 no 120 130—I
150
cmrccfflTccficcecccGTC
. . ..ctLtgccgatccgccfcccgtc. 
160 170 ISO 190 200 210 220 230 240 250 260—I
CamGGCRCCR6G6CSTQITG
.ccccAggcaccagggcgtgatg,
261 270 230 300 310 320 330 340 350 360 370 390
60n C C K flC CCTG flBG TICtC0 TrCfiBfiDCSGCflTC6T C B C C a C T666flCfiflD IT6G M M flB T C T66C flC C flC flC C n n B0 lflTBHECT6C6T6T ttC T C C C6H S M 6CflCCCCfiTSCT6CT6flC
391 400 410 420 430 440 450 460 470 490 500 510 520
C&R6GCCCCIXTQICIXCflB6GCUnUXCQCflflQnQVXQnTCin6Tn9BCCTTCflRCnCQXRGCDIT6TnC6TTGCTHnXRffiCTGT6CTnTIXCT6TIIC6CCTCTQ6CCGTRCCRCT
Figure 3.8 11.1.6 Multalin results for mRNA sequence (black letters) with primers
(blue letters) and the region encircled (red) is the exon-exon junction site.
<¡>174 CM cell -Oligo -RT RT PCR
cDNA dT H20
Figure 3.8.11.1.7 RT-PCR results for p-actin mRNA, 171bp. RPMI TAX CM and cell 
cDNA were used for the cDNA samples, everything except oligo dT was added to the - 
Oligo dT samples, -RT is the RPMI TAX CM sample that was processed using PCR 
with no reverse transcription step. UHP was used in the H20  RT and PCR samples 
instead of RNA and cDNA as controls respectively.
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HnRNPBl 155bp
Figure 3.8.11.1.8 Multalin results for mRNA sequence (black letters) with primers 
(blue letters) and the region encircled (red) is the exon-exon junction site.
+ 174 CM cell -Oligo -RT RT PCR
dTcDNA H20
Figure 3.8.11.1.7 RT-PCR results for p-acti° mRNA, 171bp. RPMI TAX CM and cell 
cDNA were used for the cDNA samples, everything except oligo dT was added to the - 
Oligo dT samples, -RT is the RPMI TAX CM sample that was processed using PCR 
with no reverse transcription step. UUP was used in the H20  RT and PCR samples 
instead o f RNA and cDNA as controls respectively.
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<(►174 CM Cell -RT RT PCR ,(,174 CM Cell -Oligo -RT RT PCR
cDNA H20  cDNA H ,0
+174 CM Cell -RT RT PCR 
cDNA H20
Figure 3.8.11.1.8 RT-PCR results for (A) MDR1, (R) GST n and (C) Bcl2a. RPMI 
TAX CM and cell cDNA were used for the cDNA samples, everything except oligo dT 
was added to the -Oligo dT samples, -RT is the RPMI TAX CM sample that was 
processed using PCR with no reverse transcription step. UHP was used in the H2O RT 
and PCR samples instead of RNA and cDNA as controls respectively.
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3.8.12 CM mRNA vs. CELL mRNA
The cells, from which CM was taken for the microarray study, were washed, trypsinised 
and RNA was extracted by other researchers (H I299 and H I299 TAX by Laura Breen, 
MDA-F, MDA-F-ADR and MDA-F-TAX by Helena Joyce and RPMI, RPMI ML and 
RPMI TAX by Isabella Bray). The RNA was extracted at the same time that RNA was 
extracted from the CM taken from the samples. The cell RNA was also amplified and 
labelled using a 1 cycle amplification kit and hybridised to Affymetrix U133A Plus 2.0 
chips by the researchers mentioned. As the microarray data generated directly related to the 
microarray data generated with the CM samples the researchers kindly gave access to the 
data so that cell /CM profiles could be compared.
All o f the raw data was normalised exactly as the CM data and imported into Genespring. 
Venn diagrams were then plotted to ascertain the number o f probe sets called Present or 
Marginal in the CM groups and also in the Cell groups.
The cell RNA microarray data was also assessed to see if  probe sets significantly up/ down- 
regulated in the parental against their drug selected variant CM samples, showed similar 
expression patterns. In order to allow larger numbers o f probe sets to be included in the 
study, the only criteria specified was that probe sets differentially expressed between the 
sample groups with a p-value less than 0.05 were included, fold change difference in 
expression and Presence/ Absence call were not included.
HI299 CM vs. Cell
Fig. 3.8.12.1 shows that 57% o f the gene transcripts called P or M in all 3 H I299 CM 
samples are also called P or M in all three HI 299 cell RNA samples. If the gene transcripts 
with an expression value o f over 100 in the 3 HI299 CM samples are overlapped with the 
gene transcripts called Present in the 3 HI299 cell RNA samples, the percentage o f gene
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transcripts common to both samples drops to 50%. However if  both o f these criterion i.e. 
Present call in 3/3 CM samples with an expression value over 100 are applied and the 
number o f gene transcripts passing this criteria (371) are overlapped with the gene 
transcripts called Present in 3/3 cell RNA samples the percentage o f gene transcripts 
common to both samples rises to 80%. On closer inspection o f the 76 gene transcripts 
(20%) still not common to both the cell and CM RNA samples, only 23 o f these were 
called absent in all three cell RNA samples.
To summarise, 80% o f the gene transcripts called Present in the 3 H1299 CM samples with 
an expression value over 100 were called also called Present in each o f the 3 HI299 cell 
RNA samples and 6% were called Absent in the 3 HI299 cell RNA samples. The other 
14% related to probe sets that were not uniformly called Present/ Absent or Marginal in 3/3 
cell RNA samples e.g. P in 1 or 2 o f the cell RNA samples and A in the remaining sample. 
This means that the poor correlation o f the probe sets called Present in both the CM and 
cell samples is attributable to the noise in the CM samples possibly due to the 2 cycle 
amplification procedure or maybe a reflection o f the RNA extractable from the CM
Figure 3.8.12.1 Probe sets called P or M in all H1299 CM and cell samples. The 
number of probe sets assigned P or M in the CM and cell RNA samples arc 
overlapped. H= H I299.
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Fig. 3.8.12.2 shows that 65% of the gene transcripts called P or M in all 3 HI 299 TAX CM 
samples are also called P or M in all three HI299 TAX cell RNA samples. If the gene 
transcripts with an expression value over 100 in all 3 CM samples (1,199) were overlapped 
with the cell RNA samples, the number of gene transcripts common to both would drop to 
50% (610). However if both of these criteria arc applied to the CM samples and they are 
overlapped with the gene transcripts called P in all 3 cell RNA samples, the number of 
overlapping gene transcripts rises to 79% (394 probe sets callcd P with an expression value 
over 100 in all 3 H1299 TAX CM samples, of which 312 are callcd P in the 3 H1299TAX 
cell RNA samples. Only 5% (20) of the gene transcripts called P with an expression value 
over 100 in the 3 H1299 TAX CM samples are called A in all 3 H1299 TAX cell RNA 
samples. The remaining 16% is attributable to probe sets with a mixture of P/A/M calls 
between the replicate HI299 TAX cell RNA samples e.g. P in 1 or 2 of the cell RNA 
samples and A in the remaining sample.
H I299 TAX CM vs. Cell
Figure 3.8.12.2 Venn diagram of probe sets called P or M in all H1299 TAX CM and
Cell samples. HT = H I299 TAX.
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Fig. 3.8.12.3 shows that 54% of the gene transcripts called P or M in both RPMI CM 
samples are also called P or M in all three RPMI cell RNA samples. The percentage of gene 
transcripts with an expression value over 100 in all 3 RPMI CM samples also called P in all 
3 RPMI cell RNA samples is 43%. The gene transcripts common to the cell and CM RNA 
samples rises to 74% however when the combination criteria of a P call with an expression 
value over 100 is applied to the CM samples and they are overlapped with the gene 
transcripts called P in all 3 RPMI cell RNA samples. Of the remaining 26%, 12% (39) are 
gene transcripts that are called P in all 3 CM samples, with an expression value over 100 
and called A in all 3 cell RNA samples. The remaining 14% is attributable to probe sets 
with a mixture of P/A/M calls within the 3 RPMI cell RNA samples e.g. P in 1 or 2 of the 
cell RNA samples and A in the remaining sample.
RPMI CM vs. Cell
Figure 3.8.12.3 Venn diagram of probe sets called P or M in all RPMI CM and Cell
samples. R= RPMI.
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Fig. 3.8.12.4 shows that 52% of the gene transcripts called P or M in all 3 RPMI ML CM 
samples are also called P or M in all three RPMI cell RNA samples. Only 41% of gene 
transcripts with an expression value over 100 in all 3 RPMI CM samples are also called P 
in all 3 RPMI ML cell RNA samples. When only gene transcripts with a P call and an 
expression value over 100 in all 3 of the RPMI ML samples are overlapped with the RPMI 
ML cell RNA samples, the percentage of gene transcripts common to both is 69%. Of the 
remaining 31% of gene transcripts not common to both sample types. 9% (29 gene 
transcripts) are called P in the 3 CM samples with an expression value over 100 and A in all 
3 of the RPMI ML cell RNA samples. 22 % of the gene transcripts called P with an 
expression value over 100 all 3 CM samples had different calls between the RPMI ML cell 
RNA samples e.g. P in 1 or 2 of the cell RNA samples and A in the remaining sample.
RPMI ML CM vs. Cell
Figure 3.8.12.4 Venn diagram of probe sets called P or M in all RPMI ML CM and 
Cell samples. RM= RPMI ML.
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Fig. 3.8.12.5 shows that 58% of the gene transcripts called P or M in all 3 RPMI TAX CM 
samples are also called P or M in all three RPMI TAX cell RNA samples. The percentage 
of gene transcripts with an expression value over 100 in the RPMI TAX CM samples that 
were called P in the RPMI TAX cell RNA samples was 47%. However 75% of gene 
transcripts were common to both CM and cell RNA samples when the gene transcripts 
called P in all 3 RPMI TAX cell RNA samples were overlapped with the gene transcripts 
called P with an expression value over 100 in ail 3 RPMI TAX CM samples. 10% (39) of 
the gene transcripts called P with an expression value over 100 in all 3 RPMI TAX CM 
samples arc called A in all 3 RPMI TAX cell RNA samples. The remaining 15% of gene 
transcripts gene transcripts called P with an expression value over 100 in all 3 RPMI TAX 
CM samples had different P/A/M calls between the 3 RPMI TAX cell RNA samples e.g. P 
in 1 or 2 of the cell RNA samples and A in the remaining sample.
RPMI TAX CM vs. Cell
Figure 3.8.12.5 Venn diagram of probe sets called P or M in all RPMI TAX CM and
Cell samples. RT= RPMI TAX.
234
Fig. 3 .8 .1 2 .6  shows that 5 7 %  of the gene transcripts called P or M in all 3 MDA-F CM 
samples arc also called P or M in all three MDA-F cell RNA samples. The percentage of 
gene transcripts with an expression value over 100 in the MDA-F CM samples that were 
called P in the MDA-F cell RNA samples was 4 7 % . However 7 7 %  of gene transcripts were 
common to both CM and cell RNA samples when the gene transcripts called P in all 3 
MDA-F cell RNA samples were overlapped with the gene transcripts called P with an 
expression value over 100 in all 3 MDA-F CM samples. 6 %  (2 0 )  of the gene transcripts 
called P with an expression value over 100 in all 3 MDA-F CM samples are called A in all 
3 MDA-F cell RNA samples. The remaining 17%  of gene transcripts called P with an 
expression value over 100 in all 3 MDA-F CM samples had different P/A/M calls between 
the 3 MDA-F cell RNA samples e.g. P in 1 or 2 of the cell RNA samples and A in the 
remaining sample.
MDA-F CM vs. Cell
Figure 3.8.12.6 Venn diagram of probe sets called P or M in all MDA-F CM and Cell
samples. M - MDA-F
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Fig. 3.8.12.7 shows that 62% of the gene transcripts called P or M in all 3 MDA-F-ADR-SI 
CM samples are also called P or M in all three MDA-F-ADR-SI cell RNA samples. The 
percentage of gene transcripts with an expression value over 100 in the MDA-F-ADR-SI 
CM samples that were called P in the MDA-F-ADR-SI cell RNA samples was 49%. 
However 75% of gene transcripts were common to both CM and cell RNA samples when 
the gene transcripts called P in all 3 MDA-F-ADR-SI cell RNA samples were overlapped 
with the gene transcripts called P with an expression value over 100 in all 3 MDA-F-ADR- 
SI CM samples. 7% (33) of the gene transcripts called P with an expression value over 100 
in all 3 MDA-F-ADR-SI CM samples are called A in all 3 MDA-F-ADR-SI cell RNA 
samples. The remaining 18% of gene transcripts called P with an expression value over 100 
in all 3 MDA-F-ADR-SI CM samples had different P/A/M calls between the 3 MDA-F- 
ADR-SI cell RNA samples e.g. P in 1 or 2 of the cell RNA samples and A in the remaining 
sample.
MDA-F-ADR-SI CM vs. Cell
Figure 3.8.12.7 Venn diagram of probe sets called P or M in all MDA-F-ADR-SI CM
and Cell samples. MA= MDA-F-ADR-SI
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MDA-F- TAX-SI CELL vs. CM
Fig. 3.8.12.8 shows that 49% of the gene transcripts called P or M both MDA-F-TAX-SI 
CM samples are also called P or M in all three MDA-F-TAX-SI cell RNA samples. The 
percentage of gene transcripts with an expression value over 100 in the MDA-F-TAX-SI 
CM samples that were called P in the MDA-F-TAX-SI cell RNA samples was 40%. 
However 62% of gene transcripts were common to both CM and cell RNA samples when 
the gene transcripts called P in all 3 MDA-F-TAX-SI cell RNA samples were overlapped 
with the gene transcripts called P with an expression value over 100 in both MDA-F-TAX- 
SI CM samples. 10% (41) of the gene transcripts called P with an expression value over 
100 in both MDA-F -TAX-SI CM samples are called A in all 3 MDA-F-TAX-SI cell RNA 
samples. The remaining 28% of gene transcripts gene transcripts called P with an 
expression value over 100 in both MDA-F-TAX-SI CM samples had different P/A/M calls 
between the 3 MDA-F-TAX-SI cell RNA samples e.g. P in 1 or 2 of the cell RNA samples 
and A in the remaining sample.
Figure 3.8.12.8 Venn diagram of probe sets called P o r M in all MDA-F-TAX-SI CM
and Cell samples. MT= MDA-F-TAX-SI.
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Table 3.8.12.1 summarises the results in this Section. It highlights the fact that the 
correlation between the gene transcripts common to both the cell and CM samples is much 
higher when a criteria of expression over 100 is applied to the CM samples. This indicates 
that the data for the CM samples with an expression under 100 may be attributable to noise 
possibly due to the 2  cycle amplification procedure.
Criteria for all 
CM samples
Criteria for all 
cell samples CM
Overlapping 3/3 
cell samples
H1299
P or M call P or M call 3269 1858 (57%)
Exp >100 P call 1260 610 (48%)
P call + exp >100 P call 371 312 (84%)
H1299 TAX
P or M call P or M call 4135 2690 (65%)
Exp >100 P call 1199 610(51%)
P call + exp >100 P call 394 312 (79%)
RPMI
P or M call P or M call 3462 1863 (54%)
Exp >100 P call 1208 516 (43%)
P call + exp >100 P call 335 249 (74%)
RPMI ML
P or M call P or M call 3120 1623 (52%)
Exp >100 P call 1208 516 (43%)
P call + exp >100 P call 335 249 (74%)
RPMI TAX
P or M call P or M call 3017 2314 (58%)
Exp > 1 0 0 P call 1150 543 (47%)
P call + exp >100 P call 375 281 (75%)
MDA-F
P or M call P or M call 2799 1407 (50%)
Exp >100 P call 1155 5 4 3  (47%)
P call + exp >100 P call 350 270 (77%)
MDA-F-
ADR-SI
P or M call P or M call 3793 2317(62%)
Exp >100 P call 1261 612 (49%)
P call + exp >100 P call 456 344(75%)
MDA-F-
TAX-SI
P or M call P or M call 4670 2289 (49%)
Exp >100 P call 1232 ‘ 496 (40%)
P call + exp >100 P call 390 241 (62%)
Table 3.8.12.1 A summary of the number of probe sets common in both CM and cel
RNA microarray results with different criteria for the probe sets. P or M = Present or 
Marginal, Exp> 100 = expression over 100.
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3.8.13 Probe sets significantly changed in CM and Cell groups 
H1299 vs. H1299TAX CM and Cells
Table 3.8.13.1 indicates that probe sets corresponding to four gene transcripts are up- 
regulated in both HI299 CM and cell RNA in relation to the HI299 CM and cell RNA 
samples. Two of these, adenylate kinase 3 and ataxin 7-like 1, also showed both a fold 
change greater than 1.2 and expression difference greater than 50 in the HI299 vs. HI299 
CM samples.
Probe sets corresponding to five gene transcripts are down-regulated in both HI299 TAX 
CM and cell RNA compared to HI299 CM and cell RNA. The remaining four gene 
transcripts that were deemed to be significantly changed were differentially regulated in 
both the CM and cell RNA samples, for example nucleosome assembly protein 1-like 2 
(219368_at) was down-regulated in H1299 TAX CM by 3.8 fold in comparison to H1299 
CM but was 2.5 fold up-regulated in H1299 TAX cell RNA compared to H1299 cell RNA.
CM CELLS
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238670ja t -CDNA FU41972 fis, clone SKNMC2003987 AI144156 
204347 at adenylate kinase 3 /// adenylate kinase 3 AI653169 
214257~s_at gb:AA89001Q /DB_XREF=gi:30168897DB XFWfi90010. 
227732 at . ataxin 7-like 1 AB033044
10.24 14.97 . 0.047459 
4.32 104.05 0.001076 
. 2.25 ' .46.98 0.039985 
2.23 83.79 0.009627
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p1^3#0:013773
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224472 x at calcium binding protein Cab45 precursor/// c!BC006211 4.34 14.35 0.033531 -1.23 -99.54 0.030905
219368 at nucleosome assembly protein 1-like 2 NM 021963 -3.78 -13.48 0.034204 2.47 60.58 0.021605
213532 at a disintegnn and metalloproteinase domain 1jA!797833 -3.39 -16.99 0.040954 1.60 222.34 10.030285
203846 at |tripartite motif-containing 32 IBC003Ï54 -1.45 -31.89 0.048034 1.27 56.94 0.035028
Table 3.8.13.1 Probe sets significantly changed in both CM and Cell RNA H1299 vs. 
H1299 TAX groups. The replicate samples in each CM sample group were averaged 
and compared to their averaged drug selected CM variant samples. Gene transcripts 
which had a P value <0.05 were included on the list regardless of fold change or
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difference in expression. The same steps were carried out with the data for the cell 
line RNA. The two lists were then cross compared to generate a list of gene transcripts 
that were called significantly changed (by criteria of P value <0.05 alone) in both CM 
and cell RNA samples. Gene transcripts shaded light grey are up- regulated in both 
samples, dark grey indicates gene transcripts down- regulated in both groups and no 
shading indicates gene transcripts that were not uniformly up/ down-regulated in both 
samples. The gene transcripts within each category are sorted based on fold change in 
the CM samples. Gene transcripts highlighted in bold also passed the criteria of 
difference in fold change> 1.2, difference of means> 50 in the CM samples and are 
also listed elsewhere in section 3.8.8.
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Table 3.8.13.2 indicates that probe sets corresponding to 19 gene transcripts were similarly 
up-regulated in the RPMI ML CM and cell RNA samples compared to the RPMI CM and 
cell RNA samples. A further seven gene transcripts were down-regulated in both RPMI ML 
CM and cell samples compared to the RPMI CM and cell samples. 10 of the 26 gene 
transcripts that showed similar trends of regulation of expression in the CM and cell RNA 
samples were also further classified as significant in the CM samples based on the fact that 
they showed a fold change greater than 1.2 with an expression difference greater than 50 
between the RPMI and RPMI CM samples.
The majority of the gene transcripts determined to be significantly differentially expressed 
in the RPMI ML CM and cell RNA samples compared to the RPMI CM and cell samples 
did not show the same trend of change in expression in the CM and cell RNA samples. 15 
of the 46 gene transcripts showing different but significant trends of expression change 
between the sample groups, were also further classified as significant in reference to the 
CM samples because both the fold change and difference in expression were greater than 
1.2 and 50 respectively in the RPMI CM group compared to the RPMI ML CM group. An 
example is manosidase, alpha, class 2 A, member 1 (226538_at), this gene is down- 
regulated 3.7 fold with a difference in expression of 80 in the RPMI ML CM samples 
compared to the RPMI CM samples, however in the cell RNA samples it is up-regulated 7 
fold in the RPMI ML cell samples compared to the RPMI cell samples.
RPMI vs. RPMI ML CM and Cells
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r  i ■ CM CELLS
probe set Accession fold 1 dlff of I| P value fold 1 dlff of I P valuegene I changel means I changel means 1
200991 _s^at sorting nexin'17 . . NMJ014748 
223732 at solute carrier family 23 (nucleobase transport AF170911 
244026 at . gb:BF063657/DB XREF—gi: 10822567/DB >BFD63657
24.27
1 7 0 2
16.98
23.27
19.7
17.26.
0.034216 
0.045717 
. 0.028985
1.38
22.72
3.77
291.82
97.1
22.72
0.033211
0.005526
0.007817
222266 at= gb:BF79G940 /OB XREF—gl:12101994' /OB BF796940 14.85 66.62 0.005071 1.3 81.57 0.037723
.1552390'a a hypothetical,protein FLJ39553 NM 173549 • 14.12 13.12 0.028815 7.03 61.41 0.000545
211945_e_at. integrin; beta 1 (fibronectin receptor, beta pol BG500301 
204755 x at hepatic leukemia factor. ’ ' ■ ’ M95585
11.24
8.03
45 66 
38.93
0.023639
0.013058
12.46
5.18
5126.4
22.06
0.000539 
0 011187
212195^at Interleukin 6 signal transducer (yp130. on AL049265 
1554512 a‘ a hypothetical protein FLJ14640 BC032307 
241904 at <jt>:BE068893 /08 XREF-gk8413543 /DB XBE068893 
229871 at hypothetical protein FLJ10211 W74622 
213931 a t. inhibitor of DNA binding 2. dominant neg AI819238
.5.67
5.1
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3.03
59.29
39.97
58.98 
153.62
82.59
,0.040941
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0.045711
.0.00284
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, 2.98 
5.43 
2.04 
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60.54
52.64
50.84
33.42
0.001289
0.004958
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0.015523
0.037183
1553162_x_a hypothetical protein BC017947 ■ 
232058_at - ; Actinin. alpha 4, ■
NM 144692 
AU158359 •
3.01.
2.93
. 36 
' é - 47.7
. 0.044058 
0.020915
• 1.51 
3.48
B5.B4
37.97
0.016061
0.010973
224617 at ’ 
200833 s at 
213005 s at
ROD1' regulator of differentiation 1 (S. pombe AI735576 
RAR1 B, member of.RAS oncogene family: ■ NM_015646 
ankyrih repeat domain 15 ' D79994
2.9 
. . ¡2.5 
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25.92' 
' 44.07 
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1.5
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0:003042
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212854~x at AG1 -
AI580142
AB051480
2.26
1.74
302.8
57.58
0.044858
0.043794
10.75
1.36
134.8
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0.001031
0.04228
[1555517* at ,Transcribed,locus, highly similar to NP_1500; BC045709. -8.9 * -22.75 0.027167 -93.24 -101.46 0.001712
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protein tyrosine phosphatase, receptor type, 
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-4.75
-12.46
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0.004057
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-17.77 
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218698 at • likely oitholog of mouse monocyte niocn NM 015957 -3.47 -141.77 0.043591 -1 .2 2 -112.97 0.020009
225276 at "
223367 at 
212113 at
G1 to S phase transition 1 - AA143579
nWilliaimsBéuren syndrome chromosome régi BC005056 
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224609 at CTL2 gene AI264216 26.75 25.75 0.045236 -3.12 -60.57 0.003005
204675_at steroid-5-alpha-reductase. alpha polypeptide NM 001047 21.65 20.86 0.047673'1 -3.26 -434.04 0.0 0 0 10 2
225957 at adult retina protein A1307750 16.92 25.63 0.046647 -1.85 -20.62, 0.049982
235048 at KlAA0888 prot e in AV720650 F 14.08 "20.79 0.030609 -2.16 -329.98 0.000295
233019 at CCR4-NOT transcription complex, subunit 7 AU145061 13.88 38 0.043313 -3.24 -43.92 0.015836
205B67 at protein tyrosine phosphatase, non-receptort\ NM 002834 13.25 12.25 0.033844 -1.71 -42.01 0.011227
232194_at methyltransferase like 4 [AA764787 11.84 12.58 0.044119 -2.43 -69.59 0.001529
235520 at gb:AW972380 /DB XREF=gi:8162226 /DB X AW97238Ü 11.03 41.73 0.014949 -1.81 -20.51 0.041727
204347 at adenylate kinase 3 i f f  adenylate kinase 31ÀIG53169 1 1 .0 1 75.31 0.00913 -7.45 -577.7 0.019387
243801 _x_at gb:AA971709 /DB XREF=qi:3146999 /DB XFAA971709 10.35 17.21 0.036532 -1.46 -80.93 'Ó.030205
218464 s at hypothetical protein FLJ10700 NM 018182 10.29 54.7" 0.018546 -1.34 -63.69 0.006886
225846 at 1Hypothetical protein FLJ20171 BF001941 10.13 17.26 0.043196 -116.18 -342.09 0 000315
230479 at |pb:AB72374 /DB XREF=gi:5546423 /DB XRAI872374 7.68 27.07 0.029527' -6.91 -186.47 0.009381
1557756“aa Chromosome 14 open reading frame 145 AWD28337 7.02 19.74 0.046678 -2.61 -15.03, 0.024204
226374 at gb:BG260087/DB XREF=gi: 12769903/DB >BG260087 5.07 30.23 0.036605 -2 .1 -327.07 Ô.016084
244007 at qb:BE0093O1 /DB XREF=qi: 10346478/DB >BE889301 3.63 33.15 0.023578 -4.93 -270.12 0.030517
238590 x at hypothetical protein MGC10744 BF981428 3.6 48.35 0.031261 -1.36 -130 55 0.028727
221580_6 at hypothetical protein MGC5306 BCOO1972 3.58 28.74 0.030651 -1.54 -284.71 0.002007
231215 at gb:AT733145/DB XREF=gi:5054258 /DB XR AÍ733145 3.3B 21.97 0.047?jy -6.77 -54.75 0.003056
1569181 x a(|l>:BC017896.1 /DB XREF— <J1:22450843 ;TI BC017896 3.12 61.211 0.037658 -2.26 -31.42 0.033741
208905 at cytochrome c. somatic B COO5299 3 52.9 0.043279 -1.41 -1626.58 '0.000564
206055_sjatl small nuclear ribonucleoprotein polypeptide ¿NM 003090 2.97 25.58 0.048927 -1.23 -327.99 0.014491
242B56_at gb:AI2918b4/DB XREF=qi:3934578 /DB XR!a I291ED4 2.94 24.84 0.03847 -28.31 -310.83 0.048618
238156 at gb:AW205632 /DB XREF=gi:6505106 /DB XAW205632 2.9 26.83 0.028741 -1.51 -54.54 0.016397
231101 at gb:AI689803 /DB XREF=qi: 4901097 /DB XR1ÂI6B9803 2.6 46.59 0.045497 -1.51 -146.26 0.024271
214323 e at UPF3 regulator of nonsense transcripts h<N36842 2.36 132.87 0.0098 -2.66 -931.261 0.00006G
2086G8 x at high-mobility gionp niicleosomal binding B COO3689 2.25 71.87 0.047983 -1.33 -1422.73 0.005078
201658_at ADP-ribosylation factor-like 1 AU151560 1 .8B 41.84 0.042816j -2.04 -508.34 0.002845
200817 x at libosomal protein S10 NM 001014 1.78 80.62 0.049138 -1.14 -1070.7 0.025345
212153 at pogo transposable element with ZNF domain AB007930 1.44 31.14 0.015545 -2 .2 -576.5 0.002132
210334 x at bacnlovlral IAP lepeat-coiitalnlng 5 (siitv AB0288GÍ) 1.34 76.11 0.010615 -1 .2 1 -267.03 0.02108
52005_ at Widely-interspaced zinc finger motif» AA422049 1.23 52.47 0.02343 -2.33 -108.84 0.001071
233816 at Solute earlier family 8 (sodium/calcium e AW668617 1 .2 1 52.85 0.034609 -9.15 -28.12 0.029041
207732_e at discs, large homolog 3 (neuroendocrine-dlq. [NM 021120 1.13 1 2 2 .1 0.022506 -3.1 -08.12 0.043847
201671 x at ubiquitin specific protease 14 (tRNA-guanine BCOO3556 1 .1 181.47 0.028099 -1.42 -245.9 “0.013316
241223 x at gb:AI821721 /DB XREF=qi:5440800 /DB XRAI821721 1.07 243.58 0.035408 -1.55 -69.88 0.022032
214614 at liomeo box HB9 AI738662 -1.2G -176.96 0.033232 1.6G 199.84 0.037287
2 10 2 0 1 x at (nidging integrator 1 AF001383 -1.27 -173.45 0.014539 13.91 206.2 0.00078
208817 at catechol-O-methyltransferase BC000419 .1.49 3^38.75 0.010668 4.72 349.52 0.005855
215482_s at eukaryotic translation initiation factor 2B. sut AJ011307 -2.47 -20.68 0.044077 1.37 192.78 0.Ó11284
206491 s at N-etliylinalelmido-sensitive factor attaclniNM 003827 -2.58 -66.53 0.014097 1.6 186.95 ÓTÓ19195
226784 at TWIST neighbor AA121481 -2.71 -36.75 0.009507 1.62 124.71 0.002578
240304 & at Tiansmembiane channel-llke 5 BG484769 -3.32 -138.84 0.014492 80.46 229.63 0.005727
226538 at niannosldase. alpha. class 2A. membei 1AV700323 -3.66 -80.41 0.015963 7.06“ 226.11 0.0 0222
231274 s at qb:RS2925 /DB XREF=qi:965279 /DB XREF: R92925 -5.09 -24.73 0.020705 1.52 61.2 0.019781
212419 at chromosome 10  open reading frame 56 IAA131324 -10.54 -30.05 0.011622 4.65 82.18 0.023895
Table 3.8.13.2 Probe sets significantly changed in both CM and Cell RNA RPMI vs.
RPMI ML groups. Gene transcripts shaded light grey are up- regulated in both 
samples, dark grey indicates gene transcripts down- regulated in both groups and no 
shading indicates gene transcripts that were not uniformly up/ down-regulated in both 
samples. The gene transcripts within each category are sorted based on fold change in 
the CM samples. Gene transcripts highlighted in bold also passed the criteria of 
difference in fold change> 1.2, difference of means> 50 in the CM samples and are 
also listed elsewhere in section 3.8.8.
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A large amount of gene transcripts (130) found to be significantly differentially expressed 
in CM samples were also found to be significantly differentially expressed in the cell 
samples when the sample groups tested were RPMI against RPMI TAX and criteria for 
classification as significant was a p-value of less than 0.05 (see Tables 3.8.13.3 (a) and (b)). 
The majority of these gene transcripts (62) were up-regulated in both RPMI TAX CM and 
cell RNA samples compared to RPMI CM and cell samples. Just 13% (10 gene transcripts), 
were down- regulated in both CM and cell RPMI TAX samples compared to the CM and 
cell RPMI samples. Of these 72 that were similarly up/ down-regulated in both the CM and 
cell samples, 20 were further classified as significant in regard to the CM samples on the 
basis that both fold change and difference in expression was greater than 12  fold and 50 
respectively.
18 of the 52 gene transcripts that showed different trends of expression change in the CM 
and cell sample groups were also further classified as significant with regard to the CM 
samples because of their fold change and difference in expression status. Interestingly three 
of these gene transcripts, showed the same expression trends in the RPMI CM and cell 
samples compared to the RPMI ML CM and cell sample groups (see Table 3.8.11.2). 
Adenylate kinase 3 (204347_at) was up-regulated by 11 fold and down-regulated by 7.5 
fold in the RPMI ML CM and cell RNA samples respectively when compared to the RPMI 
CM and cell RNA. It was similarly up-regulated by 10.7 fold and down-regulated by 7 fold 
in the RPMI TAX CM and cell RNA samples respectively in comparison to the RPMI CM 
and cell sample groups.
Catechol-O-methyltransferase (208817_at) was down-regulated by 1.4 fold and 1.8 fold in
the RPMI ML and TAX CM samples respectively in comparison to the parental RPMI CM
samples. It was also up-regulated by 4 fold and 4.7 fold in the RPMI ML and RPMI TX
243
RPMI vs. RPMI TAX CM and Cells
cell samples respectively in comparison to the RPMI parental cell RNA samples. 
Mannosidase, alpha, class 2A, member 1 gene is down-regulated by 3.7 fold and 3 fold in 
the RPMI ML and TAX CM sample groups respectively in comparison to the RPMI CM 
samples and is up-regulated by 7 fold and 6.2 fold respectively in the RPMI ML and TAX
cell RNA sample groups respectively in comparison to the RPMI cell RNA samples.
CM CELLS
probe set gene Accession fold 1 dlff of P value fold dlff of I P vainechange I means change means I
243410 at gb:AI340002 /DB XREF=gi:4076929 /DB XR AI340002 33.55 •32.55 0.024651 2.98 22.96 0.019938
225280 X at arylsulfatase D ‘ . . ‘ N51673 20.17 19.17 0.028927 3.22 51.18 0.004316
227326 at FLJ46603 protein * 1 ., . k ■ ,7 BE966768. 15:66 14.66 0.037998 1.73 76.8 0.041453
230793 at . gb:BE671038./DB XREF=gi: 10031579 /DB >BE671O30 15.06 32.62 0.031075 5.25 609.34 0.005796
237QB4 at gb:AI990122/DB_XREF=gi:5e37003./DB_XR AI990122 . . 12.96 37.54 0.008567 4.33 46.43 0.032064
215148 s at amyloid beta (A4) precursor protein-binding, 1A1141541 11.26 16.41 0.021855 2 15 79.17 0.024466
225142 at KIAA1710 protein AW294022 10.34 20.54 0:047348 1.90 15.38 0.043093
63825 at Abhydrolase domain containing 2 AI557319 . 10.23- 9.23 ; 0 038724 2.83 ' 445.82 0.013117
213044 at homeo box A5 ■ • NM 019102 9.68' 41.15 0:025493 . 54.07 30351 0.005721
200681 at glyoxalase I * . • . * NM 006708 9 48 40.94 ,0.024752 \  1.81 ' 3044.03 0 001201
1555392 at Jest is derived transcript (3 LJM domains)- AY 143171 9.32 . 24 78 0.046628 38.86 ,128.71 0.046896
218757 s at UPF3 regulator of nonsense transcripts home NM 023010 •831 ' 12:36 0.047165 .1.99 290:1 0.003452
240939 x at ,gb:T97999 /DB XREF-'gi:747344 /DB XREF=T97999 8.12 41.63 0.026289 3.07, 38.72 0.015051
1552309_a_at nexilin (F actin binding protein) ■ ■ ’ - NM -144573 7.70 20.17 0.038591 7:77 189.53 0.003345
644B6 at , cororiin.vactin binding protein,.IB ■ ' : AI341234 7.00 26.22 0.035041 .1.23 . 61.65- 0.039208227227 at Transcribed locus, m oderately sim ilar io AI344332 7.03 136.32 0.014621 1.64 44.22 0.043011
1563467 at ; Platelet derived growth factor C 
transcription'factor AP-2 alpha (activating enh
AL8332B6 6.44 24.32 0.045599 10.38 23.07 0.035595
204653 at . BF343007 6.03 19.12 . 0:042088 - 24.53 . 549.05 0.002267
201924 -ati,'; myeloid/lymphoid or mixéd-lineTage leukemia NM_005935 . ' 5.99 - '49.86 0.009319 9.11 372.84 ’ 0.002993
230621 at I * hypothetical protein LOC205140. ‘ AA602936 5.23 *34.31' 0.022221 *1.59 ; „ 788.93 0 Ò40Ì1
230466 s at* gb:AI092770;/DB X R E F-<>1:3431746 /DB XIAI092770 ' 5.07 - 66.62 0.013971 \  1-74 '525.56 0:009844
236251 at * gb:AA22S366 /DB XREF=gi:1849976 /DB XFAA228366 , 5.06. 23.89 0.017469 ‘ . 28.60 1374.93 0.006584
240594 at gb: W86659 /DBJ<REF=gi: 1400535/DB_XRE WB6659 5.01 , 37.49 0.044713 2.87 .44.14 0.03351
212608- s at Nudix (nucleoside diphosphaté linked moiety WB5912 ‘ , 4 .57 , 45.56 0.035479 ?: 1 61 251.66 0.003557
244625 a t - ' gb:AW629478 /DB XRE F=gi:7376268 /DB: X AWB29478 4.53 45.85 0.028591 « '5.05 50.57 0.016209
219108_x_at DEAD (Asp-Glu-Ala-Asp) box polypeptide NM_017895 4.51 68:77 0.029036 '  , 3.09 794.9 0.000231
237330 at - <jb:AA603494 /DB_XREF-g1:2437355 /DB_> AA603494 4.43 50.61 0.030548 2.50 22.76 0.01352
213101 s at. ARP3 actin-related protein 3 homoiog (yeast) 278330 4!30 15.82 0.032696 1.63 1384.57 0.000076
221580 s at. hypothetical protein MGC53CE - ■ ' * BC001972 4:05 .33.97 0.030329 1.53 434.08 0.001932
238549 at'.' co re-bln ding factoi. runt domain, alpha s AI420611 . 3.77 115.41 0.028758 1.77 59.65 0.029817
239811 at , gb:BF954306 /DB_XREF=gi:12371581 /DB_> BF954306 3.64 43.07 0.03211 2.09 ■ 25.15 0 038278
213221 s at salt-inducible serineAhreonine, kinase 2 ■AB018324 3.60 41.24 .* 0.03322 1.56 55.38 0.028011
202600 s at nuclear receptor interacting protein 1 AI824012 ,3.58 32.84 0.043991 4.67 •313.16 0.004754
226332 at hypothetical protein MGC40405 ÁI569932 3.40 58.41 0.039815 1.67 382A ■ 0.00359
212195,at Interleukin 6 signal transducer (gp130, oncos AUD49265 ' 3.36 30.03 0.021098 1.63 267 94 0.01027
205609 at angiopoietin.1 • 1 - / NM 001146 3.29 38.66 0.020532 .118.85 1046.47 0.008277
225412 at hypothetical protein FLJ14681 ‘ . AA761169 3.06 28.56 Ó.036369 2.84 185.45 0.046019
215693 x at DEAD (AsprGlu-Ala-Asp) box polypeptide 27 AL512707, , "3.03 48.08 • 0.021788 * • 3.11 780.36 0.000231
1554402_a_at SAR1a gene homolog 2 (S. cerevisiae) , BC002847 2.81 20.59 0.048319 - '.1 .31 ■ 63.6 0.021741
200833 s at RAP1B. m em ber of RAS oncogene fainil> NM 015646 2.78 52.3 0.034405 1.89 il 346.01^ 0.001562
239131 at ' gb: AI3048627DB ’XREF= gi:3988551 /DB XR A1304862 2.70 41.11 0.03911 : 3.02 . 88.41 0.001365
242759 at gb:AI821726 /DB_XREF-gi:54408Ò5 DB X IÀ1821726 » 2.69 83.32 0.005837 2.87 36.95 0.010399
218858 a t , DEP domain contaliilng 6 ’ NM 022783 2.58 51.64 0.035523 338.32 3906.22 01005662
236501 at gb:AI279296 /DB_XREF=gi:3917530 /DB_XR AI279296 2.52 25.80 0.Ó46949 ? 18.60 114.72 0.028721,
200641 s at .ras-related C3 botulinum toxin substrate 1 (rh BC004247 2.51 31.86 0.047.12 1.66 1073.91 0.000279
1554730 at multiple C2-domains with two transmembram BC030005 ’ ■ 2.38 . 27.23 0.02666 1.61 27.7 0.010337
241706 at gb: AI380514 /DB_XREF=gi:4190367 /DB_XR,AI380514 2; 37. . 38.51 0.049774 . 2.99 60.09 • 0.008349
232256 s at Hypothetical,gene supported"by AK09271 AF143329 2 : 2 3 96.03 0.031818 V  3.59 3 i: i9 0.01374
202845 s at ;ralA binding protein 1 NM 006788 . -2.20 35.27 0.04603 ■ .1.59 . .378.34 0.000673
212854_x_at AG1 AB051480 - 2.09 85.15 0.040579 2.66 . 825.51 0.003601
200817 x at rlbosomal protein S10 ; NM 001014 2.08 111.67 0.040589 1.23 1978.48 0.008517
214665 s at' caicium binding protein P22. AKD00095 " 2.07 ‘ 29.83 0 045841 ‘ 2.10 11739.54 0.005456
242920 at ' gb:AW5908387DB_XREF-gi:7277980 /DB_. AW590838 2.05 71.43 0.039764 4.45 - 28.02 0.009525
235429 at 1 . gb:AW965494 /DB_XREF=gi:8155330 /DB XAW965494 2,00 20.31 0.047678 • 1.36 : ' 58 . 38 0 030405
200807, s at heat shock 60kDa protein 1 (chaperonin) NM 002156 .1.97 30.05 0.048458 /■ '1.32 1985.77 -0.002192
203819 s at IGF-II mRNArbindjng protein 3 ' , ÀU160004 1.96 24.96 0.046039 ;. ,3.69 . 762.54 0.005703
200801 x at actin, beta ’’ 1. NM 001101 1.73 59.12 0.027541 1.46 ,3110.75 0.Ò04302
1560562_a_a Hypothetical pi olein MGC48625 , , AK026366 1.56 83.28 0.026495 * 8.27 295.22 0.000462
231886 at Hypothetical LOC388572. A L I37655 -  1.47 ; 51.74 0.040335 3.33 54.69 0.024656
35150 at ' tumor necrosis factor receptor superfamily. nrXE33592 ’ •• . 1.33- 41.46 ' 0.007928 2.23 ‘ 128.3 0 007043
235081 x at hypothetical protein LOC201292 AI739057 1.06 347 0.045768 , 1.76 159.02 '0.012831
2Ì5868 x at TGF-betailR beta : AW326238 • '1.06 ‘ 304.37 . 0.024296 M .1 9 ’ ’ .’663.47- 0.029022
Table 3.8.13.3 Probe sets significantly upregulated in both CM and Cell RNA in 
RPMI vs. RPMI TAX groups.
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CM CELLS
piobe set 1 gene Accession foldchamje
dlff of 
means ; P value
fold
citatine
dlff of 
means P value
1555517 at Transcribed locus, highly similar to NP 1500: BCQ45709 -8.87 *22.74 0.034106 -102.56 .*¿101:56. ■0.002681
206491 s at N<«thylmâlelmide-sensitive factor attach! NM_003827 -5.89 -90.17 0.016714 : y i i .7 8 ' •"#135182?^fÒfÒ4968
227446 s at chromosome'14 open reading frame 167 BF445127 * . -4.38 -21.63 . 0.044575 \ ; 1 f3B 7Æ Z3l19j
^ .1 Î1 9 > *4 » ? 1 £
¿0.020613 
Ì,0104Ò887218698 a t. likely ortholog of mouse monocyte macrc NM_015957 -3.89 -147.93 0.007462
225276 at G1 to S phase transition 1 AA143579 -338 -77.98 0.027384 t f 3.9p; ^ ir4 .3 3 i
231274 s at gb:R92925/DB XREF=gi:965279 /DB XREF= R92925 -2.87 -20.05 0.038728 Wsf ,47? ^-37(385 
-2 ’ 79 y f i -20D *23 i;
5^0;04574
226137 at High mobility group nucleosomal binding dorr AI288759 -2:82 -37.6 0.036898 S0.00Z224
233878 s at 5-3’ exoribonuclease 2 BE536170 -2.23 -24.28 0.031227 \-1 67 -297^061 0.003721.
208316 s_at oculocerebrorenal syndrome of Lowe M88162 -2.02 -52.76 0.027333 ' -5-1.69' * 1.97*£o.016038
^ -9 ä !2 8 ^ 0 .M l9 6221096 s at hypothetical protein PR01580 NM 018502 -1 59 -34.22 0.048443 -'1*86
212046 x at milogen-activated protein kinase 3 XE0188 ♦1 56 -49.54 0.04765 -1 86 ,-131.741 0.011983
206018 at forkhead box G1B ][NM 005249 31.09 30.09 0.006249 -753.85 -752.85 0.004867
236115 at qb:AA035771 /DB XREF=gi: 1507599 /DB XFjA/V035771 19.50 25.53 0.043478 -7.98 -272.15 0.007092
201498 at ubiqurtin specific protease 7 (herpes virus-ast AI160440 17.16 16.16 0.039074 -1.79 -420.3 0.013539
212440 at putative nucleic acid binding protein RY-1 IX76302 16.13 21.34 0.044901 -1.17 -143.52 0.012264
226602 s at Breakpoint cluster region // /  Similar to breakfT30183 15.73 14.73 0.018282 -1.73 -62.31 0.034776
232099 at protocadherin beta 16 AB046841 14.11 19.01 0.015752 -12.59 -46.92 0.004482
229533 x at hypothetical protein FLJ90430 AI963028 11.89 11.65 0.048161 -1.47 -95.54 0.027066
232355 at CDNA FLJ1Q247 fis. clone HEMBB1000705 AU146318 11.63 18.07 0.04078 -96.95 -95.95 "0.001418
204347 at adenylate kinase 3 /// adenylate kinase 3 AI653169 10.65 72.6 0.010142 -7.15 -573.84 0.017783
213191 at HR domain containing adaptor inducinq inter! AF07Q530 10.06 9.06I 0.049502 -1.58 -41.95 0.008951
233019 at CCR4-NOT transcription complex, subunit 7 ¡AU145061 8.18 21.1B 0.046068 -2.66 -39.67 0.016758
201038 s at Acidic (leucine-rich) nuclear phosphoprotein C-767821 8.16 18.82 0.027985 -1.26 -273.38 0.010899
214363 s at matrin 3 !AA129420 8.03 24.04 0.024793 -1.54 -1367 0.000578
222266 at flb:BF796940/DB XREF=gi:12101994 /OB >BF796940 7.97 33.52 0.040450 -1.35 -70.6 0.026309
224851 at cyclln-dependent kinase 6 AW274756 7.42 58.46 0.01727 -115.25 -2568.31 0.017487
230479 at flb:AJ872374 /DB_XREF=gi:5546423 /D 8 XR ÀI872374 7.33 25.63 0.033410 -2.41 -127.59 0.022553
223504 at Ras-associated protein Rap1 rAL117490 5.89 24.03 0.031577 -3.10 -56.55 0.005639
202850 at ATP .binding cassette, sub-family D (ALDh NM 002858 5.29 64.55 0.004703 -3.34 -1741.8 0.000318
204712 at W NT Inhibltoiy factoi 1 NM 007191 4.82 76.27 0.037368 -20.87 -19.87 0.031208
235381 at Hepatitis B virus x associated protein BF033855 4.73 51.6 0.032579 -1.55 -331.28 0.010527
239376 at CDNA clone IMAGE:4333081, partial cds AA489041 4.38 16.09 0.035471 -2.40 -396.57 0.001206
202960 8 at methylmalonyl Coenzyme A  mutase NM 000255 '3.87 29.24 0.04914 -1.57 -179.9 0.033708
218412 s at GTF2I repeat domain containing 1 NM 01632E 3.86 52.09 0.048293 -1.81 -475.34 0.005028
228462 at lioquols homeobox pioteln 2 A1928035 3.74 204.57 0.007047 -34.60 -34.27 0.034861
230713~at gb.BF115786/DB XREF=gi: 10985262 /DB > BF115786 3.47 50.75 0.02118 -2.08 -43.92 0.006735
239082 at Homo sapiens, clone IMAGE:5311370. mRN;BF437161 3.41 59.27 0.028984 -4.96 -677.82 0.008546
232113 at Hypothetical «jene siippotted by BX64760: N90870 3.14 92.51 0.010047 -31.56 -216.96 0.045021
1555370 a at calmodulin binding transcription activator 1 AF111804 2 99 42.34 0.047786 .2.73 -272.48 0.000465
226603 at chromosome 7 open reading frame 6 BE966604 2.91 18.53 0.028849 -3.47 -39.06 0.007781
200905 at cytochrome c, somatic BC005299 2.59 42.1 0.030713' -1.32 -1351.65 0.001339
232097 at Chromosome 14 open reading frame 92 AA65781B 2.58 35.66 0.045155 -2.11 -20.54 0.009995
232156 at CDNA: FU21268 fis. clone COLD1718 AKD24921 2.53 24.51 0.031658 -1.56 -34.72 0.028544
212153 at pogo transposable element with ZNF domain IÂB007930 1.53 38.01 0.011103 -1.93 -510.26 0.00525
236267 at zinc finger pioteln 346 ÌBG178775 1.52 68.65 0.030424 -1.72 -47.38 0.011077
221270 e at queiilne tftNA-rlbosyltiansfeiase 1 tfRNA-< NM 031209 1.44 81.11 0.036975 -2.26 -230.35 0.005677
214329 x at gb:AW474434/DB XREF=gi:7044540 /DB XAW474434 ♦1.09 -381.58 0.016468 381.26 665.46 0.035813
228541 x at Hypothetical gene supported by AKD98314 AI049608 -1.14 -266.88 0.025512 2.37 188.92 "0.022134
214643 x at bridging integrator 1 BG034080 -1.19 -132.94 0.037713 11.02 47.09 0.046574
219113 x at dehydiogenase/iediictase {SDR family} n NM 016246 -1.22 -159.85 0.033826 4.33 181.57 0.005791
218836 at tibonuclease P 21kDa subunit NM 024839 -1.26 -255.48 0.025326 1.15 159.28 0.049646
207138 at PHD finger pioteln 2 NM 005392 -1.29 -925.98 0.0104 20.29 29.52 0.017393
203565 s at m enage a nols 1 jCAK assembly factoi) NM 002431 -1.39 -98.06 0.009458 1.59 128.89 0.022958
230423 at Hypothetical LOC388638 AJ554075 -1.59 -42.23 0.041907 6.06 113.9 0.021205
219358 s at centam ln. alpha 2 NM 018404 -1.62 -166.05 0.012815 3.32 71.3 0.008742
208817 at catechol-O-methytaattsfeiase BC000419 -1.81 -161.62 0.003261 4.76 353.02 0.001387
202223 at integial m em biane pioteln 1 NMJ)02219 -2.33 .101.41 0.011746 1.90 485.37 0.003391
226784 at TWIST neiqhbor AA121481 ’  *2.78 -37.3 0.013352 2.12 224.7 0.000347
234797 at gb:ALQ49794 /DB_XREF=gi: 10280528 /FEA= ALÖ49794 -2.96 * -37.5 r  0.038123 1.93 119.08 0.021669
226538 at mannosltlase. alpha, class 2A. member 1 AV700323 -2.97 -73.43 0.033573 6.20 194.23 0.001568
201422 at Inteifeion. gamma-lnducible pioteln 30 NM 006332 -3.07 •67.49 0.046016 129.21 456.41 0.000142
212419 at chromosome 10 open reading frame 56 AA131324 -4.45 -25.74 0.027484 6.80 130.7 7 0.008499
203530 s at syntax!» 4A {placental) NM 004604 -6.36 -173.14 0.020926 3.51 267.65 0.001315
201301 s at annexin A4 BC000182 -7.94 -23.04 0.040717 2.47 677.47 0.000194
Table 3.8.13.3 (contd) Probe sets significantly downregulated/ changed in both CM
and Cell RNA in RPMI vs; RPMI TAX groups. Gene transcripts shaded light grey are 
up- regulated in both samples, dark grey indicates gene transcripts down- regulated in 
both groups and no shading indicates gene transcripts that were not uniformly up/ 
down-regulated in both samples. The gene transcripts within each category are sorted 
based on fold change in the CM samples. Gene transcripts highlighted in bold also 
passed the criteria of difference in fold change> 1.2, difference of means> 50 in the 
CM samples and are also listed elsewhere in section 3.8.7.
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The results listed in Table 3.8.13.4 show that of the 44 gene transcripts found to be 
differentially expressed in the MDA-F-ADR-SI CM and Cell RNA samples compared to 
the MDA-F CM and cell samples, the majority of these (31) are differentially regulated in 
the CM samples compared to the cell sample groups.
11 gene transcripts are similarly up-regulated in both MDA-F-ADR-SI CM and cell sample 
groups compared to the MDA-F CM and sample groups respectively. One of these gene 
transcripts, catechol-O-methyltransferase (208817_at), was found previously to be 
differentially regulated in CM compared to cell samples (see Tables 3.8.13.3 (b) and 
3.8.13.2).
Only 2 of the 44 gene transcripts listed in Table 3.8.13.4 are down-regulated in both MDA- 
F-ADR-SI CM and cell groups in comparison to the MDA-F CM and cell sample groups 
respectively.
Overall, of the 44 gene transcripts found to be significant in both MDA-F-ADR-SI CM and 
cell groups compared to the MDA-F CM and cell groups, 10 of them were further classified 
as significant in the CM samples due to the fold change and difference of expression being 
greater than 1.2 and 50 respectively between the parental and drug selected variant CM 
sample groups.
MDA F vs. MDA F ADR CM and Cells
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CM " T ellT
probe set gene Accession
fold
change
diff of 
means
P value fold
chanqe
diff of 
means
P value
1202102 s_at bromodomain containing 4 BF718610 11.79 41.98 0.005651 1.76 134.16 0.049284
1200004_at eukaryotic translation initiation factor 4 gamnNM_001418 5.26 24.56, 0.038482 1.11 608.03 0.041439
1219762 s_at ribosomal protein L36 N M 0 15414 4.50 50.99 0.042117 1.31 1350.88 0.048064
|202505_at small nuclear ribonucleoprotein polypeptide ENM_003092 3.55 34.54 0.03698 1.53 1570.72 0.00813
l212284_x_at tumor piotein. translationally-confrolled ' BG498776 3.09 127.31 0.018554 1.18 1413X2 0.028621
1 1558173_a_a leucine zipper protein 1 AK093016 2.71 56.98 0.012152 3.06 118.94 0.003801
|211943_x_at tumor protein, translationally-controlled 1 . AL565449 2.32 •34.93 0.042745 • 1.19 1452.59 0.018735
|214327_x_at tumor protein, translationally-controlled 1 AI888178 2.05 28.45 0.044854 1.14 832.03 0.041186
11553330 s_at melanoma antigen, family A, 2B /// melanom NM_005361 2.03 14.79 0.047465 2.05 491.23 0.002197
1567139 at gb:AJ297963.1 /DB_XREF=gi: 14475538 /TOAJ297963 1.41 18.78 0.046961 1.61 17.95 0.029331
208817 at catecho 1 -O-m ethyltransfe rase BC000419 1.37 190J1 0.000717 1.75 727.96 0.012579
226B36faijH GnosphoiipaselWfllDhophatiiiYlcholirrasDeciti /^iööö« ■ iliy « ^ U F 7 4 I0 !0 4 3 5 6 4 ■ fO'015622'
[l554663laTn inuclearinmottclapparatusiProtelnYlHflIBC0434991 HK lU 0ÌiliÉ 72V0!048052l «ass I 0V 1OOI8
209375 at" xeroderma pigmentosum, complementation c'D21089 12.97 11.97 0.040173 -2.82 -91.29 0.003691
1553570 x a cytochrome c oxidase II |NH 173705 12.86 223.41 0.002722 -1.11 -1222.55 0.008342
216321 s at nuclear receptor subfamily 3, group C, memb'^03348 11.63 16.05 0.033238 -1.70 -173.2 0.001617
211969 a t“ 1 heat shock 90kDa piotein 1. alpha B6420237 11.07 209.55 0.000107 -1.27 -1663.78 0.014906
226707 at similar to CG3714 gene product AI925574 9.24 19.7 0.02122 -1.36 •109.17 0.01812
200610 s at nucleolin NM 005381 7.19 56.06 0.008283 -1.10 -453.19 0.046023
232341 x at hyaluronan binding protein 4 AKD25144 6.80 23.24 0.027273 -1.84 -38.87 0.0324
200006 at IParkinson disease (autosomal recessive, ear NM 007262 5.98 57.39 0.03086 -1.40 -1755.76 0.000106
214114 x at FAST kinase AWD23141 5.92 50.16 0.043193 -1.34 -217.68 0.025542
225726 s at pleckstrin homology domain containing, familAB033H26 5.10 15.9 0.046458 -1.59 -63.2 0.010472
221637 s at hypothetical protein MGC2477 BC001434 5.04 26.49 0.022142 -1.58 -642.96 0.005023
225601 at gb:AI806853/DB XREF=gi:5393419 /DB XR AB06853 4.98 17.55 0.03389 -1.58 -72.5 0.027233
201812 s at hypothetical protein L00201725 /// transloca NM 019059 4.70 36.61 0.005587 -1.14 -638.32 0.026942
200031 s_atj ribosomal piotein $11 /// libosotnal piotegM  001015 4-24j 94.47 0.041127 -1.45 -3210.34 0.047139
201091 s ätj1 chromobox homoloq 3 (HP1 gamma homoloc'BE748755 4.01 26.82 0.023565 -1.49 -1235.6 0.000586
222390 a!__ iWW domain containing adaptor with coiled-c AL135461 3.88 35.46 10013863 -1.70 -591.59 0.006782
212333 at DKFZP564F0522 protein ALD49943 3.66 30.55 0.037507 -1.27 -266.45' 0.015118
202233 s at ubiquinokytochrome c reductase hinge proti NM 006004 3.611 16.73 0.048895 -1.22 -1167.96 0.015139
204949 at intercellular adhesion molecule 3 NM 002162 3.55 14.17 0.040598 -1.25 -54.88 0.039596
210213 s at integrin beta 4 binding protein AF022229 3.47 24.53 0.014301 -1.28 -685.72 0.006994
203113 s at eukaryotic translation elongation factor 1 delt NM 001960 3.43 34.41 0.034992 -1.20 -602.69 0.016292
221700 s at ubiquitin A-52 residue ribosomal protein fusiofAF348700 3.32 47.97 0.010711 -1.33 -1565.5 0.022225
212593 s at programmed cell death 4 (neoplastic transfon N92498 2.84 13.79 0.033609 -1.88 -222.69 0.005819
201306 s at acidic (leucine-rich) nucleai phosphoproiNM_006401 2.76 131.08 0.027315 -1.34 -930.68 0.023772
211025 x at cytochrome c oxidase subunit Vb /// cytochnBC006229 1.87 19.7 0.048589 -1.42 -1285.9 0.001017
1 1554577 _a_atproteasome (prosome, macropain) 26S subuiAY057056 1.86 19.7 .0.049893 -1.31 -285.56 0.030427
221488 s at chiomosoine 6 open leading fiame 82 AF230924 1.74 72.47 0.017006 -1.35 409.24 0.003306
201829 at neuroepithelial cell transforming gene 1 AW263232 1.58 26 0.010455 -1.34 -123.82 0.01589
223463 at RAB23, member RAS oncogene family AF1614B6 1.58 29.43 0.039727 -1.52 -97.86 0.015161
231913 s at c6.1A XB4643 -1.23 *23.89 0.04263 1.47 78.56 0.009711
206491 s at N-ethylmaleimide-sensitive factor attachment NM 003827 -2.89 -46.61 0.048118 2.04 344.53 0.01416
Table 3.8.13.4 Probe sets significantly changed in both CM and Cell RNA in MDA-F
vs. MDA-F-ADR groups. Gene transcripts shaded light grey are up- regulated in both 
samples, dark grey indicates gene transcripts down- regulated in both groups and no 
shading indicates gene transcripts that were not uniformly up/ down-regulated in both 
samples. The gene transcripts within each category are sorted based on fold change in 
the CM samples. Gene transcripts highlighted in bold also passed the criteria of 
difference in fold change> 1.2, difference of means> 50 in the CM samples and are 
also listed elsewhere in section 3.8.7.
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MDA-F vs. MD A-F-TAX-SI CM and Cells
The number of gene transcripts significantly changed in both MD A-F-T AX-SI CM and cell 
RNA samples in comparison to the parental MDA-F CM and cell RNA groups respectively 
is the smallest of the sample groups tested. None of the 9 gene transcripts listed in Table 
3.8.13.5 are similarly up-regulated in both CM and cell RNA sample groups, 2 are similarly 
down-regulated in both groups. 7 gene transcripts show different trends of change in 
expression in the two groups with 6 gene transcripts being up-regulated in the CM samples 
and down-regulated in the cell samples when the MDA-F sample groups are compared to
the MD A-F-TAX-SI groups respectively.
CM CELLS
piobe set gene Accession fold
change
diff of 
means
P value fold
change
diff of 
means
P value
242136_x_at Hypothetical L00403340 T66145 
226544 x at muted homoloq (mouse) . ‘ AV734582
2 M  -55.05 0.039278 
-1.28 -170.81 0.035781
-1.41065 -111.22 0.02193 
-1.38184 -70.59 0.023166
201498 at ubiquitin specific protease 7 (herpes virus-as; AI1S0440 3.98 -24.43 0.033032 -1.48768 -175.36 0.013647
228452 at chiomosome 17 open leading frame 39 AA827865 3.38 56.63 0.019761 -2.59255 -129.57 0.001584
222380 s at Similar to Micronenie antigen AI907083 1.% 287.% 0.013562 •2.40008 -33.84 0.011535
242539 at__ flb:AW665509 /DB_XREF=gi:7458056 /DB_XAW565509 1.95 46.29 0.007488 -2.88856 -50.84 0.003534
225845 at HSPC063 protein BG253884 1.55 46.26 0.022492 -2.03083 -204.94 0.002313
213084 at nuclear protein UKp68 N64802 1.38 35.3 0.026678 -1.58451 -126.81 0.006956
211921 x at l>iothymosin. alpha (gene sequence 28) UAF348514 -2.54 ! -302.11 0.045783 1 «28063 1509.09 0.013685
Table 3.8.13.5 Probe sets significantly changed in both CM and Cell RNA in MDA-F 
vs. MDA-F-TAX-SI groups. Gene transcripts shaded dark grey indicate gene 
transcripts down- regulated in both groups and no shading indicates gene transcripts 
that were not uniformly up/ down-regulated in both samples. No gene transcripts 
were up-regulated in both CM and cell RNA samples. The gene transcripts within 
each category are sorted based on fold change in the CM samples. Gene transcripts 
highlighted in bold also passed the criteria of difference in fold change> 1.2, difference 
of means> 50 in the CM samples and are also listed elsewhere in section 3.8.7.
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The aim of Section 3.9 was to asses whether mRNA transcripts could be amplified from the
CM of cultured normal mammary breast cells, and also whether the mRNA could be
>
amplified using the 2 cycle amplification procedure employed in Sections 3.7 and 3.8 and 
hybridised to an Affymetrix human genome Plus 2.0 microarray chip.
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3.9 Pilot Study analysis of CM from normal breast cells.
The pilot DLKP and larger cancer cell line CM array studies yielded valuable information
about the mRNA gene expression profiles of extracellular mRNA. However, the study only 
looked at the difference in gene expression between cancer cell lines. The gene transcripts 
confirmed to be up or down- regulated in the different drug selected CM samples compared 
to the parental CM samples or the gene transcripts expressed in all cancer cell line CM 
samples, whilst they may be candidates for cell- specific markers, it could not be 
determined whether they could be possible cancer- specific biomarkers.
For this reason it was decided to culture HMEC- 1001 normal human breast cells (HMEC) 
and extract RNA from both the CM and cells and perform microarray analysis of both. 
Before the samples were hybridised to the microarray chips however, RT-PCR was carried 
out to test if a few mRNA transcripts were amplifiable from the normal breast cell CM 
sample.
3.9.1 RT-PCR of HMEC CM
The results shown in Figs. 3.9.1.1-3 indicate that it is possible to amplify mRNA gene 
transcripts using the CM from normal cultured breast cells. As a result of this we decided to 
use the and process both the HMEC CM and cell RNA simultaneously using the 2 cycle 
amplification procedure for comparison with the CM RNA profile obtained for the cancer 
cell line CM samples.
¡2; CM CELL W H£     > & o
HMEC + [> jS
I
Figure. 3.9.1.1 RT-PCR of HMEC cell and CM RNA for p-actin (171bp). p-actin gene
transcripts (arrow) were expressed HMEC cell RNA with a faint band in the HMEC
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CM sample. Amplified product was detected in the positive control, RPMI TAX cell 
RNA, and was undetected in the negative control samples (-VE RT = RT reaction with 
= H2O instead of RNA, -VE PCR = PCR reaction with H2 O instead of cDNA as 
control).
Figure 3.9.1.2 RT-PCR for APIP mRNA (117bp) and Stearoyl-CoA desaturase 5 
mRNA (151bp). APIP (red arrow) and Stearoyl- CoA desaturase 5 (black arrow) 
mRNA gene transcripts are expressed in HMEC CM and cell RNA samples. 
Amplified product was detected in the positive control (DLKP cell RNA) and was 
undetected in the negative control samples (-VE RT = RT reaction with -  H2 O instead 
of RNA, -VE PCR = PCR reaction with H2 O instead of cDNA as control).
Figure 3.9.1.3 RT-PCR of HMEC CM for various transcripts detectable on 
Affymetrix microarray chip, lane 2 SMAF1 mRNA 152bp, lane 3 Clone IMAGE 
5528716 mRNA 152bp, lane 4 ABCB4 mRNA 239bp, lane 5 Clone HLUNG2003061 
mRNA 154bp. Gene transcripts were amplifiable for all transcripts except Clone 
IMAGE 5528716 mRNA. Amplified products was undetected in the negative control 
sample (-VE PCR = PCR reaction with H2O instead of cDNA as control).
5 CM CELL 
Z - HMEC HMEC ^
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3.9.2 Yield of HMEC CM and Cell cRNA after 2 rounds of IVT
There was almost five times more cRNA generated from the HMEC cell RNA than the CM 
RNA using the 2 cycle amplification procedure (see Table 3.9.2.1). Both samples yielded 
the required 15 jig required for hybridisation to the Affymetrix microarray chip.
Sample After 1st IVT (ng) After 2nd IVT (jig)
HMEC CM 131.4 21.12
HMEC cell 465.3 97.65
Table 3.9.2.1 Quantity of RNA before and during 2 cycle amplification protocol, IVT= 
in vitro transcription
3.9.3 QA parameters of Affymetrix Plus 2.0 chips
Both the HMEC CM and cell samples had acceptable QA parameters as indicated by the 
results shown in Table 3.9.3.1. However the large difference in scaling factor between the 
two samples means that the two cannot be directly compared against each other. The % 
Present call for the cell RNA sample is six times greater than the % Present call in the CM 
sample.
Parameter HMEC CM HMEC Cell
Scaling Factor 25.6 0.939
Noise 1.49 1.850
Background 48.9 61.04
% Present 7 42.4
3V 5’ GAPDH ratio 11.3 1.48
3’/M GAPDH ratio 3.93 1.12
Table 3.9.3.1 QA results of Affymetrix U133A Plus 2.0 chips for HMEC samples
252
3.9.4 Probe sets called P or M in HIM EC CM and Cell RNA
3,393 probe sets are called P or M in HMEC CM and A in HMEC cell RNA (see Fig. 
3.9.4.1). 22,527 probe sets are called P or M in HMEC cell RNA and A in HMEC CM 
RNA. 6,906 probe sets are called P or M in both samples, which is 67% of the gene 
transcripts called P or M in HMEC CM. Only 10% of these gene transcripts are expressed 
at levels over 100 in the HMEC CM RNA samples. The % correlation of the probe sets 
called P or M in both the CM and cell RNA is increased in comparison to the cancer cell 
line microarray study (Section 3.8.12). The average correlation of the probe sets called P or 
M in the CM and cell samples was 56%, this indicates that the use of two different 
amplification protocols for the CM and cell samples may have impacted slightly on the 
results obtained and perhaps if the 2 cycle amplification protocol was used for both sets of 
samples, the correlation of gene transcripts called P or M in CM and cell RNA samples 
would have been higher.
Figure 3.9.4.1 Gene transcripts called P or M in HMEC CM vs. Gene transcripts 
called P or M in HMEC cell RNA. The numbers of probe sets called P or M in HMEC 
CM RNA sample (left circle) is overlapped with the number of probe sets called P or 
M in HMEC cell RNA (right circle).
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3.9.5 Comparison of normal breast CM with cancer cell line CM
The gene transcripts that were called Present in all CM samples (including the DLKP CM
samples from Section 3.7) were compared to the gene transcripts that were called Absent in 
the HMEC CM sample. The 23 gene transcripts listed in Table 3.9.5.1 were the resulted
from that comparison.
p ro b e  s e t q e n e
131 6„at thyroid hormone receptor, alpha (erythroblastic leukem ia viral (v^erb-a) oncoqene homoloq, avian)
21 3605_s_at FLJ40092 protein
2165O0_x_at qb:AC007277 /D B _XREF-q i:5091647 /F E A -D N A  /C N T -1  /T ID -H s.283906.0 /TtER-C onsEnd /S T K -0  /U G -H s
217586_x_at qb.N35922 /D B _X R E F-q i:l 157064 /DB_XREF-yy28q05.s1 /CLO NE-IM AGE:272600 /F E A -E S T  /C N T -3  /T ID -
B ie n ^ a t Similar to Microneme ontiqen
227338_at Hypothetical qene supported by BC066916
22791 7_at M R N A  cD N A  DKFZp434N211 6 (from done DKFZp434N211 6)
230296_at
235327_>Cat
Hypothetical protein LOC146174
UBX domain containinq 4
235368_at A  disinteqrin-tike and metal I op rote as e (reprolysin type) with thrombospondin type 1 motif, 5 (aqqrecanase-2)
236841_at qb:BE4641 32 /DB_XREF-qi:9509907 /DB_XREF-hy21 b07.x1 /C LO NE-IM A G E:3197941 /F E A -E S T /C N T -6  /T
237180_at qb:T9771 7 /D B_XREF-qi:747062 /DB _XR EF-ye54e08.s1 /C LO NE-IM A G E:121 574 /F E A -E S T /C N T -5  /T ID -I-
2374B3_at
238156_at
qb:AI990790/DB_XREF-qi:5837671 /D B  X R E F-w s23q11 j<1 ^C LO N E -IM A G E :249 8084 /F E A -E S T /C N T -7 /T I 
qb AW 205632 /DB _XR EF-q i:6505106 /DBJ<REF-UI-H-Bn-atr-e-09-0-U l.s1 /CLO NE-IM AGE:2722673 /F E A -E
238348_x_at qbAW 390231 /DB_XREF-qt:6894890 /D B _X R E F -C M 3-S T0181-111199-033-al 2 /F E A -E S T  /C N T -2 5  /T ID -H :
238431 _at qb:W68845 /D B _X R EF-q i:1376076 /DB_XREF-zd43a07.s1 /C LO NE -IM A G E :343 380 /F E A -E S T  /C N T -1 3 /TIC
241835_at Hypothetical qene supported by BC03643S
241996_at qb:AIB69591 /DBJKREF-qi:4834365 /DB_XREF-tw34b09jc1 /C LO NE-IM A G E:2261561 /F E A -E S T /C N T -5 /T II
242171_at qb:AA69373D /DB_XREF-qi:2694668 /D B _X R E F -zi55d08.81 /C L O N E -IM A G E :4 3 4 7 0 3 /F E A -E S T /C N T -4 /TIC
242961 _x_ at DEAD (Asp-Glu-Ala-Asp) box polypeptide 58
1553703_at hypothetical protein FLJ90396
1555977_at LOC440476
1558982_®t FLJ0031 0 protein
Table 3.9.5.1 Probe sets/ gene transcripts called P in all human cancer cell line CM 
samples and A in HMEC CM.
The gene transcripts that were differentially expressed in the HMEC CM sample in 
comparison to the panel of cancer cell line CM samples are listed in Table 3.9.5.2. As only 
one HMEC CM sample was available, statistical significance could not be ascertained. 
Because of this, a stricter criterion for selection was employed; in order to be included on 
the list the gene transcripts had to show a fold change greater than 2 and a difference in 
expression greater than 100.
143 gene transcripts passed this criterion with 55 of them up-regulated in the HMEC CM 
compared to the panel of cancer cell line CM samples and the remaining 88 were down- 
regulated in the HMEC CM compared to the panel of cancer cell line CM samples.
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p tob e sot gene | Accession A ll CM m ean HMEC foldcli«in<ie
dtffe ience  
o f m ean s
204971 at cystatin A  (stefin A) NM 005213 4.03 195.9 48.62 191.87
204268 at S100 calcium binding protein A2 NM 005978 12.17 524.42 43.08 512.25
209351 at keratin 14 (epidermolysis bullosa simplex, IDow BC0Ò2690 7.11 175.7 24.72 168.59
203324 s at caveolin 2 NM  001233 8.79 152.73 17.37 143.94
209814 _ a f zinc finger protein 330 BC004421 6.58 106.59 16.2 100.01
207425 s at MLL septin-like fusion NM 006640 10.28 165.92 16.14 155.64
218179 8 at F U 1 2716  protein NM 021942 7.59 120.38 15.85 112.79
214211 at ferritin, heavy polypeptide 1 AA083483 14.27 191.85 13.44 177.58
1561938 at gb:ALB32704.1 /DB  XREF=gi:21733283 /T ID ^  AUB32704 10.47 135.25 12.92 124.78
212185 x at gb:NM 005953.1 /D B  XREF=gi:5174763 /G E N N M  005953 55.02 697.82 12.68 642.8
213680 at keratin 6B AI831452 9.57 114.73 11.99 105.16
33322_i_at stratifin X57348 31.47 317.68 10.1 286.21
200748 s at ferritin, heavy polypeptide 1 NMJD02032 94.23 906.55 9.62 812.32
33323 r at stratifin X57348 30.44 285.54 9.38 255.1
211628 x at ferritin, heavy polypeptide pseudogene 1 / / /  ferr J04755 179.95 1618.42 8.99 1438.47
212859 x at metallothionein 1E (functional) BF217881 13.85 124.01 8.95 110.15
215955 x at Rho GTPase activating protein 26 Y10388 225.28 1731.22 7.68 1505.94
228578_at development ally regulated RNArbinding protein AI471723 118.4 900.16 7.6 781 76
210986_s_at tropomyosin 1 (alpha) Z24727 16.46 119.7 7.27 103.24
206461 x at metallothionein 1H NM 005951 18.92 127.44 6.74 108.52
241662 x at gb:AWDS3472 /DB  XR EF=gi:8887409/D B  XR IAW 063472 24 153.79 6.41 129.79
1552853 at hypothetical protein F U 32784 NM 144623 254.97 1547.65 6.07 1292.68
222359 x at Follicular lymphoma variant translocation 1 BF573849 140.24 837.77 5.97 697.53
206286 s at teratocarcinoma-derived growth factor 1 NM 003212 26.41 153.72 5.82 127.3
242264 at gb:AJ973099 /DB_XREF=gi:5769925 /D B  XREIAJ973099 24.21 136.47 5.64 112.26
225961 at K1AA1340 protein AI334297 21.97 123.45 5.62 101.48
200912 s at eukaryotic translation initiation factor 4A, isofot NMJ001967 51.11 247.82 4.85 196.71
231821 x at Transcribed locus, weakly similar to XP 37388! AMD24248 346.81 1597.48 4.61 1250.67
231288_at Similar to 0610010D24Rik protein BF475370 43.63 183.71 4.21 140.08
233690_at Chromosome 21 open reading frame 96 AKD26743 38.28 152.77 3.99 114.49
241613 at gb:AW296081 /DB_XREF=gi:67Q2717 /DB_XRI AW 296081 43.05 156.57 3.64 113.52
243965 at Galactose-3-O-sulfotransferase 3 AI860920 51.91 181.61 3.5 129.7
216438 s at thymosin, beta 4, X-linked / / /  thymosin-like 3 AL133228 99.97 344.12 3.44 244.15
201533 at catenin (cadherin-associated protein), beta 1 .E N M  001904 50.69 167.6 3.31 116.91
228934 x at gb:AI792511 /DB XREF=gi:5340227 /DB  XREIAI792511 49.16 161.01 3.28 111.85
211956 s at putative translation initiation factor BF24643S 199.17 648.74 3.26 449.56
212284 x at tumor protein, translationally-controlled 1 BG498776 390.76 1220.54 3.12 829.79
229830 at gb:AW 205919 /DB_XREF=gi:6505393 /DB XRIAW 205919 116.12 347.77 2.99 231.64
203455 s at spermidine/spermine N1-acetyltransferase NM 002970 53.14 155.51 2.93 102.37
211943 x at tumor protein, translationally-controlled 1 AL565449 293.34 840.72 2.87 547.38
207783_x_at gb.NM 017627.1 /DB_XREF=gi:8923031 /G E N N M  017G27 308.17 880.49 2.86 572.32
214327 x at tumor protein, translationally-controlled 1 AI888178 251.55 717.03 2.85 465.48
239175 at~ gb; AW 203986 /DB_XREF=gi:6503458 /D0_XRI AW 203986 59.73 168.42 2.82 108.7
212869 x at tumor protein, translationally-controlled 1 AI721229 328.13 919.1 2.8 590.97
216520_s_at tumor protein, translationally-controlled 1 AF072098 99.86 267.58 2.68 167.72
242405 at gb:BF358388 /DB_XREF=gi:11317458 /DB_XR BF358386 81.59 214.47 2.63 132.88
213288_at O-acyltransferase (membrane bound) domain c AI761250 81.82 199.71 2.44 117.89
241593 x at gb:BF476913/D B  XREF=gi:11547740/DB XRBF476913 196.17 474.97 2.42 278.8
212788~x~at ferritin, light polypeptide BG537190 83.44 201.37 2.41 117.94
1554375_a_at nuclear receptor subfamily 1, group H, membet AF478446 98.83 234.03 2.37 135.2
210103 s at forkhead box A2 AB028021 526.42 1198.09 2.28 671.68
228253 at lysyl oxidase-like 3 AI917716 87.63 198.09 2.26 110.46
232150 at gb:AA134418 /DB_XREF=gi:1691911 /DB XREAA134418 123.84 272.38 2.2 148.54
1563754 at glutamate receptor, ionotropic, kainate 2 AJ252246 135.16 297.89 2.2 162.73
208110 x at ARC/mediator transcriptional coactivator subun NMJ030973 126.51 271.34 2.14 144.83
208668 x at higlvmobilrty group nucleosomal binding domai BC003K19 244.06 121.51 -2.01 . -122.55
211792 s at cyclin-dependent kinase inhibitor2C (p18, inhitU17074 277.87 137.24 -2.02 -140.63
200680_x_at high-mobility group box.1 NMJ002128 282.29 137.81 t2:05 -144.48
220960 x at ribosomal protein L22 V NM 000983 395.96 ' 193.47 -2.05 -202.49'
1558698 at zinc finger protein 264 BF971035 ‘ 485.88 236.16 -2.06 -249 72
211378 x at peptidylprolyl iso mera se A  (cyclophilin A) BCOO1224 375:18 180.65 -2.08 -194.53
211765 x at peptidylprolyl isomerase A  (cyclophilin A) / / /  pt BC005982 327.36 157.64 -2.08 -169.72
201293 x at peptidylprolyl isomerase A  (cyclophilin A) NM 021130 332.97 159.38 -2.09 -173.59
211978 x at peptidylprolyl isomerase A  (cyclophilin A) AI7087G7 487.62 230.15 -2.12 -257.47
221775' X at ribosomal protein L22 BG152979 388.68 182.05 -2.14 -206.64
213757 at gb:AA393940 /D 8  XREF=gi:2046909 /DB XREAA393940 500.59 232.81 -2.15 -267.77
1555373 at gb: AF304443.1 /DB_XREF=gi:16588391 /T1D=I AF304443 1537.68 711.67. -2.16 -826.02
220106 at NPC1 (Niemann-Pick disease, type C 1, gene)- NM 013389 239:66 108:67 ' -2.21 . -130.99
Table 3.9.S.2 Gene transcripts up/ down-regulated in HMEC CM compared to all
cancer cell line CM (n=26). The list is sorted by fold change, no shading = up- 
regulated, grey shading = down-regulated. Criteria for inclusion on the list were a 
difference in expression of 100 and a fold change greater than 2.
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l>iol>e se t go n e  | A ccessio  it I A ll C M  m e o » ! HM EC I fol<l I c h in in e
|< llffe ie iic e  
I o f m oon s
200021 at cofilin 1 (non-m uscle) / / /  cofilin 1 (non-muscle) N M  005507 199.77 8 9 .92 -2 .22 -109 .85
212661 x at peptidylprolyl ¡someras© A  (cyclophilin A) B E 731738 468 .25 20 8 .86 -2 .24 -259 .39
213699 8 at tyrosine 3-m onooxygenase/tryptophan 5-monot A A 854017 224 .26 97.4 -2 .3 -126 .87
200381 x at G N A S  complex locus NM  016592 192.26 78 .89 -2 .44 -113.37
215911 x at A T P as e . C a + +  transporting, plasm a membrane A W 6 1 5612 431 .25 170.01 -2 .54 -261.24
206240 at protein kinase C . epsilon N M  005400 236:13 09 .46 -2 .64 -146.67
200760 x at G N A S  complex locus N M  000516 194.08 72 .62 -2 .67 -121 .46
2 2 5413  at upregulated during skeletal m uscle growth 5 B G 291685 193.92 70 .55 -2 .75 -123 .36
217673 x at G N A S  complex locus A AS5Q 5SB 154.05 53 .68 -2 .87 -100 .38
202233 s at ubiquinol-cytochrome c reductase hinge proteir N M  006004 2 73 .75 93 .8 -2 .92 -179 .95
209251 x at tubulin alpha 6 B C 004949 194.32 65 .35 -2 .97 -128.96
203606 at NA DH  dehydrogenase (ubiquinone) Fe -S  protei N M  004553 206 .47 68 .38 -3 .02 -138.09
231628 s at gb:AW 262311 /D B _X R E F =gi:6639127 /D B  X R IA W 262311 213 .44 70.31 -3 .04 -143 .12
1553064 at H1 histone fam ily, m em ber O , oocyte*specific N M  153833 148.84 48 .75 -3 .05 -100 .09
220232 at stearoyl-CoA desaturase 4 N M  024906 ' ■ 879 .38 2 69 .12 -3 .27 -610.27
1570033 at W IPI49-Jike protein 2 B C 016912 174.35 53 .14 -3 .28 -121.21
211931 8 at heterogeneous nuclear ribonucleoprotein A 3 BG 505670 175.06 52 .24 -3 .35 -122.82
2 1 7 7 l9 _ a t eukaryotic translation initiation factor 3 , subuni* N M  016091 189.35 56.21 -3 .37 -133.15
1553588 at gb .N M _173710.1 /D B _X R E F =g i:27754195 /G E  N M  173710 950 .57 270.71 -3.51 -679.86
205987 at histone 1, H4c N M  0 0 3 5 4 2 , 282  04 79 .72 -3 .54 -202.32
201318 s at myosin regulatory light chain M RLC2 / / /  m yosii NM  006471 156.22 43 .95 -3 .55 -112.27
1555653 at NADH dehydrogenase 5 BCO12090 214 .28 59 .17 -3 .62 -155.11
211969 at heat shock 90kD a protein 1 , alpha B G 420237 208 .9 54 .03 -3 .87 -154.87
238199_x at Similar to OK/SW -CL..16 AI708524 784 .46 198.16 -3 .96 -586.31
217801 at A TP  synthase. H +transporting, mitochondrial 1 N M  006886 329 .82 83 .07 -3 .97 -246.75
224187 x at heat shock 70kD a protein 8 A F 2 17511 310 .84 77 .93 -3 .99 -2 3 2 9 1
213911 s at H 2A  histone fam ily , m em ber Z B F 7 18636 ‘179.43 44.41 -4 .04 -135 .02
230466 s at gb:A I092770 /D B _X R E F =g i:3431746 /DB_XREF AJ092770 163.59 40 .47 -4 .04 -123.12
202428 x at diazepam  binding inhibitor (G A B A  receptor m o<NM _020548 . 136.1 33 .2 -4.1 -102.9
237031 at Full length insert cD N A  clone Y P 0 8F 1 2 A I743452 167.63 39 .44 -4 .25 -128.18
1553567_s_at A T P  synthase 6 N M  173702 523 122.98 -4 .25 -400.03
208549 x at prothymosin, alpha (gene'sequence 28) NM  016171 1032.53 240 .5 -4 .29 -792.03
205644 s at small nuclear ribonucleoprotein polypeptide G NM  003096 ' 240 .76 55 .07 -4 .37 -185.71
22 4375  at ’ gb:A F271776.1 /D B _X R EF=gi: 12006208 /FEA? A F 271776 205 .95 46 .97 -4 .38 -158.98
211921 x at prothymosin, alpha (gene sequence 28) ///.p rot A F 348514 1113.15 2 53 .53 -4 .39 -859.61
200006  at Parkinson disease (autosom al recessive, early N M  007262 188.31 42 .29 -4 .45 -146.02
1553570_x_at cytochrom e c oxidase II N M  173705 671 .15 147.46 -4 .55 -523.69
216384 x at gb: A F257099  /D B _X R E F =g i:8037944 /F E A =D IN A F 257099 386 .58 8 4 .2 -4 .59 -302.38
200772 x àt prothymosin, alpha (gene sequence 28) B F686442 663 .08 191.09 -4 .62 -691.99
221891 x at heat shock 70kD a protein 8 A A 704004 34 8 .93 73 .99 -4 .72 ♦274.95
200943 at high-mobility group nucleosome binding domair NM  004965 128.31 25 .5 -5 .03 -102.81
200807 s at heat shock 60kD a protein 1 (chaperonin) N M  002156 2 0 0 .98 39 .74  ■ -5 .06 -161.23
207127 s at heterogeneous nuclear ribonucleoprotein H3 (21 N M _021644 125.05 22 .39 -5 .58 -102 .66
200642 at S uperoxide d ism u ta s e  1 , so lub le  (am yotrop h ic  N M J000454 163.31 - 29 .19 -5 .6 -134.13
211072 x at tubulin, alpha, ubiquitous / / /  tubulin, alpha, ubic BC006481 252.51 44 .86 -5 .63 ‘-207.65
211058 x at tubulin, alpha, ubiquitous / / /  tubulin, alpha, ubic BCOQ6379 268.97 46 .88 -5.74 -222.09
213507 s at karyopherin (importin) beta 1 B G 249565 131.54 21 .82 -6 .03 -109.72
1553569 at cytochrom e c oxidase II NM  173705 415 .68 65 .33 -6 .36 -350.34
208845 at voltage-dependent anion channel 3 B C 002456 138.76 21 .76 -6 .38 -117
233834 at M A R V E L  domain containing 3 B C 005052 139.72 21 -6 .65 -116.72
224372 at NA DH  dehydrogenase 4 / / /  NA DH  dehydrogen* A F253979  . 1040.52 139.47 -7 .46 -9 0 1 :06
237483 at gb:A1990790 /D B _X R E F =gi S837671 /DB_XREF A I990790 127.83 17.01 -7 .52 -110.82
229353 s at nuclear ubiquitous casein kinase and cyclin-de A W 515443 . 355 .79 45 .25 -7 .06 -310.54
212639 x at tubulin, alpha 3 / / /  tubulin, alpha, ubiquitous A L581768 139.7 17.74 -7 .87 -121.96
200633 at ubiquitin B / / /  ubiquitin B NM  018955 307.97 37 .22 -8 .27 -270.75
237180 at gb:T97717 /D B _X R E F =g i:747062 /D B _X R E F =y T97717 • 119.76 13.3 -9.01 -106.46
1553538_s_at gb:NM _173704.1 /D B _ X R E F = g i:2 7 7 5 4 2 0 3 /G E  N M  173704 1153.33 125.55 -9 .19 -1027.77
213646 x at tubulin, alpha, ubiquitous B E 300252 162.23 15.79 -10 .28 -146.44
224616 at dynein, cytoplasm ic, light intermediate polypee B G 1 10975 135.63 13.16 -10.31 -122.47
208687 x at heat shock 70kD a protein 8 A F 352832 148.45 14.15 -10.49 -134.29
214288 s at proteasom e (prosom e, macropain) subunit, bet W B 6293 2 1 5 .8 18.16 -11 .88 -197.64
201090 x at tubulin, alpha, ubiquitous NM  006082 174.26 13.85 -12.58 -160.41
214328 s at heat shock 90kD a protein 1. alpha R 01140 287 .88 22 .44 -12 .83 -265.43
201426 8 at vimentin AJ922599 123.85 7 .83 -15 .82 -116.02
20 2043  e at spermine synthase N M  004595 130.63 7 .5 8 -17.23 -123.04
224373 s at NA DH  dehydrogenase 4 / / /  NA DH  dehydrogen« A F 253979 649 .36 3 4 .9 3 r -18.59 .-614.42
222608 s at anillin, actin binding protein (scraps homolog. CAK 023208 157.68 6 .2 6 -19.08 -149.42
20 2276  at split hand/foot malformation (ectrodactyly) ty p e N M  006304 107.36 5 .5 9 -19.22 -101 .77  .
201024 x at eukaryotic translation initiation factor 5B BG 261322 114.41 5 .6 2 -20.35 -108:78
1553551_s_at NA DH  dehydrogenase 2 NM  173709 444 .69 14.33 -31.04 -430.36
200873 s at chaperonin containing T C P 1 . subunit 8  (theta) N M  006585 105.39 3 .38 -31 .2 -102.01
1SS412B at hypothetical protein M G C 39724 B C 029594 205:68 6 .37 -32 .3 '-199.31
21 1600  at NAD H dehydrogenase 5 / / /  NAD H dehydrogem U 20489 134.85 4 .16 -32 .39 -130.69
212857 x at activated R N A  polym erase II transcription cofac BG231551 113.47 2.08 -54 .58 -111.39
200738 s at phoephoqlycerate kinase 1 N M  ' 000291 112.64 1.97 -57 16 -110.67
Table 3.9.S.2 (contd) Gene transcripts up/ down-regulated in HMEC CM compared to 
all cancer cell line CM (n=26). The list is sorted by fold change, no shading = up- 
regulated, grey shading = down-regulated. Criteria for inclusion on the list were a 
difference in expression of 100 and a fold change greater than 2.
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The aim of Section 3.10 was to apply the methods developed for CM samples to clinical 
serum specimens and evaluate the usefulness of microarray technology for these samples.
In Section 3.11 transcripts were randomly selected identified by microarray technology to 
be either:
• Present in all of the CM RNA samples and A in all of the cell RNA samples or
• Significantly differentially expressed between the sample groups
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3.10 Microarray analysis of Breast cancer serum specimens
Ultimately the goal of our work is to be able to use the technology available in a clinical 
environment to help in either the detection or monitoring of disease. To this end, a study 
was designed to see if  it was possible to apply the RNA extraction and microarray 
techniques developed to cell- free serum RNA extracted from breast cancer patients (see 
Section 2.7.10) for study design. Briefly, serum was taken from four patients recently 
diagnosed with breast cancer and before they had undergone any therapy treatments/ 
lumpectomy surgery (Pre serum). Serum specimens were then taken from the same four 
patients 2- 4 months after removal of the breast tumour (Post serum) and also from six 
normal volunteers (Normal serum). Gene expression profiles of the sample groups were 
evaluated and compared to the gene expression profiles obtained from tumour and matched 
normal tissue from the four breast cancer patients mentioned above.
3.10.1 QA of serum specimens
The QA results listed in Table 3.10.1.1 show that the serum and tissue samples, as separate 
groups, are acceptable to be compared to each other, however they cannot be normalised as 
one group as the scaling factors are too far apart.
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I Pre Serum .1 Post Serum 11 Tumour Tissue 11 Matched Normal Tissuet
Patient # * 3  7 11 141 ' 3  7 11 14 * 1 3 7 11 14 * * 3 7 11 141
Scaling
Factor
18.11 15.967 20 20.6 21.09 20.047 20 22.9 0.831 1.255 0.757 2 3 1.2 1.33 2 2.74
Noise 1.31 1.59 1.4 1.28 1.1 1.27 1.22 1.15 1.91 1.7 1.95 1.24 1.7 1.31 1.37 1.78
Background 44.06 51.3 44 42.46 36.03 40.51 40 37.56 59.43 53.09 62 55 40.8 55.31 41.05 43 55.91
% Present 10.5 8 7.6 8.5 9.7 9 8.3 8.1 48.9 44.1 45.6 43.5 46.6 48.5 44 38.7
GAPDH
37 5' *
2.67 3.43 4.37 4.83 3.34 4.1 6.01 13.34
GAPDH 
37 M *
1.375 1.48 0.497 1.39 0.877 1.514 1.85 4
, Normal Serum
Volunteer # r  PW PÑ2 FN3 FN4 FN5 FN6 1
Scaling Factor 21.721 20.4 21.17 23.986 26.053 24.821
Noise 1.19 1.32 1.18 1.23 1.08 1.24
Background 38.41 42.12 37.03 40.85 37.04 39.92
% Present 8 8.8 9.2 7.3 7.2 6.5
GAPDH 3V 5* *
GAPDH 37 M *
• GAPDH level not recorded for sera samples as at least one of 57 M or 3’ probe sets called A in all samples 
T able 3.10.1.1 Q A param eters m easured for A ffym etrix A rray chips.
259
3.10.2 Expression of Two-Cycle Target Hybridisation and Labelling 
Controls
All hybridisation controls graphed in Fig.3.10.2.1 were called Present in all of the clinical 
samples. Figure 3.10.2.1 shows that the 5’ and 3’ probes are also expressed at similar levels 
across all 22 samples, which indicates that the hybridisation, washing and staining 
procedures were without incidence. The targets were detected according to the ratio of their 
concentration in the initial hybridisation cocktail i.e. ere was the most abundant followed 
by bioD, bioC and bioB.
The Poly- A controls were called Present in all of the clinical samples. Figure 3.10.2.2 
shows that the expression of the 3’ target probes (yellow lines) is higher in all samples than 
the expression of the 5’ (dark blue lines) or middle probes (pink lines). This indicates that 
there was a 3’ bias in the amplification procedure similar to that seen with the cell line CM 
samples (Fig. 3.8.3.2). At first glance it also looks as though the serum specimens 11 Pre, 7 
Post and 2 Normal did not amplify successfully but it’s actually that the amplification of 
samples 14 Pre and Normals 1, 3 and 6 were more efficient and so are skewing the results. 
This is possibly due to smaller amounts of endogenous mRNA in these samples leading to 
high amplification of the spiked- in Poly-A control RNAs.
The trend lines in Fig 3.10.2.3 suggest that the ratios of the Poly-A controls to each other 
match the ratios in the original pre-mixed control, but again like the cell line CM samples 
the actual relative expression of each Poly-A control to each other does not match the 
original pre-mixed ratios.
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Figure 3.10.2.1 Expression levels o f Hybridisation controls in serum  specim ens.
Clinical sam ples are plotted on the X-axis with the expression level o f each
hybridisation control plotted on the Y-axis. Cre, BioD, BioC and BioB arc the
hybridisation spike-in controls and the suffix denotes the region targeted by the probe
set i.e. 3 at targets the 3 ’ end. M at targets the m iddle and 5_at targets the 5* end.
AFFX-DapX-5_at AFFX-ThrX-5_at AFFX-R>eX-5_at - e — AFFX-LysX-5_at
AFFX-DepX-M at AFFX-7hrX-M_at — AFFX-RieX-M_at —e — AFFX-LysX-Mat
AFFX-OapX-3_at AFFX-ThrX-3_at AFFX-RieX-3_at AFFX-LysX-3_at
|  — —
3 12000
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Figure 3.10.2.2 Expression o f Poly A controls in serum  specim ens. Clinical sam ples 
arc labelled on the X -axis with the expression level o f  each Poly A- control plotted on 
the Y -axis. Dap, Thr, Phe, Lys are the Poly-A spike in controls and the suffix denotes 
the region targeted by the probe set i.e. 3_at targets the 3* end, M targets the m iddle
etc.
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Figure 3.10.2.3 A verage expression o f Poly-A  controls in the 22 clinical sam ples. 
A ffym etrix Poly-A controls arc plotted on the X-axis and the average expression for 
the controls plotted on the Y axis. The three linear lines (yellow , pink, and dark blue) 
are the trend lines for each data set and the black lines connect the actual relative 
expressions for the 5 A  middlc£J,and 3 *  targeted probe sets.
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3.10.3 Expression of “housekeeping” gene transcripts
The housekeeping gene transcripts GAPDH and p-actin are called Present in all of the 
tissue specimens (see Tables 3.10.3.1 and 3.10.3.2). Figs. 3.10.3.1 and 3.10.3.2 also reflect 
this status; there is a large difference in the expression of these two gene transcripts in the 
tissue samples compared to the serum specimens.
For P-actin, in the serum specimens, very similar to the CM samples, the 3’ target probe 
had a Present call in all serum specimens (with the exception of one normal serum sample). 
Apart from this all other target regions with one exception were called A in all serum 
specimens. The graph in Fig. 3.10.3.1 also shows that again, similar to the CM samples, 
expression levels of the 3’ target probes are higher than the middle or 5’ target probes in all 
clinical samples (expression levels in serum specimens more noticeable in the log2 
transformed graph inset into Fig. 3.10.3.1).
For GAPDH, the Present/ Absent call assigned to the target probes also matched those 
achieved with the CM samples i.e. the 5’ and 3’ target regions were assigned as Present in 
the majority of samples and the middle target region was assigned as Absent.
263
LU TUMOUR NORMAL PRE POST NORMAL
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Figure 3 .1 0 3 .1  Expression levels o f p-actin probe sets in clinical sam ples. C linical sam ples are listed on the X -axis with the
expression levels plotted on the Y- axis, the blue line =  5’ targeted probes, p ink line = m iddle region targeted probes, yellow »  3*
targeted probes. Inset; expression data log2 transform ed so large and sm all expression values can be m ore easily com pared.
TUMOUR NORM AL PR ESER U M POST SERUM NORM AL SERUM
3 7 11 14 3 7 11 14 3 7 11 14 3 7 11 14 1 2 3 4 5 6
5 ’ P P P P P P P P A A A A A P A A A A A A A A
M P P P P P P P P A A A A A A A A A A A A A A
3 ’ P P P P P P P P P P P P P P P P P P A P P P
T able 3 .1 0 3 .1  Presence/ Absent call assigned to P-actin probe sets in serum  specim ens.
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GAPDII
TUMOUR NORMAL PRE POST NORMAL
-------------------  TISSUE  1 I------------------------------------------------------  SERUM --------------------------------------
Figure 3.103.2 Expression levels of GAPDH probe sets in clinical samples. Clinical samples arc listed on the X-axis with the 
expression levels plotted on the Y- axis, the blue line = 5’ targeted probes, pink line = middle region targeted probes, yellow = 3* 
targeted probes. Inset; expression data log2 transformed so large and small expression values can be more easily compared.
TUMOUR NORM AL PR E SE R U M POST SERUM NORM AL SERUM
3 7 11 14 3 7 11 14 3 7 11 14 3 7 11 14 I 2 3 4 5 6
5 ’ P P P P P P P P P P P P P A P P P P P P P A
M P P P P P P P P A A A A A A A A A A A A A A
3’ P P P P P P P P P A A P P P P P P P P P P P
Table 3.103.2 Present/ Absent call assigned to GAPDH probe sets.
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3.10.4 Condition tree and hierarchical clustering of Breast clinical 
samples
Hierarchical clustering of the breast tissue and serum specimens was carried out to see if 
the different sample groups clustered together. Figs. 3.10.4.1-3 show that whilst the tissue 
groups clustered separately from the serum specimens, the Prc, Post and Normal serum 
specimens did not cluster distinctly separate from each other. When hierarchical clustering 
was performed on the serum specimens on their own using dChip, two separate groups 
were found. In one all of the Post serum specimens and three Normal samples are grouped 
with one of the Pre serum specimens, in the other group, the remaining three Pre serum 
specimens are grouped with two Normal serum specimens (Fig. 3.10.4.3).
Figure 3.10.4.1 Hierarchical clustering of the clinical samples, tissue and serum using
Genespring. The condition tree was performed using a Pearson correlation. The 
coloured boxes on the bottom of the figure indicate the sample type, red= normal 
tissue, blue= Tumour tissue, yellow* Post scrum specimens, pink= Normal serum 
specimens and light blue= Pre serum specimens.
2 6 6
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P re n o f  P r» ■ ■ ■ ■ P r e  r»r# n o r  nor. H M t t r  ■ ■ n o i 1 n o r
Figure 3.10.4.2 Hierarchical clustering of all the clinical samples using dChip, this 
clustering was carried out using a similarity’ measure. Gene transcripts that did not 
change in expression across all the CM samples were removed and the similarity of 
the samples was computed on the rest. Pre= Pre serum (pink box), Post= Post op 
(green box), FN= Female Normal serum (light blue box), N= Normal tissue (light 
green box), T= Tumour tissue (blue box). The numbers denote the patient/ volunteer 
number.
Figure 3.10.4.3 Hierarchical clustering of all the scrum clinical samples using dChip, 
this clustering was carried out using a similarity' measure. Gene transcripts that did 
not change in expression across all the CM samples were removed the similarity of the 
samples was computed on the rest. Pre= Pre serum (pink box), Post= Post serum 
(green box), FN= Female Normal serum (light blue box), the numbers denote the 
patient/ volunteer number.
It is possible that if the patient sample numbers were increased, along with the number of 
normal serum specimens, the separation of the serum specimens using dChip would 
become more apparent.
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3.10.5 Probe sets called P or M in Pre serum and A in Post serum
Figures 3.10.5.1 and 3.10.5.2 show that of the 2501 gene transcripts called Present or 
Marginal in all of the Pre serum specimens, 51 of those were also called absent in all of the 
Post serum specimens. 6 of these 51 gene transcripts were also called Absent in all normal 
samples. It was decided to take a closer look at the expression values and patterns for these 
gene transcripts. Table 3.10.5.1 shows that the difference in expression values of the probe 
sets arc not significant.
Figure 3.10.5.1 Venn diagram of probe sets called P or M in Pre serum and A in Post 
serum
Figure 3.10.5.2 Venn diagram of probe sets called P or M in all Pre scrum vs. A in all 
Post scrum vs. A in all normal scrum.
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probe set qene | 11 Pre 14Pre 3Pre 7Pre 11 Post UPost 3Post 7Post
1556436 at hypothetical protein l_OC3j 30.93 P 36.21 P 41.08 P 41.93 P 34.66 A 27.59 A 34.64 A 32.36 A
1558859 at hypothetical protein L0C2; 14.35 P 12.09 P 13.16 P 14.52 P 12.06 A 15.04 ;A 11.97 A 11.55 A
1559307 s at retinoblastoma-like 1 (p1 G: 13.64 P 16.81 P 15.70 P 18.09 P 21.88 A 21.41 A 20.63 A 20.27 A
1561430 s at chromosome 3 open readi 32.42 P 27.78 P 27.49 P 40.65 P 28.64 A; 25.61 A 18.72 A 26.41 A
1565934 at Prematurely terminated m 16.65 P 19.24 P 14.98 P 14.84 P 15.88 A; 12.16 A 11.55 A 14.55 A
1569608 x at ankyrin repeat domain 20/, 26.35 P 27.38 P 30.21 P 27.93 P 21.B4 A 24.01 A 33.10 A 32.24 A
1569917 at Cyclin-dependent kinase E 23.97 P 25.66 P 23.23 P 27.86 P 31.15 A 26.44 A 24.55 A 22.84 A
201111 at CSE1 chromosome segre; 31.77 P 23.42 P 27.00 P 24.19 P 14.76 A 17.59 A 18.62 A 24.81 A
201339 s at sterol carrier protein 2 20.82 P 20.57 P 16.65 P 15.22 P 14.34 A 18.40 A 15.03 A 10.28 A
205338 s at dopachrome tautomerase 25.62 P 26.53 P 54.67 P 27.25 P 30.53 A 28.45 A 26.85 A 21.02 A
208068_x_at chorionic somatomammot 38.51 P 35.41 P 33.86 P 40.16 P 39.19 A 33.77 A 32.95 A 36.31 A
209761 s at SP110 nuclear body prate 17.74 P 14.00 P 20.96 P 18.13 P 14.65 A 14.98 A 18.01 A 21.17 A
210616 s at SEC31-like 1 (S. cerevisia 37.50 P 36.91 P 36.57 P 38.46 P 31.97 A 36.67 A 28.70 A 36.86 A
213086 s at casein kinase 1, alpha 1 16.15 P 23.42 P 22.21 P 20.15 P 14.91 A 15.63 A 19.65 A 16.66 A
213825 at oligodendrocyte lineage tr< 41.40 P 58.24 P 44.39 P 45.41 P 40.16 A 47.97 :A 38.07 A 43.05 A
214451 at franscription factor AP-2 b.' 26.65 P 27.04 P 30.79 P 22.47 P 32.39 A 23.95 ;A 28.33 A 27.30 A
214989 x at Pleckslrin homology doms'6668.21 P 6751.031 P 6867.62 P 6844.02 P 6897.30 A 6735.69 A 6754.09 A 6836.73 A
215412 x at postmeiotic segregation in 23.42 P 23.11 P 24.45 P 20.91 P 21.32 A 16.64 A 17.97 A 16.59 A
216203 at serine palmitoyltransferase 24.02 P 29.36 P 29.99 P 26.43 P 31.50 A 32.72 A 36.82 A 36.68 A
216349 at Similar to bA215B13.2 (fur 98.04 P 81.70 P 77.79 P 69.19 P 42.51 A 62.53 A 74.64 A 68.81 A
216994 s at runt-related transcription f< 40.61 P 41.14 P 43.90 P 43.09 P 35.58 A 36.68 A 30.86 A 34.71 A
217416 x at Cjb:AKD00918.1 /DB XREF 19.41 P 16.69 P 19.68 P 16.93 P 14.89 A 14.14 A 16.23 A 18.03 A
219498 s at B-cell CLUIymphoma 11A 41.04 P 41.72 P 35.61 P 41.55 P 34.10 A 38.70 A 35.39 A 38.27 A
222D72 at qb AW450360 /DB XREP 76.48 P 74.39 P 62.88 P 81.86 P 51.01 A 72.14 A 70.01 A 67.83 A
223866 at armadillo repeat containing 18.31 P 14.27 P 13.52 P 21.09 P 8.40 A 15.92 A 13.03 A 13.21 A
224494 x at dehydrogenase/reductase 47.00 P 44.82 P 41.43 P 39.75 P 40.86 A 35.04 A 37.96 A 32.59 A
226824 ai carboxy peptidase X(M14 J 54.34 P 67.08 P 66.05 P 57.43 P 63.83 A 77.43 A 56.26 A 61.00 A
229083 at gb:AI672356/DB XREF=c 37.65 P 30.38 P 36.10 P 32.42 P 31.60 A 32.71 A 23.28 A 37.43 A
231130 at gb:AA683602 /DB XREF= 15.84 P 13.63 P 11.06 P 11.01 P 11.90 A 15.39 A 11.45 a ; 11.03 A
235772 at qb:AI07B941 /DB XREF=c 28.58 P 21.76 P 24.32 P 25.64 P 14.70 A 20.87 A 22.65 A 26.87 A
237822 at gb:AI962701 /DB XREF=c 38.38 P 33.51 P 40.43 P 28.32 P 35.74 A 35.56 A 46.94 A 42.87 A
238646 at gb:AÄ747756 /DB_XREF=. 19.29 P 22.44 P 20.94 P 13.03 P 27.64 A 21.04 A 20.30 A 14.42 A
238825 at acidic repeat containing 22.74 P 25.14 P 23.86 P 20.14 P 22.22 A 16.63 A 19.43 A 15.01 A
239018 at Williams Beuren syndromir  49.02 P 53.14 P 51.32 P 60.95 P 44.71 A 43.86 A 47.93 A 48.42 A
239234 at qb:AW452419 /DB XREF= 66.62 P 61.65 P 63.56 P 52.88 P 37.42 A 46.64 A 57.50 A 45.41 A
239856 at gb:A!701798/DB XREF=c 46.67 P 48.77 P 41.77 P 51.X P 57.81 A 51.00 A 40.85 A 48.23 A
240757 at gb:H49240/DB XREF=gi:! 20.85 P 24.72 P 21.54 P 27.52 P 25.93 A 25.57 A 20.53 A 27.23 A
241294 at gb:AB39422/DB_XREF=c 28.60 P 34.76 P 26.05 P 25.82 P 25.86 A 31.48 A 26.33 A 26.29 A
241411 at gb:AAM9838 /D8 _XREF= 60.46 P 75.99 P 61.18 P 57.25 P 72.86 A 78.20 A 72.33 A 61.35 A
242283 at hypothetical protein MGC2 14.61 P 13.42 P 13.05 P 14.43 P 10.03 A 14.61 A 12.87 A 12.35 A
242303 at gb:AB71427/DB_XREF=p 60.58 P 61.75 P 61.18 P 52.50 P 62.38 A 71.94 A 66.55 A 79.84 A
242326 at collagen, type XXII, alpha'j 52.36 P 44.32 P 31.11 P 43.57 P 34.22 A 40.31 A 37.71 A 40.03 A
243303 at Enoyl Coenzyme A hydrat 20.50 P 16.62 P 16.68 P 15.77 P 11.29 A 11.75 A 10.62 A 15.58 A
244567 at gb:BG165613 /DB _XREF= 7.92 P 7.63 P B.18 P 5.31 P 3.91 A 7.27 A 7.55 a ; 7.87 A
1554172 a at zinc finger protein 261 36.32 P 34.47 P 28.42 M 30.84 P 31.47 A 29.06 A 34.20 A 32.90 A
215219 at chromosome 21 open reac 30.43 P 33.46 P 35.01 M 32.24 P 35.08 A 33.53 A 26.07 A 25.93 A
216748 at interferon-inducible protein1 38.70 M 37.57 P 43.61 P 32.90 P 49.04 A 41.33 A 29.17 A 34.73 A
221311 x at hypothetical protein dJ122 7.50 M 10.29 P 10.85 P 8.18 P 14.85 A 7.97 A 9.18 A 8.10 A
231031 at gb:AI761573 /DB_XREF=ç 32.85 M 31.66 P 58.74 P r 41.13 P 25.48 A 26.19 A 36.70 A 30.15 A
234099 at Laminin, alpha 2 (merosin 29.94 P 28.39 P 27.73 M 26.63 P 35.25 A r~23.53 A 25.09 A 23.14 A
235927 at gb:BE350122/DB_XREF= 31.39 P 43.75 P 39.79 M 33.45 P 28.64 A 32.60 A 38.83 A 31.08 A
Table 3.10.5.1 Expression values for probe sets called P or M in pre serum and A in
post serum. Pre = Pre serum sample, Post = Post serum sample, P = Present, A = 
Absent.
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Both Table 3.10.5.1 and Fig. 3.10.5.3 show that despite the 51 gene transcripts being 
assigned as Present or Marginal in the Pre serum specimens and Absent in the Post serum 
and Normal serum specimens, the actual difference in expression is negligible. To find 
gene transcripts significantly differentially regulated dChip software was used.
Figure 3.10.5.3 Expression profile of probe sets called P or M in Pre serum and A in 
Post and Normal serum specimens. Sample groups are on the X-axis (from left) 
tumour tissue, normal tissue, pre serum, post serum and normal serum. The 
expression in plotted on the Y-axis (log scale). The expression for one probe set, 
201339_s_at, is highlighted in black showing similar levels of expression in tumour 
and normal tissue and in the different serum specimens.
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3.10.6 Probe sets significantly changed in Pre vs. Post serum
A gene list was generated examining the number of gene transcripts significantly changed 
between the Pre and Post serum specimens. The criteria used for classification as 
significant was that the gene transcripts had to have a fold change >1.2, a difference in 
expression >20 and a paired p-value <0.05. The paired p-value refers to the significance of 
changes between individual pairs (e.g. Pre and Post serum specimens from the same 
patient) and also the p- value of the group pairings e.g. all Pre vs. all Post samples.
The results presented in Tables 3.10.6.1 (a), (b) and (c) show that of the 114 gene 
transcripts deemed to be significantly changed in the Post serum specimens compared to 
the Pre serum specimens, only 5 are down-regulated in the Post serum specimens compared 
to the Pre serum specimens. This seems like an illogical result, we would have expected to 
see more mRNA transcripts either in the Pre serum specimens or at least expressed at 
higher levels in the Pre serum specimens than in the Post serum specimens.
Analysis of the gene expression profile of the matched normal and tumour tissue samples 
however shows a similar trend. Of the 3,535 gene transcripts differentially expressed 
between the tumours and matched normal tissues (selection criteria; fold change>1.2, 
expression difference>20 and p-value<0.05), 80% (2,765) are down-regulated in the 
tumour tissue compared to the matched normal.
To assure that the results presented in Section 3.10.6 were not due to sample mis- labelling, 
the Pre serum specimens were compared to the normal serum specimens (which were 
isolated at a different time to the Pre and Post serum specimens, and obviously, are samples 
originating from different people).
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Of the 542 gene transcripts that were differentially expressed between the Pre serum 
specimens and the Normal serum specimens using the same criteria as before i.e. difference 
in expression and fold change greater than 20, respectively and a p-value less than 
0.05(paired p-value not used) 97% (525 gene transcripts) are up-regulated in the Normal 
serum compared to the Pre serum specimens, with only 3% (17 gene transcripts) down- 
regulated in the Normal serum compared to the Pre serum specimens (see Tables 3.10.6 (a) 
and (b)).
probe set gene Accession fold diff pairedchange of means P value
-217839vat TRK-fused gene ‘ •• NM_006070; . -5.8 -42.26 0.018743
1554691 _a_at protein kinase C and casein kinase sut BC008037 -2.08 -25.34 0.027104
204166 at /' KIAAD963 ' ' . NM 014963 ■ ; ;-1.7 -200.05 002681
201481 s at phosphorylase, glycogen; brain' " NM_002862 ' -1.64 -232.61 0.049552
1554977 at : Transcribed locus, moderately similarti.BC036837 -1.48 "■ -128.11 0010071
Table 3.10.6.1 (a) Probe sets significantly down-regulated in the Post serum specimens 
compared to the Pre serum specimens. The list is sorted by fold change the grey 
shading means they are down-regulated in the Post serum compared to the Pre serum. 
Criteria for selection as significant; difference in expression >20, fold change >1.2 and 
p-value <0.05.
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p ro b e  s e t g e n e A c c e s s io n
fo ld <liff p a ire d
c lu in n e o f m e a n s
1562062 at gb:BM041211 /DBJ<REF=gi:1677047B B M 041211 1.23 125.76 0.03516
232481 s at S U T and NTRK-like fam ily , m em ber 6 AL137517 1.24 21.91 0.03572
207953 at gb:AF010144.1 /D B_XR EF=gi:3002526 AF010144 1.28 65.81 0.026971
233270 x at P ericentrio la r materia! 1 A U 146939 1.29 232.72 0.022563
214722 at s im ila r to  NOTCH2 protein AW 516297 1 31 101.41 0.034593
1560199 x at Z inc finqer, S W IM  dom ain contain ing 6 A U120130 1.32 75.91 0.013756
234251 at qb:AL157423.1 /D B  XREF=gi:7018452 A L157423 1.35 24.1 0.031673
230182 at gb:AI951640 /DB_XREF=gi:5743950 >D AI951640 1.39 49.74 0.043457
235601 at gb:AA907029 /D B  XREF=gi:3042489 /I AA907029 1.39 53.84 0.015268
1558426 x at chrom osom e 7 open reading fram e 19 BC016797 1 4 91.2 0.022997
1563088 a at hypothetica l protein LOC284837 BC034348 1.4 25.37 0.022096
1555268 a at glutam ate receptor, ionotropic, delta 1 BC039263 1.41 24.29 0.022917
206293 at sulfotransferase fam ily , cy toso lic , 2A , c U08024 1.44 32.31 0.044106
230731 x at Z inc finger, DHHC dom ain contain ing 8 AI453548 1.45 32.58 0.036652
1563077 at Homo sap iens, clone IM A G E :4042988, BC014346 1.45 24.56 0.011801
221155 x at gb:NM _018603.1 /D B  XREF=gi:89240E NM 018603 1.47 90.56 0.03594
1558438 a at Rearranged im m unoglobulin VH -C E in fS 55 277 1.47 29.24 0.010116
230582 at gb:BE6764Q8 /DB_XREF=gi: 10036949 BE676408 1.48 24.72 0.026937
1563571_at hypothetica l protein LOC285463 AKD92548 1.48 24.55 0.048144
232034 at hypothetica l protein L00203274 1AL117607 1.49 44.5 0.032216
21D397 at defen sin , beta 1 U73945 1.5 23.67 0.009022
232511 at RAN binding protein 2-like 1 AK022838 1.5 28.31 0.040478
1562861 at Homo sap iens, clone IM A G E :5195119, BC041456 1.5 21.82 0.049088
1555881 s at leucine zipper, putative tum or suppress ÂK 097997 1.51 40.47 0.009687
1570329 at gb:BC014497.1 /D B  XREF=gi: 1793960 BCO14497 1.51 20.67 0.044096
232834 at Transcribed locus, m oderate ly s im ila r ti À U 146764 1.52 32.19 0.026994
233380 s at RUN and FY V E  dom ain contain ing 1 |AA429145 1.52 40.75 0.03046
1553614 a at O lfactory receptor, fam ily  7, subfam ily f NM 173604 1.52 26.65 0.02064
1567622 at gb:AJ431609.1 /D B  XREF=gi:1887371CAJ431609 1.52 77.73 □.010042
218143 s at secre tory carrier m embrane protein 2 NM 005697 1.53 32.21 0.03529
220633 s at HP1-BP74 NM 016287 1.53 46.75 0.005848
1565829 at KIAA1731 protein BU619319 1.55 25.82 00 4 9 4 0 3
217888 s at A D P -ribosyla tion  fac to r GTPase activat NM 018209 1.56 28.52 0.017196
0.044758236794 at gb:AW 629436 /D B  XREF=gi:7376226 VA W 629436 1.56 34.09
233319 x at Phosphatase and actin regulator 4 AK023907 1.57 110.19 0.044141
211416 x at gam m a-glutam yltransferase-like activity L20492 1.58 22.33 0.048573
214032 at zeta-chain (TCR) associa ted protein k inA I817942 1.58 24.86 0.031465
239097 at gb:AW 296997 /D B  ,XREF=gi:6703633 /1AW296997 1.58 25.75 0.044805
207628 s at W illiam s  Beuren syndrom e chrom osorrjN M  017528 1.59 30.63 0.008715
212109 at chrom osom e 16 open reading fram e 34|AI590869 1.59 59.49 0.015363
214122 at |gb:A A086229 /D B  XREF=gi: 1628852 / ( AAD86229 1.6 22.6 0.036004
231306 at lysozym e-like  4 AI989932 1.6 36.82 0.014697
1565818 s at zinc finger prote in, subfam ily 1A, 1 (Ika BF794111 1.61 22.3 0.035552
205367 at adaptor protein w ith  p leckstrin  hom olog NM 020979 1.62 167.03 0.02477
212430 at RNA-binding region (R N P1, RRM) conti 'A L109955 1.62 31.67 0.007406
225394 s at MADP-1 protein AM 46850 1.62 70.99 0.024932
211058 x at tubulin , alpha, u b iq u ito u s / / / tubu lin , a lpBC 006379 1.63 22.7 0.037428
220696 at rP R 00478  protein ¡NM 014129 1.63 84.25 0 009298
Table 3.10.6.1 (b) Probe sets significantly up-regulated in the Post serum compared to 
the Pre serum. The list is sorted by fold change. Criteria for selection as significant; 
difference in expression >20, fold change >1.2 and a paired p-value <0.05.
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l>rol>e set cpene Accession fold cliff I paired
chonoe of moons I P value
233895 at Ankyrin repeat domain 24 IAC005578 1.63 62.38 0.042981
1566763 at CDNA clone IMAGE:5277680, partial Ci BC034915 1.63 22.44 0.022409
232516 x at YY1 associated protein AU150385 1.64 30.06 0.029117
233912 x a f l ELMO domain containing 2 jAKD21525 1.64 46.02 0.031677
1556248 at Myosin VIIA and Rab interacting protein BC031275 1.64 51.3 0.016559
1557996 at gb:AKD91784.1 /DB XREF=gi:2175023 AKD917B4 1.64 64.38 0.049877
219013 at UDF>-N-acetyl-alpha-b-galac1osamine:p|NM 022087 1.65 24.28 0.013128
223871 x at inhibitor of growth family, member 5 IBC005370 1.65 66.27 0.032576
1562946 at Transcribed locus, moderately similar t> BC007626 1.65 24 24 0.047108
242377 x at gb:AD51976 /DB XREF=gi:3307967 /D AI051976 1.66 90.56 0.041761
1570210 x at 
220828 s at
gb: BC022346.1 /DB XREF=gi: 1849062 BC022346 1.66 144 93 0.024853
hypothetical protein FLJ11292 NM Q18382 1.67 54.73 0.014091
1569380 a_at 
210981 s'at
gb: BC015447.1 /D B._XREF= g i:2195539 BCO15447 1.67 29.63 0.01552
G protein-coupled receptor kinase 6 AF040751 1.69 20.9 0.020073
231638 at hypothetical protein MGC52282 AA400057 1.69 20.22 0.048351
232731 x at Transcribed locus, moderately similar t<BCOO1607 1.69 31.53 0.019219
1554487 a at cAMP responsive element binding prot« BC008394 1.69 22.77 0.04341
225986 x at cleavage and polyadenylation specific f;lAB037788 1.7 40.69 0.023977
1568702 a at hypothetical protein FLJ11848 AM 31457 1.7 66.45 0.038734
1569345 at gb:BC026007.1 /DB _XREF=gi:2213567 BC026007 1.7 24.51 0.025699
207131 x at gamma-glutamyltransferase 1 NM 013430 1.71 20.05 0.015017
231602 at gb:AIB09150 /DB XREF=gi:5395716/D ÀI809150 1.71 39.43 0.019132
216924 s at dopamine receptor D2 S62137 1.72 50.19 0.00321
220352 x at hypothetical protein MGC4278 NM 024305 1.72 90.08 0.040646
233513 at Transcribed locus, highly similar to XP AU152Ì61 1.73 45.63 0.014733
1558792 x at Adaptor-related protein complex 2, alph‘AKD90661 1.73 72.36 0.030287
215861 at hypothetical protein FLJ14031 AKD24093 1.74 111.97 0.023972
220725 x at Dynein, axonemal, heavy polypeptide 3 NM 025095 1.74 40.39 0.010836
232145 at Hypothetical LOC388969 AU147777 1.74 25.08 0.041851
222339 x at_J 
244193 at
gb:AI054381 /DB XREF=gi:3322168 /D AI054381 1.75 54.91 0.009331
hypothetical protein FU13236 BF981786 1.75 45.96 0.023815
243178 at 
236499 at
gb:AW969703 /DB XREF=gi:8159547 AW969703 1.76 74.58 0.043607
H y p o th e tic a l protein FLJ31031 / / /LOC4 AI911410 1.79 28.76 0.019165
1566716 at gb:ALD50033.1 /DB XREF=gi:4884273!AU050033 1.79 39.63 0.02707
228576 s at 
32837 at
gb:BE219549 /DB XREF=gi:8906867 /[BE219549 1.81 92.88 0.005963
1-acylglycerol-3-phosphate O-acyltrans U56418 1.82 20.881 0.01468
1554183 s at tripartite motif-containing 50C BC033871 1.85 24.02 0.006475
215067 x at peroxiredoxin 2 AU147942 1.86 75.01 0.024907
202624 s at calcineurin binding protein 1 NM 012295 1.87 24.48 0.016945
207914 x at gb:NM_001989.1 /DB _XREF-gi:450361rNM Ó01989 1.87 73 0.003911
1562885 at Homo sapiens, clone IMAGE:5750288, BC042084 1.09 29.93 0.040361
233362 at zinc finger protein 341 AL523697 1.93 22.27 0.021026
1562771 at Transcribed locus, moderately similar t<BC042087 1.94 24 23 0.020998
1558569 at Mastermind-like 2 (Drosophila) ALB32308 1.96 73.69 0.042645
237561 x at 
1556149 af
gb:AV736334 /DB XREF=qi: 10853915 AV736334 2 26.87 0.049274
armadillo repeat gene deletes in velocai AW139431 2 20.k T 0.015864
1565661 x at Fucosyltransferase 6 (alpha (1,3) fucosiBC040472 2 ”23.57 0.029249
1562487 at 
1558407 at
Transcribed locus, moderately similar tiBC033379 2.02 21.42 0.0326
Likely ortholog of mouse common-site IAKD95957 2 03 36.68 0.017047
1558048 x at gb:BG389789 /DB XREF-gi: 13283225 BG389789 2.07 17557 0.026641
232570 s at a disintegrin and metalloproteinase dorrÀL356755 2.09 67.09 0.021287
239826 at gb:AI357143 /DB_XREF=gi:4108764 /D AI357143 2.11 i 23.091 0.035571
244544 at qb:AA812915 /DB_XREF=gi:2882979 /IAA812915 2.16 28.54 0.00499
242369 x at 
211627 Ì  at
gb:AI561070/DB_XREF=gi:4511411 /D AI561070 2.19 110.94 0.009483
Estrogen receptor 1 /// Estrogen recept M69297 2.2 76.83 0.015976
220232 at stearoyl-CoA desaturase 4 NM 024906 2.25 33.92 0.038158
1558275 at Mitochondria-associated protein involve BC006120 2.26 42.57 0.044397
229650 s at hypothetical protein MGC2747 BG538931 2.27 26.45 0.004752
217430 x at gb:Y15916.1 /DB_XREF=gi:3288488 /F Y15916 2.31 27.34 0.043388
232640 at COMM domain containing 5 AKD23070 2.88 22.61 0.025067
239333 x at Transcribed locus, weakly similar to NRBF525633 3.06 28.93 Ò.027716
Table 3.10.6.1 (b contd) Probe sets significantly up-regulated in the Post serum 
compared to the Pre serum. The list is sorted by fold change. Criteria for selection as 
significant; difference in expression >20, fold change >1.2 and a paired p-value <0.05.
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probe set cjene Accession fold
cluincie
difference 
of means P value
202449 iis£atretinoid Xlreceptbr; alphat;
217839i|àt ÿ ^ R t^ s ÎM jlg e n e W ^ ^
1554741' 's ■ at ' vfib'robìést; g ro vkh .fa c to r7  (keraiinocyts A F 52 326 5 :; ÿ '  Æ 2:.16
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/ -1772^65^0'046216  
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-214 -87^ 0:000899,
224549ix^àt; 
224254 
234723 x at
_ i r>; 4gb^l94^aiQBl)qRE^=gi:11 
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0.021455 
0:049771 
; 0 .022969 
5 0 :02895 
1586.7,7 0 .048843 
; -889! 69 Ò .022233
Table 3.10.6.2 (a) 17 gene transcripts were down-regulated in the Normal serum 
compared to the Pre serum specimens. The list is sorted by fold change and the grey 
shading indicates that the samples were down-regulated in the Normal serum 
compared to the Pre serum. Criteria for selection as significant; difference in 
expression >20, fold change >1.2 and paired p-value <0.05.
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piohe set gene Accession fold difference P valueclimi «le of means
231278 at Hypothetical LOC338731 BF063966 5.11 32.12 0.016627
21S926_x at small nuclear RNA activating complex AWD23513 4.46 25.58 0.025904
218684 at leucine rich repeat containing 5 NM 018103 4.22 20.23 0.023603
212844 at KIAA0179 AI400490 4.08 20.91 0.023571
209208 at mannose-P-dolichol utilization defect AF059752 3.41 20.3 0.011084
225767 at Hypothetical protein LOC2848Q1 AI825833 3.19 93.16 0.015115
1560741 at Ubiquitin protein ligase E3A (human pAU832250 3.18 41.16 0.009267
239060 at gb:AI222295 /DB_XREF=gi:3804498 /AI222295 3.11 35.37 0.027211
1562553 at Homo sapiens, clone IMAGE:528712: B0042964 3.01 29.69 0.023424
234084 x at Transmembrane protein induced by tu AU147104 2.94 27.01 0.01986
244156 at g b : AW296286 /DB_XREF=gi:6702932 AW2962B6 2.83 28.71 0.018482
242982_x at integrin, beta 8 AW131039 2.64 23.47 0.013663
227192 at similar to lymphocyte antigen 6 comp BF060707 2.58 30.31 0.021446
226598 s at GTP binding protein 5 (putative) AKD01603 2.45 34 0.030836
1563426 a at Homo sapiens, clone IMAGE:417747£ BC025792 2.44 55.04 0.008232
216053_x at hypothetical protein FLJ38374 AI143919 2.42 30.64 0.004069
216692 at Zinc finger protein 337 AL137428 2.42 23.27 0.044249
201541 s at zinc finger, HIT domain containing 1 NM 006349 2.41 42.75 0.004914
205300 s at U11/U12 snRNP 35K NM 022717 2.41 30.86 0.049484
219091 s at multimerin 2 NM 024756 2.41 22.59 0.021393
224067_at gb:AF132206.1 /DB XREF=gi: 11 4935 AF132206 2.41 28.65 0.043147
211074 at gb : AF000381.1 /DB_XR E F= g i :256519 AF000381 2.4 57.41 O 034717
64440 at interleukin 17 receptor C AI560217 2.38 56.44 0.007526
232966 at Similar to LPIN3 AU031667 2.37 34.48 0.012229
1557350 at Ras-GTPase-activating protein SH3-di AAQ26297 2.37 29.02 0.004201
233009 at gb : AKD24333.1 /D B_XRE F= g i : 104366 AKD24333 2.36 21.99 0.009434
1564435 a at keratin protein K6irs AKD93060 2.36 35.19 0.009615
244469 at gb: AAS34603 /DB XREF=gi:2278856 AA534603 2.34 25.13 0.036282
238405_at gb : AI792696 /D B_XRE F= gi :5340612/ AI792896 2.31 35.19 0.039556
2O3390_s at UDP-N-acetyl-aipha-D-galactosamine: NM 004482 2.29 24.39 0.021979
216691 at gb:U00956.1 /DB XREF=gi:405058 /F U00956 2.29 33.28 0.004795
221419 s at gb: NM_013307.1 /DB XREF=gi:7019* NM 013307 2.29 70 0.006794
1563108 at KIAA1904 protein BC033336 2.29 33.25 0.003431
240988_x at gb:AA207241 /DB XREF=gi: 1802734 AA207241 2.27 51.47 0.020504
241395 at g b : AL572553 /DB_XR EF—gi: 1293093¿ AL572553 2.25 20.35 0.010602
201255 X at HLA-B associated transcript 3 NM 004639 2.24 21 0.016131
244350 at gb:N33403 /DB_XREF=gi: 1153802 /D N33403 2.23 68.13 0.011083
1558275 at Mitochondria-associated protein involv BC006120 2.22 72.66 0.042835
236001 at gb:T61 953 /DB XREF=gi:665196 /DB T61953 2.19 114.86 0.008494
237768 X at g b : AA825925 /DB XREF=gi:2899237 AA825925 2.19 32.38 0.012784
214926 at KIAAD657 protein AI915513 2.10 67.62 0.009657
225059 at angiotensin |] receptor-associated pro BE875567 2.17 82.25 0.011135
223422 s at Rho GTPase activating protein 24 AI743534 2.15 25.91 0.034577
219534 X at cyclin-dependent kinase inhibitor 1C ( NM 000076 2.14 41.11 0.002954
1566848 X at Homo sapiens, clone IMAGE:401558E BC034050 2.13 285.96 0.004829
234439 at gb:AKD01097.1 /DB XREF=gi:7Q2214 AKD01097 2.12 33.04 0.005466
1566778 at gb : B C043203.1 /DB XREF=gi:276932I BC043203 2.12 20.16 0.033337
201276 at RAB5B, member RAS oncogene fami AF267863 2.1 35.62 0.031321
227513_s at gb : AWÜ27170 /DB XREF=gi:588592E AW027170 2.09 23.49 0.047504
221193 s at zinc finger, CCHC domain containing NM 017665 2.00 33.6 0.018798
241 767_at gb:AI104501 /DB_XREF=gi:37352l9 /AI184581 2.08 29.17 0.046266
238845 at solute carrier family 30 (zinc transport AA40522O 2.07 28.96 0.013832
217818 s at actin related protein 2/3 complex, sub NM 005710 2.06 23.05 0.017293
232626 at CDNA FLJ14143 fis, clone MAMMA1C AKD24205 2.05 36.17 0.029293
209038 s at EH-domain containing 1 AL579035 2.04 84.1 0.017186
243263_at hypothetical protein FLJ39421 AW008416 2.04 69.03 0.019604
224460 s at chromosome 14 open reading frame 1 BC006117 2.03 31.52 0.011031
231878 at Major vault protein AMD26112 2.03 34.13 0.001075
205910_s_at carboxyl ester lipase (bile salt-stimuls NM 001807 2.02 34.92 O 010456
219088 s at zinc finger protein 576 AA639585 2.02 20.14 0.012184
241851 X at CDNA FLJ4S5BO fis, clone BRTHA301 BE676261 2.02 30.83 0.001237
234826 at Hypothetical gene supported by BC01 AL137596 2.01 21.53 0.043431
243325 at gb: AV722006 /DB_XREF=gi: 1082406: AV722006 2.01 21.75 0.021 131
220339 s at tryptase gamma 1 NM 012467 2 23.5 0.008567
234072 at sema domain, immunoglobulin domaiiAU1 47993 2 60.71 0.004691
Table 3.10.6.3 (b) 525 gene transcripts were up-regulated in the Normal serum
specimens compare to the Pre serum specimens. The gene transcripts were sorted by 
fold change and the 64 gene transcripts with a fold change >2 are shown above. 
Criteria for selection as significant; difference in expression >20, fold change >1.2 and 
paired p-value <0.05.
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3.10.7 Study of randomly changing gene transcripts
The analysis of probe sets called P or M in Pre serum and A in Post serum yielded no leads 
of potential biomarkers as the expression difference between probe sets called Present in 
the Pre serum and Absent in the Post serum was negligible and not significant. The analysis 
of the gene transcripts determined to be significantly changed yielded results that seemed 
illogical, in so far as more transcripts were upregulated in the serum months after 
lumpectomy, than in the serum before the tumour was removed. In addition to these results, 
the hierarchical clustering did not show any tight clustering of sample groups. To test 
whether the gene transcripts found to be significantly different were related to a cancer- 
state and not simply a change in expression that has occurred by chance, various 
combinations of samples were compared against each other to see how many changes are 
found when a random selection of samples is tested against each other. 
dChip software has a false discovery rate (FDR) application whereby, it the randomly 
mixes the samples using 50 permutations to find out the FDR. The FDR is computed by 
applying the original comparison criteria (e.g. fold change, p-value) to the sample-wise 
permuted datasets and recording the number of obtained gene transcripts at each such 
permutation. If the number of gene transcripts on your list of interest is similar or close to 
the FDR, it indicates that your list may not be meaningful, and that there is a high chance 
that the changes occurred by chance. A list with a median FDR<5% or 10% is considered 
to be meaningful (dChip User’s manual 2005).
In order to test the system random samples were manually selected using combinations of 
the serum specimens, to see if the gene transcripts lists that we are interested in, i.e. Pre vs. 
Post or Pre vs. normal or Pre vs Post and Normal were deemed to be meaningful and stand 
out from any other selections tested
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Pre serum and Post serum FDR permutations
The FDR of each of the permutations are listed in table 3.10.7.1. The three permutations 
highlighted in red were deemed to be meaningful i.e. a median FDR <10%. Two out of a 
possible 10 Pre vs. Post serum permutations were deemed to be meaningful when the 
number of samples in each group was 2.
When 3 Pre serum specimens were tested against 3 Post serum specimens, the FDR % 
median for two samples came close to 10% (15.1 and 12.8% respectively) but none were 
deemed to be meaningful. However, when the 4 Pre serum specimens were tested against 4 
Post serum specimens, 1191 gene transcripts were called significantly changed, with an 
FDR of 9% indicating that the list was also meaningful suggesting that there needs to be a 
minimum number of samples in each sample group to increase the chances of our sample 
groups of interest being called meaningful.
Of the sample groups tested where either the Pre samples were mixed with the Post 
samples, or the Pre or Post samples were tested against other Pre or Post samples 
respectively, none of the lists of significantly changed gene transcripts were deemed to be 
meaningful.
The results shown here in Section 3.10.7 indicate that there is a definite pattern of gene 
expression in the Post serum specimens similar to the Normal serum specimens and distinct 
from the Pre serum specimens, indicating the potential for developing these studies further 
to perhaps aid in monitoring of success/ failure of therapy treatments.
1 Slightly different to number calculated In Section 3.10.6 for this comparison as it was calculated 
using a paired p-value which was not the case here.
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2 Pre v5ti  Port #  sig. gene transcripts
FDR 
% M edian
3 ,1 1 7 ,1 4 48 8.3
3 ,7 11, 14 65 15.4
3 ,1 4 7,11 9 100
7 ,11 3 ,1 4 43 97.7
7 ,1 4 3,11 29 24.1
3,11 3,11 17 100
3 ,7 3 ,7 48 16.7
3, 14 3, 14 11 100
7 ,1 4 7, 14 14 64.3
7 ,1 1 7 ,11 20 10
2 Pre vs. 2 Pre
11, 14 1 3, 7 7 100
3, 11 7 ,1 4 11 63.6
3 ,1 4 I 7, 11 6 116.7
2 Post vs. 2 Post
3, 111 1 7, 14 12 91.7
11, 14 3 ,7 64 18.8
3, 14 I 7, 11 6 200
2Pre/ 2Post vs. 2Pre/ 2Post
3 ,7 / 1 1 ,  14 11, 1 4 /3 ,7 8 125
3, 11/7 , 14 7 ,1 4 /3 ,  11 0 n/a
3, 1 4 /7 ,  11 | 7, 1 1 /3 ,  14 7 114
3 Pre ys.JLP^st
3, 7 ,11 3, 7,11 62 24.1
3 ,7 , 14 3, 7 ,1 4 60 18.3
7 , 1 1 , 1 4 7 , 1 1 , 1 4 93 15.1
3, 11, 14 3 , 1 1 , 1 4 78 12.8
4 P re vs. 4  Port
3, 7, 11, 14 1 3,  7 , 1 1 , 1 4 119 9
¡ able 3.10.7.1 FDRs o f Pre and Post serum  perm utations. C om parisons highlighted in 
red were deem ed to be m eaningful, i.e. with a m edian FDR less than 10% .
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Pre serum, Post serum and Normal serum FDR permutations
When the sample groups are mixed to include 2 Pre serum specimens, 2 Post serum 
specimens and three Normal serum specimens in one group and the opposite/ left over 
Normal serum specimens in the other group, none of the permutations are were found to be 
meaningful (see Table 3.10.7.2).
2Pr e/ 2Post/ 3Normal vs. 2Pre/ 2Post 3Normal # sig. gene transcripts
2
FDR 
% Median
5003 ,7 /11, 14/1 2,3 11, 1 4 / 3 , 7 / 4 ,  5,6
3 ,7 /11 , 14/1 3,5 1 1 , 1 4 / 3 , 7 / 2 ,  4,6 38 21
3,7 /11 , 14/1 4,6 11, 1 4 / 3 , 7 / 2 ,  3,5 8 87.5
3 ,7 /11 , 14/1 3,6 11, 1 4 / 3 , 7 / 2 ,  4,5 6 116.7
3 ,7 /11 , 14/3 4,5 11, 1 4 / 3 , 7 / 1 , 2 , 6 38 28.9
3 ,7 /11 , 14/2 5,6 1 1 , 1 4 / 3 , 7 / 1 , 3 , 4 2 400
3 ,7 /11 , 14/1 2,5 11, 1 4 / 3 , 7 / 3 , 4 , 6 7 114.3
3 ,7 /11 , 14/1 5,6 11, 1 4 / 3 , 7 / 2 , 3 , 4 9 66.7
3 ,7 /11 , 14/3 5,6 11, 1 4 / 3 , 7 / 1 , 2 , 4 9 122.2
3 ,7 /11 , 14/1 4,5 11, 1 4 / 3 , 7 / 2 ,  3,6 16 56.3
3, 11/7, 14/1 2,3 7, 14/3,  11/4, 5,6 10 80
3, 11/7, 14/1 3,5 7, 14/3,  11/2, 4,6 1 700
3, 11/7, 14/1 4,6 7, 14/3,  11/2,3,5 1 600
3, 11/7, 14/1 3,6 7, 14/3,  11/2,4,5 0 n/a
3 ,11/7 , 14/3 4,5 7, 14/3,  11/1,2,6 0 n/a
3, 11 / 7, 14/2 5,6 7, 14/3,  11/1,3,4 1 800
3, 11/7, 14/1 2,5 7, 14/3,  11/3,4,6 1 1100
3, 11/7, 14/1 5,6 7, 14/3,  11/2, 3,4 0 n/a
3 ,11 /7 , 14/3 5,6 7, 14/3,  11/1,2,4 0 n/a
3, 11 / 7, 14/1 4,5 7, 14 / 3 ,1 1 /2 ,3 , 6 0 n/a
3, 14/7, 11/1 2,3 7 ,11 /3 ,  14/4, 5 ,6 17 52.9
3 ,14/7 , 11/1 3,5 7, 11/3,  14/2,4,6 18 55.6
3, 14/7, 11/1 4,6 7, 11/3,  14/2, 3,5 1 1000
3, 14/7, 11/1 3,6 7, 11/3,  14/2,4,5 4 200
3, 14/7, 11/3 4,5 7, 11/3,  14/1,2,6 20 50
3, 14/7, 11/2 5,6 7, 11/3,  14/1,3,4 0 n/a
3, 14/7, 11/1 2,5 7, 11/3,  14/3,4,6 4 250
3 ,14 /7 , 11/1 5,6 7, 11/3,  14/2, 3 ,4 1 800
3, 14/7, 11/3 5,6 7, 11/3,  14/1,2,4 0 n/a
3 ,14 /7 , 11/1 4,5 7 , 1 1 / 3 , 1 4 / 2 , 3 , 6 4 250
Table 3.10.7.2 FDRs of Pre, Post and normal serum permutations.
The sample groups were then mixed so that the Pre and Post serum specimens were in the
right order but the Normal samples were split up and mixed between them. In this
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assessment 2 of the 10 comparisons were deemed to be meaningful indicating that there 
may be some ambiguity when three Normal serum specimens are added to each grouping. 
However, when the six Normal serum specimens are grouped together either with all of the 
Pre serum specimens or the Post serum specimens, the only grouping found to be 
meaningful was the Pre serum against the Post op and Normal scrum specimens. Further to 
this, when the Normal serum specimens are tested against either the Pre serum specimens 
or the Post serum specimens, only the Pre serum vs. the Normal serum list were found to be
meaningful.
4Pre/ 3Normal vs, 4Post/ 3Normal # sig. gene transcripts
FDR 
% Median
3, 7, 11, 14/ 1,2,3 3, 7, 11, 14/4, 5,6 70 44
3, 7, 11, 14/4, 5,6 3, 7, 11, 14 /1 ,2 ,3 196 15.3
3, 7, 11, 14/ 1,5,6 3, 7, 11, 14/2, 3,4 125 29.6
3, 7, 11, 14/ 1,3,4 3, 7, 11, 14/2, 5,6 18 305
3, 7, 11, 14 /1 ,3 ,6 3, 7, 11, 14/2, 4,5 64 54.7
3, 7, 11, 14 /1 ,2 ,4 3, 7, 11, 14/3, 5,6 115 29.6
3, 7, 11, 14 /1 ,2 ,5 3, 7, 11, 14 /3 ,4 ,6 58 65.5
3, 7, 11, 14 /1 ,2 ,6 3, 7, 11, 14 /3 ,4 ,5 4X8 6.4
3, 7, 11, 14 /1 ,3 ,5 3, 7, 11, 14/2, 4,6 25 180
3, 7, 11, 14 /1 ,4 ,5 3, 7, 11, 14/2, 3,6 27 163
3, 7, 11, 14 /1 ,4 ,6 3,7, 11, 14/2, 3,5 201 20.9
3, 7, 11, 14/2, 3,4 3, 7, 11, 14 /1 ,5 ,6 66 48.5
3, 7, II, 14/2, 5,6 3, 7, 11, 14 /1 ,3 ,4 305 9.8
3,7, 11, 14 /2 ,4 ,5 3, 7 ,1 1 ,1 4 /1 ,3 ,6 79 39.2
3, 7, 11, 14/3, 5,6 3,7, 11, 14 /1 ,2 ,4 70 47.1
3, 7, 11, 14 /3 ,4 ,6 3,7, 11, 14 /1 ,2 ,5 106 38.7
3, 7, 11, 14/3, 4,5 
4 Pre^
3,7, 11, 14/ 1,2,6 
ys, 6 Normal
46 104.3
3, 7, 11, 14 111, 2, 3, 4 ,5 ,6 542 63
4 Post vs, 6 Normal
3,7, 11, 14 |  1,2,3, 4 ,5 ,6 182 32.4
4 Pre / 6 Noripal vs, 4 Post
3 ,7 ,1 1 ,1 4 /1 ,2 ,3 ,4 ,5 ,6  |I 3, 7,11,14 38 36.8
4 Pre vs. 4 Po
3, 7 ,11 ,14 /1 ,2 ,3 ,4 ,5>, 6 220 3.2
Table 3.10.7.3 FDR of Pre serum vs. Post serum with normal serum permutations.
Comparisons highlighted in red were deemed to be meaningful, i.e. with a median 
FDR less than 10%.
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\The aim of Section 3.11 was to analyse the sequence of these transcripts for presence of 
known regulatory elements which may enhance the stability of the transcripts.
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Throughout this study attempts were made to identify and confirm presence of gene 
transcripts in either the CM of cancer cell lines, normal breast cells or serum from breast 
cancer patients or normal volunteers. This section covers sequence analysis of some of 
these transcripts deemed to be either called Present in CM or significantly differentially 
regulated between groups of CM samples.
335 gene transcripts were called Present in all CM samples. 20 Gene transcripts from this 
list with an “_at” probe set designation and grade A annotation were randomly chosen for 
sequence analysis. The transcript assignments for each probe set were firstly aligned with 
the Affymetrix target probes for that transcript assignment to confirm 100% identity. The 
transcript assignment sequences were used instead of the reference sequence for the probe 
sets as in many cases the reference sequence does not align 100% with either the transcript 
assignment sequence or the Affymetrix target probes.
The transcript assignment sequence for each chosen probe set was then submitted to the 
UTRscan online analysis software (see Section 2.13.10). The UTRscan programme can 
scan any submitted sequence for the presence of known 57 3’ UTR regulatory sequences. 
The results of the scan are emailed back to the submitter and the report lists the known 
sequences and how many (if any) are present in the submitted sequence. The report also 
includes the exact position of the sequence. There are HTML links to the UTR regulatory 
sequence database were further information on the regulatory sequences can be found. 
Transcripts were also randomly chosen that were called Present in all cancer cell RNA 
microarray samples and Absent in all cancer cell CM samples for comparison. Exact 
sequences detected and positions in the transcript assignment sequence for all transcripts 
are listed in the Appendix (7.2). Tables 3.11.1-3 list the different transcripts chosen for
3.11 Sequence analysis of transcripts identified in CM/ serum
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sequence analysis. The sequences contain a mixture of well annotated and un-annotated
sequences.
Piobe Set lljGene Title Gene Symbol |GO Bioloqical Process Description GO Molecutat Function Description
1316 at thyroid hormone receptor, alpha (THRA regulation of transcription, DNA-dependent HI transcription from RNA’transcription factor activity III steroid hormone recepto
1553195 at RAS and EF-hand domain contai RASEF small GTPase mediated signal transduction IK protein transport calcium ion binding HI GTP binding
1553718 at zinc finger protein 548 ZNF540 regulation of transcription, DNA-dependent nucleic acid binding III zinc ion binding
1554595 at symplekin SYMPK cell adhesion protein binding ///binding
1555373 at chromosome 21 open reading iraC21orf114 - -
1557996 at - __ |-
202136 3t_ zinc finger, MYND domain contai ZMYND11 negative regulation of transcription from RNA polymerase II promoter DNA binding III protein binding III zinc ion binding III i
202252 at RAB13, member RAS oncogene RAB13 intracellular protein transport III cell adhesion III small GTPase medi:nucleotide binding III GTPase activity III GTP binding
210230 at Chromodomain helicase DNA binLOC388388 ;-
212599 at autism susceptibility candidate 2 AUTS2 -  -L.
214235 at cytochrome P450, family 3, subfi CYP3A5 electron transport III xenobiotic metabolism HI steroid metabolism liron ion binding III oxygen binding III heme binding III
22(032 at stearoyf-CoA desaturase 5 SCD5 fatty acid biosynthesis III lipid biosynthesis stearoyl-CoA 9-desaturase activity III iron ion binding
220940 at WAA1641 KIAAÎ641 !_ .......  ........i _ . . . . . .  '_
222835 at Thrombospondin, type I, domain THSD4 _  i¡metalloendopeptidase activity///peptidase activity
225834 at family with sequence similarity 7 FAM72A i_
227227 at Hypothetical LOC388397 LOC388397 - L[
228628 at Similar to Formin binding protein RP11-343N15.3—
232975 at [Tripartite motif-containing 26 TRIM26 protein ubiguitinstion Î0NA binding III ubiguitin-protein ligase activity III proti
233331 at ISimilar to Ribosome biogenesis |LOC389953 — ii_ ■
244292 at !¡Full length insert cDNA clone 2D-
Table 3.11.1 Probe sets called P in all CM samples chosen for sequence analysis. The 
Gene Ontology (GO) for the gene transcripts that are annotated are also listed.
Piobe Set l|Gene 1itle iGene Symbol GO Biological Piocess Description |GO Molecutai Function Description
1554128 at ismall adipocyte factor 1 jSMAFI _ l_....... 1
1560325_atjClone 23786 mRNA sequent- — !_
1561305 at |CDNA clone IMAGE.483751;- t1“  (—
1561573_at jHomo sapiens, clone IMAGE— ~
Ï561813_at|MRNÀftjll length insert cDNi- _
1563754 at 1 glutamate receptor, ionotropi GRIK2 ion transport III potassium ion transport III glutamate signaling patto» receptor activity HI ionotropic glutamate receptor activit
1570505 at ATP-binding cassette, sub-fiABCB4 lipid metabolism III transport HI response to drug III transport 1nucleotide binding ///ATP binding III ATPase activity II
203045 at ninjurin 1 ÌNINJ1 cell adhesion HI nervous system development III tissue regeneration protein binding
207138 at PHD finger protein 2 ¡PHF2 regulation of transcription, DNA-dependent ;transcription factor activity III protein binding III zinc ior
207631 at neighbor of BRCA1 gene 2 ¡NBR2 ER to Golgi vesicie-mediated transport III protein transport ///transpcnucleotide binding III GTP binding
206817~at catechol-O-methyltransferasCOMT catecholamine metabolism HI neurotransmitter catabolism ¡magnesium ion binding III protein binding III catechol C
211238 at jADAM metallopeptidase donADAM7 proteolysis Imetalloendopeptidase activity
214614 at ,homeoboxHB9 |HLXB9 regulation of transcription from RNA polymerase II promoter/// humortranscription factor activity III RNA polymerase II trans«
210698j t  i, likely ortholog of mouse mor MMRP19 ~  :identical protein binding
220808 at ¡Theg homolog (mouse) ÌTHEG spermatogenesis III chaperone-mediated protein complex assembly !!_
223815_at jcoiled-coil domain contamini CCDC45 .................................................. ..........  1I protein binding
224449 at ¡DNA-damage inducible proteDDI2 protein modification !r — ......  ™  .................... -
229871 at hypothetical protein FU1021FU1Q211 L.
233658“ at Chromosome 13 open readir; C13orQ4 I -  ........ :
I
240882 at jIMRNA; cDNADKFZp313NK- I -  !L.
Table 3.11.2 Probe sets differentially expressed in parental CM samples Vs drug 
selected variant CM samples chosen for sequence analysis. The Gene Ontology (GO) 
for the gene transcripts that are annotated are also listed.
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Piobe Set Gene Title Gene Symbol GO Biological Process Description |GO Moleculai Function Description
1553978_at MADS box transcription enhancer factor 2MEF2B transcription /// regulation of transcription, DNA-depend transcription factor activity ///transcription coac
1556301 at FulUength cDNA dons CS0DB006YA03 c Ii
i_
203450 at FKD2 interactor, golgi and endoplasmic rePGEAl protein localization HI negative regulation of Wnt recept beta-catenin binding HI identical protein bindinc
203500 at glutarykCoenzyme A dehydrogenase GCDH electron transport glutaryl-CoA dehydrogenase activity III oxidore
212141 at MCM4 minichromosome maintenance defiMCM4 DNA replication III DMA replication initiation III transcri nucleotide binding III DNA binding III protein bi
217811 at selenoprotein T SELT selenocysteine incorporation III cell redox homeostasis selenium binding III selenium binding
217817 at actin related protein 2/3 complex, subunit ÄRPC4 actin filament polymerization III actin nucléation structural constituent of cytoskeleton III proteir
217989 at dehydrogenase/reductase (SDR family) mDHRS8 steroid biosynthesis III metabolism /// lipid biosynthesi oxidoreductase activity
218112 at mitochondrial ribosomal protein S34 MRPS34 - structural constituent of ribosome
218291 at mitogen-activated protein-binding protein-irMAPBPIP _ polypeptide N-acetylgalactosaminyltransferase
218308 at transforming, acidic coileikoil containing TACC3 - -
218584 at hypothetical protein FLJ21127 FU21127 - —
216838 at ribonucleaseP21kDa subunrl RPP21 tRNA processing ribonuclease P activity HI protein binding III hy
218893 at isochorismatase domain containing 2 IS0C2 metabolism protein binding HI catalytic activity
219386 at apoptosis, caspase activation inhibitor IÄVEN apoptosis III anti-apoptosis protein binding
219394 at Phosphatidylglycerophosphate synthase 1P6S1 phospholipid biosynthesis HI metabolism CDP-diacylglycerol-glycerol-3-phosphate 3-pho
219822 at mitochondrial translational release factor 1MTRF1 protein biosynthesis HI regulation of translational termirtranslation release factor activity, codon specili
222759 at suppressor of variegation 4-20 homolog 1 iSUV420H1 —
222826 at pallidin homolog (mouse) PLDN synaptic vesicle docking during exocytosis syntaxin-13 binding III identical protein binding
223482_at transmembrane protein induced by tumor TMPIT -
Table 3.11.3 Probe sets called Present in all cancer line cell RNA samples and Absent
in all CM samples chosen for sequence analysis. The Gene Ontology (GO) for the gene 
transcripts annotated are also listed.
The results for the UTRscan of the sequences called P in all CM samples are listed in Table 
3.11.4. 17/20 of the transcripts submitted came back positive for at least one 15- 
Lipoxygenase Differentiation Control Element (15-LOX-DICE) sequence, with just over 
half of those transcripts (9/16) containing multiple 15-LOX-DICE sequences. 7/20 
transcripts also came back positive for other regulatory sequences; K-box (3/20), Brd-box 
(2/20), GY-box (1/20) or ADH DRE (1/20) sequences.
The results of the UTRscan of the probe sets differentially expressed in parental CM 
samples compared to their drug selected variants are listed in Table 3.11.5. 13/20 
transcripts have at least one 15-LOX-DICE sequence, 6 of these 13 have multiple 15-LOX- 
DICE sequences. 12/20 transcripts also possess another known 5V 3’UTR regulatory 
sequence. 6/20 transcripts have at least 1 K-box sequence (3/6 have multiple sequences), 
3/20 have an IRES, 2/20 have either a GY-box or Brd-box and 1/20 have either a CPE or an
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The results of the UTRscan of the probe sets called Present in all cancer cell line RNA 
samples and Absent in the matching cancer cell line CM RNA samples are listed in Table 
3.11.6. 18/ 20 came back positive for at least one 15-LOX-DICE sequence, with just under 
half (8/18) containing multiple 15- LOX-DICE sequences. A further 8/20 also contained 
other regulatory sequences; K-Box 3/20, IRES 2/20, Brd-Box, ADH DRE, CPE, TOP and 
SECIS-2 1/20, none of which were present more than once in the sequence.
ADHDRE sequence.
Rrol>e Sot ID Gene Sym bol Accession 15-LOX-DICE Other
1316 at THRA NM 199334 5 —
1553105 at RASEF AKD5617G 4 -*-1 matchinq repeat ___
1 55371 B at ZNF548 NM 152909 3 —
1554595 at SYMRK NM 004819 5 ___
1555373 at C21 orfl 14 NM 001012707 — —
1557996 at — AKD91784 1 ___
202136 at 2MYND1 1 NM 00624 — 1 K-Box
202252 at RAB13 NM 002070 1 ___
210230 at LO C3883BS AW027091 2 1 GY-Box
212599 at AUTS2 NM 015570 7 1 Brd-Box
214235 at 
220232 at
CYP3A5
SCD5
AKDSSB79 1 —
NM 024906 — —
220940 at Kl AA1 641 NM 020970 1 —
222B35 at THSD4 AK130734 2 1 K-Box
225834 at FAM72A NM 20741B 1 1 ADH DRE. 1 Brd-Box
227227 at LO0388397 AKD57167 2 K-Box
22B62B at RP11 -343N1 5.3 BOO17972 1 1 SECIS
232975 at TRIM2G AKD23334 — —
233331 at LO0389953 AY010114 3 ___
244292 at 1— AFOB64S2 1 . . .
Table 3.11.4 Results of UTR scan for gene transcripts called Present in all CM
samples.
Paol>e Set ID |Gene Symbol (Accession 15-LOX-DICE Other
1554120 at ISMAF1 |INM 001010082 — 1 GY-Box
1560325 at — AL832767 4 2 K-Box
1561305 at — BC040325 1 —
1561573 at — BC039476 — 1 K-Box
1561013 at — AL109711 1
1563754 at GRIK2 AI252246 1 1 K-Box
1570505 at ABCB4 BC020618 — —
203045 at' NINJ1 NM 004140 —
207130 at PHF2 AF043725 6 ___
207631 at N0R2 NM 005821 1 ___
200017 at COMT NM 00754 — 1 GY-Box
211238 at ADAM7 NM 003817 1 1 K-Box
214614 at HLXB9 NM_005515 1 ___
210698 at MMRP19 NM_015957 — 1 -CPE. 11RES. 3 K-Box
220808 at THEG NM 016585 2 11RES
223815 at CCDC45 BXB41136 3 1 ADH DRE, 2 K-Box
224449 at DDI2 BC006011 1 1 Brd-Box
229871 at FLJ1021 1 AKD91238 4 1 IRES
233658 at C13orf24 AKD22413 4 —
240882 at — BX537871 — 1 Brd-Box
Table 3.11.5 Results of the UTRscan for probe sets differentially expressed in CM
samples
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Probe Set ID Gene Sym bol Accession 15-LOX-DICE Other
1553978 at MEF2B AK1 28256 5 1 K-Box
1556301 at “ 1— BC024246 1 1 (RES
203450 at PGEA1 NM 015373 — 1 CPE
203500 at GCDH NM 000159 3 —
212141 at MCM4 NM 005914 2 —
217811 at s e Lt NM 016275 1 1 SECIS-2. 1 Brd-Box
217817 at ARPC4 NM 005718 1 —
217989 at DHRS8 NM 016245 1 1 TOP
218112 at MRPS34 NM 023936 2 —
218291 at MAPBPIP NM 014017 — —
218308 at TACC3 NM 006342 2 1 1RES
218584 at FLJ21127 AKD24780 1 1 K-Box
218836 at RPP21 NM 024839 1 —
218893 at ISOC2 NM 024710 3 —
219366 at AVEN NM 020371 1 —
219394 at PGS1 NM 024419 1 —
219822 at MTRF1 NM 004294 2 —
222759 at SUV420H1 NM 016028 1 - - -
222826 at PLDN NM 012388 2 1 ADH DRE, 1 K-Box
223482 at TMPIT NM 031925 1 —
Table 3.11.6 Results of the UTRscan for probe sets called Present in all cell RNA
samples and Absent in all CM samples
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Discussion
The finding that it was possible to amplify mRNA transcripts from the serum of cancer 
patients came as a surprise to many researchers. This was especially true with cancer 
patients as they were found to display elevated levels of RNases in their serum (Reddi et al 
1976).
At the time that the work presented here in this thesis was started, only a few publications 
regarding the detection of mRNA in the serum of cancer had been published. The 
techniques utilised for the separation of serum/ plasma and extraction of RNA were 
different in all of the studies, some of them are summarised below.
Kopreski et al (1999) carried out one of the first studies on serum mRNA. They were able 
to detect tyrosinase mRNA in serum from 4/6 malignant melanoma patients with no 
detection in 20 healthy controls. The serum was collected by centrifugation of peripheral 
clotted blood and careful removal of the serum. RNA was extracted from 50|i.l of serum 
using a column-based kit for RNA isolation, Perfect RNA Total RNA Isolation kit. Nested 
PCR (consisting of 15 cycles, then dilution of the PCR solution 1:100 and a further 40 
cycles) was then carried out on the RNA for detection of the tumour-related transcript.
In 2000, Chen et al isolated serum from breast cancer patients by centrifuging clotted blood 
to separate the serum; a second centrifugation step was then used to remove cellular debris. 
RNA was isolated from lOOjxl of serum using the Promega SV Total RNA Isolation 
System. RT-PCR was then carried out on 1 or 5|il of the extracted RNA for two telomerase 
RNA subunits using 50 PCR cycles. Detection of the mRNA transcripts were found in 25- 
28% of breast cancer serum specimens for the two mRNA subunits and serum from healthy 
volunteers was negative for both.
Silva et al (2000) isolated plasma from breast cancer patients by centrifugation of
peripheral blood. RNA was then extracted using an RNeasy mini kit column-based
protocol. Nested PCR was carried out on 5-15ng of the extracted RNA for mammaglobin
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and CK-19 mRNA using 2 rounds of 40 PCR cycles. 60% and 12% of patients and healthy 
volunteers respectively were positive for detection of mammaglobin mRNA with 49% and 
20% respectively positive for CK-19 mRNA.
These studies helped to realise the potential of using mRNA detectable in serum as possible 
biomarker candidates. However, despite these early results, we felt that there were 
limitations to the studies carried out. The numbers of patients in the studies were quite 
small and only a limited range of gene transcripts were analysed. In addition to this, in 
many of the studies, the serum was subjected to different centrifugation protocols and 
filtration of the serum, to ensure prevention of cell carryover, was not always performed. 
Also, different RT-PCR protocols were carried out using very large numbers of nested PCR 
cycles in some cases. Due to the fact that the reproducibility of these techniques, in general, 
had not been addressed this is where we started our study.
By utilising CM from cultured human cancer cell lines we were able to set up experiments 
in duplicate in order to have biological replicate samples. Different methods for the 
extraction of RNA from these samples were tested and optimised. All the necessary 
precautions required for working with RNA were taken i.e. pre- cleaning workspaces with 
RNase- zap, using only DEPC treated/ RNase-free water, changing gloves regularly etc. 
These initial tests indicated that if the volume of CM from which RNA was extracted was 
too small, a variable result between duplicate samples was possible. This reinforced for us 
the advantage of the cell culture system, because in the clinical environment biological 
repeat samples are not possible. Disparity of mRNA expression between patients could 
have been explained as the result of patient-specific mRNA expression and not due to any 
limits of the detection system used, as no replicate samples were available to confirm either 
way.
Once we had established a protocol for RNA extraction and RT-PCR that was both reliable
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and reproducible, we set about testing the CM RNA for the presence of different cancer- 
related mRNAs. The cancer cell lines that we cultured for removal of CM had previously 
been studied for expression of different cancer-related mRNA transcripts e.g. MDR1, 
which guided us in the choice of mRNA transcripts to look for in the CM taken from these 
cells.
We discovered that in different cancer cell lines expressing the same mRNA transcripts, 
detection of these transcripts was not always possible in the corresponding CM samples. 
This meant that cells showed selective expression of mRNA transcripts detectable in their 
corresponding CM. The detection of mRNA transcripts in the CM samples was not simply 
a result of a cell “dumping” mechanism. Also, detection of full-length transcripts for at 
least some mRNA transcripts was possible.
This encouraged us to look for ways to enable us to look at the global expression of mRNA 
from CM samples using microarray analysis. At the time, the minimum starting RNA 
requirement for microarray work was 5fig. The recent addition to the laboratory of a 
Nanodrop enabled us to quantify the RNA extracted from CM, as previous attempts with a 
standard spectrophotometer had failed due to the small RNA content, although this method 
also was not without challenges.
Methods for concentrating the RNA using centrifugal devices were assessed. Despite 
concentration of RNA in the samples to a certain extent, they could not be concentrated 
sufficiently to yield the 5|ig minimum required.
Around this stage in the work, Affymetrix developed a 2-cycle protocol for the
amplification of RNA from small samples. This protocol was mainly targeted to studies
where only small amounts of tissue were available/ where laser capture microdissection
was used to cut single cells from tissues. RNA could be amplified from as little as lOng to
yield sufficient cRNA for hybridisation to their microarray chips, enabling the global
291
expression analysis of mRNA transcripts from these samples to be carried out.
We decided to perform a pilot study using three biological replicate CM samples as starting 
material. At this stage, or indeed since, no reports of microarray analysis of extracellular 
RNA extracted from CM were reported. Our pilot study was found to be successful i.e. 
enough cRNA was amplified from the CM samples for hybridisation to the whole genome 
microarray chips. Due to the success of the pilot study, it was decided to expand it to 
include CM obtained from other cancer cell lines in culture. CM from parental human 
cancer cell lines and their drug selected variants were processed so that the global mRNA 
expression profiles could be assessed.
Bioinformatics software including dChip and Genespring aided in the visualisation and 
manipulation of the data obtained. Hierarchical clustering was performed on the samples 
and dChip software was successfully applied to grouping most of the CM replicate samples 
together. This was a very important result in so far as we had proven that the CM from 
cultured cancer cell lines, differentiated only by their selection to a particular drug, 
exhibited unique gene expression patterns that distinguished them from the other cancer 
cell line CM sample groups analysed.
The groups of replicate parental vs. drug selected variant CM samples were then explored
for the patterns of gene expression that may distinguish them from the other samples
analysed. From a list of the most highly changing gene transcripts between parental and
drug selected variants, 10 gene transcripts were chosen for confirmation by RT-PCR.
Validation of the microarray data using RT-PCR proved problematic in that only 50%
validation was achieved. However, this discordance of microarray data with RT-PCR data
was not unique to our system. The MicroArray Quality Control Project has estimated that,
in general, above their signal threshold (of 2-10 mRNA copies/cell) microarray
measurements accurately reflect the existence and direction of expression changes in ~70-
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90% of the gene transcripts (Draghici et al 2005).
At this time a group in California published results on microarray studies that they had 
carried out on extracellular RNA extracted from saliva samples of oral cancer patients and 
healthy volunteers (Li et al 2004 (a) and (b)). We were able to compare the results obtained 
from extracellular mRNA from CM with the results they obtained from extracellular saliva 
mRNA. They, too, found some discordance when confirming the microarray results with 
RT-PCR methods.
Due to the successful application of RNA derived from CM samples to microarray
techniques, it was decided to evaluate its usefulness using serum specimens obtained from
breast cancer patients. Blood specimens were collected from patients on the morning of
surgery to remove a breast tumour and a follow-up sample was taken 2-4 months post
surgery. Tumour and matched normal tissues were also collected from the same patients
and blood specimens were obtained from healthy volunteers. All blood specimens were
treated the same i.e. processed within four hours and the serum was separated from the
clotted blood, centrifuged and filtered with a 0.45 jim filter before being stored at -80°C.
Using the methods developed and described in this thesis (with minor modifications), RNA
was extracted from the serum, and equal volumes of serum RNA were amplified and
hybridised to an Asymetrix whole genome microarray chip. The corresponding tissue RNA
(tumour and normal), were also amplified and hybridised to the microarray chips.
Whilst hierarchical clustering of the serum specimens did not yield distinct groupings of the
specimens, further analysis of gene lists generated, e.g. with Pre-operation (Pre) serum
specimens vs. post-operation (Post) serum specimens, including analysis of false discovery
rates (i.e. the chance of these changes occurring by chance), indicated that the Post serum
specimens were more similar to the gene expression profile of the serum specimens
belonging to the healthy volunteers (Normal) than the Pre serum specimens. The
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comparison of the Pre serum specimens to the Normal serum specimens yielded 542 
significantly changed gene transcripts, whilst comparison of the Post serum specimens to 
the Normal serum specimens yielded only 182 significantly changed gene transcripts. 
Further analysis of the false discovery rates of these comparisons revealed that the 
comparison of the Pre serum to the Normal serum specimens and Pre serum to the Post 
serum specimens yielded the most meaningful data i.e. the chance of falsely identifying a 
gene changed by chance was low in these comparisons.
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4.1 Identifying a suitable time point for CM collection and analysis
Cells were generally seeded at 2xl06 cells per T75cm2 flask in duplicate. Conditioned 
media (CM) samples were collected at 4 time-points after cell seeding to identify a suitable 
time-point at which amplifiable mRNA could be routinely isolated for analysis. As 
indicated in Fig 3.1.2, in the case of P-actin, mRNA could be isolated and amplified at all 
time points evaluated. The increasing intensity of the PCR bands in the samples over the 96 
hours may be due to the increasing amounts of P-actin transcripts secreted into the CM over 
the 96 hours assuming that the transcripts are stable in CM for that length of time. Another 
reason may be that as 1ml of CM was taken every 24 hours and was not replaced, the 
concentration of the P-actin gene transcripts increased due to the smaller volume of media 
in the flask with each 24 hours. As the cells were in a healthy, proliferating state at the 48 
hour time-point (see Fig 3.1.2 as example) with little or no dead cells floating in the media, 
this time point was chosen for all further studies using this RNA extraction protocol.
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4.2 Determining conditions for reproducible detection of mRNA in CM
The first RNA extraction method tested was the Promega SV Total RNA Isolation protocol.
This was to mimic the extraction method employed by Chen et al (2000) were they used the 
kit to extract RNA from lOOfil of serum. They found that they were able to amplify two 
telomerase RNA gene transcripts from the serum of breast cancer patients using RNA that 
was extracted with this protocol and 50 cycles of PCR.
Fig 3.2.1.1 (a) and (b) show that the PCR results obtained using RNA isolated with the 
Promega system, when trying to amplify the CK-19 gene transcript, were not reproducible. 
Duplicate samples showed little/ no concordance with each other e.g. Fig 3.2.1.1 (a) 
samples 24 (a) and 24 (b). The reason for this could have been that the sample size of lOOjal 
was too small and the PCR was at its detection limit or that the RNA consisted mostly of 
small fragments which could not consistently be picked up by the spin columns (shorter 
transcripts like the 5S rRNA and tRNA molecules cannot be extracted using this technique 
as they are smaller than 200 nucleotides and don’t bind to the spin columns).
Experiments were then set up to test both of these theories using 48 hour CM (for the 
reasons stated in Section 3.1 and also because these time points showed inconsistent results 
when using RNA extracted with the Promega kit (Fig 3.2.1.1)). RNA was extracted from 
two volumes of the CM, 100^1 and 250^1 and was amplified, in parallel, for a range of gene 
transcripts, to test out whether the PCR was at its limit of detection with the smaller 
volume. To overcome the possibility that the binding columns may have led to the 
inconsistent results, the RNA was extracted using the modified Tri Reagent protocol, which 
extracts the RNA (including small fragments/ nucleotides) by isopropanol precipitation 
rather than using binding columns.
The results of this experiment can be seen in Figs 3.2,2.2-3 and 3.2.2,5- 6. There was an
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overall increase in the reproducibility of all the results for RPMI TAX CM, but not for the 
RPMI ML CM. The results noticeably show that when the smaller volume of CM was used 
(samples labelled 48.100), although p-actin was amplifiable for both duplicate samples (Fig 
3.2.2.2), CK-19 and HnRNP B1 had conflicting results for the duplicate samples (Figs 
3.2.23 and 3.2.2.S).
When the larger volume of CM was used for extraction of RNA (labelled in results 48.250 
and equivalent to approximately 50jal CM/ RT as opposed to approximately 9|ilCM/ RT 
with the 48.100 samples), the results show that there were no inconsistencies between 
duplicate samples. This proved that the PCR was previously most likely at its limit of 
detection with the smaller sample volume. The Tri Reagent protocol was easily adjustable 
so that more RNA could be re-suspended in smaller amounts of DEPC treated water and so 
concentrating the volume of RNA in the final RNA sample. For this reason therefore, the 
Tri Reagent extraction method was deemed the protocol of choice for this work. Based on 
this data and the results in section 3.1, which showed that at 48 hours the cells look quite 
healthy and were not confluent, it was decided that all future CM studies would be carried 
out using 250jxl of 48hour cultured CM and extracted using the modified and optimised Tri 
Reagent protocol.
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Unlike the column-based methods for extraction of RNA (e.g. Qiagen RNeasy kit, Promega
SV isolation kit) where smaller fragments of RNA (~<200nts e.g. 5S rRNA, tRNA) can be 
lost through the column, the precipitation method used in the Tri Reagent RNA extraction 
protocol would ensure that all fragments were extracted.
The decision to use the Tri Reagent protocol for extraction of the CM RNA meant that it 
was still possible that some of the RNA transcripts amplified in the previous results 
(referred to in section 3.2) could have resulted from amplification of fragmented RNA i.e. 
degraded mRNA but with the poly-A tail still intact. Although reverse transcription was 
carried out using Oligo dT as a reverse primer, not all transcripts had 5’ targeted primer sets 
like HnRNPB 1.
In some studies of human serum/plasma it has been suggested that the RNA detected is 
probably present as short fragments (El- Hefnawy et al 2004). Similarly, extracellular RNA 
isolated from HeLa and A431 growth medium has been suggested to be represented by 
100-200 nucleotide-long fragments (Morozkin et al 2004)). Therefore, in order to check 
whether or not the RNA (at least for the P-actin gene transcript) was full-length, primers 
were designed to amplify 5’, middle and 3’regions of the p-actin gene transcript (Fig 3.3.1 
for positions of amplified regions). As the RNA was reverse transcribed using only Oligo 
dT with no random hexamers, any 5’ specific amplified regions would indicate that, for P- 
actin at least, there were full length gene transcripts present.
Fig 3.3.2 shows that it was possible to amplify different regions of the P-actin gene 
transcript. The intensity of the amplified product from the 5’ UTR region is less intense 
than the other three regions, but it clearly indicates the presence of full length P-actin gene 
transcripts and also the intensity of the 5’ coding region targeted primers PCR products are
4.3 Amplification of p-actin gene using 5’ and 3’ specific primers
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as intense as the shorter 3’ coding region targeted primer PCR bands for the CM samples.
Li et al (2004) also assessed RNA isolated from the serum of oral cancer patients for the 
presence of full length transcripts. Four housekeeping gene transcripts (ACTB, B2M, 
GAPDH and RPS9) were assessed. Primers were designed to amplify regions that covered 
56.8- 88.9% of the gene transcripts. The amplicons ranged in sized from 188bp to 1Kb. 
Gene transcripts for the four gene transcripts were amplifiable in all cases.
Studies carried out by Wong et al (2005) on extracellular placental RNA extracted from 
maternal plasma, suggested that there was a higher incidence of 5’ mRNA fragments in 
maternal plasma samples. Out of 7 gene transcripts screened, 5 of them showed higher 
concentrations of 5’ amplicons over 3’ amplicons. For one gene transcript in particular, 
phCG mRNA, the concentration of the 5’ amplicon increased with the length of gestation.
In an assessment of the RNA extracted from saliva for the presence of full-length 
transcripts, Park et al (2006) found that only 4/5 transcripts were detectable. GAPDH was 
not detected in any of the saliva RNA samples. Of the other four transcripts analysed, p- 
actin, RPS9 and IL8, gene transcripts were detected in 2/8 samples and SAT mRNA was 
detected in 4/8 samples. Relative abundances of p-actin and IL8 5’, middle and 3’ regions 
of the mRNA transcripts were assessed by real-time PCR. Park et al found that amounts of 
the middle and 3’ regions of the two transcripts were less abundant than the 5’ region.
The P-actin RT-PCR results shown in Fig. 3.3.2 do not indicate that there are more 
abundant 5’ amplicons than 3’ amplicons in RNA extracted from CM.
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4.4 Analysis of gene transcription in RNA isolated from cell lines and 
conditioned media
Expression of transcripts representing a number of gene products (including mdr-1, mrp-1, 
CK-19, HnRNP B l, GST-71, topoisomerase II, bcl-2 and P-actin; amplified products 
ranging between 157 -  383 bp (Table 2.11.1.1)) was evaluated in a range of human cancer 
cell lines (see Table 2.5.1 for the list of cell lines and their origin) and corresponding CM. 
Although 30 cycles of PCR were sufficient for amplification of RNA from cultured cells, 
45 cycles was generally found to be necessary for CM studies. However, use of nested 
primers and large numbers (70-83 cycles) of PCR cycles as reported for some of the serum 
studies (Kopreski et al 1999, Silva et al 2001)) were not found to be necessary in our 
experiments.
Two different filter sizes were also tested for each CM. According to Ng et al (2002), filter 
size can have a significant effect on the amount of RNA extractable from serum specimens. 
They found a statistically significant reduction in hPL, phCG and GAPDH mRNA levels 
detectable in the serum of pregnant women after filtration with a 0.45 [im filter.
It was decided to test CM filtered with a 0.45 jam filter (in addition to the 0.22|im filtered 
CM), which would still exclude cells from the CM, to see if there was any effect on the 
gene transcripts amplifiable.
As expected, the ubiquitously expressed “house-keeping” gene, p-actin, was detected 
following 30 cycles of PCR in all cell line extracts analysed.
For all RNA extracted from cells, p-actin was successfully co-amplified in association with 
all other gene transcripts of interest. However, although p-actin was routinely amplified 
alone in all CM, attempts to co-amplify p-actin in these samples inhibited detection of other 
gene products of interest. For this reason, p-actin was not co-amplified with other cDNAs 
when analysing CM.
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P-actin was successfully amplified following 0.22/ 0.45 p.m filtration of the CM (Fig. 3.4.1). 
Amplification of CK-19 and HnRNP B1 gene transcripts were also detected in all cell and 
CM samples similar to P-actin (Figs 3.4.2, 3.4.3).
To investigate if specific mRNAs were detectable only in CM from cell lines expressing 
that product (i.e. to ensure results did not include false positives), CM from cell lines 
expressing versus not expressing a particular gene transcript was analysed. As shown in 
Fig. 3.4.4, GST n  was detected in all cell lines studied, except MCF-7 and BT474. 
However, although GST /rwas undetected in all media conditioned by BT474 cells, a weak 
band resulted from analysis of the MCF-7 0.45 \xm CM filtrate. This result was 
reproducibly found. A possible explanation for this unexpected finding may be the use of 
45 cycles of PCR for CM analysis, with only 30 cycles routinely used for amplification of 
RNA from cell lines.
Topoisomerase II (Fig. 3.4.5) mRNA was expressed by all cell lines studied and was 
amplified following isolation from 0.45 Jim filtered CM. However, with the exception of 
medium conditioned by the nasal carcinoma cell line variant, RPMI-TAX, and the breast 
cancer cell lines, MDA-F and MDA-F-ADR-SI (very weak band), topoisomerase II was 
generally undetected in 0.22 jam filtered CM.
MRP-1 was expressed by all cell lines (Fig 3.4.6(a). It was also detected in only 5 of the 
0.45 Jim filtered CM, but in only 2 of the subsequent 0.22 |im filtrates, analysed (Fig. 3.4.6 
(b, c).
Bcl-2 was expressed (albeit at relatively low levels) in the entire 8 cell lines analysed (see 
Fig. 3.4.7 (a)). However, this gene transcript was apparently not secreted by these cells i.e. 
with the exception of a very weak band resulting following amplification of 0.45 |im 
filtered RPMI-TAX CM, bcl-2 mRNA was undetected in all CM.
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Results from this study suggest that the secretion of mRNA by human cancer cells may not 
just be a general “dumping” mechanism, but may be somewhat selective. This is supported 
by the fact that although P-actin, CK-19 and HnRNP B1 are expressed by all cell lines and 
are detected in all CM analysed, other mRNAs - such as MRP1 and bcl-2 - were present in 
RNA isolated from most/all cell lines, but were not present in all corresponding CM 
samples. An alternative explanation to selective secretion of the gene transcripts may be 
differing stabilities of mRNAs secreted. However, support for the former suggestion is the 
fact that, for example, RPMI-ML and RPMI-TAX cells grow in the same medium type, 
under the same culture conditions; both cell line variants express mrp-1; but, although this 
product is detected in both the 0.45 Jim and 0.22 \im CM from RPMI-TAX, it is undetected 
in all medium conditioned by RPMI-ML cells.
With one exception, an amplified product was never detected in CM that was not detected 
in the corresponding cell line.
To prove that the mRNA was not somehow coming from the media itself that the cells were 
cultured in, a sample of media, unconditioned by any cells, underwent the same filtration/ 
extraction protocol as the CM. Fig 3.4.1.1.1 shows that this sample was negative for p-actin 
which indicates that the mRNA found in the CM did not come from the media or FCS 
added.
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Millipore centrifugal devices are routinely used in our laboratory for concentration of 
proteins from CM samples. They are characterised by their ability to retain molecules 
above a specified molecular weight. The percent of retentate (concentrate) recovery for a 
membrane, according to the manufacturers, is over 90%. In addition to their obvious use in 
recovery of proteins from dilute samples, one of the intended uses of the devices is 
concentration of nucleic acids from dilute solutions. Despite this advertised intended use, 
the manufacturer has carried out no evaluation of the recovery yields of DNA or RNA. 
Having developed/ optimised methods for the reproducible analysis of a range of mRNAs 
in medium conditioned by a range of cancer cell lines (results in Section 3.4), we wished to 
investigate the feasibility of studying the global expression of mRNAs in CM using whole 
genome microarrays. To achieve this and to enable results from microarray analysis to be 
validated by RT-PCR, increased yield of RNA may be required. For this purpose we 
investigated the possibility of concentrating the RNA in CM samples by using the Millipore 
centrifugal devices.
The results shown in Section 3.4 indicate that the centrifugal devices did aid in 
concentration of RNA fragments found in the CM samples (see bioanalyser traces Fig
3.5.2.1 (h, i, k and 1)). However the quantity of the RNA in the concentrated samples, as 
measured by the Nanodrop, indicated a fold increase of less than 1.5 (from 59.8 ng/\i\ in the
0.45B sample to 75.55ng/^l in the 0.45C sample- see Fig 3.5.1). The fold increase was 
slightly better at 1.67 for the 0.45C (4X) sample compared to the 0.45B (4X) sample. In the 
samples taken before concentration that were filtered through a 0.45fim filter (0.45B and
0.45B (4X)) however, by extracting RNA from 4 x 250|til aliquots and re-suspending the 
four pellets into the one 15^ .1 volume (0.45B (4X)), the concentration of the RNA in the
4.5 Concentration of CM with Millipore concentrators
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resulting solution was 3 fold higher than the sample in which only one RNA pellet 
(resulting from extraction of 1 x 250^1 aliquot of CM), was resuspended. RNA fragments 
from this sample were also visible on the bioanalyser analysis of the samples (see Fig.
3.5.2.1 (h)). None of the protocols tested, despite different optimisations and an increase in 
the RNA quantity, were able to yield the 5 jig of RNA required for microarray analysis.
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4.6 Interference in quantification of small amounts of RNA
In a review of methods for real-time quantitative PCR, Ginzinger (2002) assessed the 
variables that might limit the use of real-time quantitative PCR. One of these variables 
related to nucleic acid purification methods utilised. In the review Ginzinger recommended 
that care should be taken if the protocol is a phenol/ chloroform-based method. Any trace 
amount of phenol can contribute to reduced reverse-transcription efficiencies. As traces of 
phenolic compounds absorb light in the UV range, any traces of phenol carried through the 
protocol can also result in an overestimation of the amount of RNA present when the 
samples are quantified using a UV spectrophotometer.
This was also confirmed in a study carried out by an Agilent Technologies researcher, 
Lightfoot (Agilent application note, 2002). Quantification of lOOng of RNA spiked with 
different volumes of phenol (0.5-5%) was carried out using the Agilent 2100 bioanalyser, a 
UV spectrophotometer or a ribogreen kit. The results showed that even in the presence of
0.5% phenol contamination, the UV reading for the RNA sample was overestimated.
A posting on a Yahoo microarray group also indicated that other researchers have found 
that extraction of RNA using Trizol (essentially the same as Tri Reagent), where low 
amounts of RNA are expected, can result in overestimation of the RNA content if 
quantified using a Nanodrop (see Appendix 7.1).
To assess if there was any phenol present in the CM samples that may induce an 
overestimation of the quantity of RNA in the sample, a simple experiment was designed. 
Firstly Tri Reagent was diluted 1:100 with PBS or UHP and a sample was quantified using 
the Nanodrop. Fig 3.6.1(A) shows that the diluted Tri Reagent absorbs light at 260 and 
270nm as indicated by the peaks on the graph at these wavelengths.
When 250jal of UHP was added to Tri Reagent and the RNA extraction for CM samples
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followed (see Section 2.8.2.2), quantification of the resulting solution demonstrated that the 
Nanodrop falsely calculated that there was 70-108 ng of RNA in the samples (see Fig. 3.6.1 
(B) & (C)). Utilisation of an overnight precipitation step slightly increased the false reading 
(Fig. 3.6.1 (B)). The combination of a Tri Reagent RNA extraction protocol with an 
RNeasy clean-up protocol reduced the false reading from 68.9/ 108.2ng down to 12.1 ng 
(Fig 3.6.1 (D)). The volume of water required to elute the sample from the RNeasy column 
however, was twice the volume used to resuspend the RNA pellet using the Tri Reagent 
protocol. This would have aided in the reduction of the interference by diluting the sample. 
To confirm that the interference was due to the Tri Reagent, an RNeasy extraction was 
carried out using UHP/ PBS. The RNeasy RNA extraction protocol is a binding-column 
based procedure that can bind RNA and does not rely on the use of phenol. The 
quantification of the eluted solution gave a reading of 1.7ng, which is at background levels, 
and the corresponding absorbance curve in Fig. 3.6.2 shows clearly the difference in 
absorbance at 260 and 270nm obtained using the two different protocols.
Cell derived RNA extracted using Tri Reagent however does not show evidence of any 
contaminating peaks at 270nm (see Fig. 3,6.3 (B)) which leads us to the conclusion that 
phenol carryover only affects/ interferes with the quantification of RNA when the RNA 
solution cannot be diluted before quantification (see Fig. 3.6.3 (A) for example of CM 
sample).
Alternative methods for RNA quantification were sought at this time. A Quant-it RNA 
assay kit (Molecular Probes Inc) was tested as it claimed to be able to quantify as little as 
5ng of RNA independent of any DNA that may be in the sample. Whilst it was able to 
accurately quantify diluted cell RNA diluted down to 50ng, it was unable to accurately 
quantify below this concentration and was also unable to quantify the CM RNA samples.
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4.7 Microarray Analysis of DLKP CM
4.7.1 RNA quantification and QA analysis
Whilst the Nanodrop UV readings of the DLKP CM RNA before amplification (Fig. 
3.7.1.1(a)) show two peaks at 260 and 270nm, after two rounds of amplification and with 
all the inherent cleaning steps, the amplified RNA does not show evidence of phenol 
contamination as evident by the single peak at 260nm in the amplified sample (Fig. 
3.7.1.1(b)).
The three DLKP CM samples (DLKP 1, 2 and 3), showed similar cRNA yields after the 2nd 
cycle of the two-cycle amplification protocol, despite slightly different yields after the 1st 
round IVT (Table 3.7.1.1). Bioanalyser traces in Fig. 3.7.1.2 show that although the DLKP 
3 CM sample did not show the presence of any RNA fragments before amplification, Fig.
3.7.1.2 (b) clearly shows a large amount of amplified cRNA present in the sample 
following 2 rounds of amplification. Fig. 3.7.1.2 (c) shows the efficiency of the 
fragmentation step as the labelled cRNA is uniformly fragmented to nucleotides of 
approximately 200bps long.
The samples passed the quality controls outlined by Affymetrix when hybridised to the 
chips with little/no difference between the three chips. The % Present calls were 23.2, 22.6 
and 23.5 respectively (Table 3.7.2.1), although this may seem low compared to the average 
% Present calls of 35- 50% obtained with cell RNA, Affymetrix stipulate that results may 
vary greatly depending on the sample being analysed, and as long as repeat/ duplicate 
samples have similar QA results, then a low present call is acceptable.
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4.7.2 Scatter plot and Venn diagram Analysis of DLKP CM
Although the % gene transcripts called Present between each CM sample seemed to suggest
the samples are quite similar, when these data lists were overlapped using a simple Venn 
diagram to check the concordance (as indicated by Fig 3.7.3.1), there is quite a bit of 
variation between the replicate samples. However, this variation seemed to correlate with 
the Affymetrix probes that had expression values under 100 (Fig 3.7.3.2) as indicated by 
the grey dots in the scatter plot, the probes sets with higher expression values correlated 
with the probes that were commonly expressed in all three replicates.
The CM samples were taken from DLKP cells 4 passages apart (DLKP 1= passage 54, 
DLKP 2, DLKP 3 = passage 58). Fig 3.7.3.2 shows that the difference in cell passage 
number can have an effect on the expression levels of gene transcripts in the different 
samples. CM RNA from passage 54 (DLKP 1) cells had more Affymetrix probes expressed 
at levels over 100 not commonly expressed at these levels with the CM samples taken from 
cells at passage 58 when based on gene expression over 100 (Fig. 3.7.3.2), however there 
did not seem to be a huge effect on the number of probe sets called P, M or A. This 
indicates the importance of taking the CM from cells at the same passage number in order 
to reduce any variation in the system.
It has been shown that RNA that undergoes a two- cycle amplification protocol has a 
slightly different profile than RNA that undergoes a one- cycle protocol (Wilson et al 
2004). The different profiles relate to the fold-changes observed. Certain groups of gene 
transcripts show higher/lower fold change compared to the unamplified samples. This is 
why when the CM data is compared to the cell line data; an expression cut-off of 100 is not 
applied to the DLKP cell data as it would only bias the data.
Fig 3.7.4.1 shows that when DLKP RNA cell data is plotted on a 3-D scatter plot the
amount of “noise” is greatly reduced compared to the CM samples, even at levels under
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When the number of probe sets called P or M in all DLKP cell RNA samples is compared 
to the number of probe sets called P or M in the DLKP CM samples, Fig 3.7.5.1 shows the 
number of gene transcripts called P or M common to both DLKP cells and CM is 7645. 
When only gene transcripts with an expression value of 100 or more in the CM data is 
included, Fig 3.7.6.1 shows that the number drops to 1492 indicating that the majority of 
gene transcripts commonly called P or M (between the cell and CM RNA), for DLKP CM 
has expression levels under 100. Out of the 1,492 probe sets called P or M in both the cell 
and CM DLKP samples, despite the majority of the CM probes sets having an expression 
<100, over 65% (1,432) of these probe sets have a P or M call assigned to them.
100 the correlation of the replicate data is much better.
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4.7.3 Ontology of gene expression in DLKP CM using Onto express 
software
Onto express software is part of an Onto-Tools suite of software which aids in the 
translation of lists of gene transcripts into a functional profile that offers insights into the 
cellular mechanisms. Profiles can be constructed for different gene ontology (GO) 
categories. The data generated comes from GenBank, UniGene, LocusLink and Pubmed.
A gene list was created of the 1,492 gene transcripts that were common to the DLKP CM 
and cell RNA samples (see Fig. 3.7.7.1) to assess the biological annotation for these 
transcripts. A large number of gene transcripts belong to a biological category containing 
less than 20 gene transcripts from the input list (“other” segment of pie chart Fig. 3.7.7.1). 
There are also a high number of gene transcripts on the list for which no biological 
annotation is known (“unknownP” segment of pie chart). The most highly represented 
biological process category is protein biosynthesis.
The molecular function of the same 1,492 gene transcripts belong to molecular function
categories containing less than 20 gene transcripts from the input list (Fig. 3.7.7.2). The
molecular function category represented on the input list is RNA binding, in fact 14 other
molecular function categories represented on the input list refer to binding functions.
Whilst the Onto-Express software aids in assigning biological and molecular function to the
list of probe sets, caution must be taken against placing too much value on the results
obtained for two reasons. The first reason is that gene transcripts often have more than one
molecular function assigned to it and also can be listed as involved in more than one
biological process, for this reason it is possible that one gene transcript is represented on the
pie chart more than once. This is confirmed when the number of genes in each category is
added up and the total number is higher than the number of gene transcripts on the input
list. The second reason caution must be taken when interpreting the data is that whilst the
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gene transcripts are either assigned as Present or expressed at significantly different levels 
by microarray analysis, this does not automatically mean that the gene is expressed at levels 
high enough to be biologically functional. In addition to this, because the Affymetrix probe 
sets only target the very 3’ end of gene transcripts, it is possible that some transcripts are 
degraded at the 5’ end and so are not translatable into protein.
Despite this however, the software is quite amenable to handling large lists of probe set 
numbers and converting them into pie charts that aid in understanding the underlying 
biology.
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4.8 Analysis of mRNA expressed by various cell line CM
4.8.1 cRNA yield throughout amplification procedure
The cRNA yield of the CM RNA after 2 rounds of amplification was 55.53 ± 26.5|ig when 
the RPMI 2 CM sample was excluded (because it did not amplify the minimum required 
amount of cRNA). This average is reduced to 53.3 ± 27.8ng if the RPMI 2 CM sample is 
included. The reason why the RPMI 2 CM sample did not yield enough cRNA for 
hybridisation (despite two attempts) is not clear. It is possible that the RNA in this sample 
was degraded as quantification by the Nanodrop would not have detected this, although 
RT-PCR for the 3’ region of P-actin was positive.
Although the Nanodrop may have overestimated the amount of RNA in the CM samples, 
the amount of cRNA generated after 2 rounds of linear amplification were in the range of 
quantities of cRNA generated by Schindler et al (2005) using ceil line RNA that was 
diluted to 50ng. In the study by Schindler et al (2005) they were able to generate between 
40.9 and 45.8fig of cRNA from 50ng of input RNA and for 14/24 of the CM samples in this 
study the amount of cRNA generated was higher than 46}ig. An average of 42.2^g ± 3.94 
of cRNA was also obtained by Li et al (2004) from an average of 60.5ng ± 13.12 ng of 
input RNA from cell free saliva samples of 10 healthy donors. This indicates that whilst the 
quantity of CM samples may have been over estimated, for over half of the samples, the 
yield after 2 rounds of linear amplification, was higher than achieved with 50ng of cell 
RNA/ 60ng of cell free saliva RNA which shows that the level of inaccuracy of the 
Nanodrop, for these samples, most likely was less than 40ng.
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4.8.2 Microarray QA results for CM samples
The background and noise levels for the CM samples in Section 3.8 were both within 
acceptable parameters with the exception of MDA-F-TAX-SI. The background in this 
sample was 113.2, as this fell out of the 3 fold range of most of the other samples it was 
excluded from further analysis (see Table 3.8.2.1). A high background implies that 
impurities like cell debris and salts are binding to the array in a non-specific manner.
The scaling factor for all of the CM samples in Section 3.8 were approximately twice the 
scaling factors of the DLKP CM samples assessed in Section 3.7 (Tables 3.8.2.1 and
3.7.2.1 respectively). The scaling factor is the multiplication factor applied to each signal 
value on an array and a scaling factor of 1.0 indicates that the average intensity is equal to 
the target intensity. The only guideline for assessing samples is that they must not differ by 
3 fold within an experiment.
Two other QA parameters differ from the results obtained with the DLKP samples; % 
Presence call and GAPDH ratios. The % Presence call in the DLKP samples were on 
average 23.1% (see Table 3.7.2.1), however in all of the other CM samples (with the 
exception of MDA-F-ADR-SI 1) the % Present call was 9.6 ± 2%. In addition to this the 
375’ and 37M GAPDH ratios were only attainable for some of the CM samples do to a 
large number of the middle target probes being assigned as Absent. The most likely cause 
of the lower % Present calls and missing GAPDH ratios was due to the time delay in 
processing the samples. The DLKP CM samples were processed (i.e. filtered and added to 
Tri Reagent) within 1 minute of removal from cells, whereas the time delay from filtering 
the CM samples in Section 3.8 until addition of Tri Reagent was up to twenty minutes. This 
may have lead to the degradation of the more unstable transcripts and thus result in a lower 
%Present call for these samples. It is possible also that the scaling factor is inversely
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correlated to the % Present call. For cell RNA samples hybridised to the Asymetrix Plus 
2.0 chips in our laboratory, typical % Present calls were between 35-50% with scaling 
factors close to 1, indicating that the higher the % Present call of the samples, the lower the 
scaling factor. As there are no published data on microarray analysis of CM RNA to date, 
there is nothing to compare the quality assessment measurement results to. Studies by Li et 
al (2004 (a)) detailing results obtained from microarray analysis of RNA extracted from 
cell-free saliva RNA reveal nothing about the scaling factors but do show % Present calls in 
the samples of 14.11± 2.98%.
In a study by Schindler et al (2005), a 50ng RNA sample that was subjected to two rounds 
of amplification, when compared to the standard single round of linear amplification of 
lO^ig of the same RNA, showed a reduction in % Present call from approximately 52% to 
43.7%. This reduction of % Present call was also correlated to increase with GAPDH and 
p-actin 375’ ratios. These observations were also found by Wilson et al (2004).
Schoor et al 2003 studied the effects of degradation on mRNA samples subjected to 
different amplification protocols; the standard protocol and the two round protocol (a 
precursor protocol to the 2 cycle protocol employed in this study). Both tumour and normal 
tissue samples were assessed and degradation of the RNA was carried out by incubating 
aliquots of powdered tissue in PBS at 22°C for different lengths of time. To stop 
degradation, Trizol was added. The results of the study were that moderate degradation of 
mRNA did not change the microarray gene expression profile results obtained. In addition 
to this, a higher scaling factor (2-10) was noted for the two most degraded samples and did 
result in a reduction of % Present call (although only 1 l^g  of cRNA was hybridised to the 
array chips for these samples).
The study carried out by Wilson et al (2004) compared the 2 cycle amplification protocol
using cell RNA diluted down to 100, 10 and lngs respectively, to the standard 1 cycle
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protocol. They too found a slight increase in the scaling factors of the data (up to 1.96) but 
not to the same extent as the CM samples presented in this study (see Table 3.8.2.1). This 
indicates that the high scaling factors obtained for the CM samples in this study reflect the 
origin of the RNA, and the magnitude of difference between the DLKP CM samples and 
the other CM samples reflects degradation of RNA within these samples due to the time 
delay in sample processing.
Whilst an obvious choice for repeating this work would include prompt processing of the 
CM samples with Tri Reagent to prevent degradation of the CM RNA, possibly more 
relevant would be a time- course study to look at what mRNA transcripts are degraded over 
time but more importantly, which ones remain stable.
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4.8.3 Expression of Two-Cycle Hybridisation and Labelling Controls
There are two internal controls supplied with the Asymetrix RNA amplification kits. The 
Poly-A control kit is designed to assess the efficiency of the amplification process and the 
hybridisation kit assesses the hybridisation part of the process.
The Poly-A controls are B. subtilis genes that have been modified by the addition of poly-A 
tails. These modified genes are then amplified by being cloned into vectors that contain T3 
promoters. Amplification of the Poly-A controls with T3 RNA polymerase yields sense 
RNAs that are spiked into the RNA sample of interest before amplification. The Poly-A 
controls are pre-mixed at different concentrations. Affymetrix have probe sets that target 
the 5’, middle and 3’ region of the Poly-A controls. The results shown in Fig. 3.8.3.2 show 
that for the CM samples, expression of the 3’ region of the Poly-A controls was higher than 
expression of the middle or 5’ region in all samples assessed. Comparison of these results 
to results obtained from our laboratory with cell RNA that did not undergo the 2 cycle 
protocol indicate a distinct 3’ bias in samples generated using the 2 cycle protocol. The 
profiles obtained for cell RNA that did not require the 2 cycle protocol showed 37M or 
375’ ratios much closer to 1:1 in comparison to the CM Poly-A controls where the ratios 
were as high as 8:1 with the thr Poly-A control.
This 3’ bias effect has also been noted by other users of the 2 cycle amplification protocol 
(Schoor et al 2003, Wilson et al, 2004 and Schindler et al 2005). Since Affymetrix target 
their probes to the most 3’ 600 bases of the mRNA transcripts, however, the 3’ bias 
introduced by the 2 cycle protocol should not affect the microarray data obtained. This was 
confirmed by Schindler et al (2003), whilst use of the 2 cycle protocol affected the 375’ 
ratios for p-actin and GAPDH, they found no reduction in the % Present call between the 
samples generated with either the standard labelling protocol or the 2 cycle protocol.
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The result shown in Fig. 3.8.3.3 indicates that the ratio of expression of the Poly-A controls 
did not reflect the ratio of the Poly-A RNA in the original stock solution. However, analysis 
of microarray data generated in our laboratory using cell RNA yielded similar results. This 
indicates that the most likely cause for discrepancies in the expression ratios detected was 
different hybridisation efficiencies for the different probe sets i.e. some probe sets have a 
greater affinity for their target than others and in these cases the expression values 
generated are higher. This also should not affect downstream analysis of the microarray 
data as the probe set, although displaying a higher affinity for the target sequence, will 
display this higher affinity across all samples tested.
The second controls included with the Affymetrix amplification kit are the hybridisation 
controls. These are gene transcripts from the biotin synthesis pathway of E.Coli and from 
the recombinase gene of bacteriophage P l. These control sequences are added to the 
amplified cRNA samples before hybridisation and are used to assess the efficiency of the 
hybridisation and washing steps of the procedure. The results in Fig. 3.8.3.1 show that these 
transcripts were detected in the right order and at ratios of approximately 1:1 indicating that 
the hybridisation and washing steps were without incidence.
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4.8.4 Scatter plots and Venn diagrams of CM samples
The scatter plots and Venn diagrams in Section 3.8.4 serve to function as visual aids to
interpret the large amount of microarray data generated more easily. The colour of the dots 
on the scatter plots correlate to the grouping of the probe sets on the adjoining Venn 
diagram e.g. probe sets that are common to all samples tested regardless of criteria are 
coloured white on the scatter plot and correspond to the probe sets listed in the centre of the 
three ringed Venn diagram (in cases where 2 replicate samples are available they are 
coloured yellow).
For all eight of the cell line CM samples tested, the overlap of gene transcripts common to 
the replicate samples is significantly higher when only gene transcripts with an expression 
value over 100 are included. In general, the percentage of gene transcripts commonly called 
Present or Marginal to the replicate samples was 16% or less (were there were only two 
replicate samples in the cases of RPMI and MDA-F-TAX-SI this percentage was higher at 
20-25%). However this percentage correlation of replicate samples rose to 60-70% for the 
CM samples when only probe sets with expression values over 100 were included with 2 
exceptions. In the MDA-F and MDA-F-ADR-SI CM sample groups this percentage 
correlation was 55 and 45% respectively. This drop in correlation for these samples was a 
direct result of one replicate in each group displaying either a higher % Present call or a 
high background QA parameter. This result shows that for the CM samples, there is a high 
level of “noisy” gene transcripts with expression levels under 100 i.e. the expression data at 
that level is highly variable. Schindler et al (2005) noticed a two-fold increase in 
discordance of calls assigned to probe sets when a 2 cycle amplification protocol was used 
in comparison to a standard one cycle protocol resulting in non-detection of low-abundant 
RNA with the 2 cycle protocol. This may indicate that some of the discordance in the calls
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assigned to the CM samples is attributable to the 2 cycle protocol.
4.8.5 Condition tree and hierarchical clustering of CM samples
The “Condition Tree” option in Genespring software enables similar samples/ conditions to 
be grouped together based on similar expression profiles. Fig. 3.8.6.1 shows the results 
obtained for the condition tree of the CM samples using Genespring. Three CM sample 
groups, H I299 TAX, RPMI ML and RPMI TAX are grouped beside each other. For two 
other sample groups, H I299 and MDA-F, at least two of the three replicate samples are 
grouped beside each other. A Pearson correlation was used to assess how similar the 
samples are to each other.
In dChip, a Pearson correlation can also be selected, however, some steps can be taken to 
filter out non-essential data before performing hierarchical clustering. To do this any gene 
transcripts that were not changing across the samples were removed. A second step was 
included that was not performed on the data before the condition tree analysis was carried 
out in Genespring. As gene expression data can be quite varied i.e. expression can go from 
0- 60,000 expression units, a row-wise standardisation step was carried out on the data. The 
standardisation step involves linearly scaling the data for a gene transcript across all 
samples to have a mean 0 and a standard deviation of 1. It is these standardised values that 
are used to calculate correlations between samples. This enables all data to be viewed so 
that the range of expression is pre-definable, e.g. the default range is -3 to +3.
The dChip software was able to group the samples better (Fig3.8.6.2). Only one sample, 
MDA-F 1 was really out of place. A look at the Affymetrix quality control measures 
assessed for the CM samples (and listed in Table 3.8.2.1) indicates that the reason for this 
may be due to the fact that the MDA-F 1 sample had the second highest background levels
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resulting in a lower % Present call for that sample. This may have influenced how the 
samples were grouped. For this analysis dChip was found to be better at clustering the 
samples. This result indicated that based on gene expression profiles alone, different CM 
samples were distinguishable from each other.
4.8.6 Validation of Microarray data (1)
The first parameter that we decided to attempt to validate was the Presence/ Absence call 
assigned to different probe sets. This was carried out for three transcripts. The first, P-actin, 
has probe sets on the microarray that detect the 57 middle and 3’ regions of the mRNA 
transcript. Generally, with the exception of two samples, the 5’ and middle target probes 
were assigned as Absent in all of the CM samples. The 3’ region was assigned as Present in 
all of the samples tested. The results in Figs. 3.8.7.2.1-3, show that whilst detection of P- 
actin gene transcripts corresponding to the 5’ UTR region of the p-actin mRNA was only 
possible in 6-14/ 23 CM samples, PCR products were amplifiable in all original 
unamplified CM RNA samples targeted by 5’ coding- and 3’ region specific primers.
The results obtained with the Poly-A control RNA (results Section 3.8.3 and discussion
4.9.3) indicated the possibility that the 3’ bias of the 2 cycle protocol was the reason that 
only 3’ regions of the P-actin gene transcript were detected by microarray. To investigate 
this further, two other gene transcripts, stearoyl-CoA desaturase 5 and APAF1 interacting 
protein were chosen for validation of the call assigned in the microarray analysis by RT- 
PCR. Stearoyl-CoA desaturase 5 was assigned as Present in all CM samples and APAF1 
mRNA was assigned as Absent in all samples by microarray.
The results shown in Figs. 3.8.7.3.1/2 indicate that for both samples, after 45 cycles of 
PCR, mRNA transcripts were detected in all CM samples. So whilst the discordance of RT-
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PCR and microarray results for P-actin mRNA could be explained by the 3’ bias of the 2 
cycle protocol, this bias would not have affected the detection of APAF1 interacting protein 
mRNA. It is generally thought that RT-PCR is a more sensitive technique than microarray. 
Presence of only a few mRNA transcripts is sometimes enough for a positive RT-PCR 
result, whereas microarrays depend on the hybridisation of these targets at a single 
temperature and with stringent washing steps to avoid non-specific binding for all targets. 
This may result in loss of signal for low abundant gene transcripts.
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4.8.7 Gene transcripts significantly up/ down-regulated between parental 
and drug selected variant CM
Treatment of cancer using chemotherapeutic drugs is frequently hindered by the 
development of resistance of tumour cells to the anticancer agents, often associated with the 
emergence of multidrug resistance (MDR) (Liang et al 2001). For this reason, the gene 
expression profiles of the parental CM samples compared to the drug selected variants were 
evaluated for candidate gene transcripts that may be indicative of drug resistance.
In Section 3.8.8, lists were generated using dChip of gene transcripts that were found to be 
significantly changed in the parental CM samples in comparison to the drug selected 
variant CM samples. A gene was determined to be significantly changed if it had a p-value 
of significance less than 0.05, a fold change greater than 1.2 and a difference in expression 
greater than 50 fluorescence units.
Of the five parental vs. drug selected CM comparisons, the three parental CM samples, 
when compared to their taxol selected variants showed more down-regulated gene 
transcripts in the taxol selected CM samples than for example, when RPMI was compared 
to its Melphalan selected variant. This was most notable for the MDA-F CM groups. When 
MDA-F was compared to MDA-F-TAX-SI, 80% of the significantly changed gene 
transcripts were down-regulated in the MDA-F-TAX-SI CM samples. Comparison of 
MDA-F-CM samples to MDA-F-ADR-SI CM samples indicated that 90% of the gene 
transcripts found to be significantly changed were up-regulated in the MDA-F-ADR-SI 
CM.
Attempts were made to find a gene that may be indicative of taxol resistance detectable in
the CM of all three samples. Table 3.8.8.6 shows that when the three parental CM samples
are grouped together and compared to the grouping of the taxol-selected CM samples, 34
gene transcripts were determined to be significantly changed (76% of which were down-
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regulated). However when the same 34 gene transcripts were analysed in the individual 
parental vs. taxol selected variant CM samples (Table 3.8.8.7) none of the 34 gene 
transcripts were found to be significantly changed in all three of the individual groupings. 
With the exception of 6 targets however, (five of them in the MDA-F vs. MDA-F-TAX-SI 
group) all gene transcripts displayed the same trend in change of expression. It is possible 
also that a combination of transcripts, whilst not individually significant, together may 
yield a biomarker group that would correlate to emergence of drug resistance in these cells. 
The results in Section 3.8.8 confirm the results in Section 3.4 that different gene transcripts 
are found in the CM of cancer cells. If this process was a general “dumping” mechanism/ or 
a mechanism unrelated to the cells themselves, the types of gene transcripts detected would 
be similar and the number of gene transcripts significantly differentially expressed would 
be quite small.
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4.8.8 Validation of Microarray data (2)
In order to choose gene transcripts for validation of differential expression of gene 
transcripts in parental vs. drug selected variant CM samples by RT-PCR, strict criteria were 
followed. The first was obviously that the gene transcripts were assigned as significantly 
changed (as determined by a p-value <0.05) between the two groups and the second was 
that a difference in expression of 100 fluorescent units was required. This was to reduce 
selection of gene transcripts that were expressed at levels under 100 in both samples (as 
these were shown previously to be quite variable in replicate samples (see discussion in 
Section 4.9.4)). The third criterion was that the gene transcripts needed to show a fold 
change between the groups greater than 1.2.
88 gene transcripts differentially expressed in some of the parental and drug selected 
variant CM samples passed this criterion. Of the 88 gene transcripts, only 41 of the probe 
sets corresponding to these gene transcripts were “_at” probe sets meaning they uniquely 
identified one gene transcript. From this list only transcripts with a grade A annotation (see 
Section 2.13.5) were included. All remaining sequences were examined using BLAT (see 
Section 2.11.1) to ensure exon-exon boundaries were identifiable so that mRNA specific 
primers could be designed.
From this shortened list, 10 gene transcripts were chosen for validation by RT-PCR. The 
gene transcripts chosen displayed a range of fold changes between sample groups of 1.37- 
5.6. Presence or Absence of the gene transcripts in the different samples did not influence 
the choice of gene as the results discussed in Section 4.9.7 indicated that these were not 
reliable. Interestingly, one of the gene transcripts chosen for validation by RT-PCR was 
APAF1, which was assessed in the study discussed in Section 4.9.7. Despite being assigned 
as Absent in all CM samples, it was determined to be significantly changed in both RPMI
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ML and RPMI TAX CM samples compared to the parental RPMI sample.
The results shown in Figs. 3.8.11.1-20 with corresponding expression data in Tables in 
3.8.11.1-10 show that validation of the microarray results was possible for 50% of the gene 
transcripts tested.
This correlation may seem slightly disappointing at first glance, however the pool of 
candidate gene transcripts was quite small and they were not chosen for any biological 
reason i.e. not based on background literature searches or pathway analysis software. In fact 
only 4 of the 10 gene transcripts chosen for the validation study were annotated for gene 
function. A closer look at the exact differences between the gene transcripts that were 
validated and those that were not reveals a distinct pattern.
Table 3.8.11.11 summarises the different attributes for the gene transcripts assessed by RT- 
PCR for confirmation of the microarray results. For 4 of the 5 transcripts that confirmed 
results obtained by microarray, the mRNA region targeted were close to or the same as that 
targeted by the Affymetrix probe. In comparison only 2/5 of the invalidated gene transcripts 
utilised primers that targeted the Affymetrix targeted region.
For 3 of the 4 gene transcripts, (in which primers that amplified the same region targeted by
Affymetrix were used and RT-PCR correlated with microarray data), gene function was
annotated. In comparison only 1 of the 5 transcripts not validated by RT-PCR were
annotated for gene function. And finally, although the results discussed in Section 4.9.7
indicated that Presence or Absence call assigned to a gene could not be validated by RT-
PCR, the results summarised in Table 3.8.11.11 indicate a correlation of Presence call of
transcripts studied to validation of the microarray result. 3/5 of the gene transcripts
validated by RT-PCR displayed a majority Present call amongst the samples tested in
comparison to 0/5 of the transcripts that we were unable to validate.
All of these results together indicate that the criteria employed to select gene transcripts for
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confirmation by RT-PCR was flawed. Despite the gene transcripts being statistically the 
best candidates, more weight should have been given to the Presence/ Absence call of the 
probe sets for the gene transcripts and also only gene transcripts with well described 
annotation should have been chosen. Although, as neither microarray nor confirmatory RT- 
PCR studies have been previously carried out on RNA extracted from CM samples, it is 
quite important that these criteria have been noted at this early stage. Whilst “blind” 
selection of gene transcripts for confirmatory RT-PCR resulted in less than desirable 
validation results, the information obtained, which will aid in selection of candidate gene 
transcripts in future, is invaluable.
Analysis of the limited published data on microarray studies of cell-free RNA (of which 
there are three, originating from the same lab) also show discrepancies with validation of 
the microarray results by RT-PCR methods. Two of the three publications refer to 
validation of changes found in RNA extracted from the saliva/ serum of oral cancer patients 
in comparison to healthy volunteers. In the first with saliva RNA (Li et al 2004 (b)), 7/9 of 
the gene transcripts selected were validated by quantitative RT-PCR and in the second 
more recent study concerning serum RNA only 5/10 gene transcripts selected for validation 
based on their reported cancer association were confirmed by quantitative RT-PCR to be 
significantly elevated in the oral cancer specimens (Li et al 2006). It is interesting to note 
that these discrepancies were found despite strict criteria employed for choosing gene 
transcripts to validate. These criteria were that all samples must have a Present call for the 
gene of interest and in the first study (Li et al 2004(b)) a fold change greater than 3 with a 
p-value less than 0.01 and in the second study a fold change greater than 2 with a p-value of 
significance less than 0.05.
Discrepancies relating to validation of microarray results however, are not confined to the
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limited studies on extracellular RNA or, indeed, to microarray data generated using RNA 
amplified with the 2 cycle protocol. Dallas et al (2005) tested expression levels for 48 gene 
transcripts found by microarray to be differentially expressed between their tissues of 
interest e.g. brain tumour vs. normal. The authors calculated the degree of correlation 
between the microarray expression scores and expression levels measured for the same 
gene transcripts using qPCR. The microarray data generated was normalised by MAS 5.0 
and also separately by RMA. MAS 5.0 algorithm uses a scalar normalisation technique 
taking into account perfect match (PM) and mismatch (MM) probe pairs to correct for non­
specific hybridisation and RMA is based on a quantile normalisation approach that ignores 
the MM values.
They noted that for gene transcripts in which the PCR primers don’t recognise the same 
subset of transcripts identified by the Affymetrix probe sets correlation of results was only 
41% (7/17 gene transcripts) with both sets of normalised data. Of the remaining 31 gene 
transcripts for which the microarray probe sets were deemed to recognise the exact same 
transcript/ subset of transcripts as the qPCR probes 26/31 were validated for MAS 5.0 
normalised data and 27/31 were validated for RMA normalised data. This gave an overall 
non-concordance rate of 13-16%.
A review paper by Draghici et al (2005) indicated that results from the Microarray Quality
Control Project, a project initiated and led by FDA researchers, shows that above their
sensitivity threshold (of between one and ten copies of mRNA per cell), microarray
measurements accurately reflect the existence and direction of expression changes in ~70-
90% of the gene transcripts. The magnitude of the changes measured with technologies
such as RT-PCR however tend to be different to the microarray data.
Etienne et al (2004) found that RT-PCR data correlated well with microarray data for gene
transcripts with moderate levels of expression that have PCR primers located to the
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microarray target region. The authors analysed 26 gene transcripts that had previously been 
found in their laboratory by RT-PCR to be of interest to their particular study. They 
concluded that gene transcripts with very high or low levels of expression, or those with 
larger separation between the location of the PCR primers and microarray target region, 
often displayed reduced agreement between the two methods. Etienne et al (2004) also 
noted that the region targeted by the Affymetrix probes were mainly in the 3’UTR region of 
the gene transcripts (only 3/26 were outside of this region).
Whilst carrying out RT-PCR using primers that target the same region as the Affymetrix 
probes may increase the chances that the results from the two techniques will correlate, 
consideration must be placed on the question being asked. By only targeting the region of 
the mRNA transcript targeted by Affymetrix probes (i.e. within last 600 bases of 3’UTR 
region), the question of whether the mRNA is full length and in a position to be translated, 
remains unanswered. If presence of the 3’ region of the transcript alone however, can be 
correlated to prognostic status, e.g. presence is correlated with overall survival, then 
information about the ability of the mRNA to be translated into protein is not necessary.
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4.8.8.1 No Reverse Transcription Controls
The results in Section 3.8,11.1 highlight the importance of including proper and M l 
controls for every experiment. Despite careful design, the RT-PCR primers chosen for the 
microarray validation work were able to amplify a PCR product when no reverse- 
transcription step was carried out. It is possible that the low annealing temperature (54°C) 
and position of exon-exon junction in primer sequence (i.e. with enough of the mRNA- 
specific primer annealing to DNA to enable amplification of PCR product in the presence 
of DNA) contributed to the amplification of a PCR product in the absence of a reverse 
transcription step. Another likely reason for amplification of a PCR product is the presence 
of pseudogenes. A lot of the transcripts chosen for validation were poorly annotated so the 
presence /sequence of psuedogenes are unlikely to be known.
There are a few options for solving this problem, the first would be to treat all RNA 
solutions with RNase-free DNase. However this has proven problematic in our laboratory 
on previous occasions, degradation of RNA has occurred. A second solution is to design 
primers that anneal to both RNA and DNA but have an intron between them. This would 
mean that DNA would effectively be distinguishable from RNA as the RNA would not 
contain the intron sequence and so would be much shorter. This solution would also help to 
identify whether intron-less pseudogenes are present. Any amplification of a PCR product 
the same size as the RNA product in a sample that is either; reverse transcribed without 
reverse transcription enzyme or does not undergo a reverse transcription step would 
identify the presence of a pseudogene.
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4.8.9 Gene Ontology of probe sets called Present in all CM samples or 
significantly differentially expressed between parent and drug 
selected variants
The gene transcripts found to be called Present in all CM samples or significantly 
differentially expressed in parent CM samples compared to their drug selected variants 
were submitted to Netaffx for assessment of their gene ontology (GO). Netaffx was used in 
this analysis instead of Onto-Express (that was used for GO analysis of the DLKP CM 
samples see Section 3.7.7) because there a fixed number of parent categories e.g. binding, 
catalytic activity etc. This meant that a quick visual comparison could be made of the 
overall gene ontology of the gene transcripts in each list. The annotations, as with Onto- 
Express are derived from public databases such as UniGene, LocusLink and Homologene. 
Fig 3.8.5.1 indicates that the majority of gene transcripts called Present in all CM samples 
are un-annotated, with binding as the largest represented molecular function group. 
Comparison of the pie chart in Fig. 3.8.5.1 with the pie chart in Fig. 3.8.9.1 shows that 
binding is also the largest represented molecular function group assigned to the gene 
transcripts that were significantly differentially expressed between the parent and drug 
selected variant groups.
The gene ontology categories of the transcripts significantly differentially expressed 
between parent and drug selected variant groups however; do not follow the same pattern as 
the gene transcripts called Present in all CM samples. A smaller percentage of the gene 
transcripts differentially regulated between the parent and drug selected variant groups 
relate to structural molecule activity and larger percentage relate to transcription regulator 
activity and signal transducer activity.
As mentioned before elsewhere, looking at the molecular function of gene transcripts
detected by microarray relies on the assumption that the transcripts are full length and
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available for translation, however this analysis does enable us to see the differences in the 
two lists as determined by the biological function of the gene transcripts on those lists.
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4.8.10 Analysis of CM mRNA expression profiles against cell mRNA 
expression profiles
The gene expression profiles of the CM RNA samples were compared to the cell RNA 
profiles to assess the amount of overlap between the two samples. The aim was to see if (1) 
gene transcripts called P/ A/ M in the CM samples were equally called P/A/M in the cell 
RNA samples and (2) to assess how many (if any) gene transcripts found to be significantly 
up-/ down-regulated in the CM parental vs. drug selected variants were similarly up-/ 
down-regulated in the cell RNA samples. It is important to note that the RNA used in the 
microarray study of the cell RNA was generated using the standard one cycle protocol 
compared to the CM RNA which was processed using the two cycle protocol.
4.8.10.1 Probe sets called P or M in both CM and cell mRNA profiles
The Results shown in Section 3.8.12 show the overlap of gene transcripts called P or M in 
all three CM samples compared to the gene transcripts called P or M in all three 
corresponding cell RNA samples. Table 3.8.12.1 summarises all the results for Section 
3.8.12. Looking at the results listed in Table 3.8.12.1, it is clear that based on Present/ 
Absent or Marginal call alone, there is a poor correlation between the gene expression 
profiles for the CM and cell samples. The results would seem to suggest that as many as 
35-51% of gene transcripts present in the CM samples were not present in the 
corresponding cell RNA samples.
Schindler et al (2005) found that when the same cell RNA was processed using the 
standard one cycle protocol or diluted and processed using a two-cycle protocol that the 
concordance of P/A calls assigned to probe sets between the two methods was reduced. Up 
to 10% of probe sets that were called Present in the data obtained with RNA processed with 
the one cycle were called Absent in the data generated from the same RNA that had been
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diluted and subjected to the 2 cycle amplification protocol. A further 1-2% of probe sets 
went from Absent to Present in the data generated from RNA using the 2 cycle 
amplification protocol.
The overlap between the CM data and corresponding cell data drops further (40-51%) if the 
probe sets with an expression value over 100 in the 3 replicate CM samples are overlapped 
with the probes sets called Present in the 3 replicated cell RNA samples are included. This 
was carried out because the results shown in Section 3.8.4 indicated that for all the CM 
samples, gene transcripts that were expressed at levels under 100 were quite variable 
between the replicate samples. If the replicate samples were overlapped based on the probe 
sets expressed at values over 100 the correlation between the replicate CM samples 
increased from an average of 16% (based on Present or Marginal call) to an average of 65% 
when only the probe sets with an expression value over 100 were included.
The results in Section 3.8.4 indicated that a number of the probe sets with an expression 
value over 100 in the three replicate samples were also called Absent. For an example see 
Fig 3.8.4.2, white dots on scatter plot represent probe sets expressed at levels over 100, and 
compare to Fig. 3.8.4.1, where a number of the probe sets that were coloured white in Fig
3.8.4.2 indicating a high expression value, are coloured grey in Fig. 3.8.4.1, indicating that 
despite having a high expression value an Absent call was assigned to that probe set. For 
this reason, the third test was to compare the overlap of probe sets called Present in all three 
cell RNA samples to the probe sets called Present and with an expression value over 100 in 
all three CM samples. This was to filter out any noisy gene transcripts (i.e. those with an 
expression value under 100) and also to filter out any gene transcripts not called Present. 
The results are also summarised in Table 3.8.12.1. The percentage of gene transcripts 
overlapping in the cell and CM, when this filter is applied increases from 40-51% up to 62- 
84%.
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A final comparison of the probe sets called P with an expression value over 100 in all 
replicate samples for a CM group were overlapped with the probe sets called A in all 
replicate samples for the corresponding cell RNA group. This reduced the discordant 
number of probe sets to an average of 8% for all of the CM and cell groups.
4.8.10.2 Probe sets significantly changed in both CM groups and cell groups
The gene transcripts deemed to be significantly changed in both CM and cell were 
compared to see if the trend of up-/ down-regulation in the parental group compared to the 
drug selected variant group was the same regardless of the origin of the RNA i.e. CM or 
cell derived.
Schindler et al (2005) found that in the comparison of microarray gene expression profiles 
of RNA that was processed with two different amplification protocols (one cycle and two 
cycle), that not only was there variation in the call assigned to the probe sets but also in the 
signal intensities and fold changes. The difference in expression of probe sets between the 
two protocols was 17.3% of probe sets increased (5.8% of which increased by 2 fold) and 
20.9% decreased (of which 8.5% were decreased by 2 fold). For this reason a p-value <0.05 
was the only criteria used for selection of probes sets significantly changed.
The results shown in Section 3.8.13 indicate that for all the parental and drug selected 
variant groups tested, (with the exception of MDA-F vs. MDA-F-TAX) there was a mixture 
of gene transcripts up-regulated and down-regulated in both CM and cell RNA along with a 
number of gene transcripts that were differentially regulated in both.
The gene transcripts that were significantly differentially expressed between the parental 
and drug selected variant CM samples that had a p-value <0.05 with a fold change> 1.2 and 
a difference in expression over 50 are highlighted in bold in Tables 3.8.13.1- 3.8.13.5.
334
Analysis of these gene transcripts (which were filtered to exclude some of the gene 
transcripts that may lie in the “noisy” range of expression in the CM samples- i.e. 
expression under 100), the correlation of change in expression between the parental and 
drug selected variants does not increase. This may indicate that gene transcripts are 
differentially expressed in the two samples as part of a cell specific process. For example, if 
as a result of selection with a chemotherapeutic drug a cell secretes more of a particular 
transcript than it retains for translation in the cell, there would be an increase in the amount 
of that transcript detected in the CM RNA and a decrease in the amount detected in the cell 
RNA. This is however only a theory and confirmation of such could only be obtained if the 
RNA samples were both processed with the one amplification protocol i.e. one or two 
cycle.
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4.8.10.3 MICROARRRAY ANALYSIS HMEC CM AND CELLS
One of the end goals of the work presented in this thesis is to identify gene transcripts for 
further analysis as potential cancer-specific biomarkers. In Section 3.8 gene transcripts that 
were differentially expressed between different cancer cell line CM samples were 
identified. Unfortunately no single transcripts were detected in the CM samples that would 
identify with resistance of that cell line to a chemotherapeutic drug (see Section 3.8.8, 
Tables 3.8.8.6 and 3.8.8.7).
To assess the possibility that we may be able to detect a transcript in CM that is a cancer- 
specific marker, we set up a pilot study to culture normal cells. We used HMEC 1001-10 
breast mammary cells (HMEC). Unfortunately biological replicates were not available for 
this sample. As only one 25cm2 flask was available and the cells are only viable for 
approximately 15 days, there was not enough time/ cells to split the flask and passage 3 
times to obtain biological replicate samples.
As the CM from normal cells had not been tested previously by us to ensure that mRNA 
transcripts were detectable from the CM, RT-PCR was firstly carried out on a few 
transcripts to see if it was possible. Fig. 3.9.1.1 indicates that p-actin primers that target the 
5’UTR region of the gene transcript were able to amplify gene transcripts (although the 
band is quite faint). The PCR results in Figs. 3.9.1.2 and 3.9.1.3 show that other gene 
transcripts were also detectable.
We then proceeded to amplify lOOng of HMEC CM and cell RNA as quantified by the 
Nanodrop using the 2 cycle amplification protocol (see Section 2.12). Table 3.9.2.1 shows 
that there was more cRNA amplified in the cell RNA sample compared to the CM sample 
(97.65|ag compared to 21.12^ig).
The details of the QA results of the chips indicate that the two samples cannot be
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normalised together as the scaling factors are so different. The scaling factor for the HMEC 
CM sample, although high, is comparable to the scaling factors obtained for the cancer cell 
line CM samples (see Table 3.8.2.1). The CM sample used for this pilot study was 
processed promptly and added to Tri Reagent post filtration within 1 minute. This means 
that the low % Present call for the HMEC CM sample cannot be attributed to any time 
delay in sample processing. The most likely explanation is that there are more gene 
transcripts assigned as Present in the cancer cell CM than in the HMEC CM.
The three regions of (3-actin targeted by Affymetrix probe sets were assigned as present in 
both samples. This is also a reflection of the promtness by which the samples were 
processed. As with the DLKP CM samples, also processed promptly, P-actin was called P 
at the 3’ target regions. With the CM samples analysed in Section 3.8, only the 3’ target 
region was called P. A possible reason is that p-actin is not stable in CM and most likely is 
constantly secreted into the CM and mostly degraded (within 15 minutes). With the 
exception of the GAPDH middle region in the CM sample, the three target regions were 
also assigned as Present in both samples.
As both samples were amplified using the same protocol it was hoped that the concordance
of probe sets called Present in the CM sample would overlap better with the cell RNA than
previously for the CM and cell RNA samples (see Table 3.8.12.1 for summary of results for
cancer cell line CM and cell RNA samples). The average percentage overlap for the probe
sets called Present or Marginal in the cancer cell line RNA with its corresponding CM
RNA was 16% (although the probe sets had to be called P or M in all of the replicate
samples for each). The percentage overlap of probe sets called P or M in the HMEC CM
and cell RNA samples was 67% (see Fig. 3.9.4.1). If an additional cut-off of expression
over 100 is applied to the CM sample, the percentage of gene transcripts common to both
the CM and cell RNA samples rises to 80%. If the same additional cut-off is applied to the
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HMEC cell RNA (i.e. expression over 100) and compared to the HMEC CM RNA the 
percentage probe sets overlapping between the cell and CM RNA samples decreases to 
24%. A criterion of a Present call and expression over 100 in both samples reduces the 
number of probe sets common to both down to just 3%.
This indicates that whilst comparison of samples using the two different amplification 
protocols itself introduces discrepancies between the probe sets called Present, Marginal or 
Absent (as in Schindler et al 2005), in the samples studied during this work, a high 
proportion of the non-concordance is also attributable to the different origins of the RNA
i.e. CM vs cell.
The comparison of probe sets that were called Absent in the HMEC compared to the probe 
sets called present in all of the CM samples studied in this thesis (Section 3.7 and 3.8) 
yielded a list of 23 gene transcripts called Present in all 26 CM samples and Absent in the 
HMEC sample. Table 3.9.5.1 shows that most of the gene transcripts are un-annotated.
A second comparison was then generated comparing the gene transcripts expressed in the 
26 CM samples compared to the HMEC CM sample. As there were no replicate HMEC 
samples available statistical significance could not be assigned to the results so a stricter 
criteria of fold change and difference in expression was employed; fold change >2 and 
difference in expression >100. The 143 gene transcripts that resulted from this comparison 
are shown in Table 3.9.5.2. The majority of the transcripts were found to be up-regulated in 
the cancer cell line CM samples compared to the normal cell CM sample (88 up-regulated 
and 55 down-regulated in cancer cell line CM compare to the HMEC CM.
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4.8.11 Microarray analysis of Breast cancer serum specimens
4.8.11.1 Analysis of QA Parameters, Expression of 2-Cycle Controls and 
Housekeeping Gene transcripts for Breast Cancer Specimens
The QA results listed in Table 3.10.1.1 show large differences in the serum and tissue 
samples in regard to the scaling factor, % Present call and GAPDH ratios. The choice of 
using 2^1 of RNA extracted from 1ml of serum for all serum specimens resulted in a 
decrease of the standard deviation for amplification of the samples. An average of 86 ± 
17.17jxg of cRNA was generated using this volume of RNA solution. The respective yields 
of prostate and lung cancer serum specimens generated in our laboratory using lOOng of 
RNA as determined by the Nanodrop, were 59.26± 30.7^g and 41.7± 24|ig. This indicates 
that the choice to amplify volume amounts over quantified amounts helped decrease the 
standard deviation of the cRNA generated.
The GAPDH ratios for all tissues except the normal tissue from patient 14 were acceptable. 
With the tissue from patient 14, the larger GAPDH ratios correlated with a decrease in % 
Presence call and an increase in the scaling factor compared to the other samples (see Table 
3.10.1.1).
Results shown in Section 3.10.2.1 show that the hybridisation controls indicated that the 
hybridisation and washing steps were without incidence. In Section 3.10.1.2 however there 
seems to be some discrepancies for the amplification of the Poly-A controls, this may have 
been due to the quality and quantity of the endogenous RNA content of the samples. For 
example, the two tissues with the lowest % Present call and highest scaling factors belong 
to the tissue samples corresponding to patient 14. The % Present calls were 43.5 and 38.7 
% and the scaling factors 23. and 2.74 in the normal and tumour tissues respectively. These 
two tissue samples, as shown in Fig. 3.10.1.2, show higher levels of expression of the 3’
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region of the dap spike in control. This may indicate that the lower quality of RNA in these 
samples resulted in higher amplification of the Poly- A controls. Another possible 
explanation is that it is a patient specific phenomena, the expression levels of the dap 3’ 
target region in all samples corresponding to this patient are all expressed at high levels. 
Lower expression of this Poly-A control target region in the serum specimens 1 IPre, 7Post 
and FN2 did not correlate with a reduction in % Present call for all of the samples. Reasons 
for the non correlation o f the detected expression of the Poly-A controls compared to their 
original concentration before amplification have been discussed already in Section 4.9.3. 
The results showing the expression of the housekeeping gene transcripts p-actin and 
GAPDH are shown in Figs. 3.10.2.1 and 3.10.2.2 and Tables 3.10.2.1 and 3.10.2.2. There 
was low expression detected for the three target regions of both transcripts in all of the 
serum specimens. Whilst expression of GAPDH and P-actin were much higher in the tissue 
samples there was a distinct difference in the expression of the 3’ region of p-actin to the 5’ 
and middle regions (ratio of approximately 5:1).
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4.8.11.2 Condition Tree and Hierarchical Clustering of Breast Clinical Samples
The results of the condition tree and hierarchical clustering o f the breast clinical samples 
shown in section 3.10.4 indicates that the results generated using dChip were better at 
distinguishing the samples from each other (as was the case for the CM samples, see 
Section 4.8.5 for discussion). Both types of software distinguished that the tissue samples 
were different to the serum samples (see Figs. 3.10.4.1 and 3.10.4.2). This was most likely 
as a result of the large differences in % Present call between the tissue and serum samples 
(-45% in the tissue specimens compared to -8.3% in the serum specimens) rather than the 
result of any specific gene expression profile patterns.
When the serum samples were analysed on their own, so that the gene expression data 
relating to the tissue samples didn’t influence the clustering, a better separation of the 
serum samples was achieved. Fig 3.10.4.3 shows the results of this clustering. The serum 
specimens are divided into two groups, in one there are 3 Pre serum specimen samples and 
2 Normal specimen samples and the other group contains all 4 Post serum specimens along 
with 4 Normal serum specimens and 1 Pre serum specimen. This indicates the possibility, 
that with a larger sample number, a distinct gene expression profile for Pre-op/ Post-op/ 
normal serum specimens may be possible.
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4.8.11.3 Probe sets called P or M in different serum groups \
Analysis of the overlap of probe sets called Present or Marginal in the pre- operative (Pre) 
serum specimens compared to the probe sets called Absent in the post- operative (Post) 
serum specimens shown in Fig. 3.10.5.1 indicate that there are 51 probe sets called P or M 
in the Pre serum sample and A in the Post serum sample. However, closer inspection of the 
expression values for these probe sets (see Table 3.10.5.1) reveal that the expression 
difference between the Pre and the Post samples is very small (if indeed there is any 
difference at all). This is also reflected in the 6 probe sets that are called P or M in the Pre 
serum and A in both the Post and normal serum specimens (see Figs. 3.10.5.2 and
3.10.5.3).
This may indicate that these 51 probe sets are borderline calls i.e. just over the threshold to 
be called P or just under the threshold and so are called M or A. In microarray comparison 
studies carried out on RNA that was amplified with either 1 or 2 cycles of linear 
amplification, Schindler et al (2005) noted that with the 2 cycle protocol, changes in 
expression calls assigned to the samples were found but only for probe sets with expression 
levels under 100. Approximately 10% of the probe sets assigned as P with samples 
amplified using the standard protocol were switched to A when the 2 cycle protocol was 
used. Analysis of Table 3.10.5.1 reveals that 49/50 transcripts displayed levels of 
expression under 100.
This indicates that no gene transcripts were reliably Present in the Pre serum and Absent in 
the Post serum, and as expected, the changes in gene expression are more subtle making the 
search for a diagnostic biomarker much harder.
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4.8.11.4 Probe sets significantly changed in Pre vs. Post serum specimens
Because of the results discussed in the previous section, it was decided to assess the 
difference in the Pre and Post serum specimens based on their differential expression. The 
criteria chosen for gene transcripts to be called significant were that there had to be a 
difference in expression of 20 fluorescence units, a fold change greater than 1.2 and a 
significant paired p-value of less than 0.05. The lower difference in expression criteria was 
employed simply to increase the chances of picking up gene transcripts that may display 
subtle but significant changes as a direct result of the lumpectomy surgery in the individual 
patients. The use of the paired p-value was employed to increase the power of the statistical 
results obtained, i.e. the probe set not only had to show differential expression in the 
groupwise Pre vs. Post specimen comparisons but also in the individual patient Pre vs. Post 
specimen comparisons.
Only 4% (5/114) of probe sets were down-regulated in the Post serum specimens, which 
seems to be an illogical result. We would have expected that removal of the tumour would 
have corresponded to a decrease in mRNA transcripts detectable in the serum; however this 
was not the case. To rule out the possibility that using a volume RNA amount rather than a 
quantified RNA amount in the amplification process may have resulted in this discrepancy, 
the corresponding tissue samples were then compared. The tissue samples were compared 
to see if  the differentially expressed gene transcripts reflected the results found in the serum 
specimens. It was found that 80% of the gene transcripts differentially expressed between 
the tumour and normal tissues were also down-regulated in the tumour tissue compared to 
the matched normal, indicating that despite being illogical, the results for the gene 
transcripts differentially expressed in the serum specimens, reflected the overall trend gene 
expression of the tissue samples.
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A third analysis was then performed to rule out whether the differential gene expression 
profiles were somehow due to patient specific reasons, the expression of the gene 
transcripts in the pre serum were compared to the expression of the gene transcripts in the 
normal serum. The result of that analysis showed that 83% of the gene transcripts 
differentially expressed in the two samples were down-regulated in the Pre serum 
specimens compared to the normal serum specimens. As the trend of change was similar
i.e. the majority of gene transcripts were up-regulated in the normal serum specimens 
similar to the Post serum specimens any patient- specific reasons for the unusual gene 
expression pattern were ruled out.
In the microarray study of extracellular saliva mRNA from oral cancer patients and healthy 
donors, of the 1,679 transcripts deemed to be significantly different (criteria; fold change 
>2, p-value <0.05), 836 were up-regulated and 843 were down-regulated in the saliva of 
cancer patients (Li et al 2004(b)). A stricter criteria of fold change >3 was used in selection 
of gene transcripts to validate and 17 gene transcripts passed this criterion, all of which 
were down-regulated in the serum of healthy controls.
The microarray study of serum mRNA carried out by Li et al (2006) identified 335 gene 
transcripts significantly different in the comparison of oral cancer patients and healthy 
controls (criteria for significance; fold change >2, p-value <0.05). Of the 335 gene 
transcripts significantly differentially expressed, 223 were up-regulated and 112 were 
down-regulated in the serum of cancer patients compared to healthy controls.
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4.8.11.5 Study of Randomly Changing Gene Transcripts
The false discovery rate (FDR) is a measurement of how meaningful your gene list is. Since 
thousands of genes are compared, many genes can be false positives. dChip estimates the 
false discovery rate by permutation. Other methods of multiple-comparison adjusted p- 
values, significance analysis of microarray (SAM) and re-sampling based multiple test 
methods are also available.
To determine the false discovery rate, dChip randomly permutes samples in group-wise 
comparisons to determine how many gene transcripts would be obtained by the same 
comparison if the samples were permuted randomly e.g. in a comparison of four samples 
vs. four samples the false discovery rate would be assessed by moving the eight samples 
around randomly to compare any 4 samples vs. any four samples. The default in dChip is to 
test 50 permutations of your data to find the false discovery rate. A meaningful list is 
determined if the false discovery rate is less than 10% i.e. for every 100 gene transcripts on 
the comparison gene list, 10 or less will be falsely discovered.
To take this comparison a little further with the serum specimens, the false discovery rate of 
each list was determined for the sample groupings that make sense e.g. Pre serum vs. Post 
serum specimens, and also for permutations of the samples to assess if the scrambled 
groupings also have the ability to generate gene lists with a low false discovery rate.
The results of the false discovery rate generated for all of the different sample groupings 
are listed in Tables 3.10.7.1, 3.10.7.2 and 3.10.7.3.
With two exceptions, the only sample groupings to generate false discovery rates that were 
determined to be meaningful (with a minimum number of 4 samples in each group) were 
the groupings of either Pre vs. Post specimens, Pre vs. Normal specimens or Pre vs. Post 
and Normal specimens. The two exceptions to this were in the grouping of 4 Pre vs. 4 Post
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specimens with 3 Normal specimens randomly added to each group.
None of the comparisons of mixed groups vs. mixed groups yielded gene lists determined 
to be meaningful. For example, Table 3.10.7.2 lists the false discovery rates attained when 
any 2 Pre, 2 Post and 3 Normal specimens are compared to a group of the remaining 2 Pre, 
2 Post and 3 Normal specimens. None of the group wise comparisons were determined to 
be meaningful i.e. have a false discovery rate <10%.
Whilst this was not surprising as the sample groups i.e. Pre serum, Post serum and Normal 
serum were mixed up. What is surprising is that the comparison of these intact groups to 
each other did not always generate gene lists determined to be meaningful. For example in 
Table 3.10.7.3, the comparison of the 4 Post serum specimens to the 6 Normal specimens 
generated a gene list with a false discovery rate of 32.4% indicating that nearly 1/3 of the 
gene transcripts on that list could have come through by chance. The comparison of the 4 
Pre serum specimens with the 6 Normal specimens however, generated a gene list with a 
false discovery rate of 6.3% which is classed as meaningful.
To summarise, only the gene lists generated with the 4 Pre serum specimens compared to 
either the 4 Post serum specimens or the 6 Normal serum specimens, or the 4 Pre serum 
specimens compared to the combination of the 4 Post serum and 6 Normal serum 
specimens yielded gene lists that were determined to be meaningful. This indicates that 
despite the fact that the sample groups could not be separated based on their Presence or 
Absence call, there are distinct differences that separates the Pre serum specimens from 
both the Post serum specimens and the Normal serum specimens. This finding is also 
exciting because the Pre and Post serum specimens obviously originate from the same 
person. The fact that the specimens are more similar to the normal specimens indicates a 
huge potential for the development of this work in a clinical setting to find a cancer-specific 
signature of gene expression.
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4.8.11.6 SEQUENCE ANALYSIS
The results shown in section 3.11 indicate that there may be subtle changes in the presence 
of regulatory sequences in the transcripts significantly differentially regulated in parental 
CM vs. the drug selected CM samples compared to the number of regulatory sequences 
found in transcripts called Present in the cell RNA and Absent in the CM RNA,
Transcripts in each of the three groups ((1) gene transcripts called Present in all CM 
samples, (2) gene transcripts significantly differentially regulated between parental and 
drug selected variant CM samples and (3) gene transcripts called Present in all cell RNA 
samples and Absent in all CM samples) were positive for 15- Lipoxygenase Differentiation 
Control Element (15-LOX-DICE) sequences. 15-LOX-DICE sequences are tandem repeat 
sequences found in Erythroid 15-Lopoxygnease (15-LOX) capable of binding regulatory 
proteins HnRNP K and HnRNP El. Binding of these proteins in 15-LOX specifically 
inhibits 15-LOX mRNA translation.
Whilst the gene transcripts in group (1) (called Present in all CM samples) contained a 
mixture of multiple 15-LOX-DICE sequences detected in the transcripts, the other two 
groups showed a subtle pattern to the amount of multiple 15-LOX-DICE sequences found. 
In group (2), 3/6 of the transcripts contained 4 15-LOX-DICE sequences, with the 
remaining 3 transcripts containing 2, 3 & 6 15-LOX-DICE sequences.
In group (3), 5/8 of the transcripts had 2 15-LOX-DICE sequences, of the remaining 3 
transcripts in the group, 2 had 3 15-LOX-DICE sequences and 1 had 5 15-LOX-DICE 
sequences in their mRNA sequences.
The majority of sequences called Present in the cell RNA and Absent in the CM RNA, that 
were positive for multiple 15-LOX-DICE sites, contained 2 15-LOX-DICE sequences. The 
majority of sequences differentially expressed in the parent vs. drug selected variant CM
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samples contained 4 15-LOX-DICE sequences.
In addition to this, multiple K-Box regulatory sequences were found only in the transcripts 
significantly differentially expressed between the parent CM samples and the drug selected 
variant samples (3/20). K-Box sequences are present in one or more copies of many 
3’UTRs and mediate negative post-transcriptional regulation. Regulation by the K-box is 
spatially and temporally ubiquitous, and likely involves the formation of RNA-RNA 
duplexes with complementary sequences found at the 5’ end of many micro RNAs. 
However, whilst these subtle changes are noted, it is quite possible that analysis of larger 
number of sequences from the three categories would show non- compliance to the results 
noted here. It is also quite possible that presence of regulatory sequences in these 
transcripts, whilst interesting to note, do not automatically infer that they are functionally 
active. The reason this analysis was carried out in the first place was because of the few 
studies carried out to assess the mechanism by which extracellular RNA remains stable. 
Most of the studies speculate that binding of the RNA to proteins confers stability of the 
RNA transcripts. Yet no definite reason for the unexpected stability of the transcripts in 
CM/ serum/ saliva has been elucidated.
The RNA may possibly be complexed to lipids, proteins, lipoproteins, or phospholipids 
(Rosi et al 1988, Stroun et al 1978, Masella et al 1989, Wieczorek et al 1985); bound with 
DNA in nucleosomes (Stroun et al 1978, Sisco et al 2001) or protected within apoptotic 
bodies (Halicka et al 2000) or other vesicular structures.
Wieczorek et al (1985) were able to isolate an RNA- proteolipid complex from both patient
serum or supernatants from cultured cells that seemed to be associated with a malignant
state in humans. The RNA- proteolipid complex required respiration for its appearance in
the culture medium as production and/ or secretion was inhibited by cytochalasin B7 CN'
and monensin that indicates that the complex is not merely a degradation product of the
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cancer cells. They were unable to detect the complex in normal cells even when the 
homogenates were concentrated. They also found that serum RNase C cleaved the isolated 
RNA under physiological conditions but not RNA associated with the complex. This 
suggested that the RNA-proteolipid-complex consisted of RNA within a vesicular lipid 
complex, and the authors felt that the high lipid content of the structure played a part in the 
inclusion of the RNA within the complex. Investigation of the RNA extracted, showed that 
95-98% of it was poly (A) RNA that had double stranded stretches.
Halicka et al (2000) studied the location of cellular DNA and RNA both histochemically 
and immunocytochemically. Cellular RNA was labelled with BrU for different periods of 
time and the incorporated BrU was detected using anti- BrU mAb while counterstaining 
DNA with 7-aminoactinomycin D. Also cellular DNA and RNA were differentially stained 
with Hoechst 33342 and pyronin Y and visualised using fluorescence microscopy. 
Apoptosis was induced by camptothecin (CPT- a DNA topoisomerase I inhibitor) in MCF- 
7 cells. They found that cellular RNA became sequestered and packaged into granules and 
then into apoptotic bodies, separately from DNA in over 90% of the apoptotic bodies.
Sisco, (2001) exposed ethidium bromide-containing serum to different concentrations of 
RNaseH to selectively degrade RNA in an RNA-DNA heteroduplex molecule. 
Fluorescence measurements were then taken using a spectrophotometer. As ethidium 
bromide fluorescence is dependent on base pairing for the highest quantum yield, any 
decrease in fluorescence would indicate RNaseH activity and presence of RNA-DNA 
hybrids. The author found a concentration dependent reduction in fluorescence (10% 
reduction in fluorescence was obtained after incubating the serum with 120 kU/L of RNase 
H) leading to the conclusion that at least some of the RNA was present in an RNA-DNA 
heteroduplex.
Hasselmann et al (2001) showed that tumour-derived mRNA associated with apoptotic
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bodies remained stable in serum. This was possible by culturing a melanoma cell line and 
inducing apoptosis in the cells using anti- CD95 monoclonal antibody. The cell supernatant 
was removed after 48 hours exposure and passed through a 0.45 .^m filter. They then 
confirmed that the supernatant contained apoptotic bodies and also that RNA was present in 
some of the apoptotic bodies. Baseline readings of nucleic acid content of the serum were 
established, and then the supernatant was then mixed with serum from controls for time 
points ranging from 1 minute to 60 minutes at 37°C. The RNA was subsequently extracted 
from this mix and also from a separate sample of serum that had lp-g of free/ “naked” RNA 
(from the melanoma cell line) added. They were able to successfully amplify tyrosinase 
mRNA from the serum that was mixed with the cell supernatant for time points of 1 minute 
to 30 minutes but not from the 60 minute sample or from any of the serum specimens that 
had been mixed with free RNA. This lead the authors to conclude that the apoptotic body 
structure protected the RNA from degradation.
Tsui et al (2002) also showed the stability of plasma/ serum RNA by comparing yields of 
RNA from plasma/ serum obtained from healthy volunteers. They too found that free RNA 
added to plasma was rapidly degraded. In the first five seconds after addition of the 
commercially available extracted RNA, the concentration decreased from 67,605ng/L to 
116ng/L and >99% of the RNA was undetectable after 15 seconds incubation. The study 
also included filtration studies whereby concentrations of endogenous RNA in plasma/ 
serum were quantified before and after filtration with different size filters and also over 
time post filtration. They concluded that that most of the RNA was particle- bound in some 
way that stabilised it and protected it from degradation.
A more recent study by El-Hefnawy et al (2004) sought to determine the nature of this
protection. They tested the theory that the RNA is protected because it is part of a DNA-
RNA hybrid. After addition of RNase-H to plasma samples (which is the only nuclease that
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such a hybrid would not be resistant to), they found that there was no difference in the 
concentrations of RNA extractable from the samples. They also tested the theory that the 
RNA is protected by inclusion in lipoprotein vesicles that are either actively secreted or 
released during programmed cell death. Detergents were added (SDS or Triton-X) in an 
attempt to disrupt any RNA-protein or RNA-lipid complexes. After the addition of the 
detergents the authors were no longer able to amplify 18SrRNA, which favoured the theory 
that the RNA is protected in a lipid-containing vesicle.
Studies by Park et al (2006) on saliva RNA also revealed that incubation of saliva with 
Triton X-100 accelerated degradation of the RNA. In addition to this, they tested the 
recovery of saliva RNA after filtration through 0.22 or 0.45 ¿im pore filters. This was 
carried out also on purified total RNA as a control. The results showed that >80% of P-actin 
in the control RNA was recoverable post filtration however, less than 5% of p-actin mRNA 
was recoverable after filtration of the saliva through the 0.22 and 0.45 pore filters. 
Analysis of serum RNA also revealed a significant loss in p-actin mRNA post-filtration. 
Approximately 8% was recoverable after filtration through a 0.45p,m filter and less than 1% 
was recoverable after filtration through a 0.22jim filter.
Different elements in the 5’ and 3’ UTR region, like the regulatory elements found in the 
CM RNA sequences as shown in Section 3.11, are known to confer either stability or 
instability to an RNA transcript. Examples of these include the occurrence of upstream 
AUG, upstream ORFs and IRES in 5’UTRs and Poly-A tail in the 3’UTRs which can 
increase transcript stability and AU-Rich Elements (AREs) in the 3’UTR of RNA sequence 
which can decrease stability.
In addition to this, different RNA-binding proteins are involved in the regulation of splicing
and processing, export of mRNA to the cytoplasm, maintenance of mRNA in the cytoplasm
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There are RNA-binding proteins that shuttle between the nucleus and the cytoplasm with a 
few of these staying with an mRNA molecule for its lifespan, whilst other RNA-binding 
proteins are transiently associated with the mRNA. Some RNA-binding proteins have been 
shown to play a role in the regulation of gene expression by stabilising or destabilising a 
particular mRNA. A number of stimuli can alter the affinity of RNA-binding proteins for 
their target c/s-elements, including hormones and cytokines, redox changes, UV light, cell 
cycle and developmental stage (Hollams et aI 2002). Competition between protection or 
degradation factors or translation activators/ inhibitors will ultimately determine the overall 
amount of protein produced by one mRNA.
A number of RNA-binding motifs have been characterised like the RNA recognition motif 
(RRM), which is 90-100 amino acids (aa) in length and often present in one or more copies 
in the protein sequence. Other binding motifs include the RGG box, the K homology motif 
(KH), the double-stranded RNA-binding motif (DSRM), the zinc finger/knuckle domain 
and the cold shock domain (Hollams et al 2002). /
for translation, and ultimately decay of the mRNA.
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To summarise, when we started the work shown in this thesis, no proven methods were 
known for the reproducible and reliable extraction and detection of extracellular mRNA 
transcripts. It was also not known whether these extracellular mRNA transcripts were 
present as intact full-length transcripts or whether the detection of these transcripts resulted 
from cell apoptosis/ non-selective secretion.
To this end, we have answered all of these questions and developed reliable and 
reproducible methods for the extraction of these mRNA transcripts and subsequent analysis 
by RT-PCR. PCR primers that amplified either different regions of the same transcript or 5’ 
regions of different transcripts were designed. Use of these primers in conjunction with an 
oligo dT reverse transcription primer in RT-PCR studies enabled us to confirm the presence 
of full-length transcripts. As CM samples were taken from healthy viable cultured cells, 
any interference by apoptosing cells was minimal.
In addition to this, we successfully applied 2 cycle amplification protocols to extracellular 
RNA isolated from both serum and CM samples to enable global expression analysis of 
these samples to be performed. No studies have been published regarding the microarray 
analysis of extracellular RNA from CM samples so this work is very novel. One serum 
microarray study has since been published relating to microarray analysis of samples taken 
from oral cancer patient serum and healthy patient serum, however our study design of 
taking serum specimens pre and post lumpectomy surgery in addition to serum specimens 
from normal volunteers adds another novel dynamic range to this type of study. The 
success of this study indicates the possibility that this work could lead to useful diagnostic/ 
prognostic tests based on gene expression profiles obtained from analysis of the microarray 
data.
However this work, although having been brought to this stage is still only at an early stage
of development. The results need to be confirmed for interesting biomarker candidates. A
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much larger study would also need to be performed and results confirmed by RT-PCR 
methods before application in a clinical environment could be established.
Whilst analysis of the sequences of mRNAs detectable in CM samples compared to those 
found in cell RNA samples and Absent in CM samples did not identify any significant 
leads, this work too is in its infancy. Future work is needed on mRNA transcripts confirmed 
by RT-PCR to be detected in CM to elucidate if the regulatory elements identified in their 
sequence are in fact functionally active i.e. are they are actively involved in stabilising 
these transcripts extracellularly. In addition to this, protein-RNA interaction studies should 
be carried out to assess what role, if any, proteins may have on the stability of the mRNA 
transcripts. Studies should also be performed to elucidate how the mRNA gets out of the 
cell.
To conclude we now know that despite the low RNA yields and challenges involved in 
quantifying and amplifying extracellular mRNA, we can reproducibly amplify and detect 
extracellular mRNA transcripts by RT-PCR. We also now know that microarray studies on 
extracellular mRNA from both CM and serum are possible. This has lead to the exciting 
and very real possibility that methods developed during the course of this study may aid in 
the selection of cancer biomarkers that would allow on-going/ sequential monitoring of the 
course of disease (progression, response to therapy, etc.).
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4.9 SUMMARY
We have demonstrated that many gene transcripts from a broad range o f healthy, 
proliferating, human cancer cell lines can be reproducibly detected in the CM o f these cell 
lines using the protocols developed. The RT-PCR results suggest that the detection o f 
particular transcripts by a given cell line may be somewhat selective. The mRNA found in 
the CM o f cancer cells are apparently full-length transcripts; some o f which may be 
particle-bound.
The utilisation o f linear amplification techniques, allowing the CM and serum mRNA to be 
amplified to amounts required for hybridisation to array chips, enabled global expression 
analysis of the mRNA found in these samples. Despite the problems encountered when 
validating the microarray data using RT-PCR, the fact is distinct patterns o f expression 
were achievable for many o f the sample groups tested using the microarray data on its own. 
This indicates the potential for development o f disease-specific/ stage-specific/ response-to- 
therap- specific expression patterns applicable to a clinical environment.
The function o f extracellular mRNA remains unclear along with the mechanism by which it 
remains stable, and also how it gets out of the cell. However its’ potential as a future 
biomarker does not rely on elucidating these roles and Absence/ Presence o f transcripts at a 
particular expression level may be enough to qualify as a diagnostic/ prognostic or 
predictive biomarker.
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4.10 CONCLUSIONS
1. Extracellular mRNA is readily extractable from biological samples using a modified 
Tri Reagent extraction protocol.
2. The presence o f extracellular mRNA in CM samples may be the result o f a selective 
secretion process, as gene transcripts were not always detectable in all CM samples 
from different cell lines even if  the gene was expressed in the different cell types.
3. The mRNAs are derived from the cells and not from the serum in which they are 
cultured.
4. Gene transcripts are present as full- length mRNAs.
5. The use o f different filter sizes affected the abundance o f certain mRNA transcripts 
detected, suggesting that at least some o f the extracellular mRNA is likely to be 
particle- associated in some form.
6. Bioanalyser RNA chips were unable to detect any intact ribosomal RNA, but were 
able to identify the presence of RNA fragments up to 1000 nucleotides in length 
from concentrated CM samples.
7. A reliable method for quantification o f RNA extracted using Tri Reagent where the 
sample cannot be diluted, has yet to be found.
8. Extracellular mRNA from CM and serum specimens can be linearly amplified using 
two rounds o f amplification to yield enough cRNA for hybridisation to Affymetrix 
Human Genome Plus 2.0 microarray chips.
9. Whilst the microarray mRNA profiles o f CM mRNA from a range o f cancer cell 
lines/ cancer types are quite similar, distinct sample- specific profiles were 
achievable for the majority o f the samples tested.
10. Although attempts to validate the microarray data using RT-PCR was only partially
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successful (approx 50%), it did not take away from the value o f the data as a 
microarray study on its own, as the techniques are inherently different and work on 
different principles.
11. Application o f this microarray technology to serum specimens obtained from the 
same patient before and after lumpectomy was possible.
12. Despite the small number o f patients tested, meaningful gene lists were generated 
from the groupings o f Pre-op specimens against Post-op specimens and normal 
specimens, and also from the groupings of Pre-op specimens against the normal 
specimens as defined by their low false discovery rates.
13. The microarray studies shown in this thesis indicate the potential for this technology 
to be applied to a clinical environment. The matching o f distinct gene expression 
patterns to different diseases or disease states may ultimately aid in the early 
detection of disease and prediction o f prognosis/ response to therapy by monitoring 
o f expression profiles taken during treatment.
14. The function of extracellular mRNA is still unclear, as is the mechanisms by which 
it remains stable and how it gets out o f the cell.
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FUTURE WORK
5.1 Validation of Breast Cancer Serum Study M icroarray Results using 
RT-PCR/ qPCR
The results o f the Breast Cancer Serum Study (see Section 3.10) did not include any 
validation o f the results by a second method e.g. RT-PCR. Some gene transcripts o f interest 
should be chosen for validation by RT-PCR or qPCR (e.g. transcripts expressed highly in 
the Pre serum specimens and down-regulated in the Post/ Normal serum specimens). The 
transcripts chosen for validation should be chosen whilst keeping in mind the information 
obtained from the validation of the CM microarray work, (i.e. choose transcripts called 
Present in all specimens that are also functionally annotated).
The study should also be enlarged to include serum specimens from many more patients 
and matched controls. Ideally the samples would be analysed by microarray also, however 
if  this was not possible (e.g. due to the high cost o f such an experiment), the serum samples 
could be tested for the Presence/ expression o f any gene transcripts validated in the smaller 
study to be o f interest (i.e. as possible biomarkers).
In addition to this, serum should be collected from a variety of cancer patients and patients 
with non-malignant diseases together with age/sex matched controls and subjected to 
microarray analysis using whole genome microarray chips. This would help to establish 
whether potential biomarkers not only diagnose cancer from normal/ non-malignant disease 
serum specimens, or predict response to therapy, but also distinguish different types o f 
cancer. It would be also important to include serum from patients with cancers that are 
typically diagnosed at a late stage e.g. lung or kidney, as with these cancers in particular, 
late diagnosis often leads to a poorer prognosis for the patients. If a marker could be 
identified that would indicate development o f cancer at an early stage this would be 
invaluable.
359
5.2 M icroarray Analysis of Conditioned Media from normal cells
The pilot study performed using CM from one batch o f HMEC- 1001 breast cells was 
successful in so far as the yield o f labelled cRNA was sufficient to permit hybridisation to 
whole genome microarrays, and the QA parameters were all acceptable.
The fact that we were able to amplify enough cRNA for hybridisation to the Affymetrix 
chips means that we can plan a larger study to culture cells from various tissue sources e.g. 
breast, lung, nasal, etc and build up a profile o f the gene expression o f mRNA detectable 
from the CM of these cultured cells, including as many biological replicates as desired. The 
study would be directly comparable to the CM array work described in this thesis.
It may also be possible to subtract the expression o f mRNAs found in the CM of normal 
cells from those found in the cancer cell lines to help to build a picture of cancer-specific 
mRNAs detectable in the CM of cancer cell lines. In the pilot study this was carried out but 
as only one CM sample from the normal cells was available, statistical significance could 
not be assessed.
In addition to this, CM from larger panels o f drug resistant/ non-resistant, invasive/ non- 
invasive samples could be included. Whilst drug selected variants were studied in the work 
presented here, the numbers were too small and the samples too varied to read too much 
into the results. It may be possible, for example, with a larger panel of invasive and non- 
invasive CM samples that markers could be identified that would be indicative o f an 
invasive phenotype.
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5.3 Determination of RNA-protein interactions
One conclusion in this thesis is that at least some o f the RNA is likely to be is particle- 
bound. Future studies could, therefore, take this further to try to elucidate if  the RNA is 
bound to proteins which are protecting it from degradation.
Many elements that aid in the translation and regulation o f a gene transcript are regulated 
by cis-elements found in the 3’UTR. In 2002, Hartley et a l  described a technique that could 
identify sequence-specific RNA binding proteins (RNA-BPs) by using UV-crosslinking 
methods. This method involves cloning the mRNA sequence o f interest (e.g. in Hartley et 
al the 3’UTR sequence o f EG and c-mos Xenopus laevis maternal mRNAs) into plasmids 
that have been modified to enable in vitro transcription o f the sequence using a T3/ T7 
promoter. For in vitro transcription the plasmids were linearized and 32P-labeled uncapped 
transcripts transcribed using a Riboprobe transcription kit (Promega). The 32P-labeled 
transcripts were then incubated with cytoplasmic extracts (prepared from 4 hour Xenopus 
embryos) before being exposed to UV light. Exposure to UV light causes protein to be 
covalently linked to RNA. The RNA-protein complex was then digested with RNase A to 
degrade any single stranded RNA i.e. unbound. The results of the reaction were assessed by 
resolving the entire reaction by SDS-PAGE on a 10% Laemmli gel and visualising the 
fixed and dried gel by autoradiography. Only proteins with bound radiolabelled transcripts 
(i.e. our in vitro transcribed transcript o f interest) would be visible on the gel.
To adapt this protocol for our work, the procedure would be carried out as above with one 
exception. Instead o f incubating in a cytoplasmic extract, the 32P-labeled transcripts could 
be incubated in conditioned media so that only proteins endogenously found in CM would 
be targeted. As it has also been suggested that cell-free mRNA may also be sequestered 
within vesicles, methods may have to be developed that would reversibly disrupt any
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vesicles in the CM long enough for the radiolabelled RNA to get in. Although this method 
would not identify the protein (if any) that binds the RNA, further analysis using proteomic 
techniques may aid in the identification o f the protein.
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7.2 UTRScan sequence results
7.2.1 Gene transcripts called P in all CM samples
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Table 7.2.1 Sequence of regulatory elements found In gene transcripts called P in all CM samples
7.2.2 Gene transcripts differentially regulated between parental CM samples and tbeir drug selected variants
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